

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. **AU 2002317940 B9**

(54) Title  
**Mycobacterial antigens expressed under low oxygen tension**

(51) International Patent Classification(s)  
**G01N 33/569** (2006.01) **C07K 16/12** (2006.01)  
**A61K 39/04** (2006.01) **C12N 1/21** (2006.01)  
**A61K 39/395** (2006.01) **C12N 9/99** (2006.01)  
**A61K 45/00** (2006.01) **C12N 15/09** (2006.01)  
**A61K 48/00** (2006.01) **C12Q 1/68** (2006.01)  
**A61P 31/06** (2006.01) **A61K 38/00** (2006.01)  
**C07K 14/35** (2006.01)

(21) Application No: **2002317940** (22) Date of Filing: **2002.06.21**

(87) WIPO No: **WO03/000721**

(30) Priority Data

| (31) Number      | (32) Date         | (33) Country |
|------------------|-------------------|--------------|
| <b>0115365.9</b> | <b>2001.06.22</b> | <b>GB</b>    |
| <b>0121780.1</b> | <b>2001.09.07</b> | <b>GB</b>    |

(43) Publication Date: **2003.01.08**

(43) Publication Journal Date: **2003.06.19**

(44) Accepted Journal Date: **2007.12.20**

(48) Corrigenda Journal Date: **2008.06.05**

(71) Applicant(s)  
**Health Protection Agency**

(72) Inventor(s)  
**James, Brian William;Marsh, Philip;Bacon, Joanna**

(74) Agent / Attorney  
**Griffith Hack, Level 29, Northpoint 100 Miller Street, North Sydney, NSW, 2060**

(56) Related Art  
**US 6572865**  
**Sharman et al. PNAS, 2001,98(13): 7534-39**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
3 January 2003 (03.01.2003)

PCT

(10) International Publication Number  
**WO 03/000721 A3**

(51) International Patent Classification<sup>7</sup>: **C07K 14/35**

(21) International Application Number: PCT/GB02/02845

(22) International Filing Date: 21 June 2002 (21.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0115365.9 22 June 2001 (22.06.2001) GB  
0121780.1 7 September 2001 (07.09.2001) GB

(71) Applicant (*for all designated States except US*): **MICRO-BIOLOGICAL RESEARCH AUTHORITY** [GB/GB]; CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **JAMES, Brian, William** [GB/GB]; Microbiological Research Authority, CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (GB). **BACON, Joanna** [US/US]; Microbiological Research Authority, CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (US). **MARSH, Philip** [GB/GB]; Microbiological Research Authority, CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (GB).

(74) Agents: **MACLEAN, Martin, Robert** et al.; Mathys & Squire, 100 Gray's Inn Road, London WC1X 8AL (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
26 June 2003

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: MYCOBACTERIAL ANTIGENS EXPRESSED UNDER LOW OXYGEN TENSION

(57) Abstract: A method is provided for identifying mycobacterial genes that are induced or up-regulated under continuous culture conditions defined by a dissolved oxygen tension of up to 10 % air saturation measured at 37 °C when compared with a dissolved oxygen tension of at least 40 % air saturation measured at 37 °C. Said induced or up-regulated genes form the basis of nucleic acid vaccines, or provide targets to allow preparation of attenuated mycobacteria for vaccines against mycobacterial infections. Similarly, peptides encoded by said induced or up-regulated genes are employed in vaccines. In a further embodiment, the identified genes/peptides provide the means for identifying the presence of a mycobacterial infection in a clinical sample by nucleic acid probe or antibody detection.



WO 03/000721 A3

## MYCOBACTERIAL ANTIGENS EXPRESSED UNDER LOW OXYGEN TENSION

The present invention relates to a method of identifying a gene in mycobacteria the expression of which gene is induced or up-regulated during continuous culture of mycobacteria under growth conditions defined by a low dissolved oxygen tension, to the isolated peptide products, variants, derivatives or fragments thereof, to antibodies that bind to said peptides, variants, derivatives or fragments, to DNA and RNA vectors that express said peptides, variants, derivatives or fragment, to attenuated mycobacteria in which the activity of at least one of said induced or up-regulated genes has been modified, to vaccines against mycobacterial infections, and to methods of detecting a mycobacterial infection.

Many microorganisms are capable of forming intracellular infections. These include: infections caused by species of *Salmonella*, *Yersinia*, *Shigella*, *Campylobacter*, *Chlamydia* and *Mycobacteria*. Some of these infections are exclusively intracellular, others contain both intracellular and extracellular components. However, it is the intracellular survival cycle of bacterial infection which is suspected as a main supportive factor for disease progression.

Generally, these microorganisms do not circulate freely in the body, for example, in the bloodstream, and are often not amenable to drug treatment regimes. Where drugs are available, this problem has been exacerbated by the development of multiple drug resistant microorganisms.

A number of factors have contributed to the problem of microbial resistance. One is the accumulation of mutations over time and the subsequent horizontal and vertical transfer of the mutated genes to other organisms. Thus, for a given pathogen, entire classes of antibiotics have been rendered inactive. A further factor has been the absence of a new class of antibiotics in recent years. The emergence of multiple drug-resistant pathogenic bacteria represents a serious threat to public health and new forms of therapy are urgently required.

For similar reasons, vaccine therapies have not proved effective against such intracellular microorganisms. Also, increased systemic concentration of antibiotics to improve bioavailability within cells may result in severe side effects.

*Mycobacterium tuberculosis* and closely related species make up a small group

-2-

of mycobacteria known as the *Mycobacterium tuberculosis* complex (MTC). This group comprises four species *M. tuberculosis*, *M. microti*, *M. bovis* and *M. africanum* which are the causative agent in the majority of tuberculosis (TB) cases throughout the world.

5

*M. tuberculosis* is responsible for more than three million deaths a year world-wide. Other mycobacteria are also pathogenic in man and animals, for example *M. avium* subsp. *paratuberculosis* which causes Johne's disease in ruminants, *M. bovis* which causes tuberculosis in cattle, *M. avium* and *M. intracellulare* which cause tuberculosis in immunocompromised patients (eg. AIDS patients, and bone marrow transplant patients) and *M. leprae* which causes leprosy in humans. Another important mycobacterial species is *M. vaccae*.

10

*M. tuberculosis* infects macrophage cells within the body. Soon after macrophage infection, most *M. tuberculosis* bacteria enter, persist and replicate within cellular phagosome vesicles, where the bacteria are sequestered from host defences and extracellular factors.

15

It is the intracellular survival and multiplication or replication of bacterial infection which is suspected as a main supportive factor for mycobacterial disease progression.

20

A number of drug therapy regimens have been proposed for combatting *M. tuberculosis* infections, and currently combination therapy including the drug isoniazid has proved most effective. However, one problem with such treatment regimes is that they are long-term, and failure to complete such treatment can promote the development of multiple drug resistant microorganisms.

25

A further problem is that of providing an adequate bioavailability of the drug within the cells to be treated. Whilst it is possible to increase the systemic concentration of a drug (eg. by administering a higher dosage) this may result in severe side effects caused by the increased drug concentration.

30

The effectiveness of vaccine prevention against *M. tuberculosis* has varied widely. The current *M. tuberculosis* vaccine, BCG, is an attenuated strain of *M. bovis*. It is effective against severe complications of TB in children, but it varies greatly in its effectiveness in adults particularly across ethnic groups. BCG

35



vaccination has been used to prevent tuberculous meningitis and helps prevent the spread of *M. tuberculosis* to extra-pulmonary sites, but does not prevent infection.

- 5 The limited efficacy of BCG and the global prevalence of TB has led to an international effort to generate new, more effective vaccines. The current paradigm is that protection will be mediated by the stimulation of a Th1 immune response.
- 10 BCG vaccination in man was given orally when originally introduced, but that route was discontinued because of loss of viable BCG during gastric passage and of frequent cervical adenopathy. In experimental animal species, aerosol or intra-tracheal delivery of BCG has been achieved without adverse effects, but has varied in efficacy from superior protection than parenteral inoculation in
- 15 primates, mice and guinea pigs to no apparent advantage over the subcutaneous route in other studies.

Conventional mycobacterial culture systems for analysing gene and protein expression profiles have been based on simple batch-type systems, such as

20 those described in:- Sherman, D.R. *et al* (2001) PNAS, vol. 98, no.13, pp. 7534-7539; Boon, C. *et al* (2001) J. Bacteriol, vol. 183, no.8, pp. 2672-2676; Cunningham, A.F. *et al* (1998) J. Bacteriol, vol. 180, no.4, pp. 801-808; and Murugasu-Oei, B. *et al* (1999) Mol. Gen. Genet, vol. 262, pp. 677-682. In these batch-type systems, mycobacterial growth follows a typical sigmoid

25 growth curve involving an exponential growth phase and a stationary phase. The transition from exponential phase to stationary phase involves rapid and transient switches in terms of gene and protein expression, which switches are initiated by a complex set of undefined or poorly defined interactive stimuli as the mycobacteria become starved of essential nutrients.

30 There is therefore a need for an improved and/or alternative vaccine or therapeutic agent for combatting mycobacterial infections.

According to a first aspect of the invention there is provided a therapeutic agent when used for preventing or treating a mycobacterial infection, comprising an isolated *M. tuberculosis* peptide selected from the group consisting of SEQ ID

5 NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135 and 137, or a variant thereof having at least 70% amino acid homology therewith, or a derivative thereof, or a fragment thereof

10 having at least 10 amino acid residues, wherein said variant, derivative or fragment has a common antigenic cross-reactivity to said isolated peptide, wherein the peptide is encoded by a gene the expression of which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation

15 measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C.

20

5 The continuous culture methods employed by the present invention are particularly advantageous when compared with batch culture methods. This is because continuous culture permits strict control of growth culture parameters such as pH, available nutrients, constant growth rate, and dissolved oxygen tension.

10 Thus, in use of the present invention it is possible to ensure that the principal, preferably the only mycobacterial virulence induction parameter is that of a low dissolved oxygen tension. This means that the accidental induction or up-regulation of genes that are solely responsive to environmental switches other than to a low dissolved oxygen tension may be substantially prevented. Accordingly, false-positive identification of genes whose induction or up-regulation is unrelated to a low dissolved oxygen tension may be substantially avoided.

15 20 Mycobacterial batch culture systems involve a variety of interactive stimuli as the mycobacteria become starved of essential nutrients. As a result, the mycobacteria are exposed to a complex range of starvation stimuli, which stimuli may obscure or modify the cellular effects associated with a single rapid or transient stimulus in isolation. In contrast, the present invention concerns the principal stimulus of oxygen limitation.

A further distinction between the continuous culture conditions of the present invention and batch-type systems is that the present invention employs oxygen limitation as the principal stimulus and does not involve oxygen starvation.

30 During oxygen limitation, the mycobacteria are capable of growth and reproduction, and the present invention therefore maintains mycobacterial growth under carefully controlled environmental conditions. In contrast, mycobacteria do not substantially grow and reproduce when exposed to starvation stimuli such as those experienced with batch-type culture systems.

35 Such starvation stimuli are typically associated with stress-type environmental conditions, and invoke mycobacterial cellular responses that are different from those associated with nutrient limitation.

The dissolved oxygen tension parameter is calculated by means of an oxygen electrode and conventional laboratory techniques. Thus, 100 % air saturation corresponds to a solution that is saturated with air, whereas 0% corresponds to a solution that has been thoroughly purged with an inert gas such as nitrogen.

- 5 Calibration is performed under standard atmospheric pressure conditions, and with conventional air comprising approximately 21 % oxygen.

- 10 The low oxygen tension induction conditions of the present invention are culture conditions which are conducive for a mycobacterium to express at least one gene which would be normally expressed *in vivo* during infection of the mycobacterium's natural target cell, which the present inventors believe to involve a low oxygen environment.

- 15 Described herein is an isolated *M. tuberculosis* peptide selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135 and 137, or a variant thereof having at least 70% amino acid homology therewith, or a derivative  
20 thereof, or a fragment thereof having at least 10 amino acid residues, wherein said variant, derivative or fragment has a common antigenic cross-reactivity to said isolated peptide, wherein the peptide is encoded by a gene the expression of which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to  
25 10% air saturation measured at 37°C when a dissolved oxygen tension of at least 40% air saturation measured at 37°C.

- The terms "isolated", "substantially pure", and "substantially homogenous" are used interchangeably to describe a peptide which has been separated from  
30 components which naturally accompany it. A peptide is substantially pure when at least about 60 to 75% of a sample exhibits a single peptide sequence. A substantially pure peptide will typically comprise about 60 to 90% w/w of a protein sample, more usually about 95%, and preferably will be over about 99% pure. Peptide purity or homogeneity may be indicated by, for example,  
35 polyacrylamide gel electrophoresis of a protein sample, followed by visualizing a single polypeptide band upon staining the gel. Alternatively, higher resolution may be provided by using, for example, HPLC.

5 A peptide is considered to be isolated when it is separated from the contaminants which accompany it in its natural state. Thus, a peptide which is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be substantially free from its naturally associated components.

10 The present invention provides peptides which may be purified from mycobacteria as well as from other types of cells transformed with recombinant nucleic acids encoding these peptides.

If desirable, the amino acid sequence of the proteins of the present invention may be determined by protein sequencing methods.

-6-

The terms "peptide", "oligopeptide", "polypeptide", and "protein" are used interchangeably and do not refer to a specific length of the product. These terms embrace post-translational modifications such as glycosylation, acetylation, and phosphorylation.

5

The term "fragment" means a peptide having at least five, preferably at least ten, more preferably at least twenty, and most preferably at least thirty-five amino acid residues of the peptide which is the gene product of the induced or up-regulated gene in question. The fragment preferably includes an epitope of the gene product in question.

10

The term "variant" means a peptide or peptide "fragment" having at least seventy, preferably at least eighty, more preferably at least ninety percent amino acid sequence homology with the peptide which is the gene product of the induced or up-regulated gene in question. An example of a "variant" is a peptide or peptide fragment of an induced/up-regulated gene which contains one or more analogs of an amino acid (eg. an unnatural amino acid), or a substituted linkage. The terms "homology" and "identity" are considered synonymous in this specification. In a further embodiment, a "variant" may be a mimic of the peptide or peptide fragment, which mimic reproduces at least one epitope of the peptide or peptide fragment. The mimic may be, for example, a nucleic acid mimic, preferably a DNA mimic.

15

20

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences may be compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequent coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percentage sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

25

30

Optimal alignment of sequences for comparison may be conducted, for example, by the local homology alignment algorithm of Smith and Waterman [Adv. Appl. Math. 2: 484 (1981)], by the algorithm of Needleman & Wunsch [J. Mol. Biol. 48: 443 (1970)] by the search for similarity method of Pearson & Lipman [Proc. Nat'l. Acad. Sci. USA 85: 2444 (1988)], by computer implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA -

35

-7-

Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705), or by visual inspection [see Current Protocols in Molecular Biology, F.M. Ausbel et al, eds, Current Protocols, a joint venture  
5 between Greene Publishing Associates, In. And John Wiley & Sons, Inc. (1995 Supplement) Ausubel].

Examples of algorithms suitable for determining percent sequence similarity are the BLAST and BLAST 2.0 algorithms [see Altschul (1990) J. Mol. Biol. 215:  
10 pp. 403-410; and "<http://www.ncbi.nlm.nih.gov/>" of the National Center for Biotechnology Information].

In a preferred homology comparison, the identity exists over a region of the sequences that is at least 50 nucleotides in length.

15 The term "derivative" means a peptide comprising the peptide (or fragment, or variant thereof) which is the gene product of the induced or up-regulated gene in question. Thus, a derivative may include the peptide in question, and a further peptide sequence which may introduce one or more additional epitopes.  
20 The further peptide sequence should preferably not interfere with the basic folding and thus conformational structure of the peptide in question. Examples of a "derivative" are a fusion protein, a conjugate, and a graft. Thus, two or more peptides (or fragments, or variants) may be joined together to form a derivative. Alternatively, a peptide (or fragment, or variant) may be joined to an  
25 unrelated molecule (eg. a peptide). Derivatives may be chemically synthesized, but will be typically prepared by recombinant nucleic acid methods. Additional components such as lipid, and/or polysaccharide, and/or polyketide components may be included.

30 All of the molecules "fragment", "variant" and "derivative" have a common antigenic cross-reactivity and/or substantially the same *in vivo* biological activity as the gene product of the induced or up-regulated gene in question from which they are derived. For example, an antibody capable of binding to a fragment, variant or derivative would be also capable of binding to the gene  
35 product of the induced or up-regulated gene in question. It is a preferred feature that the fragment, variant and derivative each possess the active site of the peptide which is the induced or up-regulated peptide in question. Alternatively,

all of the above embodiments of a peptide as described herein share a common ability to induce a "recall response" of a T-lymphocyte which has been previously exposed to an antigenic component of a mycobacterial infection.

5 In a preferred embodiment, the peptide is selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, and 137.

10

Described herein is a method of identifying a mycobacterial gene the expression of which is induced or up-regulated during culture of a mycobacterium under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C, said method comprising:-

15

culturing a first mycobacterium under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C;

20

culturing a second mycobacterium under continuous culture conditions defined by a dissolved oxygen tension of at least 40% air saturation measured at 37°C;

obtaining first and second mRNA populations from said first and second mycobacteria, respectively;

25

preparing first and second cDNA populations from said first and second mRNA populations, respectively, during which cDNA preparation a detectable label is introduced into the cDNA molecules of the first and second cDNA populations;

30

isolating corresponding first and second cDNA molecules from the first and second cDNA populations, respectively;

comparing relative amounts of label or corresponding signal emitted from the label present in the isolated first and second cDNA molecules;

identifying a greater amount of label or signal provided by the isolated first cDNA molecule than that provided by the isolated second cDNA molecule;

35

and

identifying the first cDNA and the corresponding mycobacterial gene



which is induced or up-regulated during culture of a mycobacterium under continuous culture conditions defined by a dissolved oxygen tension of up to 10 % air saturation measured at 37°C.

- 5 Reference to gene throughout this specification embraces open reading frames (ORFs).

The various embodiments described for the first aspect of the present invention apply equally for other aspects of the present invention.

10

- "Corresponding first and second cDNA molecules from the first and second cDNA populations" refers to cDNAs having substantially the same nucleotide sequence. Thus, by isolating the cDNA copies relating to a given gene under each culture condition (ie. high oxygen, and low oxygen), it is possible to  
15 quantify the relative copy number of cDNA for that gene for each culture condition. Since each cDNA copy has been produced from an mRNA molecule, the cDNA copy number reflects the corresponding mRNA copy number for each culture condition, and thus it is possible to identify induced or up-regulated genes.

20

- The mycobacterium is selected from the species *M. phlei*, *M. smegmatis*, *M. africanum*, *M. caneti*, *M. fortuitum*, *M. marinum*, *M. ulcerans*, *M. tuberculosis*, *M. bovis*, *M. microti*, *M. avium*, *M. paratuberculosis*, *M. leprae*, *M. lepraemurium*, *M. intracellulare*, *M. scrofulaceum*, *M. xenopi*, *M. genavense*, *M. kansasii*, *M. simiae*, *M. szulgai*, *M. haemophilum*, *M. asiaticum*, *M. malmoense*, *M. vaccae*  
25 and *M. shimoidei*. Of particular interest are members of the MTC, preferably *M. tuberculosis*. Similarly, all embodiments of the present invention may be based on the above-identified mycobacterial sources.

30

- Suitable media for culturing mycobacteria are described in Wayne, L.G. (1994) [*in* Tuberculosis: Pathogenesis, Protection, and Control published by the American Society for Microbiology, pp. 73-83]. These include Middlebrook 7H9 Medium [see Barker, L.P., *et al.* (1998) *Molec. Microbiol.*, vol. 29(5), pp. 1167-1177], and WO00/52139 in the name of the present Applicant.

35

In one embodiment, the first and second cDNA molecules are isolated from the corresponding cDNA populations by hybridisation to an array containing

immobilised DNA sequences that are representative of each known gene (or ORF) within a particular mycobacterial species' genome. Thus, a first cDNA may be considered "corresponding" to a second cDNA if both cDNAs hybridise to the same immobilised DNA sequence. Alternatively, representative DNA  
5 sequences from a particular mycobacterial strain, or from a number of different species and/or strains may be employed in the array.

In one embodiment, the first and second cDNAs are prepared by incorporation of a fluorescent label. The first and second cDNAs may incorporate labels  
10 which fluoresce at different wavelengths, thereby permitting dual fluorescence and simultaneous detection of two cDNA samples.

The type of label employed naturally determines how the output of the detection method is read. When using fluorescent labels, a confocal laser scanner is  
15 preferably employed.

In use, it is preferred that those genes (ie. as represented by cDNAs in the detection assay) which are up-regulated by at least 1.5-fold under low oxygen culture conditions *vis-a-vis* high oxygen culture conditions are selected. In  
20 more preferred embodiments, the corresponding up-regulation selection criterium is at least 2-fold, more preferably 3-fold, most preferably 4-fold. In further embodiments up-regulation levels of at least 10-fold, preferably 50-fold may be employed.

25 The preferred nucleic acid and peptide sequences are those that are up-regulated by the above-identified levels.

According to one embodiment, fluorescently labelled cDNA sequences from low and high oxygen cultured systems were allowed to hybridise with a whole  
30 mycobacterial genome array. The first cDNA population was labelled with fluorescent label A, and the second cDNA population was labelled with fluorescent label B. The array was scanned at two different wavelengths corresponding to the excitable maxima of each dye and the intensity of the emitted light was recorded. Multiple arrays were prepared for each cDNA and a  
35 mean intensity value was calculated across the two cDNA populations for each spot with each dye, against which relative induction or up-regulation was quantified.

In addition to the above mRNA isolation and cDNA preparation and labelling, genomic DNA may be isolated from the first and second mycobacteria. Thus, in a preferred embodiment, labelled DNA is also prepared from the isolated DNA. The labelled DNA may be then included on each array as a control.

As an alternative to the above-described transcriptomics based method for identifying up-regulated or induced genes, identification may be performed at the protein level rather than at the mRNA level. In more detail, protein samples may be removed from the first and second mycobacteria, and then exposed to conventional separation techniques such as SDS-PAGE or non-denaturation electrophoresis prior to conventional analysis such as by densitometer analysis. By comparing the relative amounts of a particular protein from each of the first and second mycobacteria, those proteins the production of which is up-regulated or induced under oxygen limitation may be identified.

The preferred maximum dissolved oxygen tension threshold defining the low oxygen culture condition is up to 5% air saturation measured at 37°C, more preferably up to 2% air saturation measured at 37°C, and most preferably up to 1% air saturation measured at 37°C. The corresponding minimum DOT is typically at least 0.5% air saturation measured at 37°C, preferably at least 1% air saturation measured at 37°C.

Similarly, the preferred minimum dissolved oxygen tension threshold defining the high oxygen culture condition is 45% air saturation measured at 37°C, and more preferably 50% air saturation measured at 37°C.

The pH of the culture medium is preferably maintained between pH 6 and 8, more preferably between pH 6.5 and 7.5, most preferably at about pH 6.9.

Preferred nucleic acid and peptide sequences are those that are up-regulated under the above-identified DOT and pH conditions.

Also described herein is an inhibitor of a mycobacterial peptide, wherein the peptide is encoded by a gene the expression of which is induced or up-regulated during culture of a mycobacterium under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when

compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C, and wherein the inhibitor is capable of preventing or inhibiting the mycobacterial peptide from exerting its native biological effect.

- 5 Inhibition of the mycobacterial peptide may be effected at the nucleic acid level (ie. DNA, or RNA), or at the peptide level.

10 In one embodiment, the inhibitor is capable of inhibiting one or more of acyl carrier protein, monooxygenase, mycobactin synthesis protein, transcription regulator, oxidoreductase, acyl CoA dehydrogenase, esterase/acetyl hydrolase, cytochrome D, methyl transferase, transaminase, PPE protein, valyl-tRNA synthetase, guanylate kinase, ketol acid reductoisomerase, ABC transporter, ATP-binding protein, protoporphyrinogen oxidase, sigma factor, pyruvate kinase, heat shock protein, and aminotransferase.

15 In a further embodiment, the inhibitor may be an antibiotic capable of targeting the induced or up-regulated mycobacterial gene identifiable by the method described herein, or the gene product thereof. The antibiotic is preferably specific for the gene and/or gene product.

20 Inhibitors may be prepared utilizing the sequence information provided herein. For example, this may be performed by overexpressing the peptide, purifying the peptide, and then performing X-ray crystallography on the purified peptide to obtain its molecular structure. Next, compounds are created which have  
25 similar molecular structures to all or portions of the polypeptide or its substrate. The compounds may be then combined with the peptide and attached thereto so as to block one or more of its biological activities.

Also described herein are isolated or recombinant polynucleotides that bind to  
30 the regions of the mycobacterial chromosome containing sequences that are associated with induction/up-regulation under low oxygen tension (ie. virulence), including antisense and triplex-forming polynucleotides. As used herein, the term "binding" refers to an interaction or complexation between an oligonucleotide and a target nucleotide sequence, mediated through hydrogen  
35 bonding or other molecular forces. The term "binding" more specifically refers to two types of internucleotide binding mediated through

base-base hydrogen bonding. The first type of binding is "Watson-Crick-type" binding interactions in which adenine-thymine (or adenine-uracil) and guanine-cytosine base-pairs are formed through hydrogen bonding between the bases. An example of this type of binding is the binding traditionally associated with the DNA double helix and in RNA-DNA hybrids; this type of binding is normally detected by hybridization procedures.

The second type of binding is "triplex binding". In general, triplex binding refers to any type of base-base hydrogen bonding of a third polynucleotide strand with a duplex DNA (or DNA-RNA hybrid) that is already paired in a Watson-Crick manner.

In a preferred embodiment, the inhibitor may be an antisense nucleic acid sequence which is complementary to at least part of the inducible or up-regulatable gene.

The inhibitor, when in the form of a nucleic acid sequence, in use, comprises at least 15 nucleotides, preferably at least 20 nucleotides, more preferably at least 30 nucleotides, and most preferably at least 50 nucleotides.

According to a second aspect of the invention, there is provided an antibody which binds to a peptide selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135 and 137, or a variant thereof having at least 70% amino acid homology therewith, or a derivative thereof, or a fragment thereof having at least 10 amino acid residues, wherein said variant, derivative or fragment has a common antigenic cross-reactivity to said isolated peptide, wherein the peptide is encoded by a gene, the expression of which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C, when used for preventing or treating a mycobacterial infection.

The antibody preferably has specificity for the peptide in question, and following binding thereto may initiate coating of the mycobacterium. Coating of the

bacterium preferably leads to opsonization thereof. This, in turn, leads to the bacterium being destroyed. It is preferred that the antibody is specific for the mycobacterium (eg. species and/or strain) which is to be targeted.

- 5 Opsonization by antibodies may influence cellular entry and spread of mycobacteria in phagocytic and non-phagocytic cells by preventing or modulating receptor-mediated entry and replication in macrophages.

The peptides, fragments, variants or derivatives described herein may be used to produce antibodies, including polyclonal and monoclonal. If polyclonal antibodies are desired, a selected mammal (eg. mouse, rabbit, goat, horse, etc.) is immunized with an immunogenic polypeptide. Serum from the immunized animal is collected and treated according to known procedures. If serum containing polyclonal antibodies to a desired mycobacterial epitope contains antibodies to other antigens, the polyclonal antibodies may be purified by immunoaffinity chromatography.

Alternatively, general methodology for making monoclonal antibodies by hybridomas involving, for example, preparation of immortal antibody-producing cell lines by cell fusion, or other techniques such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus may be employed.

The antibody employed in this aspect of the invention may belong to any antibody isotype family, or may be a derivative or mimic thereof. Reference to antibody throughout this specification embraces recombinantly produced antibody, and any part of an antibody which is capable of binding to a mycobacterial antigen.

In one embodiment the antibody belongs to the IgG, IgM or IgA isotype families.

In a preferred embodiment, the antibody belongs to the IgA isotype family.

Reference to the IgA isotype throughout this specification includes the secretory form of this antibody (ie. sIgA). The secretory component (SC) of sIgA may be added *in vitro* or *in vivo*. In the latter case, the use of a patient's natural SC labelling machinery may be employed.

In one embodiment, the antibody may be raised against a peptide from a member of the MTC, preferably against *M. tuberculosis*.

The antibody is capable of binding to a peptide selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, and 137 (or

fragment, variant, or derivative thereof).

In a further embodiment, the antigen is an exposed component of a mycobacterial bacillus. In another embodiment, the antigen is a cell surface component of a mycobacterial bacillus.

The antibody of the present invention may be polyclonal, but is preferably monoclonal.

Without being bound by any theory, it is possible that following mycobacterial infection of a macrophage, the macrophage is killed and the bacilli are released. It is at this stage that the mycobacteria are considered to be most vulnerable to antibody attack. Thus, it is possible that the antibodies of the present invention act on released bacilli following macrophage death, and thereby exert a post-infection effect.

It is possible that the passive protection aspect (ie. delivery of antibodies) of the present invention is facilitated by enhanced accessibility of the antibodies of the present invention to antigens on mycobacterial bacilli harboured by the infected macrophages. Indeed, *acr* expression is low during logarithmic growth, but increases at the stationary or oxygen limiting stage, and particularly in organisms which replicate within macrophages. As *acr* expression appears to be necessary for mycobacterial infectivity, it is possible that antibody binding may block macrophage infection by steric hindrance or disruption of its oligomeric structure. Thus, antibodies acting on mycobacterial bacilli released from killed, infected macrophages may interfere with the spread of re-infection to fresh macrophages. This hypothesis involves a synergistic action between antibodies and cytotoxic T cells, acting early after infection, eg. ( $\gamma\delta$  and NK T cells, but could later involve also CD8 and CD4 cytotoxic T cells.

According to a third aspect of the invention, there is provided an attenuated *M. tuberculosis* mycobacterium in which a gene has been modified thereby tendering the mycobacterium substantially non-pathogenic, wherein the gene is a gene the expression of which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at



37°C, wherein said gene has a wild-type coding sequence corresponding to one of the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136 and 138, when used for preventing or treating a mycobacterial infection.

The term "modified" refers to any genetic manipulation such as a nucleic acid or nucleic acid sequence replacement, a deletion, or an insertion which renders the mycobacterium substantially non-pathogenic. In one embodiment the entire inducible or up-regulatable gene may be deleted.

The gene to be modified has a wild-type coding sequence corresponding to one of the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136 and 138.

It will be appreciated that the wild-type sequences may include minor variations depending on the Database employed.

According to a fourth aspect of the invention there is provided an attenuated microbial carrier when used for preventing or treating a mycobacterial infection, comprising a peptide selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135 and 137, or a variant thereof having at least 70% amino acid homology therewith, or a derivative thereof, or a fragment thereof having at least 10 amino acid residues, wherein said variant, derivative or fragment has a common antigenic cross-reactivity to said isolated peptide, wherein said peptide is encoded by a gene, the expression of which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C.

In use, the peptide (or fragment, variant or derivative) is either at least partially exposed at the surface of the carrier, or the carrier becomes degraded *in vivo* so that at least part of the peptide (or fragment, variant or derivative) is otherwise exposed to a host's immune system.

In one embodiment, the attenuated microbial carrier is selected from the group consisting of attenuated salmonella, attenuated vaccinia virus, attenuated fowlpox virus, or attenuated *M. bovis* (eg. BCG strain).

The peptide is selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135 and 137 (or fragment, variant, of derivative thereof).

According to a fifth aspect of the invention, there is provided a DNA plasmid comprising a promoter, a polyadenylation signal and a DNA sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136 and 138, or a variant thereof having at least 70% nucleotide sequence identity therewith, or a derivative thereof, or a fragment thereof having at least 15 nucleotides, wherein the peptide encoded by said variant, derivative or fragment has a common antigenic cross-reactivity to the peptide encoded by said DNA sequence, wherein said DNA sequence corresponds to the coding sequence of a gene, the expression of which is induced or up-regulated during culture of a wild-type version of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C, wherein the promoter and polyadenylation signal are operably linked to the DNA sequence, when used for preventing or treating a mycobacterial infection.

The term DNA "fragment" used in this invention will usually comprise at least about 5 codons (15 nucleotides), more usually at least about 7 to 15 codons, and most preferably at least about 35 codons. This number of nucleotides is

usually about the minimal length required for a successful probe that would hybridize specifically with such a sequence.

5 In preferred embodiments, the DNA "fragment" has a nucleotide length which is at least 50%, preferably at least 70%, and more preferably at least 80% that of the coding sequence of the corresponding induced/up-regulated gene.

10 The term DNA "variant" means a DNA sequence which has substantial homology or substantial similarity to the coding sequence (or a fragment thereof) of an induced/up-regulated gene. A nucleic acid or fragment thereof is "substantially homologous" (or "substantially similar") to another if, when optimally aligned (with appropriate nucleotide insertions or deletions) with the other nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 60% of the nucleotide bases, usually at least about  
15 70%, more usually at least about 80%, preferably at least about 90%, and more preferably at least about 95 to 98% of the nucleotide bases. Homology determination is performed as described *supra* for peptides.

-18-

Alternatively, a DNA "variant" is substantially homologous (or substantially similar) with the coding sequence (or a fragment thereof) of an induced/up-regulated gene when they are capable of hybridizing under selective hybridization conditions. Selectivity of hybridization exists when hybridization occurs which is substantially more selective than total lack of specificity. Typically, selective hybridization will occur when there is at least about 65% homology over a stretch of at least about 14 nucleotides, preferably at least about 70%, more preferably at least about 75%, and most preferably at least about 90%. See, Kanehisa (1984) Nuc. Acids Res. 12:203-213. The length of homology comparison, as described, may be over longer stretches, and in certain embodiments will often be over a stretch of at least about 17 nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 32 nucleotides, and preferably at least about 36 or more nucleotides.

Nucleic acid hybridization will be affected by such conditions as salt concentration (eg. NaCl), temperature, or organic solvents, in addition to the base composition, length of the complementary strands, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. Stringent temperature conditions are preferably employed, and generally include temperatures in excess of 30°C, typically in excess of 37°C and preferably in excess of 45°C. Stringent salt conditions will ordinarily be less than 1000 mM, typically less than 500 mM, and preferably less than 200 mM. The pH is typically between 7.0 and 8.3. However, the combination of parameters is much more important than the measure of any single parameter. See, eg., Wetmur and Davidson (1968) J. Mol. Biol. 31:349-370.

The term DNA "derivative" means a DNA polynucleotide which comprises a DNA sequence (or a fragment, or variant thereof) corresponding to the coding sequence of the induced/up-regulated gene and an additional DNA sequence which is not naturally associated with the DNA sequence corresponding to the coding sequence. The comments on peptide derivative *supra* also apply to DNA "derivative". A "derivative" may, for example, include two or more coding sequences of a mycobacterial operon that is induced during oxygen limitation. Thus, depending on the presence or absence of a non-coding region between the coding sequences, the expression product/s of such a "derivative" may be

a fusion protein, or separate peptide products encoded by the individual coding regions.

5 The above terms DNA "fragment", "variant", and "derivative" have in common with each other that the resulting peptide products have cross-reactive antigenic properties which are substantially the same as those of the corresponding wild-type peptide. Preferably all of the peptide products of the above DNA molecule embodiments of the present invention bind to an antibody which also binds to the wild-type peptide. Alternatively, all of the above peptide products are  
10 capable of inducing a "recall response" of a T lymphocyte which has been previously exposed to an antigenic component of a mycobacterial infection.

The promoter and polyadenylation signal are preferably selected so as to ensure that the gene is expressed in a eukaryotic cell. Strong promoters and  
15 polyadenylation signals are preferred.

In a sixth aspect, the present invention provides an isolated RNA sequence which is encoded by a DNA sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38,  
20 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136 and 138, or a variant thereof having at least 70% nucleotide sequence identity therewith, or a derivative thereof, or a fragment thereof having at least 15 nucleotides, wherein the  
25 peptide encoded by said variant, derivative or fragment has a common antigenic cross-reactivity to the peptide encoded by said DNA sequence, wherein the DNA sequence corresponds to the coding sequence of a gene which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to  
30 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C, when used for preventing or treating a mycobacterial infection.

An "isolated" RNA is an RNA which is substantially separated from other  
35 mycobacterial components that naturally accompany the sequences of interest, eg., ribosomes, polymerases, and other mycobacterial polynucleotides such as DNA and other chromosomal sequences.

The above RNA molecule may be introduced directly into a host cell as, for example, a component of a vaccine.

- 5 Alternatively the RNA molecule may be incorporated into an RNA vector prior to administration.

10 In a seventh aspect, the present invention provides an RNA vector when used for preventing or treating a mycobacterial infection, comprising the RNA sequence of the sixth aspect and an integration site for a chromosome of a host cell.

15 The polynucleotide sequences (DNA and RNA) of the present invention include a nucleic acid sequence which has been removed from its naturally occurring environment, and recombinant or cloned DNA isolates and chemically synthesized analogues or analogues biologically synthesized by heterologous systems.

The term "recombinant" as used herein intends a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation: (1) is not associated with all or a portion of a polynucleotide with which it is associated in nature; or (2) is linked to a polynucleotide other than that to which it is linked in nature; and (3) does not occur in nature. This artificial combination is often accomplished by either chemical synthesis means, or by the artificial manipulation of isolated segments of nucleic acids, eg., by genetic engineering techniques. Such is usually done to replace a codon with a redundant codon encoding the same or a conservative amino acid, while typically introducing or removing a sequence recognition site. Alternatively, it is performed to join together nucleic acid segments of desired functions to generate a desired combination of functions.

In embodiments of the invention the polynucleotides may encode a peptide which is induced or up-regulated under low oxygen tension. A nucleic acid is said to "encode" a peptide if, in its native state or when manipulated, it can be transcribed and/or translated to produce the peptide or a fragment or variant or derivative thereof. The anti-sense strand of such a nucleic acid is also said to encode the sequence.

Also contemplated are expression vectors comprising the polynucleotide of interest. Expression vectors generally are replicable polynucleotide constructs that encode a peptide operably linked to suitable transcriptional and translational regulatory elements. Examples of regulatory elements usually included in expression vectors are promoters, enhancers, ribosomal binding sites, and transcription and translation initiation and termination sequences. These regulatory elements are operably linked to the sequence to be translated. A nucleic acid sequence is operably linked when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects its transcription or expression. Generally, operably linked means that the DNA sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame. The regulatory elements employed in the expression vectors containing a polynucleotide encoding a virulence factor are functional in the host cell used for expression.

The polynucleotides described herein may be prepared by any means known in the art. For example, large amounts of the polynucleotides may be produced by replication in a suitable host cell. The natural or synthetic DNA fragments coding for a desired fragment will be incorporated into recombinant nucleic acid

constructs, typically DNA constructs, capable of introduction into and replication in a prokaryotic or eukaryotic cell. Usually the DNA constructs will be suitable for autonomous replication in a unicellular host, such as yeast or bacteria, but may also be intended for introduction to and integration within the genome of a

5 cultured insect, mammalian, plant or other eukaryotic cell lines.

The polynucleotides described herein may also be produced by chemical synthesis, e.g., by the phosphoramidite method or the triester method, and may be performed on commercial automated oligonucleotide synthesizers. A double-

10 stranded fragment may be obtained from the single stranded product of chemical synthesis either by synthesizing the complementary strand and annealing the strand together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.

15 DNA constructs prepared for introduction into a prokaryotic or eukaryotic host will typically comprise a replication system recognized by the host, including the intended DNA fragment encoding the desired peptide, and will preferably also include transcription and translational initiation regulatory sequences operably linked to the polypeptide encoding segment. Expression vectors may include, for example, an origin of replication or autonomously replicating sequence (ARS) and expression control sequences, a promoter, an enhancer and necessary processing information sites, such as ribosome-binding sites, RNA splice sites, polyadenylation sites, transcriptional terminator sequences, and

20 mRNA stabilizing sequences. Secretion signals from polypeptides secreted from the host cell of choice may also be included where appropriate, thus allowing the protein to cross and/or lodge in cell membranes, and thus attain its functional topology or be secreted from the cell.

30 Appropriate promoter and other necessary vector sequences are selected so as to be functional in the host, and may, when appropriate, include those naturally associated with mycobacterial genes. Promoters such as the trp, lac and phage promoters, tRNA promoters and glycolytic enzyme promoters may be used in prokaryotic hosts. Useful yeast promoters include the promoter regions for

35 metallothionein, 3-phosphoglycerate kinase or other glycolytic enzymes such as enolase or glyceraldehyde-3-phosphate dehydrogenase, enzymes responsible for maltose and galactose utilization, and others.

Appropriate non-native mammalian promoters may include the early and late

40 promoters from SV40 or promoters derived from murine moloney leukemia



virus, mouse mammary tumour virus, avian sarcoma viruses, adenovirus II, bovine papilloma virus or polyoma. In addition, the construct may be joined to an amplifiable gene (e.g., DHFR) so that multiple copies of the gene may be made.

5

While such expression vectors may replicate autonomously, they may less preferably replicate by being inserted into the genome of the host cell.

10

Expression and cloning vectors will likely contain a selectable marker, a gene encoding a protein necessary for the survival or growth of a host cell transformed with the vector. The presence of this gene ensures the growth of only those host cells which express the inserts. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxic substances, e.g. ampicillin, neomycin, methotrexate, etc.; (b) complement auxotrophic deficiencies; or (c) supply critical nutrients not available from complex media, e.g. the gene encoding D-alanine racemase for Bacilli. The choice of appropriate selectable marker will depend on the host cell.

15

20

The vectors containing the nucleic acids of interest can be transcribed *in vitro* and the resulting RNA introduced into the host cell (e.g., by injection), or the vectors can be introduced directly into host cells by methods which vary depending on the type of cellular host, including electroporation; transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; infection (where the vector is an infectious agent, such as a retroviral genome). The cells into which have been introduced nucleic acids described above are meant to also include the progeny of such cells.

25

30

Large quantities of the nucleic acids and peptides described herein may be prepared by expressing the nucleic acids or portions thereof in vectors or other expression vehicles in compatible prokaryotic or eukaryotic host cells. The most commonly used prokaryotic hosts are strains of *Escherichia coli*, although other prokaryotes, such as *Bacillus subtilis* or *Pseudomonas* may also be used.

35

Mammalian or other eukaryotic host cells, such as those of yeast, filamentous fungi, plant, insect, amphibian or avian species, may also be useful for production of the proteins described herein. Propagation of mammalian cells in culture is *per se* well known. Examples of commonly used mammalian host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cells, and WI38,

BHK, and COS cell lines, although other cell lines may be appropriate, e.g., to provide higher expression, desirable glycosylation patterns.

- 5 Clones are selected by using markers depending on the mode of the vector construction. The marker may be on the same or a different DNA molecule, preferably the same DNA molecule. The transformant may be screened or, preferably, selected by any of the means well known in the art, e.g., by resistance to such antibiotics as ampicillin, tetracycline.
- 10 The polynucleotides described herein may be inserted into the host cell by any means known in the art, including for example, transformation, transduction, and electroporation. As used herein, "recombinant host cells", "host cells", "cells", "cell lines", "cell cultures", and other such terms denoting microorganisms or higher eukaryotic cell lines cultured as unicellular entities
- 15 refer to cells which can be, or have been, used as recipients for recombinant vector or other transfer DNA, and include the progeny of the original cell which has been transformed. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or
- 20 deliberate mutation. "Transformation", as used herein, refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, for example, direct uptake, transduction, f-mating or electroporation. The exogenous polynucleotide may be maintained as a non-integrated vector, for example, a plasmid, or alternatively, may be integrated
- 25 into the host cell genome.

In one embodiment, a DNA plasmid or RNA vector may encode a component of the immune system which is specific to an immune response following challenge with a peptide, wherein said peptide is encoded by a mycobacterial

30

gene which is induced or up-regulated during oxygen limitation of mycobacterial growth.

5 An example of such a component is an antibody to the peptide product of an induced or up-regulated gene. Thus, in one embodiment, the nucleic acid sequence (eg. DNA plasmid or RNA vector) encodes the antibody in question.

An eighth aspect provides use of an isolated *M. tuberculosis* peptide selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23,  
10 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135 and 137, or a variant thereof having at least 70% amino acid homology therewith, or a derivative thereof, or a fragment thereof having at least 10 amino acid residues,  
15 wherein said variant, derivative or fragment has a common antigenic cross-reactivity to said isolated peptide, wherein the peptide is encoded by a gene the expression of which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C,  
20 an antibody according to the second aspect,  
an attenuated mycobacterium according to the third aspect,  
an attenuated microbial carrier according to the fourth aspect,  
a DNA sequence selected from the group consisting of SEQ ID NO: 2,  
25 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136 and 138, or a variant thereof having at least 70% nucleotide sequence identity therewith, or a derivative thereof, or a  
30 fragment thereof having at least 15 nucleotides, wherein the peptide encoded by said variant, derivative or fragment has a common antigenic cross-reactivity to the peptide encoded by said DNA sequence, wherein said DNA sequence corresponds to the coding sequence of a gene which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by  
35 a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C or a fragment or variant or derivative of said DNA sequence,

a DNA plasmid according to the fifth aspect,  
an RNA sequence according to the sixth aspect, and/or  
an RNA vector according to the seventh aspect,  
in the manufacture of a medicament for treating or preventing a mycobacterial  
5 infection.

The term "preventing" includes reducing the severity/intensity of, or initiation of,  
a mycobacterial infection.

10 The term "treating" includes post-infection therapy and amelioration of a  
mycobacterial infection.

In a ninth aspect, there is provided a method of treating or preventing a  
mycobacterial infection, by administering to a patient an isolated *M. tuberculosis*  
15 peptide selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15,  
17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59,  
61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101,  
103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133,  
135 and 137, or a variant thereof having at least 70% amino acid homology  
20 therewith, or a derivative thereof, or a fragment thereof having at least 10 amino  
acid residues, wherein said variant, derivative or fragment has a common  
antigenic cross-reactivity to said isolated peptide, wherein the peptide is  
encoded by a gene the expression of which is induced or up-regulated during  
culture of *M. tuberculosis* under continuous culture conditions defined by a  
25 dissolved oxygen tension of up to 10% air saturation measured at 37°C when  
compared with a dissolved oxygen tension of at least 40% air saturation  
measured at 37°C,

an antibody according to the second aspect,  
an attenuated mycobacterium according to the third aspect,  
30 an attenuated microbial carrier according to the fourth aspect,  
a DNA sequence selected from the group consisting of SEQ ID NO: 2,  
4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46,  
48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88,  
90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122,  
35 124, 126, 128, 130, 132, 134, 136 and 138, or a variant thereof having at least  
70% nucleotide sequence identity therewith, or a derivative thereof, or a  
fragment thereof having at least 15 nucleotides, wherein the peptide encoded

by said variant, derivative or fragment has a common antigenic cross-reactivity to the peptide encoded by said DNA sequence, wherein said DNA sequence corresponds to the coding sequence of a gene which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by

5 a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C or a fragment or variant or derivative of said DNA sequence,

a DNA plasmid according to the fifth aspect,

an RNA sequence according to the sixth aspect, and/or

10 an RNA vector according to the seventh aspect.

The medicament may be administered by conventional routes, eg. intravenous, intraperitoneal, intranasal routes.

The immunogenicity of the epitopes of the peptides described herein may be enhanced by preparing them in mammalian or yeast systems fused with or assembled with particle-forming proteins such as, for example, that associated with hepatitis B surface antigen. Vaccines may be prepared from one or more immunogenic peptides described herein.

Typically, such vaccines are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified, or the peptide encapsulated in liposomes. The active immunogenic ingredients are often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine. Examples of adjuvants which may be effective include but are not limited to: aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn - glycerol-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835A, referred to as MTP-PE), and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion.

The vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscularly. Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations or formulations suitable for distribution as aerosols. For suppositories, traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1%-2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain

-26-

10%-95% of active ingredient, preferably 25%-70%.

5 The peptides may be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or with organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic  
10 bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

15 The vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be prophylactically and/or therapeutically effective. The quantity to be administered, which is generally in the range of 5 micrograms to 250 micrograms of antigen per dose, depends on the subject to be treated, capacity of the subject's immune system to synthesize antibodies, and the degree of protection desired. Precise amounts of active ingredient required to be administered may depend on the judgment  
20 of the practitioner and may be peculiar to each subject.

The vaccine may be given in a single dose schedule, or preferably in a multiple dose schedule. A multiple dose schedule is one in which a primary course of vaccination may be with 1-10 separate doses, followed by other doses given  
25 at subsequent time intervals required to maintain and or re-enforce the immune response, for example, at 1-4 months for a second dose, and if needed, a subsequent dose(s) after several months. The dosage regimen will also, at least in part, be determined by the need of the individual and be dependent upon the judgment of the practitioner.

30 In addition, the vaccine containing the immunogenic mycobacterial antigen(s) may be administered in conjunction with other immunoregulatory agents, for example, immunoglobulins, as well as antibiotics.

35 The outcome of administering antibody-containing compositions may depend on the efficiency of transmission of antibodies to the site of infection. In the case of a mycobacterial respiratory infection (eg. a *M. tuberculosis* infection),

-27-

this may be facilitated by efficient transmission of antibodies to the lungs.

In one embodiment the medicament may be administered intranasally (i.n.). This mode of delivery corresponds to the route of delivery of a *M. tuberculosis* infection and, in the case of antibody delivery, ensures that antibodies are present at the site of infection to combat the bacterium before it becomes intracellular and also during the period when it spreads between cells.

An intranasal composition may be administered in droplet form having approximate diameters in the range of 100-5000 $\mu$ m, preferably 500-4000 $\mu$ m, more preferably 1000-3000 $\mu$ m. Alternatively, in terms of volume, the droplets would be in the approximate range of 0.001-100 $\mu$ l, preferably 0.1-50 $\mu$ l, more preferably 1.0-25 $\mu$ l.

Intranasal administration may be achieved by way of applying nasal droplets or via a nasal spray.

In the case of nasal droplets, the droplets may typically have a diameter of approximately 1000-3000  $\mu$ m and/or a volume of 1-25  $\mu$ l.

In the case of a nasal spray, the droplets may typically have a diameter of approximately 100-1000  $\mu$ m and/or a volume of 0.001-1  $\mu$ l.

It is possible that, following i.n. delivery of antibodies, their passage to the lungs is facilitated by a reverse flow of mucosal secretions, although mucociliary action in the respiratory tract is thought to take particles within the mucus out of the lungs. The relatively long persistence in the lungs' lavage, fast clearance from the bile and lack of transport to the saliva of some antibodies suggest the role of mucosal site specific mechanisms.

In a different embodiment, the medicament may be delivered in an aerosol formulation. The aerosol formulation may take the form of a powder, suspension or solution.

The size of aerosol particles is one factor relevant to the delivery capability of an aerosol. Thus, smaller particles may travel further down the respiratory airway towards the alveoli than would larger particles. In one embodiment, the



-28-

aerosol particles have a diameter distribution to facilitate delivery along the entire length of the bronchi, bronchioles, and alveoli. Alternatively, the particle size distribution may be selected to target a particular section of the respiratory airway, for example the alveoli.

5

The aerosol particles may be delivered by way of a nebulizer or nasal spray.

In the case of aerosol delivery of the medicament, the particles may have diameters in the approximate range of 0.1-50 $\mu$ m, preferably 1-25 $\mu$ m, more preferably 1-5 $\mu$ m.

10

The aerosol formulation of the medicament of the present invention may optionally contain a propellant and/or surfactant.

By controlling the size of the droplets which are to be administered to a patient to within the defined range of the present invention, it is possible to avoid/minimise inadvertent antigen delivery to the alveoli and thus avoid alveoli-associated pathological problems such as inflammation and fibrotic scarring of the lungs.

20

In. vaccination engages both T and B cell mediated effector mechanisms in nasal and bronchus associated mucosal tissues, which differ from other mucosae-associated lymphoid tissues.

The protective mechanisms invoked by the intranasal route of administration may include: the activation of T lymphocytes with preferential lung homing; upregulation of co-stimulatory molecules, eg. B7.2; and/or activation of macrophages or secretory IgA antibodies.

Intranasal delivery of antigens may facilitate a mucosal antibody response is invoked which is favoured by a shift in the T cell response toward the Th2 phenotype which helps antibody production. A mucosal response is characterised by enhanced IgA production, and a Th2 response is characterised by enhanced IL-4 production.

30

Intranasal delivery of mycobacterial antigens allows targeting of the antigens to submucosal B cells of the respiratory system. These B cells are the major

35

local IgA-producing cells in mammals and intranasal delivery facilitates a rapid increase in IgA production by these cells against the mycobacterial antigens.

5 In one embodiment administration of the medicament comprising a mycobacterial antigen stimulates IgA antibody production, and the IgA antibody binds to the mycobacterial antigen. In another embodiment, a mucosal and/or Th2 immune response is stimulated.

10 In another embodiment monoclonal antibodies, in particular, may be used to raise anti-idiotypic antibodies. Anti-idiotypic antibodies are immunoglobulins which carry an "internal image" of the antigen of the infectious agent against which protection is desired. These anti-idiotypic antibodies may also be useful for treatment, vaccination and/or diagnosis of mycobacterial infections.

15 In a tenth aspect, the invention provides use of an isolated *M. tuberculosis* peptide selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 20 135 and 137, or a variant thereof having at least 70% amino acid homology therewith, or a derivative thereof, or a fragment thereof having at least 10 amino acid residues, wherein said variant, derivative or fragment has a common antigenic cross-reactivity to said isolated peptide, wherein the peptide is encoded by a gene the expression of which is induced or up-regulated during 25 culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C,

an antibody according to the second aspect, 30 or a polynucleotide probe comprising at least 8 nucleotides wherein said probe binds to at least part of a gene which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation 35 measured at 37°C, in the manufacture of a diagnostic reagent for identifying a mycobacterial infection.

The peptides described herein and antibodies to them are useful in immunoassays to detect the presence of antibodies to mycobacteria, or the presence of the virulence associated antigens in biological samples. Design of  
5 the immunoassays is subject to a great deal of variation, and many formats are known in the art. The immunoassay may utilize at least one epitope derived from a peptide described herein. In one embodiment, the immunoassay uses a combination of such epitopes. These epitopes may be derived from the same or from different bacterial peptides, and may be in separate recombinant or natural  
10 peptides, or together in the same recombinant peptides.

An immunoassay may use, for example, a monoclonal antibody directed towards a virulence associated peptide epitope(s), a combination of monoclonal antibodies directed towards epitopes of one mycobacterial antigen, monoclonal  
15 antibodies directed towards epitopes of different mycobacterial antigens, polyclonal antibodies directed towards the same antigen, or polyclonal antibodies directed towards different antigens. Protocols may be based, for example, upon competition, or direct reaction, or sandwich type assays. Protocols may also, for example, use solid supports, or may be by  
20 immunoprecipitation. Most assays involve the use of labelled antibody or polypeptide; the labels may be, for example, enzymatic, fluorescent, chemiluminescent, radioactive, or dye molecules. Assays which amplify the signals from the probe are also known; examples of which are assays which

25

-30-

utilize biotin and avidin, and enzyme-labelled and mediated immunoassays, such as ELISA assays.

Typically, an immunoassay for an antibody(s) to a peptide, will involve selecting and preparing the test sample suspected of containing the antibodies, such as a biological sample, then incubating it with an antigenic (i.e., epitope-containing) peptide(s) under conditions that allow antigen-antibody complexes to form, and then detecting the formation of such complexes. The immunoassay may be of a standard or competitive type.

The peptide is typically bound to a solid support to facilitate separation of the sample from the peptide after incubation. Examples of solid supports that can be used are nitrocellulose (e.g., in membrane or microtiter well form), polyvinyl chloride (e.g., in sheets or microtiter wells), polystyrene latex (e.g., in beads or microtiter plates, polyvinylidene fluoride (known as Immulon), diazotized paper, nylon membranes, activated beads, and Protein A beads. For example, Dynatech Immulon microtiter plates or 60 mm diameter polystyrene beads (Precision Plastic Ball) may be used. The solid support containing the antigenic peptide is typically washed after separating it from the test sample, and prior to detection of bound antibodies.

Complexes formed comprising antibody (or, in the case of competitive assays, the amount of competing antibody) are detected by any of a number of known techniques, depending on the format. For example, unlabelled antibodies in the complex may be detected using a conjugate of antixenogeneic Ig complexed with a label, (e.g., an enzyme label).

In immunoassays where the peptides are the analyte, the test sample, typically a biological sample, is incubated with antibodies directed against the peptide under conditions that allow the formation of antigen-antibody complexes. It may be desirable to treat the biological sample to release putative bacterial components prior to testing. Various formats can be employed. For example, a "sandwich assay" may be employed, where antibody bound to a solid support is incubated with the test sample; washed; incubated with a second, labelled antibody to the analyte, and the support is washed again. Analyte is detected by determining if the second antibody is bound to the support. In a competitive format, a test sample is usually incubated with antibody and a labelled,

competing antigen is also incubated, either sequentially or simultaneously. Also, described herein is an immunoassay kit comprised of one or more peptides described herein, or one or more antibodies to said peptides, and a buffer, packaged in suitable containers.

5

10

As used herein, a "biological sample" refers to a sample of tissue or fluid isolated from an individual, including but not limited to, for example, plasma, serum, spinal fluid, lymph fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, blood cells, tumours, organs, and also samples of in vitro cell culture constituents (including but not limited to conditioned medium resulting from the growth of cells in cell culture medium, putatively virally infected cells, recombinant cells, and cell components).

15

In a related diagnostic assay, described herein are nucleic acid probes for detecting a mycobacterial infection.

20

25

Using the polynucleotides described herein as a basis, oligomers of approximately 8 nucleotides or more can be prepared, either by excision from recombinant polynucleotides or synthetically, which hybridize with the mycobacterial sequences, and are useful in identification of mycobacteria. The probes are a length which allows the detection of the induced or up-regulated sequences by hybridization. While 6-8 nucleotides may be a workable length, sequences of 10-12 nucleotides are preferred, and at least about 20 nucleotides appears optimal. These probes can be prepared using routine methods, including automated oligonucleotide synthetic methods. For use as probes, complete complementarity is desirable, though it may be unnecessary as the length of the fragment is increased.

30

35

For use of such probes as diagnostics, the biological sample to be analyzed, such as blood or serum, may be treated, if desired, to extract the nucleic acids contained therein. The resulting nucleic acid from the sample may be subjected to gel electrophoresis or other size separation techniques; alternatively, the nucleic acid sample may be dot blotted without size separation. The probes are usually labeled. Suitable labels, and methods for labeling probes are known in the art, and include, for example, radioactive labels incorporated by nick translation or kinasing, biotin, fluorescent probes, and chemiluminescent

probes. The nucleic acids extracted from the sample are then treated with the labeled probe under hybridization conditions of suitable stringencies.

5 The probes may be made completely complementary to the virulence encoding polynucleotide. Therefore, usually high stringency conditions are desirable in order to prevent false positives. The stringency of hybridization is determined by a number of factors during hybridization and during the washing procedure, including temperature, ionic strength, length of time, and concentration of formamide.

10 It may be desirable to use amplification techniques in hybridization assays. Such techniques are known in the art and include, for example, the polymerase chain reaction (PCR) technique.

15 The probes may be packaged into diagnostic kits. Diagnostic kits include the probe DNA, which may be labeled; alternatively, the probe DNA may be unlabeled and the ingredients for labeling may be included in the kit in separate containers. The kit may also contain other suitably packaged reagents and materials needed for the particular hybridization protocol, for example, standards, as well as instructions for conducting the test.

20 A peptide (or fragment or variant or derivative) as described herein may be used in a diagnostic assay to detect the presence of a T-lymphocyte which T lymphocyte has been previously exposed to an antigenic component of a mycobacterial infection in a patient.

25 In more detail, a T-lymphocyte which has been previously exposed to a particular antigen will be activated on subsequent challenge by the same antigen. This activation provides a means for identifying a positive diagnosis of mycobacterial infection. In contrast, the same activation is not achieved by a  
30 T-lymphocyte which has not been previously exposed to the particular antigen.

The above "activation" of a T-lymphocyte is sometimes referred to as a "recall response" and may be measured, for example, by determining the release of interferon (eg. IFN- $\gamma$ ) from the activated T-lymphocyte. Thus, the presence of  
35 a mycobacterial infection in a patient may be determined by the release of a minimum concentration of interferon from a T-lymphocyte after a defined time period following *in vitro* challenge of the T-lymphocyte with a peptide (or

Fragment or variant or derivative) described herein.

5 In use, a biological sample containing T-lymphocytes is taken from a patient,  
and then challenged with a peptide (or fragment, variant, or derivative thereof)  
described herein.

10 The above T-lymphocyte diagnostic assay may include an antigen presenting  
cell (APC) expressing at least one major histocompatibility complex (MHC) class  
II molecule expressed by the patient in question. The APC may be inherently  
provided in the biological sample, or may be added exogenously. In one  
embodiment, the T-lymphocyte is a CD4 T-lymphocyte.

-34-

**Example 1 - continuous culture of mycobacteria****Materials and Methods****5 Strain**

Studies were performed with *M. tuberculosis* strain H37Rv (NCTC cat. no. 7416) - a representative strain of *M. tuberculosis*. Stock cultures were grown on Middlebrook 7H10 + OADC for 3 weeks at  $37 \pm 2^\circ\text{C}$  harvested and stored at  $-70^\circ\text{C}$  as a dense suspension in deionised water.

**Culture Medium**

A chemically defined culture medium was developed, and was designated CAMR Mycobacterial Medium (see WO00/52139). The medium was prepared with high quality water from a Millepore water purification system and filter sterilised by passage through a  $0.07 \mu\text{m}$  pore size cellulose acetate membrane filter capsule (Sartorius Ltd). Middlebrook 7H10 + OADC agar was used to prepare inoculum cultures, enumerate the number of culturable bacteria in chemostat samples, and to assess culture purity.

**Culture apparatus**

Culture experiments were performed in a one litre glass vessel operated at a working volume of 500 ml. The culture was agitated by a magnetic bar placed in the culture vessel coupled to a magnetic stirrer positioned beneath the vessel. Culture conditions were continuously monitored and controlled by an Anglicon Microlab Fermentation System (Brighton Systems, Newhaven), linked to sensor probes inserted into the culture through sealed ports in the top plate. The oxygen concentration was monitored with a galvanic oxygen electrode (Uniprobe, Cardiff) and was controlled through feedback control of the agitation rate. Temperature was monitored by an Anglicon temperature probe, and maintained by a heating pad positioned beneath the culture vessel. Culture pH was measured using an Ingold pH electrode (Mettler-Toledo, Leicester) and controlled by automatic addition of either sodium hydroxide (0.5 M) or sulphuric acid (0.5 M). For continuous culture, the culture system was operated by controlling nutrient addition from the medium reservoir and a constant culture



-35-

volume was maintained by an overflow tube fitted to the side of the vessel.

### Inoculation and culture

5 The vessel was filled with 350 ml of sterile culture medium and parameters were allowed to stabilise at  $37^{\circ}\text{C} \pm 2^{\circ}\text{C}$ ,  $\text{pH } 6.9 \pm 0.2$  and a dissolved oxygen tension of approximately 70% air saturation. A dense inoculum suspension was prepared by resuspending Middlebrook agar cultures, grown at  $37 \pm 2^{\circ}\text{C}$  for 3 weeks, in sterile deionised water. The inoculum was aseptically  
10 transferred to the culture vessel, to provide an initial culture turbidity of approximately 0.25 at 540 nm. After inoculation the culture was allowed to establish for approximately 50 h. As the culture entered exponential growth, a further 100 ml medium was added and batch growth was monitored by optical density and viable count determination.

15 For continuous culture, the culture was inoculated and allowed to establish for approximately 50 h as detailed. The culture was then operated in fed batch mode for 48 h with medium addition (approx. 100 ml) as the culture entered exponential growth and 24 h later. Continuous culture was then initiated at a  
20 dilution rate of  $0.03 \text{ h}^{-1}$  [equivalent to a mean generation time (MGT) of 24 h]. Culture parameters were maintained at a dissolved oxygen tension (DOT) of 50 % (v/v) air saturation at  $37 \pm 2^{\circ}\text{C}$  and  $\text{pH } 6.9 \pm 0.2$  for "high" dissolved oxygen culture conditions, and a DOT of 1 % (v/v) air saturation at  $37 \pm 2^{\circ}\text{C}$  and  $\text{pH } 6.9 \pm 0.2$  for "low" dissolved oxygen culture conditions. Growth was  
25 monitored by optical density, dry weight and viable count determination.

### Continuous culture

30 Steady-state growth, at a MGT of 24 h, was normally reached 10 days after initiation of continuous culture. Cultures were dense suspensions containing approximately  $5 \times 10^8 \text{ cfu ml}^{-1}$  and a biomass yield of approximately  $1.2 \text{ g l}^{-1}$  cell dry weight. Cells were short rods 2 to 3  $\mu\text{m}$  long with occasional clumps of up to 20 cells. Glycerol, the principal carbon source was not depleted during steady state growth, with a residual concentration of  $1.25 \text{ g l}^{-1}$ . Tween<sup>®</sup> 80 was  
35 present in an amount of 0.1 % and enabled the growth of *M. tuberculosis* in a homogeneous suspension made up substantially of single cells at a growth rate conducive to chemostat culture. Cultures grown in the absence of Tween<sup>®</sup> 80

-36-

formed large clumps and surface pellicles and continuous culture was not possible.

#### Example 2 - virulence data

5

Cultures grown at a DOT of 50 % were virulent in the guinea pig model of infection as determined by their ability to establish infection after aerosol delivery, proliferate in the lung, disseminate to the spleen and cause histopathology indicative of primary pulmonary tuberculosis.

10

A new virulence assay has developed to assess and compare the virulence of culture samples based on their ability to cause a disseminated infection. The assay determined the dose required in the lung at day 0 in order to produce a disseminated infection with  $3.0 \log_{10}$  cfu in the spleen at day 16. This value

15

was termed the infectivity index.

Using this assay, the infectivity of cells grown in aerobic chemostat culture was comparable to that of cells grown on standard Middlebrook agar. This supports our previous finding that cells grown in our culture system are virulent and there is no loss in virulence associated with growth in our culture system (see Table 1).

20

The infectivity index for cells grown at low oxygen tension (1% DOT) was significantly lower than that for aerobic cells indicating that growth at low oxygen tension enhances the virulence of *M. tuberculosis* i.e. a significantly lower dose is required in order to produce a comparable infection.

25

**Table 1**

30

| <u>Sample</u>                  | <u>Infectivity Index*</u> |
|--------------------------------|---------------------------|
| Plate                          | 2.0                       |
| Aerobic chemostat (50 % DOT)   | 2.1, 2.2                  |
| Low oxygen chemostat (1 % DOT) | 1.4, 1.5                  |

35

\* Values are the dose  $\log_{10}$  required in the lung at day 0 in order to produce a disseminated infection with  $3.0 \log_{10}$  in the spleen at day 16.

-37-

**Example 3 - RNA extraction from *M. tuberculosis* for microarray analysis****Materials and Methods**

- 5 Trizol (Life Technologies)- formulation of phenol and guanidine thiocyanate.

GTC lysis solution containing: 5M guanidine thiocyanate, 0.5% N-lauryl sarcosine, 25mM tri-sodium citrate, 0.1M 2-mercaptoethanol, and 0.5% Tween 80.

10

Chloroform  
Isopropanol  
3M sodium acetate  
70% Ethanol

15

microfuge  
ribolyser

Sterile plasticware-Falcon tubes, screw capped eppendorfs, gilson tips –all RNase free

20

Glassware – baked at 160 °C for at least 16 hours

**Method**

- 25 Steps performed at Containment level 3; within a Class III microbiological safety cabinet.

Remove 10 or 20 ml of culture ( $10^9$ /ml) and immediately add this to 4 volumes of GTC lysis buffer in a plastic specimen pot. Seal the pot tightly.

30

Incubate the cells in GTC lysis buffer for 1 hour at room temperature. Surface decontaminate the plastic pot with 5% Hycolin for 5 minutes. Transfer the sample to the pass box and place it into a plastic carry tin with a sealable lid. Close the container securely and transport it to a non-toxic cabinet CL3 cabinet.

35

Equally distribute the lysis mixture between Falcon tubes. Place these tubes into centrifuge buckets and seal the buckets tightly. Surface-decontaminate the

-38-

buckets for 5 minutes with 5% Hycolin. Then transfer them to the centrifuge (Baird and Tatlock Mark IV refrigerated bench-top centrifuge). Spin the tubes at 3,000 rpm for 30 minutes.

- 5 Return the unopened buckets to the cabinet. Remove the centrifuge tubes and pour the supernatant into a waste bottle for GTC lysis buffer.

- 10 Resuspend each pellet in 1 ml of Trizol (formulation of phenol and GTC cat no. 15596-026). The manufacturers guidelines recommend lysing cells by repetitive pipetting. Although this action alone will not lyse *M. tuberculosis*, it is important to completely resuspend the pellet in Trizol.

Transfer 1 ml of cells into a FastRNA tube and ribolyse it at power setting 6.5 for 45 seconds.

15

Leave the tube to incubate at room temperature for 5 minutes.

Remove the aqueous layer from the tube and add this to 200  $\mu$ l of chloroform in a screw-capped eppendorf tube. Shake each tube vigorously for about 15 seconds.

20

Incubate for 2-3 minutes at room temperature.

Spin the tube at 13,000 rpm for 15 minutes. Following centrifugation, the liquid separates into red phenol/chloroform phase, an interface, and a clear aqueous phase.

25

Carefully remove the aqueous phase and transfer it to a fresh eppendorf tube containing 500  $\mu$ l of chloroform/isoamyl alcohol (24:1). Spin the tubes at 13,000 rpm for 15 minutes.

30

Transfer the aqueous phase to an eppendorf tube containing 50  $\mu$ l of sodium acetate and 500  $\mu$ l of isopropanol.

Surface decontaminate the eppendorf tube with 5% Hycolin for 5 minutes. Remove the tube from the CL3 laboratory and continue with the procedure in laboratory 157.

35

Steps performed at Containment level 2:

-39-

Precipitate the RNA at -70 °C for at least 30 minutes-can do this step overnight.

Spin the precipitated RNA down at 13,000 rpm for 10 minutes. Remove the supernatant and wash the pellet in 70% ethanol. Repeat centrifugation.

5

Remove the 70% ethanol and air-dry the pellet. Dissolve the pellet in RNase free water.

Freeze the RNA at -70 °C to store it.

10

#### Example 4 - cDNA labelling, hybridisation, and analysis

##### Preparation of the arrays

15 PCR-amplified products are generated from *M. tuberculosis* genomic DNA using ORF-specific primers. Each gene of the genome is represented. These are spotted in a grid onto a standard glass microscope slide using a BioRobotics microgrid robot (MWG Biotech) at a resolution of >4000 spots/cm<sup>2</sup>.

20 Fluorescently-labelled cDNA is transcribed from RNA which has been isolated from bacteria grown under different environmental conditions. The cDNA is labelled by incorporation of either Cy3 or Cy5 labelled dCTP (Dyes are supplied by Amersham Pharmacia Biotech). Dual fluorescence is used, allowing simultaneous detection of two cDNA samples. The output of the arrays is read using a confocal laser scanner  
25 (Affymetrix 428 scanner from MWG Biotech). More detailed information can be found web site [www.sghms.ac.uk/depts/medmicro/bugs](http://www.sghms.ac.uk/depts/medmicro/bugs); Mujumdar, R.B. (1993) Bioconjugate Chemistry, 4(2), pp.105-111; Yu, H. (1994) Nucl. Acids Res. 22, pp.3226-3232; and Zhu, Z. (1994) Nucl. Acids Res. 22, pp. 3418-3422.

#### 30 Labelling and hybridisation of the cDNA

##### 1. Cy3/Cy5 label cDNA

Prepare one Cy3 and one Cy5 labelled cDNA sample per microarray slide.

35

|              |                              |        |
|--------------|------------------------------|--------|
| Each sample: | RNA.....                     | 2-10µg |
|              | Random primers (3µg/µl)..... | 2µl    |

-40-

H<sub>2</sub>O.....to 11µl

Heat at 95°C for 5min, snap cool on ice and briefly centrifuge.

5        Add to each:        5xFirst Strand Buffer.....5µl  
                                  DTT (100mM).....2.5µl  
                                  dNTPs (5mM dA/G/TTP, 2mM dCTP).....2.3µl  
                                  Cy3 OR Cy5 dCTP.....1.7µl  
                                  SuperScript II (200U/µl).....2.5µl

10

Incubate at 25°C for 10min followed by 42°C for 90min.

2. Prehybridise slide

15        Mix the prehybridisation solution in a coplin jar and incubate at 60° during the labelling reaction to equilibrate.

20        Prehybridisation:    20xSSC.....8.75ml (3.5xSSC)  
                                  20% SDS.....250µl (0.1% SDS)  
                                  BSA (100mg/ml).....5ml (10mg/ml)  
                                  H<sub>2</sub>O.....to 50ml

25        Incubate the microarray slide in the pre-heated prehybridisation solution at 60°C for 20min. Rinse slide in H<sub>2</sub>O for 1min followed by rinse in propan-2-ol for 1min and centrifuge slide in 50ml centrifuge tube at 1500rpm for 5min to dry. Store slide until hybridisation.

3. Purify Cy3/Cy5 labelled cDNA

30        Combine the Cy3 and Cy5 labelled cDNA samples together in a single tube.

      Add:            3M sodium acetate pH4.8.....5µl (0.1 volume)  
                          Propan-2-ol.....40µl (0.8 volume)

35        Wrap the tube in foil and incubate at room temperature for 30min. Centrifuge at 13000rpm for 20min and remove supernatant. Rinse pellet with 100µl 70% ethanol and centrifuge at 13000rpm for 5min. Remove the

-41-

supernatant and air dry the pellet for 10min. Resuspend the pellet in 10.5µl H<sub>2</sub>O.

5 4. Hybridise slide with Cy3/Cy5 labelled cDNA

Place the prehybridised microarray slide in the hybridisation cassette and add two 15µl aliquots of H<sub>2</sub>O to the wells in the cassette. Mix resuspended Cy3/Cy5 labelled cDNA sample with hybridisation solution.

Hybridisation: Cy3/Cy5 labelled cDNA sample.....10.5µl  
20xSSC .....3.2µl (4xSSC)  
2% SDS.....2.3µl (0.3% SDS)

15 Heat hybridisation solution at 95°C for 2min. Do NOT snap cool on ice but allow to cool slightly and briefly centrifuge. Pipette the hybridisation solution onto the slide at the edge of the arrayed area avoiding bubble formation. Using forceps carefully drag the edge of a cover slip along the surface of the slide towards the arrayed area and into the hybridisation solution at the edge of the array. Carefully lower the cover slip down over the array avoiding any additional movement once in place. Seal the hybridisation cassette and submerge in a water bath at 60 °C for 16-20h.

5. Wash slide

Remove microarray slide from hybridisation cassette and initially wash slide carefully in staining trough of Wash A to remove cover slip. Once cover slip is displaced place slide(s) in slide rack and continue agitating in Wash A for a further 2min.

|         |                       |          |             |
|---------|-----------------------|----------|-------------|
| Wash A: | 20xSSC.....           | 20ml     | (1xSSC)     |
|         | 20% SDS.....          | 1ml      | (0.05% SDS) |
|         | H <sub>2</sub> O..... | to 400ml |             |

35      Transfer slide(s) to a clean slide rack and agitate in first trough of Wash B for 2min. Wash in second trough of Wash B with agitation for 2min.

-42-

Wash B (x2):      20xSSC.....1.2ml    (0.06xSSC)  
                          H<sub>2</sub>O.....to 400ml

5                    Place slide into a 50ml centrifuge tube and centrifuge at 1500rpm for 5mins to dry slide.

6.    Scan slide

10                   Scan slide using a ScanArray 3000 dual-laser confocal scanner and analyse data.

**Reagents**

Random primers (3µl/µl) [Life Technol., Cat# 48190-011]  
 15    dNTPs (5mM dATP, dGTP, dTTP, & 2mM dCTP) [Life Technol., Cat# 10297-018]  
       Cy3 dCTP Fluorolink [Amersham Pharmacia Biotech, Cat# PA53021]  
       Cy5 dCTP Fluorolink [Amersham Pharmacia Biotech, Cat# PA55021]  
       SuperScript II Reverse Transcriptase (200U/µl) [Life Technol., Cat# 18064-014]  
       5xFirst Strand Buffer [Life Technol., supplied with Cat# 18064-014]  
 20    Dithiothreitol (DTT) (100mM) [Life Technol., supplied with Cat# 18064-014]  
       Bovine serum albumin (BSA) Fraction V 96-99% (100mg/ml) [Sigma, Cat# A9418]

General:      20xSSC  
 25                   20% SDS  
                   3M sodium acetate pH4.8  
                   Propan-2-ol  
                   70% ethanol  
                   2% SDS

30

**Equipment**

Microarray hybridisation cassette [Telechem International (ArrayIt.com), Cat# AHC-1]  
 35    Coplin staining jar [Fisher Scientific, Cat# MNK-820-H]  
       3x slide staining troughs (Fisher Scientific, Cat# MNK-836-K)  
       2x slide staining racks [Fisher Scientific, Cat# MNK-841-K]



-43-

Glass cover slips 22x22mm [BDH, Cat# 406/0187/33].

### Scanning and Analysis

- 5 The slides were scanned using an Affymetrix 428 scanner. The raw data were initially analysed in software known as ImaGene, which was supplied with the scanner. The scanned images were then transferred to another software package known as GeneSpring. This is a very powerful tool, which draws information from many databases allowing the complete analysis of the expression of each gene.

10

### Results

- 15 Total RNA was extracted from steady state chemostat culture according to the protocol described above. RNA microarray hybridisation was performed in duplicate to compare RNA extracted from *M. tuberculosis* grown in aerobic (50% DOT) and low oxygen environments (1% DOT).

- 20 The two expression profiles were analysed and compared. Genes that appeared to be up regulated at least 1.5-fold under low oxygen conditions were selected for identification.

Nucleic acid sequences are given from the transcription start site to the stop codon.

**Example 5 - Delete one or more of the genes from *M. tuberculosis* in order to attenuate its virulence while retaining immunogenicity**

- 5 One or more genes that are identified may be disrupted using allelic exchange. In brief, the gene of interest is cloned with 1-2kb of flanking DNA either side and is inactivated by deletion of part of the coding region and insertion of an antibiotic resistance marker, such as hygromycin.
- 10 The manipulated fragment is then transferred to a suitable suicide vector e.g. pPR23 and is transformed into the wild-type parent strain of *M. tuberculosis*. Mutants are recovered by selecting for antibiotic resistant strains. Genotypic analysis (Southern Blotting with a fragment specific to the gene of interest) is performed on the selected strains to confirm that the gene has been disrupted.
- 15 The mutant strain is then studied to determine the effect of the gene disruption on the phenotype. In order to use it as a vaccine candidate it would be necessary to demonstrate attenuated virulence. This can be done using either a guinea pig or mouse model of infection. Animals are infected with the mutant strain and the progression of disease is monitored by determining the bacterial load in different organs, in particular the lung and spleen, at specific time points post infection, typically up to 16 weeks.
- 20 Comparison is made to animals infected with the wild-type strain which should have a significantly higher bacterial load in the different organs. Long-term survival studies and histopathology can also be used to assess virulence and pathogenicity.
- 25 Once attenuated virulence has been established, protection and immunogenicity studies can be performed to assess the potential of the strain as a vaccine. Suitable references for allelic exchange and preparation of TB mutants are McKinney et al., 2000 and Pelicic et al., 1997, [1, 2].
- 30

- Example 6 - Select one or more of our genes, which encode proteins that are immunogenic, and put them into BCG or an attenuated strain of *M. tuberculosis* to enhance its overall immunogenicity**
- 35

The gene of interest is amplified from the *M. tuberculosis* genome by PCR. The

-45-

amplified product is purified and cloned into a plasmid (pMV306) that integrates site specifically into the mycobacterial genome at the attachment site (attB) for mycobacteriophage L5 [3].

- 5 BCG is transformed with the plasmid by electroporation, which involves damaging the cell envelope with high voltage electrical pulses, resulting in uptake of the DNA. The plasmid integrates into the BCG chromosome at the attB site generating stable recombinants. Recombinants are selected and are checked by PCR or Southern blotting to ensure that the gene has been integrated. The recombinant  
10 strain is then used for protection studies.

**Example 7 - Use recombinant carriers such as attenuated salmonella and the Vaccinia virus to express and present TB genes.**

- 15 One of the best examples of this type of approach is the use of Modified Vaccinia virus Ankara (MVA) [4]. The gene of interest is cloned into a vaccinia virus shuttle vector, e.g. pSC11. Baby Hamster Kidney (BHK) cells are then infected with wild-type MVA and are transfected with the recombinant shuttle vector. Recombinant virus is then selected using a suitable selection marker and viral  
20 plaques, selected and purified.

- Recombinant virus is normally delivered as part of a prime-boost regime where animals are vaccinated initially with a DNA vaccine encoding the TB genes of interest under the control of a constitutive promoter. The immune response is  
25 boosted by administering recombinant MVA carrying the genes of interest to the animals at least 2 weeks later.

**Example 8 - Sub-unit vaccines containing a single peptide/protein or a combination of proteins**

- 30 To prepare sub-unit vaccines with one or more peptides or proteins it is first of all necessary to obtain a supply of protein or peptide to prepare the vaccine. Up to now, this has mainly been achieved in mycobacterial studies by purifying proteins of interest from TB culture. However, it is becoming more common to clone the  
35 gene of interest and produce a recombinant protein.

The coding sequence for the gene of interest is amplified by PCR with restriction

-46-

sites inserted at the N terminus and C terminus to permit cloning in-frame into a protein expression vector such as pET-15b. The gene is inserted behind an inducible promoter such as lacZ. The vector is then transformed into *E. coli* which is grown in culture. The recombinant protein is over-expressed and is purified.

5

One of the common purification methods is to produce a recombinant protein with an N-terminal His-tag. The protein can then be purified on the basis of the affinity of the His-tag for metal ions on a Ni-NTA column after which the His-tag is cleaved. The purified protein is then administered to animals in a suitable adjuvant [5].

10

#### **Example 9 - Plasmid DNA vaccines carrying one or more of the identified genes**

DNA encoding a specific gene is amplified by PCR, purified and inserted into specialised vectors developed for vaccine development, such as pVAX1. These vectors contain promoter sequences, which direct strong expression of the introduced DNA (encoding candidate antigens) in eukaryotic cells (e.g. CMV or SV40 promoters), and polyadenylation signals (e.g. SV40 or bovine growth hormone) to stabilise the mRNA transcript.

20

The vector is transformed into *E. coli* and transformants are selected using a marker, such as kanamycin resistance, encoded by the plasmid. The plasmid is then recovered from transformed colonies and is sequenced to check that the gene of interest is present and encoded properly without PCR generated mutations.

25

Large quantities of the plasmid is then produced in *E. coli* and the plasmid is recovered and purified using commercially available kits (e.g. Qiagen Endofree-plasmid preparation). The vaccine is then administered to animals for example by intramuscular injection in the presence or absence of an adjuvant.

30

#### **Example 10 - Preparation of DNA expression vectors**

DNA vaccines consist of a nucleic acid sequence of the present invention cloned into a bacterial plasmid. The plasmid vector pVAX1 is commonly used in the preparation of DNA vaccines. The vector is designed to facilitate high copy number replication in *E. coli* and high level transient expression of the peptide of interest in most mammalian cells (for details see manufacturers protocol for pVAX1(

35

-47-

catalog no. V260-20 [www.invitrogen.com](http://www.invitrogen.com)) .

The vector contains the following elements

- 5     \* Human cytomegalovirus immediate-early (CMV) promoter for high-level expression in a variety of mammalian cells
- \* T7 promoter/priming site to allow *in vitro* transcription in the sense orientation and sequencing through the insert
- \* Bovine growth hormone (BGH) polyadenylation signal for efficient transcription
- 10    termination and polyadenylation of mRNA
- \* Kanamycin resistance gene for selection in *E. coli*
- \* A multiple cloning site
- \* pUC origin for high-copy number replication and growth in *E. coli*
- \* BGH reverse priming site to permit sequencing through the insert

15

Vectors may be prepared by means of standard recombinant techniques which are known in the art, for example Sambrook *et al.*, (1989). Key stages in preparing the vaccine are as follows:

- 20    \* The gene of interest is ligated into pVAX1 via one of the multiple cloning sites
- \* The ligation mixture is then transformed into a competent *E. coli* strain (e.g. TOP10) and LB plates containing 50µg/ml kanamycin are used to select transformants.
- \* Clones are selected and may be sequenced to confirm the presence and
- 25    orientation of the gene of interest.
- \* Once the presence of the gene has been verified, the vector can be used to transfect a mammalian cell line to check for protein expression. Methods for transfection are known in the art and include, for example, electroporation, calcium phosphate, and lipofection.
- 30    \* Once peptide expression has been confirmed, large quantities of the vector can be produced and purified from the appropriate cell host, e.g. *E. coli*.

pVAX1 does not integrate into the host chromosome. All non-essential sequences have been removed to minimise the possibility of integration. When constructing

35    a specific vector, a leader sequence may be included to direct secretion of the encoded protein when expressed inside the eukaryotic cell.

-48-

Other examples of vectors that have been used are V1Jns.tPA and pCMV4 (Lefevre *et al.*, 2000 and Vordermeier *et al.*, 2000).

5 Expression vectors may be used that integrate into the genome of the host, however, it is more common and more preferable to use a vector that does not integrate. The example provided, pVAX1, does not integrate. Integration would lead to the generation of a genetically modified host which raises other issues.

#### 10 **Example 11 - RNA vaccine**

As discussed on page 15 of US patent US5,783,386, one approach is to introduce RNA directly into the host.

15 Thus, the vector construct (Example 10) may be used to generate RNA *in vitro* and the purified RNA then injected into the host. The RNA would then serve as a template for translation in the host cell. Integration would not occur.

20 Another option is to use an infectious agent such as the retroviral genome carrying RNA corresponding to the gene of interest. Here you will get integration into the host genome

25 Another option is the use of RNA replicon vaccines which can be derived from virus vectors such as Sindbis virus or Semliki Forest virus. These vaccines are self-replicating and self-limiting and may be administered as either RNA or DNA which is then transcribed into RNA replicons *in vivo*. The vector eventually causes lysis of the transfected cells thereby reducing concerns about integration into the host genome. Protocols for RNA vaccine construction are detailed in Cheng *et al.*, (2001).

#### 30 **Example 12 - Diagnostic assays based on assessing T cell responses**

35 For a diagnostic assay based on assessing T cell responses it would be sufficient to obtain a sample of blood from the patient. Mononuclear cells (monocytes, T and B lymphocytes) can be separated from the blood using density gradients such as Ficoll gradients.

Both monocytes and B-lymphocytes are both able to present antigen, although less

-49-

efficiently than professional antigen presenting cells (APCs) such as dendritic cells. The latter are more localised in lymphoid tissue.

5 The simplest approach would be to add antigen to the separated mononuclear cells and incubate for a week and then assess the amount of proliferation. If the individual had been exposed to the antigen previously through infection, then T-cell clones specific to the antigen should be more prevalent in the sample and should respond.

10 It is also possible to separate the different cellular populations should it be desired to control the ratio of T cells to APC's.

Another variation of this type of assay is to measure cytokine production by the responding lymphocytes as a measure of response. The ELISPOT assay described  
15 below in Example 13 is a suitable example of this variation.

#### **Example 13 - detection of latent mycobacteria**

20 A major problem for the control of tuberculosis is the presence of a large reservoir of asymptomatic individuals infected with tubercle bacilli. Dormant bacilli are more resistant to front-line drugs.

The presence of latent mycobacteria-associated antigen may be detected indirectly either by detecting antigen specific antibody or T-cells in blood samples.  
25

The following method is based on the method described in Lalvani *et al.* (2001) in which a secreted antigen, ESAT-6, was identified as being expressed by members of the *M. tuberculosis* complex but is absent from *M. bovis* BCG vaccine strains and most environmental mycobacteria. 60 - 80% of patients also have a strong  
30 cellular immune response to ESAT-6. An *ex-vivo* ELISPOT assay was used to detect ESAT-6 specific T cells.

As applied to the present invention:

35 A 96 well plate is coated with cytokine (e.g. interferon- $\gamma$ , IL-2) -specific antibody. Peripheral blood monocytes are then isolated from patient whole blood and are applied to the wells.

-50-

Antigen (ie. one of the peptides, fragments, derivatives or variants of the present invention) is added to stimulate specific T cells that may be present and the plates are incubated for 24h. The antigen stimulates cytokine production which then binds to the specific antibody.

5

The plates are washed leaving a footprint where antigen-specific T cells were present.

10

A second antibody coupled with a suitable detection system, e.g. enzyme, is then added and the number of spots are enumerated after the appropriate substrate has been added.

15

The number of spots, each corresponding to a single antigen-specific T cell, is related to the total number of cells originally added.

The above Example also describes use of an antigen that may be used to distinguish TB infected individuals from BCG vaccinated individuals. This could be used in a more discriminative diagnostic assay.

#### 20 **Example 14 - Alternative protocol for transcriptomics analysis**

##### a) Experimental design

25 RNA was extracted from aerobic (50% DOT) and low-oxygen (1% DOT) cultures and fluorescently labelled cDNA was transcribed from each sample of RNA. Fluorescently labelled cDNA was also transcribed from genomic DNA which had been extracted from *M. tuberculosis*.

30

In each microarray experiment a whole genome array was hybridised with a sample of labelled cDNA generated from RNA from one culture sample (Test sample). Each array was also hybridised with control cDNA prepared from genomic DNA (Control sample). The test and control cDNAs were each labelled with a different cy dye.

35

Nine separate arrays were performed for aerobic samples and seven low-oxygen arrays were performed. Each array was scanned at two different wavelengths corresponding to the excitation maxima of each dye using an Affymetric 428 array



-51-

scanner. The intensity of the emitted light was recorded and the data was analysed using GeneSpring software.

5 The test sample data on each chip was normalised against the control data followed by per chip normalisation about the median intensity value, using the 50th percentile, and finally per gene normalisation across all the arrays. In this instance those genes which were expressed at least 1.5-fold higher under low-oxygen conditions relative to aerobic culture were selected for identification.

10 b) RNA extraction from *M. tuberculosis* for microarray analysis

Materials and Methods

Trizol (Life Technologies) - formulation of phenol and guanidine thiocyanate.

15 GTC lysis solution containing: 5M guanidine thiocyanate, 0.5% N-lauryl sarcosine, 25mM tri-sodium citrate, 0.1M 2-mercaptoethanol, and 0.5% Tween 80.

Chloroform, Isopropanol

3M sodium acetate

20 70% Ethanol

microfuge, ribolyser

Sterile plasticware-Falcon tubes, screw capped eppendorfs, gilson tips - all RNase free

Glassware - baked at 160 °C for at least 16 hours

25

Method

Steps performed at Containment level 3; within a Class III microbiological safety cabinet.

30 \* Remove 10 or 20 ml of culture ( $10^9$ /ml) and immediately add this to 4 volumes of GTC lysis buffer in a plastic specimen pot. Seal the pot tightly.

\* Incubate the cells in GTC lysis buffer for 1 hour at room temperature. Surface decontaminate the plastic pot with 5% Hycolin for 5 minutes. Transfer the sample to the pass box and place it into a plastic carry tin with a sealable lid. Close the container securely and transport it to a non-toxic cabinet CL3 cabinet.

35

-52-

- 5      \* Equally distribute the lysis mixture between Falcon tubes. Place these tubes into centrifuge buckets and seal the buckets tightly. Surface-decontaminate the buckets for 5 minutes with 5% Hycolin. Then transfer them to the centrifuge (Baird and Tatlock Mark IV refrigerated bench-top centrifuge). Spin the tubes at 3,000 rpm for 30 minutes.
- \* Return the unopened buckets to the cabinet. Remove the centrifuge tubes and pour the supernatant into a waste bottle for GTC lysis buffer.
- 10     \* Resuspend each pellet in 1 ml of Trizol (formulation of phenol and GTC cat no. 15596-026). The manufacturers guidelines recommend lysing cells by repetitive pipetting. Although this action alone will not lyse *M. tuberculosis*, it is important to completely resuspend the pellet in Trizol.
- 15     \* Transfer 1 ml of cells into each FastRNA tube and ribolyse them at power setting 6.5 for 45 seconds.
- \* Leave the tubes to incubate at room temperature for 5 minutes.
- 20     \* Remove the aqueous layer from each tube and add this to 200 µl of chloroform in a screw-capped eppendorf tube. Shake each tube vigorously for about 15 seconds. Incubate for 2-3 minutes at room temperature.
- 25     \* Spin the tubes at 13,000 rpm for 15 minutes. Following centrifugation, the liquid separates into red phenol/chloroform phase, an interface, and a clear aqueous phase.
- 30     \* Carefully remove the aqueous phase and transfer it to fresh eppendorf tubes containing 500 µl of chloroform/isoamyl alcohol (24:1). Spin the tubes at 13,000 rpm for 15 minutes.
- \* Transfer the aqueous phase to eppendorf tubes containing 50 µl of sodium acetate and 500 µl of isopropanol.
- 35     \* Surface decontaminate the eppendorf tubes with 5% Hycolin for 5 minutes. Remove the tubes from the CL3 laboratory and continue with the procedure in laboratory 157.

-53-

Steps performed at Containment level 2:

- \* Precipitate the RNA at -70 °C for at least 30 minutes-can do this step overnight.
- \* Spin the precipitated RNA down at 13,000 rpm for 10 minutes. Remove the supernatant and wash the pellet in 70% ethanol. Repeat centrifugation.

5

- \* Remove the 70% ethanol and air-dry the pellet. Dissolve the pellet in RNase free water.

- \* Freeze the RNA at -70 °C to store it.

10

- \* The RNA was treated with DNase1 to remove genomic DNA and was then purified using RNeasy mini columns (Qiagen). Both methods were performed according to the manufacturers guidelines.

c) Isolation of genomic DNA from *M. tuberculosis* grown in chemostat culture

15

DNA is then used to generate Cy3 or Cy5 labelled DNA for use as a control in microarray experiments

Materials and Methods

20

Beads 0.5 mm in diameter

Bead beater

Bench top centrifuge

Platform rocker

Heat block

25

Falcon 50 ml centrifuge tubes

Sorvall RC-5C centrifuge

250 ml polypropylene centrifuge pots.

Screw capped eppendorf tubes

Pipettes 1ml, 200µl, 10ml, 5ml

30

Breaking buffer -

50 mM Tris HCL pH 8.0

10 mM EDTA

100 mM NaCl

35

Procedure

Mechanical disruption of Mtb cells

-54-

- \* 150 ml of chemostat cells (O.D of 2.5 at 540 nm) are spun down at 15,000 rpm for 15 minutes in 250 ml polypropylene pots using centrifuge Sorvall RC-5C.
- \* The supernatant is discarded.
- \* Cells are re-suspended in 5 ml of breaking buffer in a 50 ml Falcon tube and centrifuged at 15,000 rpm for a further 15 minutes.
- \* The supernatant is removed and additional breaking buffer is added at a volume of 5 ml. Beads are used to disrupt the cells. These are used at a quantity of 1ml of beads for 1 ml of cells. Place the sample into the appropriate sized chamber. Place in the bead beater and secure the outer unit (containing ice) and process at the desired speed for 30 seconds.
- \* Allow the beads to settle for 10 minutes and transfer cell lysate to a 50 ml Falcon centrifuge tube
- \* Wash beads with 2-5 ml of breaking buffer by pipetting washing buffer up and down over the beads.
- \* Add this washing solution to the lysate in the falcon tube

Removal of proteins and cellular components.

- \* Add 0.1volumes of 10% SDS and 0.01 volumes of proteinase K.
- \* Mix by inversion and heat at 55 °C in a heat block for 2-3 hours
- \* The resulting mix should be homogenous and viscous. If it isn't then add more SDS to bring the concentration up to 0.2%
- \* Add an equal volume of phenol/chloroform/Isoamyl alcohol in the ratio: 25/24/1.
- \* Gently mix on a platform rocker until homogenous
- \* Spin down at 3,000 rpm for 20 minutes
- \* Remove the aqueous phase and place in a fresh tube
- \* Extract the aqueous phase with an equal volume of chloroform to remove traces of cell debris and phenol. Chloroform extractions may need to be repeated to remove all the debris.
- \* Precipitate the DNA with 0.3 M sodium acetate and an equal volume of isopropanol.
- \* Spool as much DNA as you can with a glass rod
- \* Wash the spooled DNA in 70% ethanol followed by 100 % ethanol
- \* Leave to air dry
- \* Dissolve the DNA in sterile deionised water (500 µl)
- \* Allow DNA to dissolve at 4 °C for approximately 16 hours.
- \* Add RNase 1 (500U) to the dissolved DNA

-55-

- \* Incubate for 1 hour at 37 °C.
- \* Re-extract with an equal volume of phenol/chloroform followed by a chloroform extraction and precipitate as before
- \* Spin down the DNA at 13,000 rpm
- 5 \* Remove the supernatant and wash the pellet in 70% ethanol
- \* Air dry
- \* Dissolve in 200-500 µl of sterile water.

d) Preparation of Cy3 or Cy5 labelled DNA from DNA

10

Prepare one Cy3 or one Cy5 labelled DNA sample per microarray slide.

For each sample:

|    |                  |                |
|----|------------------|----------------|
|    | DNA              | 2-5 µg         |
|    | Random primers   | (3 µg/µl) 1 µl |
| 15 | H <sub>2</sub> O | to 41.5 µl     |

Heat at 95 °C for 5min, snap cool on ice and briefly centrifuge.

Add to each:

|    |                                |        |
|----|--------------------------------|--------|
| 20 | 10xREact 2 buffer              | 5 µl   |
|    | dNTPs (5mM dA/G/TTP, 2mM dCTP) | 1 µl   |
|    | Cy3 OR Cy5 dCTP                | 1.5 µl |
|    | Klenow (5U/µl)                 | 1 µl   |

Incubate at 37 °C in dark for 90min.

25

Prehybridise slide

Mix the prehybridisation solution in a Coplin jar and incubate at 65 °C during the labelling reaction to equilibrate.

|    |                          |                   |
|----|--------------------------|-------------------|
| 30 | Prehybridisation: 20xSSC | 8.75 ml (3.5xSSC) |
|    | 20% SDS                  | 250 µl (0.1% SDS) |
|    | BSA (100mg/ml)           | 5ml (10mg/ml)     |
|    | H <sub>2</sub> O         | to 50ml           |

- 35 Incubate the microarray slide in the pre-heated prehybridisation solution at 65 °C for 20min. Rinse slide thoroughly in 400ml H<sub>2</sub>O for 1min followed by rinse in 400ml propan-2-ol for 1min and centrifuge slide in 50ml centrifuge tube at

-56-

1,500rpm for 5min to dry. Store slide in dark, dust-free box until hybridisation (<1h).

#### Purify Cy3/Cy5 labelled DNA - Qiagen MinElute Purification

- 5 \* Combine Cy3 and Cy5 labelled DNA samples in single tube and add 500 µl Buffer PB.
- \* Apply to MinElute column in collection tube and centrifuge at 13,000rpm for 1min.
- \* Discard flow-through and place MinElute column back into same collection tube.
- 10 \* Add 500 µl Buffer PE to MinElute column and centrifuge at 13,000rpm for 1min.
- \* Discard flow-through and place MinElute column back into same collection tube.
- \* Add 250 µl Buffer PE to MinElute column and centrifuge at 13,000rpm for 1min.
- \* Discard flow-through and place MinElute column back into same collection tube.
- \* Centrifuge at 13,000rpm for an additional 1min to remove residual ethanol.
- 15 \* Place the MinElute column into a fresh 1.5ml tube.
- \* Add 10.5 µl H<sub>2</sub>O to the centre of the membrane and allow to stand for 1min.
- \* Centrifuge at 13,000rpm for 1min.

#### e) Preparation of Cy3 or Cy5 label cDNA from RNA

20

Prepare one Cy3 and one Cy5 labelled cDNA sample per microarray slide.

For each sample:

|    |                          |          |
|----|--------------------------|----------|
|    | RNA                      | 2-10 µg  |
|    | Random primers (3 µg/µl) | 1 µl     |
| 25 | H <sub>2</sub> O         | to 11 µl |

Heat at 95 °C for 5min, snap cool on ice and briefly centrifuge.

Add to each:

|    |                                |        |
|----|--------------------------------|--------|
|    | 5xFirst Strand Buffer          | 5 µl   |
| 30 | DTT (100mM)                    | 2.5 µl |
|    | dNTPs (5mM dA/G/TTP, 2mM dCTP) | 2.3 µl |
|    | Cy3 OR Cy5 dCTP                | 1.7 µl |
|    | SuperScript II (200U/µl)       | 2.5 µl |

- 35 Incubate at 25 °C in dark for 10min followed by 42 °C in dark for 90min.

Prehybridise slide

-57-

Mix the prehybridisation solution in a Coplin jar and incubate at 65 °C during the labelling reaction to equilibrate.

|   |                           |                   |
|---|---------------------------|-------------------|
|   | Prehybridisation: 20 xSSC | 8.75 ml (3.5xSSC) |
|   | 20% SDS                   | 250 µl (0.1% SDS) |
| 5 | BSA (100mg/ml)            | 5ml (10mg/ml)     |
|   | H <sub>2</sub> O          | to 50ml           |

10 Incubate the microarray slide in the pre-heated prehybridisation solution at 65 °C for 20min. Rinse slide thoroughly in 400ml H<sub>2</sub>O for 1min followed by rinse in 400ml propan-2-ol for 1min and centrifuge slide in 50ml centrifuge tube at 1500rpm for 5min to dry. Store slide in dark, dust-free box until hybridisation (<1h).

Purify Cy3/Cy5 labelled cDNA - Qiagen MinElute Purification

- 15 \* Combine Cy3 and Cy5 labelled DNA samples in single tube and add 250 µl Buffer PB.  
 \* Apply to MinElute column in collection tube and centrifuge at 13,000rpm for 1min.  
 \* Discard flow-through and place MinElute column back into same collection tube.  
 20 \* Add 500 µl Buffer PE to MinElute column and centrifuge at 13,000rpm for 1min.  
 \* Discard flow-through and place MinElute column back into same collection tube.  
 \* Add 250 µl Buffer PE to MinElute column and centrifuge at 13,000rpm for 1min.  
 \* Discard flow-through and place MinElute column back into same collection tube.  
 \* Centrifuge at 13,000rpm for an additional 1min to remove residual ethanol.  
 25 \* Place the MinElute column into a fresh 1.5ml tube.  
 \* Add 10.5 µl H<sub>2</sub>O to the centre of the membrane and allow to stand for 1min.  
 \* Centrifuge at 13,000rpm for 1min.

f) Hybridise slide with Cy3/Cy5 labelled cDNA/DNA

30

Place the prehybridised microarray slide in the hybridisation cassette and add two 15 µl aliquots of H<sub>2</sub>O to the wells in the cassette. Mix resuspended Cy3/Cy5 labelled cDNA sample with hybridisation solution.

35

Hybridisation:

|                              |                |
|------------------------------|----------------|
| Cy3/Cy5 labelled cDNA sample | 10.5 µl        |
| 20xSSC                       | 3.2 µl (4xSSC) |

-58-

2% SDS

2.3  $\mu$ l (0.3% SDS)

Heat hybridisation solution at 95 °C for 2min. Do NOT snap cool on ice but allow to cool slightly and briefly centrifuge. Pipette the hybridisation solution onto the slide at the edge of the arrayed area avoiding bubble formation. Using forceps carefully drag the edge of a cover slip along the surface of the slide towards the arrayed area and into the hybridisation solution at the edge of the array. Carefully lower the cover slip down over the array avoiding any additional movement once in place. Seal the hybridisation cassette and submerge in a water bath at 60 °C for 16-20h.

Wash slide

Remove microarray slide from hybridisation cassette and initially wash slide carefully in staining trough of Wash A, preheated to 65 °C, to remove cover slip. Once cover slip is displaced place slide(s) in slide rack and continue agitating in Wash A for a further 2min.

Wash A:

20 x SSC.....20ml (1xSSC)  
 20% SDS.....1ml (0.05% SDS)  
 H<sub>2</sub>O.....to 400ml

Transfer slide(s) to a clean slide rack and agitate in first trough of Wash B for 2min. Wash in second trough of Wash B with agitation for 2min.

Wash B (x2):

20xSSC.....1.2ml (0.06xSSC)  
 H<sub>2</sub>O.....to 400ml

Place slide into a 50ml centrifuge tube and centrifuge at 1500rpm for 5mins to dry the slide and then scan fluorescence using a microarray slide scanner. The slides were scanned using an Affymetrix 428 scanner. The raw data was analysed using a combination of ImaGene and GeneSpring software.

#### g) Preparation of the arrays

Whole *M. tuberculosis* genome arrays were prepared from *M. tuberculosis*



-59-

genomic DNA using ORF-specific primers. PCR products corresponding to each ORF were spotted in a grid onto a standard glass microscope slide using a BioRobotics microgrid robot (MWG Biotech) at a resolution of  $> 4000$  spots/cm<sup>2</sup>.

## 5 RESULTS

Transcriptomics analysis of *M. tuberculosis* DNA coding sequences that are up-regulated under low DOT continuous culture conditions has identified the following SEQ IDs (see Table 2). Referring to the SEQ. ID. NO. column, the first identified  
10 number is an amino acid sequence and the second identified number is the corresponding DNA sequence.

TABLE 2

|    | Gene            | Assigned function                                                              | SEQ ID NO. |
|----|-----------------|--------------------------------------------------------------------------------|------------|
| 5  | Rv 1344         | Acyl carrier protein                                                           | 1, 2       |
|    | Rv0283          |                                                                                | 3, 4       |
|    | Rv3402c         | Aminotransferase in polysaccharide biosynthesis                                | 5, 6       |
|    | Rv3049c         | Monooxygenase                                                                  | 7, 8       |
| 10 | Rv2382c (mbtC)  | Involved in mycobactin biosynthesis                                            | 9, 10      |
|    | Rv2381c (mbtD)  | Involved in mycobactin biosynthesis                                            | 11, 12     |
|    | Rv2379c (mbtF)  | Involved in mycobactin biosynthesis                                            | 13, 14     |
|    | Rv1994c         | Transcription regulator, similar to eg MERR probable mercury resistance operon | 15, 16     |
| 15 | Rv0251c (hsp)   | Heat shock protein belonging to HSP20 family                                   | 17, 18     |
|    | Rv3174          | Oxidoreductase                                                                 | 19, 20     |
|    | fadE14 (Rv1346) | Acyl CoA dehydrogenase                                                         | 21, 22     |
|    | LipK (Rv2385)   | Esterase/acetyl hydrolase                                                      | 23, 24     |
|    | appC (Rv1623c)  | Cytochrome D                                                                   | 25, 26     |
|    | Rv0725c         |                                                                                | 27, 28     |
|    | Rv3639c         |                                                                                | 29, 30     |
|    | Rv0560c         | Methyltransferase                                                              | 31, 32     |

|    | Gene           | Assigned function                                       | SEQ ID NO. |
|----|----------------|---------------------------------------------------------|------------|
|    | Rv2053c        |                                                         | 33, 34     |
| 5  | lpqS (Rv0847)  | Lipoprotein containing a signal peptide                 | 35, 36     |
|    | Rv3767c        | Protein with a probable N-terminal signal peptide       | 37, 38     |
|    | Rv3812         |                                                         | 39, 40     |
|    | Rv2210c (ilvE) | Branched chain amino acid transaminase                  | 41, 42     |
|    | Rv2516c        | Protein containing a helix-turn-helix motif             | 43, 44     |
|    | Rv0870c        | Hydrophobic protein                                     | 45, 46     |
| 10 | Rv1168c        | PPE protein                                             | 47, 48     |
|    | Rv2448c (valS) | Valyl-tRNA synthetase                                   | 49, 50     |
|    | Rv2378c (mbtG) | Involved in mycobactin biosynthesis. Lysine hydroxylase | 51, 52     |
|    | Rv2377c (mbtH) | Involved in mycobactin biosynthesis                     | 53, 54     |
|    | Rv0135c        | Transcriptional regulator                               | 55, 56     |
| 15 | Rv2025c        |                                                         | 57, 58     |
|    | Rv0985c (mscL) |                                                         | 59, 60     |
|    | Rv0938         |                                                         | 61, 62     |
|    | Rv2554c        |                                                         | 63, 64     |
|    | Rv1342c        | Membrane protein                                        | 65, 66     |

|    | Gene           | Assigned function                                                                                           | SEQ ID NO. |
|----|----------------|-------------------------------------------------------------------------------------------------------------|------------|
|    | Rv0397         |                                                                                                             | 67, 68     |
|    | Rv1389 (gmk)   | Guanylate kinase                                                                                            | 69, 70     |
| 5  | Rv0123         |                                                                                                             | 71, 72     |
|    | Rv3001c (ilvC) | Ketol acid reducto isomerase                                                                                | 73, 74     |
|    | Rv3839         |                                                                                                             | 75, 76     |
|    | Rv2164c        | Proline rich protein                                                                                        | 77, 78     |
|    | Rv2017         | Transcriptional regulator                                                                                   | 79, 80     |
| 10 | Rv1982c        |                                                                                                             | 81, 82     |
|    | Rv3758c (proV) | ABC transporter. ATP binding protein                                                                        | 83, 84     |
|    | Rv3697c        |                                                                                                             | 85, 86     |
|    | Rv1228 (lpqX)  | Protein containing a signal peptide                                                                         | 87, 88     |
|    | Rv3000         |                                                                                                             | 89, 90     |
| 15 | Rv3037c        |                                                                                                             | 91, 92     |
|    | Rv1634         | Membrane protein of major facilitator super family, similar to many antibiotic resistance (efflux) proteins | 93, 94     |
|    | Rv1300 (hemK)  | Protoporphyrinogen oxidase                                                                                  | 95, 96     |
|    | Rv2327         | unknown                                                                                                     | 97, 98     |
|    | Rv1221 (sigE)  | Sigma factor                                                                                                | 99, 100    |

5

10

| Gene          | Assigned function                                                                       | SEQ ID NO. |
|---------------|-----------------------------------------------------------------------------------------|------------|
| Rv1617 (pykA) | Pyruvate kinase                                                                         | 101, 102   |
| Rv0792c       | Transcriptional regulator, similar to many of GntR family e.g. <i>Bacillus subtilis</i> | 103, 104   |
| Rv1509        |                                                                                         | 105, 106   |
| Rv3081        | Contains PS0 0850                                                                       | 107, 108   |
| Rv0347        | Similar to Rv0831c                                                                      | 109, 110   |
| Rv0573c       |                                                                                         | 111, 112   |
| Rv2019        |                                                                                         | 113, 114   |

-64-

**Example 15 - Protocol for Protein Extraction and Characterisation**

5 *M. tuberculosis* H37Rv was grown in continuous culture under aerobic (50% DOT) and low oxygen (1% DOT) conditions and samples were collected during the steady-state (see Example 1).

Harvesting of culture cell pellets

- \* 300 - 350 ml of culture is collected overnight on ice.
- \* The culture is centrifuged for 10 minutes at 15,000 rpm in dry-spin tubes using a Sorvall RC5B centrifuge at 4 °C.
- \* The supernatant is decanted off and the cell pellets are collected in to tubes and stored frozen at -40 °C.

Preparation of protein extracts from cell pellets

- 15 \* One sample of steady state cell pellets from each of 3 aerobic and 2 low oxygen chemostat cultures were removed from the freezer and allowed to thaw at room temperature for 1 hour.
- \* Each pellet is resuspended in 40 mls Tris-HCL buffer [40mM Tris, 1mM EDTA (pH 6.9) and 200 µl protease inhibitor cocktail (Sigma, P8645) per 40mls] and re-pelleted by centrifugation at 12,000 rpm at 4 °C.
- \* Each cell pellet is then resuspended with approximately 1ml of buffer.
- \* 0.5 ml aliquots of the bacterial suspensions are dispensed into separate ribolyser tubes (Anachem).
- \* Each tube is ribolysed for 3 x 90 seconds cycles (maximum power - setting 6.5) with 5 mins on ice between each cycle.
- 25 \* After ribolysing the protein preparations for each sample were pooled and the following chemicals added:

|    |         |                                                  |
|----|---------|--------------------------------------------------|
| 30 | 3.2 g   | Urea                                             |
|    | 64.8 mg | DTT                                              |
|    | 300 µl  | Ampholytes (servalyte 2-4 serva electrophoresis) |
|    | 0.24 g  | CHAPS                                            |

- \* Each chemical is allowed to dissolve before adding the next.
- 35 \* The samples are incubated for 30 minutes at room temperature.
- \* The samples were dispensed in to eppendorf tubes and centrifuged at 12,000 rpm for 5 minutes.

-65-

\* The clear soluble protein preparations are then removed and double filtered through a 0.2  $\mu$ m cellulose acetate filter membrane.

\* Protein determinations of the samples using a Biorad assay was performed with a Bovine serum albumin standard curve and the samples found to contain between  
5 6 - 8.5 mg/ml of protein.

#### Proteomics analysis using 2D Electrophoresis

Representative protein samples of the low-oxygen and aerobic chemostat cultures were sent away for 2D Electrophoresis analysis to the Wittman Institute of  
10 Technology and Analysis of Biomolecules (WITA), Berlin.

\* Protein separation of each sample by 2D electrophoresis (Jungblut et al., Infect Immun 2001 Sep; 69(9):5905-7) was carried out on both Coomassie brilliant blue and silver stained gels produced using 70  $\mu$ l and 25  $\mu$ l of protein samples  
15 respectively.

#### Protein identification

\* The most abundant protein spots on the Coomassie low oxygen gel were excised and sent for Mass spectrometry determination by Robin Wait (Jungblut et  
20 al., Infect Immun 2001 Sep; 69(9):5905-7) for protein identification.

The following proteins were identified, and are listed (together with their corresponding DNA coding sequences) in Table 3.

**TABLE 3**

|    | Gene    | Assigned function                                                                | SEQ ID NO. |
|----|---------|----------------------------------------------------------------------------------|------------|
| 5  | Rv3040  | 31.5kDa protein                                                                  | 115, 116   |
|    | Rv1288  | Antigen 85B-precursor                                                            | 117, 118   |
|    | Rv0649  | Malonyl CoA-acyl carrier protein transacylase                                    | 119, 120   |
|    | Rv1357c | 29.8 and 31.7 kDa proteins                                                       | 121, 122   |
|    | Rv2230c | 39.6 kDa protein                                                                 | 123, 124   |
| 10 | Rv2468c |                                                                                  | 125, 126   |
|    | Rv3011c | Glutamyl-tRNA (Gln) amidotransferase subunit/ ATPB MYCTU ATP synthase beta chain | 127, 128   |
|    | Rv2868c | GcpE protein homolog                                                             | 129, 130   |
|    | Rv0718  | 30S ribosomal protein S8                                                         | 131, 132   |
|    | Rv1267c | Response regulator, similar to AFSR_STRCO P25941                                 | 133, 134   |
| 15 | Rv1294  | Homoserine dehydrogenase                                                         | 135, 136   |
|    | Rv0844c | Nitrate/nitrite response regulator (NARL)                                        | 137, 138   |



**References:**

1. McKinney, J.D., et al., Persistence of *Mycobacterium tuberculosis* in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase [see  
5 comments]. *Nature*, 2000. 406(6797): p. 735-8.
2. Pelicic, V., et al., Efficient allelic exchange and transposon mutagenesis in *Mycobacterium tuberculosis*. *Proc Natl Acad Sci U S A*, 1997. 94(20): p. 10955-60.  
10
3. Lee, M.H., et al., Site-specific integration of mycobacteriophage L5: integration- proficient vectors for *Mycobacterium smegmatis*, *Mycobacterium tuberculosis*, and bacille Calmette-Guerin. *Proc Natl Acad Sci U S A*, 1991. 88(8): p. 3111-5.  
15
4. McShane, H., et al., Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. *Infect Immun*, 2001. 69(2): p. 681-6.
- 20 5. Movahedzadeh, F., M.J. Colston, and E.O. Davis, Characterization of *Mycobacterium tuberculosis* LexA: recognition of a Cheo (Bacillus-type SOS) box. *Microbiology*, 1997. 143(Pt 3): p. 929-36.

**Additional References:**

- 25 Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. *Molecular cloning: a laboratory manual*, 2nd ed. Cold Spring Harbour Laboratory Press, Cold Spring Harbour, N. Y.
- 30 Lefever, P., O. Denis, L. De Wit, A. Tanghe, P. Vandenbussche, J. Content, and K. Huygen. 2000. Cloning of the gene encoding a 22-kilodalton cell surface antigen of *Mycobacterium bovis* BCG and analysis of its potential for DNA vaccination against tuberculosis. *Infection and Immunity*. 68:1040-1047.
- 35 Vordermeire, H. M., P. J. Cockle, A. O. Whelan, S. Rhodes, M. A. Chambers, D. Clifford, K. Huygen, R. Tascon, D. Lowrie, M. J. Colston, and R. G. Hewinson. 2000. Effective DNA vaccination of cattle with the mycobacterial antigens MPB83

and MPB70 does not compromise the specificity of the comparative intradermal tuberculin skin test. Vaccine. 19:1246-1255.

Cheng, W., C. Hung, C. Chai, K. Hsu, L. He, C. Rice, M. Ling, and T. Wu. 2001.

- 5 Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of *Mycobacterium tuberculosis* heat shock protein 70 gene to an antigen. J. Immunol. 166:6218-6226.

Lalvani, A. *et al.*, 2001. Enhanced contact tracing and spatial tracking of

- 10 *Mycobacterium tuberculosis* infection by enumeration of antigen-specific T cells. The Lancet 357:2017-2021.

- 15 In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.

20

It is to be understood that a reference herein to a prior art document does not constitute an admission that the document forms part of the common general knowledge in the art in Australia or any other country.

## THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A therapeutic agent when used for preventing or treating a mycobacterial infection, comprising an isolated *M. tuberculosis* peptide selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135 and 137, or a variant thereof having at least 70% amino acid homology therewith, or a derivative thereof, or a fragment thereof having at least 10 amino acid residues, wherein said variant, derivative or fragment has a common antigenic cross-reactivity to said isolated peptide, wherein the peptide is encoded by a gene the expression of which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C.
2. An antibody which binds to a peptide selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135 and 137, or a variant thereof having at least 70% amino acid homology therewith, or a derivative thereof, or a fragment thereof having at least 10 amino acid residues, wherein said variant, derivative or fragment has a common antigenic cross-reactivity to said isolated peptide, wherein the peptide is encoded by a gene, the expression of which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C, when used for preventing or treating a mycobacterial infection.
3. An attenuated *M. tuberculosis* mycobacterium in which a gene has been modified thereby tendering the mycobacterium substantially non-pathogenic, wherein the gene is a gene the expression of which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation

measured at 37°C, wherein said gene has a wild-type coding sequence corresponding to one of the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136 and 138, when used for preventing or treating a mycobacterial infection.

4. An attenuated microbial carrier when used for preventing or treating a mycobacterial infection, comprising a peptide selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135 and 137, or a variant thereof having at least 70% amino acid homology therewith, or a derivative thereof, or a fragment thereof having at least 10 amino acid residues, wherein said variant, derivative or fragment has a common antigenic cross-reactivity to said isolated peptide, wherein said peptide is encoded by a gene, the expression of which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C.

5. An attenuated microbial carrier according to claim 4, wherein the attenuated microbial carrier is attenuated salmonella, attenuated vaccinia virus, attenuated fowlpox virus, or attenuated *M. bovis* (eg. BCG strain).

6. A DNA plasmid comprising a promoter, a polyadenylation signal and a DNA sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136 and 138, or a variant thereof having at least 70% nucleotide sequence identity therewith, or a derivative thereof, or a fragment thereof having at least 15 nucleotides, wherein the peptide encoded by said variant, derivative or fragment has a common antigenic cross-reactivity to the peptide encoded by said DNA sequence, wherein said DNA sequence corresponds to the coding sequence of a gene, the expression of which is

induced or up-regulated during culture of a wild-type version of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C, wherein the promoter and polyadenylation signal are operably linked to the DNA sequence when used for preventing or treating a mycobacterial infection.

7. A DNA plasmid according to claim 6, wherein the promoter is selected from the group consisting of CMV and SV40 promoters, and the polyadenylation signal is selected from SV40 and bovine growth hormone polyadenylation signals.

8. An isolated RNA sequence which is encoded by a DNA sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136 and 138, or a variant thereof having at least 70% nucleotide sequence identity therewith, or a derivative thereof, or a fragment thereof having at least 15 nucleotides, wherein the peptide encoded by said variant, derivative or fragment has a common antigenic cross-reactivity to the peptide encoded by said DNA sequence, wherein the DNA sequence corresponds to the coding sequence of a gene which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C, when used for preventing or treating a mycobacterial infection.

9. An RNA vector when used for preventing or treating a mycobacterial infection comprising the RNA sequence of claim 8 and an integration site for a chromosome of a host cell.

10. Use of an isolated *M. tuberculosis* peptide selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135 and 137, or a variant thereof having at least 70% amino acid homology therewith, or a derivative

thereof, or a fragment thereof having at least 10 amino acid residues, wherein said variant, derivative or fragment has a common antigenic cross-reactivity to said isolated peptide, wherein the peptide is encoded by a gene the expression of which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C,

an antibody according to claim 2,

an attenuated mycobacterium according to claim 3,

an attenuated microbial carrier according to claim 4 or 5,

a DNA sequence selected from the group consisting of SEQ ID NO: 2,

4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122,

124, 126, 128, 130, 132, 134, 136 and 138, or a variant thereof having at least 70% nucleotide sequence identity therewith, or a derivative thereof, or a

fragment thereof having at least 15 nucleotides, wherein the peptide encoded by said variant, derivative or fragment has a common antigenic cross-reactivity to the peptide encoded by said DNA sequence, wherein said DNA sequence corresponds to the coding sequence of a gene which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C or a fragment or variant or derivative of said DNA sequence,

a DNA plasmid according to claim 6 or 7,

an RNA sequence according to claim 8, and/or

an RNA vector according to claim 9,

in the manufacture of a medicament for treating or preventing a mycobacterial infection.

11. Use of an isolated *M. tuberculosis* peptide selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135 and 137, or a variant thereof having at least 70% amino acid homology therewith, or a derivative thereof, or a fragment thereof having at least 10 amino acid residues, wherein said variant, derivative or fragment has a common antigenic cross-reactivity to

said isolated peptide, wherein the peptide is encoded by a gene the expression of which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C,

an antibody according to claim 2,

or a polynucleotide probe comprising at least 8 nucleotides wherein said probe binds to at least part of a gene which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C,

in the manufacture of a diagnostic reagent for identifying a mycobacterial infection.

12. A method of treating or preventing a mycobacterial infection, by administering to a patient an isolated *M. tuberculosis* peptide selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135 and 137, or a variant thereof having at least 70% amino acid homology therewith, or a derivative thereof, or a fragment thereof having at least 10 amino acid residues, wherein said variant, derivative or fragment has a common antigenic cross-reactivity to said isolated peptide, wherein the peptide is encoded by a gene the expression of which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C,

an antibody according to claim 2,

an attenuated mycobacterium according to claim 3,

an attenuated microbial carrier according to claim 4 or 5,

a DNA sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136 and 138, or a variant thereof having at least

70% nucleotide sequence identity therewith, or a derivative thereof, or a fragment thereof having at least 15 nucleotides, wherein the peptide encoded by said variant, derivative or fragment has a common antigenic cross-reactivity to the peptide encoded by said DNA sequence, wherein said DNA sequence  
5 corresponds to the coding sequence of a gene which is induced or up-regulated during culture of *M. tuberculosis* under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37°C when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37°C or a fragment or variant or derivative of said DNA sequence,

- 10 a DNA plasmid according to claim 5 or 7,  
an RNA sequence according to claim 8, and/or  
an RNA vector according to claim 9.

13. A therapeutic agent, an antibody, an attenuated *M. tuberculosis*  
15 mycobacterium, an attenuated microbial carrier, an isolated RNA molecule, an RNA vector, or a DNA plasmid substantially as hereinbefore described with reference to the Examples, when used for preventing or treating a mycobacterial infection.

20 14. A therapeutic agent according to claim 1, substantially as hereinbefore described with reference to any one of the Examples.

15. An antibody according to claim 2, substantially as hereinbefore described with reference to any one of the Examples.

25 16. An attenuated *M. tuberculosis* mycobacterium according to claim 3, or attenuated microbial carrier according to claim 4, substantially as hereinbefore described with reference to any one of the Examples.

30 17. A DNA plasmid according to claim 6, substantially as hereinbefore described with reference to any one of the Examples.

18. An isolated RNA sequence according to claim 8, substantially as hereinbefore described with reference to any one of the Examples.

35 19. A use according to claim 10 or 11, substantially as hereinbefore described with reference to any one of the Examples.



20. A method according to claim 12, substantially as hereinbefore described with reference to any one of the Examples.

-1-

## SEQUENCE LISTING

&lt;110&gt; Microbiological Research Authority

James, Brian

Bacon, Joanna

Marsh, Philip

&lt;120&gt; Mycobacterial antigens expressed under low oxygen tension

&lt;130&gt; GWS/MRM/23434

&lt;150&gt; GB 0115365.9

&lt;151&gt; 2001-06-01

&lt;150&gt; GB 0121780.1

&lt;151&gt; 2001-09-07

&lt;160&gt; 138

&lt;170&gt; PatentIn version 3.1

&lt;210&gt; 1

&lt;211&gt; 106

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 1

Met Trp Arg Tyr Pro Leu Ser Thr Arg Leu Ala Leu Pro Asn Thr Pro  
1 5 10 15

-2-

Gly Val Ala Ser Phe Ala Met Thr Ser Ser Pro Ser Thr Val Ser Thr  
                   20                  25                  30

Thr Leu Leu Ser Ile Leu Arg Asp Asp Leu Asn Ile Asp Leu Thr Arg  
           35                  40                  45

Val Thr Pro Asp Ala Arg Leu Val Asp Asp Val Gly Leu Asp Ser Val  
       50                  55                  60

Ala Phe Ala Val Gly Met Val Ala Ile Glu Glu Arg Leu Gly Val Ala  
   65                  70                  75                  80

Leu Ser Glu Glu Glu Leu Leu Thr Cys Asp Thr Val Gly Glu Leu Glu  
                   85                  90                  95

Ala Ala Ile Ala Ala Lys Tyr Arg Asp Glu  
           100                  105

&lt;210&gt; 2

&lt;211&gt; 318

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

<400> 2  
 atgtggcgat atccactaag tacaaggcta gccttgcccta ataccccagg ttagcctcc 60  
 ttcgccatga cctcatcgcc gtccaccgtc agcactacgc tgctgagcat cctgcgcgac 120  
 gacctcaaca ttgacctgac tcgagtcacg cctgatgccca ggttggtcga cgatgtggga 180  
 ctggattcgg tggccttcgc ggtcggtatg gtggccatcg aggagcggct cggagtcgca 240  
 ctgtccgaag aggagctctt gacgtgcgac acggtcggag aactggaggc agcgatcgcg 300  
 gccaaatacc gcgatgag 318

&lt;210&gt; 3

&lt;211&gt; 538

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

-3-

&lt;400&gt; 3

Met Thr Asn Gln Gln His Asp His Asp Phe Asp His Asp Arg Arg Ser  
 1 5 10 15

Phe Ala Ser Arg Thr Pro Val Asn Asn Asn Pro Asp Lys Val Val Tyr  
 20 25 30

Arg Arg Gly Phe Val Thr Arg His Gln Val Thr Gly Trp Arg Phe Val  
 35 40 45

Met Arg Arg Ile Ala Ala Gly Ile Ala Leu His Asp Thr Arg Met Leu  
 50 55 60

Val Asp Pro Leu Arg Thr Gln Ser Arg Ala Val Leu Met Gly Val Leu  
 65 70 75 80

Ile Val Ile Thr Gly Leu Ile Gly Ser Phe Val Phe Ser Leu Ile Arg  
 85 90 95

Pro Asn Gly Gln Ala Gly Ser Asn Ala Val Leu Ala Asp Arg Ser Thr  
 100 105 110

Ala Ala Leu Tyr Val Arg Val Gly Glu Gln Leu His Pro Val Leu Asn  
 115 120 125

Leu Thr Ser Ala Arg Leu Ile Val Gly Arg Pro Val Ser Pro Thr Thr  
 130 135 140

Val Lys Ser Thr Glu Leu Asp Gln Phe Pro Arg Gly Asn Leu Ile Gly  
 145 150 155 160

Ile Pro Gly Ala Pro Glu Arg Met Val Gln Asn Thr Ser Thr Asp Ala  
 165 170 175

Asn Trp Thr Val Cys Asp Gly Leu Asn Ala Pro Ser Arg Gly Gly Ala  
 180 185 190

Asp Gly Val Gly Val Thr Val Ile Ala Gly Pro Leu Glu Asp Thr Gly  
 195 200 205

Ala Arg Ala Ala Ala Leu Gly Pro Gly Gln Ala Val Leu Val Asp Ser  
 210 215 220

-4-

Gly Ala Gly Thr Trp Leu Leu Trp Asp Gly Lys Arg Ser Pro Ile Asp  
 225 230 235 240

Leu Ala Asp His Ala Val Thr Ser Gly Leu Gly Leu Gly Ala Asp Val  
 245 250 255

Pro Ala Pro Arg Ile Ile Ala Ser Gly Leu Phe Asn Ala Ile Pro Glu  
 260 265 270

Ala Pro Pro Leu Thr Ala Pro Ile Ile Pro Asp Ala Gly Asn Pro Ala  
 275 280 285

Ser Phe Gly Val Pro Ala Pro Ile Gly Ala Val Val Ser Ser Tyr Ala  
 290 295 300

Leu Lys Asp Ser Gly Lys Thr Ile Ser Asp Thr Val Gln Tyr Tyr Ala  
 305 310 315 320

Val Leu Pro Asp Gly Leu Gln Gln Ile Ser Pro Val Leu Ala Ala Ile  
 325 330 335

Leu Arg Asn Asn Asn Ser Tyr Gly Leu Gln Gln Pro Pro Arg Leu Gly  
 340 345 350

Ala Asp Glu Val Ala Lys Leu Pro Val Ser Arg Val Leu Asp Thr Arg  
 355 360 365

Arg Tyr Pro Ser Glu Pro Val Ser Leu Val Asp Val Thr Arg Asp Pro  
 370 375 380

Val Thr Cys Ala Tyr Trp Ser Lys Pro Val Gly Ala Ala Thr Ser Ser  
 385 390 395 400

Leu Thr Leu Leu Ala Gly Ser Ala Leu Pro Val Pro Asp Ala Val His  
 405 410 415

Thr Val Glu Leu Val Gly Ala Gly Asn Gly Gly Val Ala Thr Arg Val  
 420 425 430

Ala Leu Ala Ala Gly Thr Gly Tyr Phe Thr Gln Thr Val Gly Gly Gly  
 435 440 445

Pro Asp Ala Pro Gly Ala Gly Ser Leu Phe Trp Val Ser Asp Thr Gly  
 450 455 460

-5-

Val Arg Tyr Gly Ile Asp Asn Glu Pro Gln Gly Val Ala Gly Gly Gly  
465 470 475 480

Lys Ala Val Glu Ala Leu Gly Leu Asn Pro Pro Pro Val Pro Ile Pro  
485 490 495

Trp Ser Val Leu Ser Leu Phe Val Pro Gly Pro Thr Leu Ser Arg Ala  
500 505 510

Asp Ala Leu Leu Ala His Asp Thr Leu Val Pro Asp Ser Arg Pro Ala  
515 520 525

Arg Pro Val Ser Ala Glu Gly Gly Tyr Arg  
530 535

&lt;210&gt; 4

&lt;211&gt; 1614

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 4

```

atgacgaacc agcagcacga ccacgacttc gaccacgacc gtcgctcggt cgcctcccga      60
accccggtca acaacaaccc cgacaagggt gtctaccgcc gcggcttcgt cacccgccat      120
caggtgacgg gctggcggtt cgtgatgcgc cgaatcgccg ccggaatcgc attgcacgac      180
accgcgatgc tggtcgaccc gttgcgcact cagtcacgcg cgggtgctgat ggggtgtgctg      240
attgtgatca cggggttgat cggctccttc gtattctcgt tgattcggcc caatgggcag      300
gcgggtagca acccggtgct tgccgaccgg tccaccgcgg cgtgtatgt gcgggtgggc      360
gagcagctgc acccggtgct caacctgacc tcggcccggc tgatcgtcgg ccggccggtg      420
agcccgacga cggtgaaaag tactgagttg gaccagtttc cgcgcggaaa cctgatcggc      480
atcccggtg cgccggagcg gatggtgcag aacacctcca ccgacgcgaa ctggacggtg      540
tgtgacggcc tcaacgcacc gtcgcggggc ggtgcggatg gcgtgggtgt gacggtgatt      600
gccggccccg tggaggacac cggcgcacgc gcggcgcgcg tcgggcccgg gcaggcggtg      660
ctggtcgaca gggcgccggg cacctggctg ttgtgggacg gcaagcgag cccgattgat      720
ctggccgatc atgcggtcac cagcggcctc ggccctgggc cgcagctgcc cgcgcccgcg      780

```

-6-

```

atcatcgctt cggggctgtt caacgcgata ccgaagcac cgccactgac ggcgccgac 840
atcccgcatg cgggcaaccc ggcgagcttc ggtgtgccgg cgccgatcgg cgcggtggtg 900
agttcctacg ccctgaaaga ctggggcaag accatatcgg acaccgtgca gtactacgcg 960
gtgctgccgg acggtttgca gcagatttcg ccggtattgg cggcaatcct gcgcaacaac 1020
aactcctatg gtctgcagca gccgcctcgg ctggggggcg acgaggtcgc caagctgccg 1080
gtgtcgccgg tgttgacac caggcgctat ccagcgagc cggtaagtct cgtcgacgtt 1140
acccgtgacc ccgtcacctg cgcgtactgg agcaagccgg tgggtgcggc caccagctcg 1200
ttgactctgt tggcaggctc ggcgctgccg gtgccagatg cgggtgcacac cgtcgagctg 1260
gtcggcgccg gcaacgggtg tgtggcaacc cgagtggcgt tagcggccgg tactggctac 1320
ttcaccacga cgggtggcg cggcccagat gcgcggggcg ccgggtcgtt gttctgggtg 1380
tcggataccg ggggtgcgta ccggtatcgac aatgagcctc agggagtggc tggaggcggc 1440
aaagcggttg aggccttgg cctgaaccgg ccccggtcc ccatcccggtg gtcggtgctg 1500
tcgctgtttg tgcccgccc gacgtgtcgc cgtgccgacg cgctgctggc acacgacacc 1560
ttggtgcccg acagcaggcc cgctcgtccg gtatcggccg agggagggtg ccgg 1614

```

&lt;210&gt; 5

&lt;211&gt; 412

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 5

```

Met Lys Ile Arg Thr Leu Ser Gly Ser Val Leu Glu Pro Pro Ser Ala
1           5           10           15

```

```

Val Arg Ala Thr Pro Gly Thr Ser Met Leu Lys Leu Glu Pro Gly Gly
20           25           30

```

```

Ser Thr Ile Pro Lys Ile Pro Phe Ile Arg Pro Ser Phe Pro Gly Pro
35           40           45

```

```

Ala Glu Leu Ala Glu Asp Phe Val Gln Ile Ala Gln Ala Asn Trp Tyr
50           55           60

```

```

Thr Asn Phe Gly Pro Asn Glu Arg Arg Phe Ala Arg Ala Leu Arg Asp

```

-7-

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 65  |     | 70  |     | 75  |     | 80  |     |     |     |     |     |     |     |     |     |
| Tyr | Leu | Gly | Pro | His | Leu | His | Val | Ala | Thr | Leu | Ala | Asn | Gly | Thr | Leu |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Ala | Leu | Leu | Ala | Ala | Leu | His | Val | Ser | Phe | Gly | Ala | Gly | Thr | Arg | Asp |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Arg | Tyr | Leu | Leu | Met | Pro | Ser | Phe | Thr | Phe | Val | Gly | Val | Ala | Gln | Ala |
|     | 115 |     |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
| Ala | Leu | Trp | Thr | Gly | Tyr | Arg | Pro | Trp | Phe | Ile | Asp | Ile | Asp | Ala | Asn |
|     | 130 |     |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |
| Thr | Trp | Gln | Pro | Cys | Val | His | Ser | Ala | Arg | Ala | Val | Ile | Glu | Arg | Phe |
| 145 |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     |     | 160 |
| Arg | Asp | Arg | Ile | Ala | Gly | Ile | Leu | Leu | Ala | Asn | Val | Phe | Gly | Val | Gly |
|     |     |     | 165 |     |     |     |     |     | 170 |     |     |     |     | 175 |     |
| Asn | Pro | Gln | Ile | Ser | Val | Trp | Glu | Glu | Leu | Ala | Ala | Glu | Trp | Glu | Leu |
|     |     | 180 |     |     |     |     |     | 185 |     |     |     |     | 190 |     |     |
| Pro | Ile | Val | Leu | Asp | Ser | Ala | Ala | Gly | Phe | Gly | Ser | Thr | Tyr | Ala | Asp |
|     | 195 |     |     |     |     | 200 |     |     |     |     |     | 205 |     |     |     |
| Gly | Glu | Arg | Leu | Gly | Gly | Arg | Gly | Ala | Cys | Glu | Ile | Phe | Ser | Phe | His |
|     | 210 |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |
| Ala | Thr | Lys | Pro | Phe | Ala | Val | Gly | Glu | Gly | Gly | Ala | Leu | Val | Ser | Arg |
| 225 |     |     |     | 230 |     |     |     |     |     | 235 |     |     |     |     | 240 |
| Asp | Pro | Arg | Leu | Val | Glu | His | Ala | Tyr | Lys | Phe | Gln | Asn | Phe | Gly | Leu |
|     |     |     | 245 |     |     |     |     | 250 |     |     |     |     |     | 255 |     |
| Val | Gln | Thr | Arg | Glu | Ser | Ile | Gln | Leu | Gly | Met | Asn | Gly | Lys | Leu | Ser |
|     |     | 260 |     |     |     |     |     | 265 |     |     |     |     | 270 |     |     |
| Glu | Ile | Ser | Ala | Ala | Ile | Gly | Leu | Arg | Gln | Leu | Val | Gly | Leu | Asp | Arg |
|     | 275 |     |     |     |     |     | 280 |     |     |     |     | 285 |     |     |     |
| Arg | Leu | Ala | Ser | Arg | Arg | Lys | Val | Leu | Glu | Cys | Tyr | Arg | Thr | Gly | Met |
|     | 290 |     |     |     |     | 295 |     |     |     |     | 300 |     |     |     |     |



-8-

Ala Asp Ala Gly Val Arg Phe Gln Asp Asn Ala Asn Val Ala Ser Leu  
 305 310 315 320

Cys Phe Ala Ser Ala Cys Cys Thr Ser Ala Asp His Lys Ala Ala Val  
 325 330 335

Leu Gly Ser Leu Arg Arg His Ala Ile Glu Ala Arg Asp Tyr Tyr Asn  
 340 345 350

Pro Pro Gln His Arg His Pro Tyr Phe Val Thr Asn Ala Glu Leu Val  
 355 360 365

Glu Ser Thr Asp Leu Ala Val Thr Ala Asp Ile Cys Ser Arg Ile Val  
 370 375 380

Ser Leu Pro Val His Asp His Met Ala Pro Asp Asp Val Ala Arg Val  
 385 390 395 400

Val Ala Ala Val Gln Glu Ala Glu Val Arg Gly Glu  
 405 410

&lt;210&gt; 6

&lt;211&gt; 1236

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 6

|                                                                     |     |
|---------------------------------------------------------------------|-----|
| atgaagatcc gaacgttatac cggctcgggtg ctggagccgc cgtccgcagt acgcgcgacc | 60  |
| ccaggcacgt ccatgttaaa actcgagccg ggtggctcga cgatcccca gatcccttc     | 120 |
| atcgcgccga gctttcccg gccagccgag ctgcgcgagg acttcgtaca gatcgccag     | 180 |
| gctaactggt acacgaactt cgggtccgaac gagcggcggt ttgccgcgc cctgcgcgac   | 240 |
| tatctgggac ctcatctgca cgttgctacc ctgcaccaac gcaccctggc actcctcgcg   | 300 |
| gcgtccaacg tcagtttcgg cgcgggtacg cgggaccgct acctgctgat gccgtcgttc   | 360 |
| acgttcgtcg gcgtggtcga ggctgcgcta tggactgggt accgtccctg gttcatcgac   | 420 |
| atcgacgcca acacatggca gccatgcgtc cactccgcc gcgcgcgtcat cgaacgcttc   | 480 |
| cgcgaccgga tcgccggcat cctgctggcc aatgtgttcg gcgtcggcaa tccccagatc   | 540 |
| agcgtctggg aggagctcgc cgccgaatgg gagctaccga ttgtgctcga ctcggcggcc   | 600 |

-9-

```

ggcttcggtt ccacgtacgc cgacggcgag cgctcgggtg gacgcggtgc atgcgagatc   660
ttctccttcc atgcgaccaa gccgttcgcg gttggtgagg gcggcgctct ggtttctcgc   720
gatccacggc tcgtcgagca cgcatacaag ttccagaact tcggcttggt gcaaacacgc   780
gagtccatcc agctcggaat gaacggcaag ctgtcggaga tcagcgccgc tattggccta   840
cgccaactag tggggcttga tcgcccctg gcaagtcgcc gcaaggtoct cgagtgtat   900
cgcaccggta tggccgacgc ggggtgtgctg ttccaggaca acgccaatgt tgcgtcgctc   960
tggttcgcga gcgcttgctg cagtcgccg gaccacaagg ccgcggttct gggtagcctg  1020
cgtaggcacg cgatcgaggc gcgcgactac tacaaccac cgagcacccg acatccgtac  1080
tttgtgacga atgccgagtt agtcgagtcg accgatctag ccgtcacggc ggacatttgc  1140
tcgcgaatcg tgtcgctgcc agtcacgac cacatggccc cggatgacgt tgcccgggtc  1200
gtcgccgcgc tgcaggaagc ggaggtgcgc ggtgaa                                1236

```

&lt;210&gt; 7

&lt;211&gt; 524

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 7

```

Val Ser Ile Ala Asp Thr Ala Ala Lys Pro Ser Thr Pro Ser Pro Ala
1              5              10              15

```

```

Asn Gln Pro Pro Val Arg Thr Arg Ala Val Ile Ile Gly Thr Gly Phe
          20              25              30

```

```

Ser Gly Leu Gly Met Ala Ile Ala Leu Gln Lys Gln Gly Val Asp Phe
          35              40              45

```

```

Val Ile Leu Glu Lys Ala Asp Asp Val Gly Gly Thr Trp Arg Asp Asn
          50              55              60

```

```

Thr Tyr Pro Gly Cys Ala Cys Asp Ile Pro Ser His Leu Tyr Ser Phe
65              70              75              80

```

```

Ser Phe Glu Pro Lys Ala Asp Trp Lys His Leu Phe Ser Tyr Trp Asp
          85              90              95

```

-10-

Glu Ile Leu Gly Tyr Leu Lys Gly Val Thr Asp Lys Tyr Gly Leu Arg  
                   100                  105                  110

Arg Tyr Ile Glu Phe Asn Ser Leu Val Asp Arg Gly Tyr Trp Asp Asp  
           115                  120                  125

Asp Glu Cys Arg Trp His Val Phe Thr Ala Asp Gly Arg Glu Tyr Val  
       130                  135                  140

Ala Gln Phe Leu Ile Ser Gly Ala Gly Ala Leu His Ile Pro Ser Phe  
       145                  150                  155                  160

Pro Glu Ile Ala Gly Arg Asp Glu Phe Ala Gly Pro Ala Phe His Ser  
                   165                  170                  175

Ala Gln Trp Asp His Ser Ile Asp Leu Thr Gly Lys Arg Val Ala Ile  
                   180                  185                  190

Val Gly Thr Gly Ala Ser Ala Ile Gln Ile Val Pro Glu Ile Val Gly  
           195                  200                  205

Gln Val Ala Glu Leu Gln Leu Tyr Gln Arg Thr Pro Pro Trp Val Val  
       210                  215                  220

Pro Arg Thr Asn Glu Glu Leu Pro Val Ser Leu Arg Arg Ala Leu Arg  
       225                  230                  235                  240

Thr Val Pro Gly Leu Arg Ala Leu Leu Arg Leu Gly Ile Tyr Trp Ala  
                   245                  250                  255

Gln Glu Ala Leu Ala Tyr Gly Met Thr Lys Arg Pro Asn Thr Leu Lys  
                   260                  265                  270

Ile Ile Glu Ala Tyr Ala Lys Tyr Asn Ile Arg Arg Ser Val Lys Asp  
           275                  280                  285

Arg Glu Leu Arg Arg Lys Leu Thr Pro Arg Tyr Arg Ile Gly Cys Lys  
       290                  295                  300

Arg Ile Leu Asn Ser Ser Thr Tyr Tyr Pro Ala Val Ala Asp Pro Lys  
       305                  310                  315                  320

Thr Glu Leu Ile Thr Asp Arg Ile Asp Arg Ile Thr His Asp Gly Ile  
                   325                  330                  335

-11-

Val Thr Ala Asp Gly Thr Gly Arg Glu Val Phe Arg Glu Ala Asp Val  
                   340                  345                  350

Ile Val Tyr Ala Thr Gly Phe His Val Thr Asp Ser Tyr Thr Tyr Val  
                   355                  360                  365

Gln Ile Lys Gly Arg His Gly Glu Asp Leu Val Asp Arg Trp Asn Arg  
                   370                  375                  380

Glu Gly Ile Gly Ala His Arg Gly Ile Thr Val Ala Asn Met Pro Asn  
                   385                  390                  395                  400

Leu Phe Phe Leu Leu Gly Pro Asn Thr Gly Leu Gly His Asn Ser Val  
                   405                  410                  415

Val Phe Met Ile Glu Ser Gln Ile His Tyr Val Ala Asp Ala Ile Ala  
                   420                  425                  430

Lys Cys Asp Arg Met Gly Val Gln Ala Leu Ala Pro Thr Arg Glu Ala  
                   435                  440                  445

Gln Asp Arg Phe Asn Gln Glu Leu Gln Arg Arg Leu Ala Gly Ser Val  
                   450                  455                  460

Trp Asn Ser Gly Gly Cys Arg Ser Trp Tyr Leu Asp Glu His Gly Lys  
                   465                  470                  475                  480

Asn Thr Val Leu Trp Cys Gly Tyr Thr Trp Gln Tyr Trp Leu Thr Thr  
                   485                  490                  495

Arg Ser Val Asn Pro Ala Glu Tyr Arg Phe Phe Gly Ile Gly Asn Gly  
                   500                  505                  510

Leu Ser Ser Asp Arg Ala Thr Val Ala Ala Ala Asn  
                   515                  520

<210> 8

<211> 1572

<212> DNA

<213> Mycobacterium tuberculosis

-12-

<400> 8  
 gtgagcattg ccgatacggc tgccaagccg tccacgccaa gcccggccaa ccagccgcgc 60  
 gtacgtaccc gcgcgcgtcat catcggaacc ggattctccg gtttgggcat ggccatcgca 120  
 ctgcaaaaagc aaggagtggc cttcgtcata ttggagaaag ccgacgacgt cggcggcacc 180  
 tggcgcgcaca acacctaccc cggtgcgcgc tgcgacatcc cgtgcacact gtactccttc 240  
 tcgttcgagc ccaaggcggc ctggaaacac ctgttttcct actgggacga aatcttgggc 300  
 tacctcaaag gggtcaccga caagtacggc ctgcgcgcgt acatcgagtt caattcgctc 360  
 gtcgatcgcg gctactggga cgacgacgaa tgccgctggc acgtgttcac cgccgacggg 420  
 cgtgaatacg tcgcgcagtt cctgatctcc ggggcgggtg cgttgacat cccgtccttc 480  
 cccgagatcg caggtcgcga cgaattcgcc ggccccgctt tccattccgc ccagtgggac 540  
 cacagtatcg acctgaccgg caagcgggtg gcgatcgctg ggaccgggtg cagcgcgac 600  
 cagatcgctg ccgagatcgt cggccaggtc gcgaacttc agctctatca gcgcaccccg 660  
 ccgtgggtgg tcccgcgcac caacgaagag ctgccggtgt cgctgcgcgc ggctgtgcga 720  
 accgtccccg ggctacgggc actgttgccg ctcggcatct actgggcca ggaggcgctg 780  
 gcctacggca tgaccaagcg gcccaacacg ttgaagatca tcgaggccta tgccaaatac 840  
 aatattcgct gatcggtgaa ggatcgcgag ctgcggcgca agctgacgcc gcggtatcgc 900  
 atcggctgca aacggatcct gaactcctct acctattacc ccgcgggtggc ggaccggaag 960  
 accgaactga tcaccgaccg catcgaccgg atcacgcacg acgggatcgt caccgccgac 1020  
 ggcactggcc gtgaggtcct ccgggaagcc gatgtgatcg tgtacgccac cggcttccac 1080  
 gtcaccgact cctataccta tgtgcagatc aaggggcgtc acggcgagga cctggtcgac 1140  
 cgctggaacc gtgagggcac cgggtgcacac cgcgggatca ccgtcgccaa catgccccac 1200  
 ctgttcttcc tgctggggcc gaacactggg ctgggacaca actccgtggg gttcatgatc 1260  
 gaatcgcaga tccattacgt ggccgatcgc atcgcgaaat gcgaccgat gggcgtgcaa 1320  
 gcgctggccc ccaccgcga ggcgcaagac cggttcaacc aggagctgca gcgcaggctg 1380  
 gctgggtcgg tgtggaacag tggcggctgc cgcagctggg atctcgacga gcacggcaag 1440  
 aacaccgtgc tctggtgcgg ctacacctgg caatactggc tgaccacccg ctcggtcaac 1500  
 cccgcgagt accggttctt cgggatcggc aacggtttgt cgagcgaccg cgcgacggtc 1560  
 gctgcggcga ac 1572

&lt;210&gt; 9

-13-

&lt;211&gt; 444

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 9

Met Ser Asp Asn Asp Pro Val Val Ile Val Gly Leu Ala Ile Glu Ala  
1 5 10 15

Pro Gly Gly Val Glu Thr Ala Asp Asp Tyr Trp Thr Leu Leu Ser Glu  
20 25 30

Gln Arg Glu Gly Leu Gly Pro Phe Pro Thr Asp Arg Gly Trp Ala Leu  
35 40 45

Arg Glu Leu Phe Asp Gly Ser Arg Arg Asn Gly Phe Lys Pro Ile His  
50 55 60

Asn Leu Gly Gly Phe Leu Ser Ser Ala Thr Thr Phe Asp Pro Glu Phe  
65 70 75 80

Phe Arg Ile Ser Pro Arg Glu Ala Thr Ala Met Asp Pro Gln Gln Arg  
85 90 95

Val Gly Leu Arg Val Ala Trp Arg Thr Leu Glu Asn Ser Gly Ile Asn  
100 105 110

Pro Asp Asp Leu Ala Gly His Asp Val Gly Cys Tyr Val Gly Ala Ser  
115 120 125

Ala Leu Glu Tyr Gly Pro Ala Leu Thr Glu Phe Ser His His Ser Gly  
130 135 140

His Leu Ile Thr Gly Thr Ser Leu Gly Val Ile Ser Gly Arg Ile Ala  
145 150 155 160

Tyr Thr Leu Asp Leu Ala Gly Pro Ala Leu Thr Val Asp Thr Ser Cys  
165 170 175

Ser Ser Ala Leu Ala Ala Phe His Thr Ala Val Gln Ala Ile Arg Ala  
180 185 190

-14-

Gly Asp Cys Asp Leu Ala Leu Ala Gly Gly Val Cys Val Met Gly Thr  
 195 200 205

Pro Gly Tyr Phe Val Glu Phe Ser Lys Gln His Ala Leu Ser Asp Asp  
 210 215 220

Gly His Cys Arg Pro Tyr Ser Ala His Ala Ser Gly Thr Ala Trp Ala  
 225 230 235 240

Glu Gly Ala Ala Met Phe Leu Leu Gln Arg Arg Ser Arg Ala Thr Ala  
 245 250 255

Asp Arg Arg Arg Val Leu Ala Glu Val Arg Ala Ser Cys Leu Asn Ser  
 260 265 270

Asp Gly Leu Ser Asp Gly Leu Thr Ala Pro Ser Gly Asp Ala Gln Thr  
 275 280 285

Arg Leu Leu Arg Arg Ala Ile Ala Gln Ala Ala Val Val Pro Ala Asp  
 290 295 300

Val Gly Met Val Glu Gly His Gly Thr Ala Thr Arg Leu Gly Asp Arg  
 305 310 315 320

Thr Glu Leu Arg Ser Leu Ala Ala Ser Tyr Gly Thr Ala Pro Ala Gly  
 325 330 335

Arg Gly Pro Leu Leu Gly Ser Val Lys Ser Asn Ile Gly His Ala Gln  
 340 345 350

Ala Ala Ala Gly Gly Leu Gly Leu Val Lys Val Ile Leu Ala Ala Gln  
 355 360 365

His Ala Ala Ile Pro Pro Thr Leu His Val Asp Glu Pro Ser Arg Glu  
 370 375 380

Ile Asp Trp Glu Lys Gln Gly Leu Arg Leu Ala Asp Lys Leu Thr Pro  
 385 390 395 400

Trp Arg Ala Val Asp Gly Trp Arg Thr Ala Ala Val Ser Ala Phe Gly  
 405 410 415

Met Ser Gly Thr Asn Ser His Val Ile Val Ser Met Pro Asp Thr Val  
 420 425 430

-15-

Ser Ala Pro Glu Arg Gly Pro Glu Cys Gly Glu Val  
 435 440

&lt;210&gt; 10

&lt;211&gt; 1332

&lt;212&gt; DNA

<213> *Mycobacterium tuberculosis*

&lt;400&gt; 10

```

atgtccgata acgacccggg cgtcatcgtc gggctggcca tcgaggcacc cggtaggtgtc      60
gaaaccgccc acgactactg gacactgctc tccgaacagc gcgagggact cggaccgttc      120
cccaccgatc gaggttgggc acttcgcgag ctgttcgacg ggtcgcgtcg aaacggattc      180
aaaccgatcc acaaccttgg cggattcctt tccagcgcaa ctacattcga tcctgagtcc      240
ttcgcacatc caccgcgcga ggcgacggcg atggaccgcg agcagcgggt ggggctgcga      300
gtagcatggc gcaccttggg gaacagcggg atcaatcccg atgacctggc cggtcacgat      360
gtgggctgtt atgtcgggtc ctgggcgctc gaatacggtc ccgctttgac cgaattctcc      420
caccacagtg gccatctgat caccgggacg tcgctgggtg tcctctccgg gcgcacgcgc      480
tacacccttg acctggccgg gccggcgctg accgtcgata cctcgtgttc gtcggcgctg      540
ggggcctttc acaccgcggg tcaagctatc cgggcccggc actgcgacct ggcactcgcc      600
ggcggcggtg gcgtgatggg tacgcccggc tatttcgtcg agttctccaa gcagcacgcg      660
ctatccgagc acggccactg ccggccctac agcgcgcacg ccagcggaac cgcctgggca      720
gagggcgccc ccattgttct cctgcagcgc cggctcgcggg caaccgctga ccggcgctcg      780
gtcctcgccg aggtgctgtc cagttgcctg aactccgatg gacttagcga cgggctgacc      840
gcgccagcgc gcgacgcgca aacgcgactg ctccggcgcg ccatcgcgca ggcagcagtt      900
gtgcccgccc atgtcgggat ggtcgaaggg cacggcaccg cgaccgggct cggcgatcgc      960
accgaattgc ggtcactggc agccagctac ggcaccgccc cggccggacg cgggcccgtg     1020
ttgggatcgg tcaagtcaaa catcgggcat gctcaggcgg cggcggggcg gctgggcctt     1080
gtgaaggtca ttctggccgc ccagcacgcc gcgatccgcg cgacactgca cgtcgacgag     1140
cccagccgcg aaatcgattg ggagaaacag ggtctgcggc tggccgacaa actcacgcgc     1200
tggggggccc ttgacggatg gcgcaccgcg gcggtgtccg cgttcgggat gagcgggtacc     1260

```



-16-

aatagccacg tgatcgtttc gatgccggac accgtttccg cgcccgagcg tggccccgag 1320

tgtggggagg tg 1332

&lt;210&gt; 11

&lt;211&gt; 1004

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 11

Met Ala Pro Lys Gln Leu Pro Asp Gly Arg Val Ala Val Leu Leu Ser  
 1 5 10 15

Ala His Ala Glu Glu Leu Ile Gly Pro Asp Ala Arg Ala Ile Ala Asp  
 20 25 30

Tyr Leu Glu Arg Phe Pro Ala Thr Thr Val Thr Glu Val Ala Arg Gln  
 35 40 45

Leu Arg Lys Thr Arg Arg Val Arg Arg His Arg Ala Val Leu Arg Ala  
 50 55 60

Ala Asp Arg Leu Glu Leu Ala Glu Gly Leu Arg Ala Leu Ala Ala Gly  
 65 70 75 80

Arg Glu His Pro Leu Ile Ala Arg Ser Ser Leu Gly Ser Ala Pro Arg  
 85 90 95

Gln Ala Phe Val Phe Pro Gly Gln Gly Gly His Trp Pro Gly Met Gly  
 100 105 110

Ala Val Ala Tyr Arg Glu Leu Pro Thr Tyr Arg Thr Ala Thr Asp Thr  
 115 120 125

Cys Ala Ala Ala Phe Ala Ala Ala Gly Val Asp Ser Pro Leu Pro Tyr  
 130 135 140

Leu Ile Ala Pro Pro Gly Thr Asp Glu Arg Gln Ala Phe Cys Glu Ile  
 145 150 155 160

Glu Ile Glu Gly Ala Gln Phe Val His Ala Val Ala Leu Ala Glu Val

-17-

165

170

175

Trp Arg Ser Cys Gly Val Leu Pro Asp Leu Thr Val Gly His Ser Leu  
 180 185 190

Gly Glu Val Ala Ala Ala Tyr Leu Ala Gly Ser Ile Thr Leu Ser Asp  
 195 200 205

Ala Val Ala Val Val Ala Ala Arg Ala Asn Val Val Gly Arg Leu Pro  
 210 215 220

Gly Arg Tyr Ala Val Ala Ala Leu Gly Ile Gly Glu Gln Asp Ala Ser  
 225 230 235 240

Ala Leu Ile Ala Thr Thr Gly Gly Trp Leu Glu Leu Ser Val Val Asn  
 245 250 255

Ala Ser Ser Thr Val Ala Val Ser Gly Glu Arg Gln Ala Val Ala Ala  
 260 265 270

Ile Val Asp Thr Val Arg Ser Ser Gly His Phe Ala Arg Gly Ile Thr  
 275 280 285

Val Gly Phe Pro Val His Thr Ser Val Leu Glu Ser Leu Arg Asp Glu  
 290 295 300

Leu Cys Glu Gln Leu Pro Asp Ser Glu Phe Met Glu Ala Pro Val Gln  
 305 310 315 320

Phe Ile Gly Gly Thr Thr Gly Asp Val Val Ala Pro Gly Thr Thr Phe  
 325 330 335

Gly Asp Tyr Trp Tyr Ala Asn Leu Arg His Thr Val Arg Phe Asp Arg  
 340 345 350

Ala Val Glu Ser Ala Ile Arg Cys Gly Ala Arg Ala Phe Ile Glu Ile  
 355 360 365

Ser Ala His Pro Ala Leu Leu Phe Ala Ile Gly Gln Asn Cys Glu Gly  
 370 375 380

Ala Ala Asn Leu Pro Asp Gly Pro Ala Val Leu Val Gly Ser Ala Arg  
 385 390 395 400

-18-

Arg Gly Glu Arg Phe Val Asp Ala Leu Ser Ala Asn Ile Val Ser Ala  
                     405                    410                    415

Ala Val Ala Asp Pro Gly Tyr Pro Trp Gly Asp Leu Gly Gly Asp Pro  
                     420                    425                    430

Leu Asp Gly Asp Val Asp Leu Ser Gly Phe Pro Asn Ala Pro Met Arg  
                     435                    440                    445

Ala Val Pro Met Trp Ala His Pro Glu Pro Leu Pro Pro Val Ser Gly  
                     450                    455                    460

Leu Thr Ile Ala Val Glu Arg Trp Glu Arg Met Val Pro Ser Thr Pro  
                     465                    470                    475                    480

Val Ala Gly Arg His Arg His Leu Ala Val Leu Asp Leu Gly Ala His  
                     485                    490                    495

Arg Ala Leu Ala Gln Thr Leu Cys Ala Ala Ile Asp Ser His Pro Asp  
                     500                    505                    510

Thr Glu Leu Ser Ala Ala Arg Asp Ala Glu Leu Ile Leu Val Ile Ala  
                     515                    520                    525

Pro Asp Phe Glu His Thr Asp Ala Val Arg Ala Ala Gly Ala Leu Ala  
                     530                    535                    540

Asp Leu Val Gly Ala Gly Leu Leu Asp Tyr Pro Met His Ile Gly Ala  
                     545                    550                    555                    560

Arg Cys Gln Ser Val Cys Leu Val Thr Val Gly Ala Glu Gln Val Asp  
                     565                    570                    575

Ala Ala Asp Ala Val Pro Ser Ala Gly Gln Ala Ala Leu Ala Ala Met  
                     580                    585                    590

His Arg Ser Ile Gly Phe Glu His Pro Glu Gln Thr Phe Ser His Leu  
                     595                    600                    605

Asp Leu Pro Ser Trp Asp Leu Asp Pro Val Leu Gly Val Ser Val Ile  
                     610                    615                    620

Thr Ala Val Leu Arg Gly Phe Gly Glu Thr Ala Leu Arg Gly Ser Val  
                     625                    630                    635                    640

-19-

Asn Gly Tyr Thr Leu Phe Glu Arg Thr Leu Ala Asp Ala Pro Ala Val  
 645 650 655

Pro Asn Trp Ser Leu Asp Ser Gly Val Leu Asp Asp Val Val Val Thr  
 660 665 670

Gly Gly Ala Gly Ala Ile Gly Met His Tyr Ala Arg Tyr Leu Ala Glu  
 675 680 685

His Gly Ala Arg Arg Ile Val Leu Leu Ser Arg Arg Ala Ala Asp Gln  
 690 695 700

Ala Thr Val Ala Met Leu Arg Lys Gln His Gly Thr Val Ile Val Ser  
 705 710 715 720

Pro Pro Cys Asp Ile Thr Asp Pro Thr Gln Leu Ser Ala Ile Ala Ala  
 725 730 735

Glu Tyr Gly Gly Val Gly Ala Ser Leu Ile Val His Ala Ala Gly Ser  
 740 745 750

Val Ile Ser Gly Thr Ala Pro Gly Val Thr Ser Ala Ala Val Val Asp  
 755 760 765

Asn Phe Ala Ala Lys Val Leu Gly Leu Ala Gln Met Ile Glu Leu Trp  
 770 775 780

Pro Leu Arg Pro Asp Val Arg Thr Leu Leu Cys Ser Ser Val Met Gly  
 785 790 795 800

Val Trp Gly Gly His Gly Val Val Ala Tyr Ser Ala Ala Asn Arg Leu  
 805 810 815

Leu Asp Val Met Ala Ala Gln Leu Arg Ala Gln Gly Arg His Cys Val  
 820 825 830

Ala Val Lys Trp Gly Leu Trp Gln Ala Pro Lys Ala Gly Glu Pro Ala  
 835 840 845

Arg Gly Ile Ala Asp Ala Val Thr Ile Ala Arg Val Glu Arg Ser Gly  
 850 855 860

Leu Arg Gln Met Ala Pro Gln Gln Ala Ile Glu Ala Ser Leu His Glu

[illegible]

<213> Mycobacterium tuberculosis

|            |            |            |            |            |            |     |
|------------|------------|------------|------------|------------|------------|-----|
| atggcccca  | aacagctgcc | cgatgggcgg | gttgcggttt | tgctcagcgc | ccatgccgag | 60  |
| gaactgatcg | ggccggacgc | tggggccatc | gccgactacc | tcgagcgctt | tccggctacg | 120 |
| accgtgaccg | aagtggctcg | gcagctgcgc | aagacccgac | gggtccgctg | gcacgggcgc | 180 |
| gtgcttcggg | cgcgcgaccg | gctggaactc | gccgagggct | tgcgcgcgct | ggccgcggga | 240 |
| cgcgagcatc | cgctcatcgc | gcggtcgctg | ttgggctcgg | ccccgcgcca | ggcgttcgtc | 300 |
| tttcccqcc  | agggtggtca | ttggccgggc | atgggcgcgc | tgcctaccg  | cgagctgccg | 360 |

-21-

|             |             |             |             |            |            |      |
|-------------|-------------|-------------|-------------|------------|------------|------|
| acctatcggg  | ccgcgaccga  | cacgtgcgcc  | gccgcatttg  | cggccgctgg | tgtcgactcg | 420  |
| ccgctgccat  | acctgatcgc  | cccgcccgga  | accgatgagc  | ggcaagcgtt | ctgcgagatc | 480  |
| gagatcgaag  | gcgcgcagtt  | cgtccatgcc  | gttgcgctgg  | cggaggtatg | gcgttcctgc | 540  |
| gggtgtgctgc | ccgatcctaac | agtcgggtcat | agcctcggcg  | aagtagcggc | ggcctatctc | 600  |
| gcaggaagta  | tcaccttgtc  | ggatgctgtg  | gccgtggtgg  | cggcccgcgc | caacgtggtg | 660  |
| ggccgcttgc  | ctggtcgcta  | tgcggtggcg  | gcgctgggca  | tcggtgaaca | ggacgcgagc | 720  |
| gcgctgatcg  | cgaccaccgg  | cggctggctg  | gaactgtctg  | tggccaatgc | ctcctcgacc | 780  |
| gtcgccgtgt  | cgggtgagcg  | ccaagcggta  | gcggccatcg  | ttgacacagt | cgggtccagc | 840  |
| ggtcacttcg  | cccgcgggat  | caccgtgggc  | ttcccgggtg  | ataccagcgt | gctcgaatcg | 900  |
| ctccgcgatg  | aattatgcga  | gcagctgcct  | gactccgaat  | ttatggaagc | gccagtgcaa | 960  |
| ttcatcggcg  | gaaccaccgg  | cgacgtggtg  | gcgccaggca  | ccactttcgg | cgactactgg | 1020 |
| tacgcaaacc  | tgcgccatac  | gggtgcgtttc | gaccgcgctg  | tcgaatcggc | aatccgctgt | 1080 |
| ggagcacggg  | cgttcacoga  | gatatcggcc  | catcccgcgc  | tgttgtttgc | gatcggtcag | 1140 |
| aactgtgagg  | gcgcgcgcaa  | cctgccggac  | ggcccccgtg  | tgctggtcgg | gtcggcacgt | 1200 |
| cgtggcgagc  | ggtttgttga  | tgcgttgctg  | gcgaatattg  | ttagcgcggc | ggtcgctgac | 1260 |
| cctggctacc  | cgtgggggtga | cctggggcgt  | gacccactcg  | acggcgacgt | cgatctgtcc | 1320 |
| gggttcccga  | acgcgccgat  | gcgtgcggtg  | ccgatgtggg  | cgacccccga | accgctgccg | 1380 |
| ccggtgtccg  | gactgaccat  | tgcggttgag  | cgggtgggaac | ggatggtgcc | gtcgacaccg | 1440 |
| gtcgctgggc  | ggcaccgtca  | cctcgcagtg  | ctcgatctcg  | gtgctcaccg | cgcgctggct | 1500 |
| caaacactgt  | gcgcagcaat  | tgattcgcac  | cccgataaccg | agctgagtgc | tgcgcgggac | 1560 |
| gccgagttga  | tcctgggtgat | cgcgcccgc   | ttcgaacaca  | cgaacgccgt | ccgggcccgc | 1620 |
| gggtgcaactg | ccgacctcgt  | cggggccggg  | ttgctggact  | atccgatgca | tatcggtgcc | 1680 |
| cgttgccaat  | cggatatgtc  | ggtcaccgtc  | ggcgccgagc  | aggtcgacgc | agcggacgcg | 1740 |
| gtgccgtcgg  | ccggccaggc  | cgcgctggcc  | gcgatgcac   | gaagcatcgg | attcgagcat | 1800 |
| cccgaacaga  | ctttcagcca  | cctggacttg  | ccgtcgtggg  | acttggaccc | ggccctcggc | 1860 |
| gtctcggtea  | taacggcggg  | actgcggggc  | ttcgggtgaga | ccgcgctacg | cggctcggta | 1920 |
| aacgggtaca  | cgctgttcga  | gcgaaccctc  | gccgatgccc  | cggccgtccc | gaactggctg | 1980 |
| ttggactccg  | gcgtgctcga  | cgatgtcgtc  | gtcaccgggtg | gcgcgggtgc | catcgggatg | 2040 |
| cactacgcgc  | ggatatctgc  | cgagcatggc  | gcacggcgca  | tcgtgctgct | cagccggcgc | 2100 |

-22-

```

gccgcggatc aggcgacggt ggccatgctc agaaagcaac atggcaccgt gatcgtgtcg 2160
ccgccgtgcg atatcaccca tcccaccagc ttgtcagcga ttgcagccga atacggtggc 2220
gtcggcgccct cgttgatcgt gcacgeggca ggcagcgtga tctctggtac cgcaccgggg 2280
gtgacgtcgg ccgccgtcgt tgacaacttc ggggccaaagg tgctcggcct ggcccagatg 2340
atcgagctgt ggccgctgcg ccgggatgtg cgaaccctgc tgtgttcctc ggtgatgggg 2400
gtgtgggggtg gacacgggggt ggtcgcgtac tggcgggcca accggctgct cgacgtgatg 2460
gccgcccagc tcgcgcacca gggcaggcac tgcgtggcgg tgaaatgggg cctatggcag 2520
gcccccaagg ccggcgaacc agctcgggga atcgcggatg cggttacgat cgccgcgctc 2580
gagcgggtctg gactccgcca gatggcgccc cagcaggcga tcgaggcgag cctgcacgaa 2640
ttcactgtcg acccgctagt gttcgccgcc gacgcggccc ggttgacgat gttgttggac 2700
agcaggcaat tcgaacggta cgagggtcca accgaccca acctgacgat cgtggacgcg 2760
gtgcgcaccc aattggcggc cgtgctcggg atcccgagg ccggcgaggt gaacctgcag 2820
gaatcgctgt tcgatctcgg tgtcgattcc atgctggcac tggacttgcg taaccgactc 2880
aaacgatcaa tcggcgcgac ggtgtcgtcg gccacgtca tgggcgacat caccggtgat 2940
ggacttgtcg cgaaactcga agatgccgac gagcgctcac acaccgcaca gaaagtggac 3000
atttcgctg ac 3012

```

&lt;210&gt; 13

&lt;211&gt; 1461

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 13

```

Met Gly Pro Val Ala Val Thr Arg Ala Asp Ala Arg Gly Ala Ile Asp
1           5           10           15

```

```

Asp Val Met Ala Leu Ser Pro Leu Gln Gln Gly Leu Phe Ser Arg Ala
20           25           30

```

```

Thr Leu Val Ala Ala Glu Ser Gly Ser Glu Ala Ala Glu Ala Asp Pro
35           40           45

```

```

Tyr Val Ile Ala Met Ala Ala Asp Ala Ala Gly Pro Leu Asp Ile Ala

```

-23-

|                                                                 |     |     |     |     |
|-----------------------------------------------------------------|-----|-----|-----|-----|
| 50                                                              |     | 55  |     | 60  |
| Leu Leu Arg Asp Cys Ala Ala Ala Met Leu Thr Arg His Pro Asn Leu |     |     |     |     |
| 65                                                              |     | 70  |     | 75  |
|                                                                 |     |     |     | 80  |
| Arg Ala Ser Phe Leu His Gly Asn Leu Ser Arg Pro Val Gln Val Ile |     |     |     |     |
|                                                                 | 85  |     | 90  | 95  |
| Pro Ser Ser Ala Glu Val Leu Trp Arg His Val Arg Ala His Pro Ser |     |     |     |     |
|                                                                 | 100 |     | 105 | 110 |
| Glu Val Gly Ala Leu Ala Ala Glu Glu Arg Arg Arg Arg Phe Asp Val |     |     |     |     |
|                                                                 | 115 |     | 120 | 125 |
| Gly Arg Gly Pro Leu Ile Arg Phe Leu Leu Ile Glu Leu Pro Asp Glu |     |     |     |     |
| -130                                                            |     | 135 |     | 140 |
| Cys Trp His Leu Val Ile Val Ala His His Ile Val Ile Asp Gly Trp |     |     |     |     |
| 145                                                             |     | 150 |     | 155 |
|                                                                 |     |     |     | 160 |
| Ser Leu Pro Leu Phe Val Ser Glu Leu Leu Ala Leu Tyr Arg Ala Gly |     |     |     |     |
|                                                                 | 165 |     | 170 | 175 |
| Gly His Val Ala Ala Leu Pro Ala Ala Pro Arg Pro Tyr Arg Asp Tyr |     |     |     |     |
|                                                                 | 180 |     | 185 | 190 |
| Ile Gly Trp Leu Ala Gly Arg Asp Gln Thr Ala Ser Arg Ala Met Trp |     |     |     |     |
|                                                                 | 195 |     | 200 | 205 |
| Ala Asp His Leu Asn Gly Leu Asp Gly Pro Thr Leu Leu Ser Pro Ala |     |     |     |     |
|                                                                 | 210 |     | 215 | 220 |
| Leu Ala Asp Thr Pro Val Gln Pro Gly Ile Pro Gly Arg Thr Glu Val |     |     |     |     |
| 225                                                             |     | 230 |     | 235 |
|                                                                 |     |     |     | 240 |
| Arg Leu Asp Arg Glu Ala Thr Ala Glu Leu Ala Asp Ala Ala Arg Thr |     |     |     |     |
|                                                                 | 245 |     | 250 | 255 |
| Arg Gly Val Thr Ile Ser Thr Leu Val Gln Met Ala Trp Ala Thr Thr |     |     |     |     |
|                                                                 | 260 |     | 265 | 270 |
| Leu Ser Ala Phe Thr Gly Arg Gly Asp Val Thr Phe Gly Val Thr Val |     |     |     |     |
|                                                                 | 275 |     | 280 | 285 |



-24-

Ser Gly Arg Pro Ser Glu Leu Ser Gly Val Glu Thr Met Ile Gly Leu  
 290 295 300

Phe Ile Asn Thr Val Pro Leu Arg Val Arg Leu Asp Ala Arg Ala Thr  
 305 310 315 320

Val Gly Gly Gln Cys Ala Val Leu Gln Arg Gln Phe Ala Met Leu Arg  
 325 330 335

Asp His Ser Tyr Leu Gly Phe Asn Glu Phe Arg Ala Ile Ala Gly Ile  
 340 345 350

Gly Glu Met Phe Asp Thr Leu Leu Val Tyr Glu Asn Phe Pro Pro Gly  
 355 360 365

-----Glu-Val Val Gly Thr Ala-Glu Phe Val Ala-Asn Gly Val Thr Phe Arg  
 370 375 380

Pro Val Ala Leu Glu Ser Leu Ser His Phe Pro Val Thr Val Ala Ala  
 385 390 395 400

His Arg Ser Thr Gly Glu Leu Thr Leu Leu Val Glu Val Leu Asp Gly  
 405 410 415

Ala Leu Gly Thr Met Ala Pro Glu Ser Leu Gly Arg Arg Val Leu Ala  
 420 425 430

Val Leu Gln Arg Leu Val Ser Arg Trp Asp Arg Pro Leu Arg Asp Val  
 435 440 445

Asp Ile Leu Leu Asp Gly Glu His Asp Pro Thr Ala Pro Gly Leu Pro  
 450 455 460

Asp Val Thr Thr Ser Ala Pro Ala Val His Thr Arg Phe Ala Glu Ile  
 465 470 475 480

Ala Ala Ala Gln Pro Asp Ser Val Ala Val Ser Trp Ala Asp Gly Gln  
 485 490 495

Leu Thr Tyr Arg Glu Leu Asp Ala Leu Ala Asp Arg Leu Ala Thr Gly  
 500 505 510

Leu Arg Arg Ala Asp Val Ser Arg Glu Thr Pro Val Ala Val Ala Leu  
 515 520 525

-25-

Ser Arg Gly Pro Arg Tyr Val Ala Ala Met Leu Ala Val Leu Lys Ala  
 530 535 540

Gly Gly Met Ile Val Pro Leu Asp Pro Ala Met Pro Gly Glu Arg Val  
 545 550 555 560

Ala Glu Ile Leu Arg Gln Thr Ser Ala Pro Val Val Ile Asp Glu Gly  
 565 570 575

Val Phe Ala Ala Ser Val Gly Ala Asp Ile Leu Glu Glu Asp Arg Ala  
 580 585 590

Ile Thr Val Pro Val Asp Gln Ala Ala Tyr Val Ile Phe Thr Ser Gly  
 595 600 605

Thr Thr Gly Thr Pro Lys Gly Val Ile Gly Thr His Arg Ala Leu Ser  
 610 615 620

Ala Tyr Ala Asp Asp His Ile Glu Arg Val Leu Arg Pro Ala Ala Gln  
 625 630 635 640

Arg Leu Gly Arg Pro Leu Arg Ile Ala His Ala Trp Ser Phe Thr Phe  
 645 650 655

Asp Ala Ala Trp Gln Pro Leu Val Ala Leu Leu Asp Gly His Ala Val  
 660 665 670

His Ile Val Asp Asp His Arg Gln Arg Asp Ala Gly Ala Leu Val Glu  
 675 680 685

Ala Ile Asp Arg Phe Gly Leu Asp Met Ile Asp Thr Thr Pro Ser Met  
 690 695 700

Phe Ala Gln Leu His Asn Ala Gly Leu Leu Asp Arg Ala Pro Leu Ala  
 705 710 715 720

Val Leu Ala Leu Gly Gly Glu Ala Leu Gly Ala Ala Thr Trp Arg Met  
 725 730 735

Ile Gln Gln Asn Cys Ala Arg Thr Ala Met Thr Ala Phe Asn Cys Tyr  
 740 745 750

Gly Pro Thr Glu Thr Thr Val Glu Ala Val Val Ala Ala Val Ala Glu

-26-

|                                                                 |     |     |     |         |
|-----------------------------------------------------------------|-----|-----|-----|---------|
| 755                                                             |     | 760 |     | 765     |
| His Ala Arg Pro Val Ile Gly Arg Pro Thr Cys Thr Thr Arg Ala Tyr |     |     |     |         |
| 770                                                             |     | 775 |     | 780     |
| Val Met Asp Ser Trp Leu Arg Pro Val Pro Asp Gly Val Ala Gly Glu |     |     |     |         |
| 785                                                             |     | 790 |     | 795 800 |
| Leu Tyr Leu Ala Gly Ala Gln Leu Thr Arg Gly Tyr Leu Gly Arg Pro |     |     |     |         |
|                                                                 | 805 |     | 810 | 815     |
| Ala Glu Thr Ala Ala Arg Phe Val Ala Glu Pro Asn Gly Arg Gly Ser |     |     |     |         |
|                                                                 | 820 |     | 825 | 830     |
| Arg Met Tyr Arg Thr Gly Asp Val Val Arg Arg Leu Pro Asp Gly Gly |     |     |     |         |
|                                                                 | 835 |     | 840 | 845     |
| Leu Glu Phe Leu Gly Arg Ser Asp Asp Gln Val Lys Ile Arg Gly Phe |     |     |     |         |
|                                                                 | 850 |     | 855 | 860     |
| Arg Val Glu Pro Gly Glu Ile Ala Ala Val Leu Asn Gly His His Ala |     |     |     |         |
|                                                                 | 865 |     | 870 | 875 880 |
| Val His Gly Cys His Val Thr Ala Arg Gly His Ala Ser Gly Pro Arg |     |     |     |         |
|                                                                 | 885 |     | 890 | 895     |
| Leu Thr Ala Tyr Val Ala Gly Gly Pro Gln Pro Pro Pro Val Ala Glu |     |     |     |         |
|                                                                 | 900 |     | 905 | 910     |
| Leu Arg Ala Met Leu Leu Glu Arg Leu Pro Arg Tyr Leu Val Pro His |     |     |     |         |
|                                                                 | 915 |     | 920 | 925     |
| His Ile Val Val Leu Asp Glu Leu Pro Leu Thr Pro His Gly Lys Ile |     |     |     |         |
|                                                                 | 930 |     | 935 | 940     |
| Asp Glu Asn Ala Leu Ala Ala Ile Asn Val Thr Glu Gly Pro Ala Thr |     |     |     |         |
|                                                                 | 945 |     | 950 | 955 960 |
| Pro Pro Gln Thr Pro Thr Glu Leu Val Leu Ala Glu Ala Phe Ala Asp |     |     |     |         |
|                                                                 | 965 |     | 970 | 975     |
| Val Met Glu Thr Ser Asn Val Asp Val Thr Ala Gly Phe Leu Gln Met |     |     |     |         |
|                                                                 | 980 |     | 985 | 990     |

-27-

Gly Leu Asp Ser Ile Val Ala Leu Ser Val Val Gln Ala Ala Arg Arg  
 995 1000 1005

Arg Gly Ile Ala Leu Arg Ala Arg Leu Met Val Glu Cys Asp Thr  
 1010 1015 1020

Ile Arg Glu Leu Ala Ala Ala Ile Asp Ser Asp Ala Ala Trp Gln  
 1025 1030 1035

Ala Pro Ala Asn Asp Ala Gly Glu Pro Ile Pro Val Leu Pro Asn  
 1040 1045 1050

Thr His Trp Leu Tyr Glu Tyr Gly Asp Pro Arg Arg Leu Ala Gln  
 1055 1060 1065

Thr Glu Val Ile Arg Leu Pro Asp Arg Ile Thr Arg Glu Arg Leu  
 1070 1075 1080

Asp Ala Val Leu Ala Ala Val Val Asp Gly His Glu Val Leu Arg  
 1085 1090 1095

Cys Arg Phe Asp Arg Asp Ala Met Ala Leu Val Ala Gln Pro Lys  
 1100 1105 1110

Thr Asp Ile Leu Ser Glu Val Trp Val Ser Gly Glu Leu Val Thr  
 1115 1120 1125

Ala Val Ala Glu Gln Thr Leu Gly Ala Leu Ala Ser Leu Asp Pro  
 1130 1135 1140

Gln Ala Gly Arg Leu Leu Ser Ala Val Trp Leu Arg Glu Pro Asp  
 1145 1150 1155

Gly Pro Gly Val Leu Val Leu Thr Ala His Val Leu Ala Met Asp  
 1160 1165 1170

Pro Ala Ser Trp Arg Ile Val Leu Gly Glu Leu Asp Ala Gly Leu  
 1175 1180 1185

His Ala Leu Ala Ala Gly Arg Ala Pro Ser Pro Ala Arg Glu Asn  
 1190 1195 1200

Thr Ser Tyr Arg Gln Trp Ser Arg Leu Leu Ala Gln Arg Ala Lys  
 1205 1210 1215

-28-

|      |     |     |     |     |     |      |     |     |     |     |      |     |     |     |
|------|-----|-----|-----|-----|-----|------|-----|-----|-----|-----|------|-----|-----|-----|
| Ala  | Leu | Asp | Ser | Val | Asp | Phe  | Trp | Val | Ala | Glu | Leu  | Glu | Gly | Ala |
| 1220 |     |     |     |     |     | 1225 |     |     |     |     | 1230 |     |     |     |
| Asp  | Pro | Pro | Leu | Gly | Ala | Arg  | Arg | Val | Ala | Pro | Gln  | Thr | Asp | Arg |
| 1235 |     |     |     |     |     | 1240 |     |     |     |     | 1245 |     |     |     |
| Val  | Gly | Glu | Leu | Ala | Ile | Thr  | Met | Ser | Ile | Ser | Asp  | Ala | Asp | Leu |
| 1250 |     |     |     |     |     | 1255 |     |     |     |     | 1260 |     |     |     |
| Thr  | Ala | Arg | Leu | Leu | Ser | Thr  | Gly | Arg | Ser | Met | Thr  | Asp | Leu | Leu |
| 1265 |     |     |     |     |     | 1270 |     |     |     |     | 1275 |     |     |     |
| Ala  | Thr | Ala | Ala | Ala | Arg | Met  | Val | Thr | Ala | Trp | Arg  | Arg | Gln | Arg |
| 1280 |     |     |     |     |     | 1285 |     |     |     |     | 1290 |     |     |     |
| Gly  | Gln | Gln | Thr | Pro | Ala | Pro  | Leu | Leu | Ala | Leu | Glu  | Thr | His | Gly |
| 1295 |     |     |     |     |     | 1300 |     |     |     |     | 1305 |     |     |     |
| Arg  | Ala | Asp | Val | His | Val | Asp  | Lys | Thr | Ala | Asp | Thr  | Ser | Asp | Thr |
| 1310 |     |     |     |     |     | 1315 |     |     |     |     | 1320 |     |     |     |
| Val  | Gly | Leu | Leu | Ser | Ala | Ile  | Tyr | Pro | Leu | Arg | Ile  | His | Cys | Asp |
| 1325 |     |     |     |     |     | 1330 |     |     |     |     | 1335 |     |     |     |
| Gly  | Ala | Thr | Asp | Phe | Ala | Arg  | Ile | Pro | Gly | Ser | Gly  | Ile | Asp | Tyr |
| 1340 |     |     |     |     |     | 1345 |     |     |     |     | 1350 |     |     |     |
| Gly  | Leu | Leu | Arg | Tyr | Leu | Arg  | Ala | Asp | Thr | Ala | Glu  | Arg | Leu | Arg |
| 1355 |     |     |     |     |     | 1360 |     |     |     |     | 1365 |     |     |     |
| Ala  | His | Arg | Glu | Pro | Gln | Leu  | Leu | Leu | Asn | Tyr | Leu  | Gly | Ser | Leu |
| 1370 |     |     |     |     |     | 1375 |     |     |     |     | 1380 |     |     |     |
| His  | Val | Gly | Val | Gly | Asp | Leu  | Ala | Val | Asp | Arg | Ala  | Leu | Leu | Ala |
| 1385 |     |     |     |     |     | 1390 |     |     |     |     | 1395 |     |     |     |
| Asp  | Val | Gly | Gln | Leu | Pro | Glu  | Pro | Glu | Gln | Pro | Val  | Arg | His | Glu |
| 1400 |     |     |     |     |     | 1405 |     |     |     |     | 1410 |     |     |     |
| Leu  | Thr | Val | Leu | Ala | Ala | Leu  | Leu | Gly | Pro | Ala | Asp  | Ala | Pro | Val |
| 1415 |     |     |     |     |     | 1420 |     |     |     |     | 1425 |     |     |     |
| Leu  | Ala | Thr | Arg | Trp | Arg | Thr  | Leu | Pro | Asp | Ile | Leu  | Ser | Ala | Asp |

Ile Thr Ala  
1460

<210> 14

<211> '4383

<212> DNA

<213> Mycobacterium tuberculosis

<400> 14

|            |            |            |            |            |             |      |
|------------|------------|------------|------------|------------|-------------|------|
| atgggaccag | tggccgtgac | gcgagccgac | gcgcggggcg | ccatcgacga | tgtgatggcg  | 60   |
| ctcagcccat | tgcaacaggg | actgttttct | agggcgacac | tggtcgccgc | ggagtccggc  | 120  |
| tctgaggccg | cagaggccga | cccgatatgt | atcgcgatgg | cggccgacgc | ggccggccccg | 180  |
| ctcgacatcg | cottgcttcg | cgactgcgct | gccgcgatgc | tgaccgggca | ccccaacctg  | 240  |
| cgggcgagct | tcctacacgg | gaacctgagc | cggcccgtgc | aggtaatacc | atccagtgcc  | 300  |
| gaggtgcttt | ggcgtcacgt | gcgcgcccac | cccagtgagg | tcggggcgct | ggcagccgaa  | 360  |
| gagcgccggc | gccgcttcga | cgtcgccgcg | ggaccactca | tccggttcct | gtcatcgaa   | 420  |
| ctaccggacg | aatgttgga  | tctggtcatc | gtcgcgcacc | acatcgtcac | cgacggatgg  | 480  |
| tcgttgccgc | tgttcgtctc | cgagctgctc | gccttgatc  | gggctgggtg | tcacgtcgcc  | 540  |
| gcgttgccgg | cagcgccgcg | gccgtatcgc | gactacatcg | gctggctggc | cggccgcgat  | 600  |
| cagacggcta | gccgcgcaat | gtgggcggac | cacctcaatg | gcctggacgg | cccgaactctg | 660  |
| ttatcgccgg | cactcgccga | cactcctgtg | cagccgggta | ttccgggacg | caccgaagtg  | 720  |
| cgccctgacc | gtgaagccac | cgcggagctg | gccgatgccg | ccgcacccg  | tggcgctcacg | 780  |
| atcagcacac | ttgttcaa   | ggcttgggct | accacgcttt | cagcattcac | cggctcgtggc | 840  |
| gatgtgacgt | tcggtgtgac | ggtgtccggc | agggccagcg | aactgtccgg | cgtggaaacg  | 900  |
| atgatcggcc | tgttcacaa  | tacggtgcca | ctgcgggtcc | gcctggacgc | ccgcgctacc  | 960  |
| gtcggcgggc | aatgcgctgt | cctacaacgt | caattcgcca | tgttgcgcca | ccacagctat  | 1020 |
| ctcggtttca | acgagtttcg | tgccatcgcc | ggtatcggtg | agatgttcga | caccctactg  | 1080 |

-30-

|            |            |             |            |            |             |      |
|------------|------------|-------------|------------|------------|-------------|------|
| gtgtatgaga | acttcccgcc | cggcgagggtg | gtgggcaccg | cggagttcgt | cgcaaaccggg | 1140 |
| gtgacgttcc | gtccggtggc | gctagagagt  | ttgtcgcact | ttccggtgac | cgtcgcccg   | 1200 |
| caccgcagca | ccggtgagct | cacgctgcta  | gtggagggtg | tcgacggtgc | gctgggcacg  | 1260 |
| atggcgcccc | aaagcctcgg | caggcggggtg | ctggctgtgt | tacagcgctt | ggtcagccgg  | 1320 |
| tgggatcggc | cgctgcgcga | cgtcgacatt  | ctgctggacg | gcgagcacga | tccgaccgca  | 1380 |
| cccggcctgc | cggatgtgac | gacgtcggca  | cccgcggtgc | atacccgggt | cgccgaaatc  | 1440 |
| gctgcggcac | agcctgactc | ggtggcggtc  | agttgggcgg | atggtcagct | gacgtaccgg  | 1500 |
| gagctggatg | cattggccga | ccggtcggcc  | actgggctgc | gccgcgcgga | cgtgagtcgc  | 1560 |
| gagaccccg  | tggccgtcgc | gctgtcccgt  | ggtccgcgct | acgtggccgc | catgctggcg  | 1620 |
| gtcctcaagg | cgggtggcat | gatcgtgccg  | ctggaccgg  | cgatgcccg  | tgagcgtgtc  | 1680 |
| gccgagatct | tcgccagac  | atcggtccg   | gtggtcatcg | atgagggcgt | gttcgccgct  | 1740 |
| tcggttggcg | ctgacatact | cgaggaggac  | cgtgccatca | cggtgccgg  | ggaccaggcg  | 1800 |
| gcctacgtga | ttttcacctc | cggcaccacc  | ggtacccgga | aagggtgcat | cggcaccat   | 1860 |
| cgggcgctgt | cggcctacgc | cgacgaccac  | atcgagcgcg | tgttgccggc | ggcggccag   | 1920 |
| cggctcgggc | gcccgtcgc  | aatcgcgcat  | gcctggctgt | tcaccttcga | cgcggcggtg  | 1980 |
| cagccgttgg | tcgcaactgt | tgacggccac  | gcggtgcaca | ttgtcgacga | ccatcgtcag  | 2040 |
| cgggacgcag | gggcgtgggt | cgaagcgatc  | gaccgattcg | gtctggacat | gattgacacc  | 2100 |
| acgcgctcga | tgttcgccca | gctgcacaac  | gctggactgc | tcgaccgggc | gccgttggcg  | 2160 |
| gtgcttgccg | tcggcgggca | agccttgggc  | gccgcgacgt | ggcggtgat  | ccagcagaac  | 2220 |
| tgcgcgcgca | cggccatgac | ggccttcaac  | tgctacgggc | ctaccgagac | cacggtcgaa  | 2280 |
| gccgtggctg | ccgccgttgc | tgagcatgcg  | cgaccggtca | tcggacgtcc | gacctgcacc  | 2340 |
| accgcgcct  | acgtcatgga | ctcctggctg  | cggccggtgc | ccgatggcgt | cgcggcgag   | 2400 |
| ctgtatctgg | cgggcgccca | gttgaccgcg  | ggttacctcg | gccgccgggc | cgagactgcg  | 2460 |
| gcgcgctttg | tcgctgagcc | aaacggggcg  | ggtagccgaa | tgtaccgcac | cggagatgtg  | 2520 |
| gtgcgcgcgc | tgcccgacgg | tggactggag  | ttcctcgggc | gcagcgatga | ccaggtgaag  | 2580 |
| atccgcggtt | tccgcgtcga | gccgggtgag  | attgccgcgg | tgctcaacgg | ccaccatgcg  | 2640 |
| gtgcacgggt | gcatgtgac  | ggcccgcggc  | catgccagtg | gcccccggt  | gacggcgat   | 2700 |
| gtggcaggcg | gaccacaacc | gccaccgggtg | gccgaattgc | ggcgatgct  | gctagagcgg  | 2760 |
| ttgccgcggt | atctagtccc | gcaccatata  | gtcgtcctcg | acgagttacc | gctgactcca  | 2820 |

-31-

|                                                                    |      |
|--------------------------------------------------------------------|------|
| cacggcaaga tcgacgaaaa cgctttggcg gcaatcaatg tcaccgaagg accggcaact  | 2880 |
| ccgccgcaga caccgaccga gctggtgctg gccgaggcgt tcgccgatgt catggaaacc  | 2940 |
| tcgaacgtcg atgtcaccgc gggttttttg cagatgggtc tagacagcat cgtggcgctg  | 3000 |
| tcggtggtgc aggccgcgcg ccgtcgtggg attgcgttgc gggccaggct gatggtggag  | 3060 |
| tgcgacacca tccgtgaact cgcggcgcc attgactccg atgccgatg gcaggcaccg    | 3120 |
| gccaacgatg ccggcgagcc gatcccgtg ctacccaaca ctcatggct ctacgagtac    | 3180 |
| ggcgaccgc gccggctggc acaaaccgag gtcattcaggt tgcccgaccg gatcaccgcg  | 3240 |
| gaacgcctgg atgccgtgtt ggccgcggtc gtcgacggac acgagggtgtt gcggtgcggg | 3300 |
| ttcgaccggg atgcgatggc ccttgctgca caaccgaaaa cggacattct cagcgagggt  | 3360 |
| tgggtcagcg gtgaactggt caccgcggtg gccgagcaga ctcttggcg gctggcgagt   | 3420 |
| ctcgaccccc aggccggccg actgctctcg gcggtgtggc tgcgcgaacc cgacgggccc  | 3480 |
| ggtgttctgg tgctgaccgc ccatgtgctg gcgatggacc cagcctctcg gcgattgtg   | 3540 |
| ctgggtgaac tcgacgcgg cctgcacgcg ctggcgcccg ggcgcgcgcc cagcccagcg   | 3600 |
| cgcgagaaca ccagctaccg gcagtggctg cggtgctgg cgcagcgggc taaggcgctg   | 3660 |
| gatagcgttg atttctgggt cgccgaactc gagggcgccg atccgcggtt ggggtcccgc  | 3720 |
| aggggtggcg cgcagaccga cggggttggg gagctagcga tcaccatgtc gatctccgac  | 3780 |
| gccgatctga ccgcgcggct gctttcgacg ggacggtcga tgaccgatct gctggctacc  | 3840 |
| gccgtgcgc ggatggtgac cgctggcg cggcaacgcg gtcaacaaac accagcaccg     | 3900 |
| ctgttggcgt tggagacgca tggccgcgcg gacgtccacg tcgataagac tgccgacacc  | 3960 |
| agcgacacgg tcgggctgct cagcgcatc tatccgtgc gcattccactg cgacggcgcg   | 4020 |
| accgacttgc cgcggatacc cggcagcggc atcgattacg gcctgctgcg gtacctgcgc  | 4080 |
| gccgataccg cggagcgact acgcgccac cgcgaacccc agctgctgct gaactatctg   | 4140 |
| ggtagcctgc acgtcggggt gggagatctg gcggtcgacc gcgcactact ggetgatgtg  | 4200 |
| gggcaactgc ctgaaccgga acagccggtg cgccacgaac tgacgggtgct ggcggcgctc | 4260 |
| ctcgggcccg ccgacgctcc cgtgctagcc acgcggtggc gcacgctgcc cgacatctg   | 4320 |
| tccgccgacg acgtcgccac gctgcaatca ctgtggcagg gcgcgctggc ggagataaca  | 4380 |
| gca                                                                | 4383 |

&lt;210&gt; 15

&lt;211&gt; 118



-32-

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 15

Met Leu Thr Cys Glu Met Arg Glu Ser Ala Leu Ala Arg Leu Gly Arg  
 1 5 10 15

Ala Leu Ala Asp Pro Thr Arg Cys Arg Ile Leu Val Ala Leu Leu Asp  
 20 25 30

Gly Val Cys Tyr Pro Gly Gln Leu Ala Ala His Leu Gly Leu Thr Arg  
 35 40 45

Ser Asn Val Ser Asn His Leu Ser Cys Leu Arg Gly Cys Gly Leu Val  
 50 55 60

Val Ala Thr Tyr Glu Gly Arg Gln Val Arg Tyr Ala Leu Ala Asp Ser  
 65 70 75 80

His Leu Ala Arg Ala Leu Gly Glu Leu Val Gln Val Val Leu Ala Val  
 85 90 95

Asp Thr Asp Gln Pro Cys Val Ala Glu Arg Ala Ala Ser Gly Glu Ala  
 100 105 110

Val Glu Met Thr Gly Ser  
 115

&lt;210&gt; 16

&lt;211&gt; 354

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 16

atgctgacgt gtagatgcg ggaatcggcc ctggctcgac tcggccgggc tctggctgat 60  
 ccgacgcgggt gccggattct ggtggcggtt ctggatggcg tttgctatcc cggccagcta 120  
 gctgcgcacc tcgggttgac ccgatcgaat gtgtccaacc atctgtcgtg tttgcggggc 180  
 tgcgggctgg tagtcgcaac ctatgagggc cggcagggtc ggtatgcgct ggccgacagt 240

-33-

cacctggcgc gagccttggg cgagttggtc caggtcgttc tcgcggtgga taccgaccaa 300

ccctgtgtcg ccgagcgcgc cgcgtccggg gaggcggtcg agatgacagg tagc 354

<210> 17

<211> 159

<212> PRT

<213> Mycobacterium tuberculosis

<400> 17

Met Asn Asn Leu Ala Leu Trp Ser Arg Pro Val Trp Asp Val Glu Pro  
1 5 10 15

Trp Asp Arg Trp Leu Arg Asp Phe Phe Gly Pro Ala Ala Thr Thr Asp  
20 25 30

Trp Tyr Arg Pro Val Ala Gly Asp Phe Thr Pro Ala Ala Glu Ile Val  
35 40 45

Lys Asp Gly Asp Asp Ala Val Val Arg Leu Glu Leu Pro Gly Ile Asp  
50 55 60

Val Asp Lys Asp Val Asn Val Glu Leu Asp Pro Gly Gln Pro Val Ser  
65 70 75 80

Arg Leu Val Ile Arg Gly Glu His Arg Asp Glu His Thr Gln Asp Ala  
85 90 95

Gly Asp Lys Asp Gly Arg Thr Leu Arg Glu Ile Arg Tyr Gly Ser Phe  
100 105 110

Arg Arg Ser Phe Arg Leu Pro Ala His Val Thr Ser Glu Ala Ile Ala  
115 120 125

Ala Ser Tyr Asp Ala Gly Val Leu Thr Val Arg Val Ala Gly Ala Tyr  
130 135 140

Lys Ala Pro Ala Glu Thr Gln Ala Gln Arg Ile Ala Ile Thr Lys  
145 150 155

<210> 18

-34-

&lt;211&gt; 477

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 18

```

atgaacaatc tgcattgtg gtcgctccg gtgtgggacg ttgagccctg ggaccgctgg      60
ctacgtgact ttttcggccc tgcgcgacg acggactggg accgcccggg cgccggagac      120
ttcacgccgg ccgcccagat cgtcaaggat ggcgacgacg cgggtgggccg tttggaactg      180
cccggcattg acgtcgacaa ggacgtcaac gtcgagcttg accctggcca gccggtgagc      240
cgcttggtga tccgcggcga acaccgcgac gagcacacgc aagacgccgg agacaaagac      300
ggccgcaccc tgcgtgagat ccgctacgga tcattccgcc gctcgttccg gctgcccgcg      360
cacgtcacca gcgaggccat cgcggcttcc tatgacgccg gtgtgctgac cgtccggggt      420
gccggcgcct acaaggcccc agccgaaact caggcgcagc gcatcgccat cacgaag      477

```

&lt;210&gt; 19

&lt;211&gt; 235

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 19

```

Met Thr Ser Leu Ala Glu Arg Thr Val Leu Val Thr Gly Ala Asn Arg
1              5              10              15

Gly Met Gly Arg Glu Tyr Val Ala Gln Leu Leu Gly Arg Lys Val Ala
                20              25              30

Lys Val Tyr Ala Ala Thr Arg Asn Pro Leu Ala Ile Asp Val Ser Asp
                35              40              45

Pro Arg Val Ile Pro Leu Gln Leu Asp Val Thr Asp Ala Val Ser Val
                50              55              60

Ala Glu Ala Ala Asp Leu Ala Thr Asp Val Gly Ile Leu Ile Asn Asn
65              70              75              80

```

-35-

Ala Gly Ile Ser Arg Ala Ser Ser Val Leu Asp Lys Asp Thr Ser Ala  
85 90 95

Leu Arg Gly Glu Leu Glu Thr Asn Leu Phe Gly Pro Leu Ala Leu Ala  
100 105 110

Ser Ala Phe Ala Asp Arg Ile Ala Glu Arg Ser Gly Ala Ile Val Asn  
115 120 125

Val Ser Ser Val Leu Ala Trp Leu Pro Leu Gly Met Ser Tyr Gly Val  
130 135 140

Ser Lys Ala Ala Met Trp Ser Ala Thr Glu Ser Met Arg Ile Glu Leu  
145 150 155 160

Ala Pro Arg Gly Val Gln Val Val Gly Val Tyr Val Gly Leu Val Asp  
165 170 175

Thr Asp Met Gly Arg Phe Ala Asp Ala Pro Lys Ser Asp Pro Ala Asp  
180 185 190

Val Val Arg Gln Val Leu Asp Gly Ile Glu Ala Gly Lys Glu Asp Val  
195 200 205

Leu Ala Asp Glu Met Ser Arg Gln Val Arg Ala Ser Leu Asn Val Pro  
210 215 220

Ala Arg Glu Arg Ile Ala Arg Leu Met Gly Asn  
225 230 235

<210> 20

<211> 705

<212> DNA

<213> Mycobacterium tuberculosis

<400> 20

atgacttcac tagccgagcg gaccgtgctc gtcaccggcg ccaaccgcgg catggggccgc 60

gaatacgtcg ctcagcttct cggtcgcaaa gtggcacaagg tctatgccgc taccgcgaac 120

ccgctggcaa tcgacgttag cgatccgcgc gtgattccgc tccaactcga cgtcaccgac 180

gcggtgtcgg tcgccgaggg agccgactta gcaaccgatg toggcattct gatcaacaat 240

-36-

```

gccggcatct cccgggcgtc ctcggtgctc gacaaggaca catccgcgct tcgcggcgag      300
ctggagacga acctgttcgg accgctcgcg ctggcctccg cgttcgccga ccgcatcgcc      360
gagagatccg gtgccatcgt caacgtttcc tcggtactcg cctggcttcc ccttggcatg      420
agctatggag tgtccaaggc ggcgatgtgg agcgcgacgg agtcgatgcg tatcgagctg      480
gcgccgcgcg gtgtgcaggt ggtgggcgtc tacgtggggc tggtcgacac cgacatgggt      540
cgattcgccg acgcgccgaa gtccgatcct gccgatgtgg tccgccaggt gctcgacgga      600
atagaggctg gcaaggagga cgtgctggcc gacgagatga gccgtcaggt gcgcgcgtcg      660
ctgaatgtcc ctgcgcggga acgtatcgcg cggttgatgg gtaac                        705

```

&lt;210&gt; 21

&lt;211&gt; 386

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 21

```

Met Thr Ala Gly Ser Asp Leu Asp Asp Phe Arg Gly Leu Leu Ala Lys
1          5          10          15

```

```

Ala Phe Asp Glu Arg Val Val Ala Trp Thr Ala Glu Ala Glu Ala Gln
20          25          30

```

```

Glu Arg Phe Pro Arg Gln Leu Ile Glu His Leu Gly Val Cys Gly Val
35          40          45

```

```

Phe Asp Ala Lys Trp Ala Thr Asp Ala Arg Pro Asp Val Gly Lys Leu
50          55          60

```

```

Val Glu Leu Ala Phe Ala Leu Gly Gln Leu Ala Ser Ala Gly Ile Gly
65          70          75          80

```

```

Val Gly Val Ser Leu His Asp Ser Ala Ile Ala Ile Leu Arg Arg Phe
85          90          95

```

```

Gly Lys Ser Asp Tyr Leu Arg Asp Ile Cys Asp Gln Ala Ile Arg Gly
100         105         110

```

```

Ala Ala Val Leu Cys Ile Gly Ala Ser Glu Glu Ser Gly Gly Ser Asp

```

-37-

|                                                                 |  |     |  |     |
|-----------------------------------------------------------------|--|-----|--|-----|
| 115                                                             |  | 120 |  | 125 |
| Leu Gln Ile Val Glu Thr Glu Ile Arg Ser Arg Asp Gly Gly Phe Glu |  |     |  |     |
| 130                                                             |  | 135 |  | 140 |
| Val Arg Gly Val Lys Lys Phe Val Ser Leu Ser Pro Ile Ala Asp His |  |     |  |     |
| 145                                                             |  | 150 |  | 155 |
|                                                                 |  |     |  | 160 |
| Ile Met Val Val Ala Arg Ser Val Asp His Asp Pro Thr Ser Arg His |  |     |  |     |
|                                                                 |  | 165 |  | 170 |
|                                                                 |  |     |  | 175 |
| Gly Asn Val Ala Val Val Ala Val Pro Ala Ala Gln Val Ser Val Gln |  |     |  |     |
|                                                                 |  | 180 |  | 185 |
|                                                                 |  |     |  | 190 |
| Thr Pro Tyr Arg Lys Val Gly Ala Gly Pro Leu Asp Thr Ala Ala Val |  |     |  |     |
|                                                                 |  | 195 |  | 200 |
|                                                                 |  |     |  | 205 |
| Cys Ile Asp Thr Trp Val Pro Ala Asp Ala Leu Val Ala Arg Ala Gly |  |     |  |     |
|                                                                 |  | 210 |  | 215 |
|                                                                 |  |     |  | 220 |
| Thr Gly Leu Ala Ala Ile Ser Trp Gly Leu Ala His Glu Arg Met Ser |  |     |  |     |
|                                                                 |  | 225 |  | 230 |
|                                                                 |  |     |  | 235 |
|                                                                 |  |     |  | 240 |
| Ile Ala Gly Gln Ile Ala Ala Ser Cys Gln Arg Ala Ile Gly Ile Thr |  |     |  |     |
|                                                                 |  | 245 |  | 250 |
|                                                                 |  |     |  | 255 |
| Leu Ala Arg Met Met Ser Arg Arg Gln Phe Gly Gln Thr Leu Phe Glu |  |     |  |     |
|                                                                 |  | 260 |  | 265 |
|                                                                 |  |     |  | 270 |
| His Gln Ala Leu Arg Leu Arg Met Ala Asp Leu Gln Ala Arg Val Asp |  |     |  |     |
|                                                                 |  | 275 |  | 280 |
|                                                                 |  |     |  | 285 |
| Leu Leu Arg Tyr Ala Leu His Gly Ile Ala Glu Gln Gly Arg Leu Glu |  |     |  |     |
|                                                                 |  | 290 |  | 295 |
|                                                                 |  |     |  | 300 |
| Leu Arg Thr Ala Ala Ala Val Lys Val Thr Ala Ala Arg Leu Gly Glu |  |     |  |     |
|                                                                 |  | 305 |  | 310 |
|                                                                 |  |     |  | 315 |
|                                                                 |  |     |  | 320 |
| Glu Val Ile Ser Glu Cys Met His Ile Phe Gly Gly Ala Gly Tyr Leu |  |     |  |     |
|                                                                 |  | 325 |  | 330 |
|                                                                 |  |     |  | 335 |
| Val Asp Glu Thr Thr Leu Gly Lys Trp Trp Arg Asp Met Lys Leu Ala |  |     |  |     |
|                                                                 |  | 340 |  | 345 |
|                                                                 |  |     |  | 350 |

-38-

Arg Val Gly Gly Gly Thr Asp Glu Val Leu Trp Glu Leu Val Ala Ala  
           355                                  360                                  365

Gly Met Thr Pro Asp His Asp Gly Tyr Ala Ala Val Val Gly Ala Ser  
           370                                  375                                  380

Lys Ala  
       385

<210> 22

<211> 1158

<212> DNA

<213> Mycobacterium tuberculosis

<400> 22

|                                                                              |      |
|------------------------------------------------------------------------------|------|
| atgacggccg gctccgacct cgacgacttc cgcgggttgc tcgccaaagc gttcgacgag            | 60   |
| cggggtggtgg catggaccgc agaagcggaa ggcaggaac gttttccgcg ccagttgata            | 120  |
| gaacacctgg gtgtctgcgg cgtattcgat gcgaagtggg cgaccgacgc ccgtcccgac            | 180  |
| gtcggtaaac tcgtcgaact cgctttccgcg ttggggccagc tggcctctgc cggcatcggt          | 240  |
| gtgggtgtca gcttgcatga ctggcgata gcgattttgc gccggtttgg taagtgggac             | 300  |
| tacttgcggg atatctgcga tcaggcgata cgtggcgccg cgggtgctgt catcggagcc            | 360  |
| tcggaggagt cggcgggata cgacctgcag atcgtcgaaa ccgagatacg gtcccgtagc            | 420  |
| <del>ggtgggttgc aggtccgcgc cgtcaagaaa ttggtgtcgc tgtctccgat cgccgaccac</del> | 480  |
| atcatggtgg tggcccgcag cgtcgaccac gatccgacca gtaggcacgg caatgtcgcg            | 540  |
| gtcgtggccg tgccggccgc acaagtcagc gtgcagacc cctaccgcaa ggtcgggtgcg            | 600  |
| ggaccgctgg ataccgccc ggtctgcata gacacctggg taccggccga tgcaactggt             | 660  |
| gcgcgggccc gcacggggct ggcagccatc agttggggac tggctcatga gcggatgtcg            | 720  |
| atcgccgggc agatcgagc gtcgtgtcaa cgggcgatac gaatcacctt ggcccgcata             | 780  |
| atgagtcgac gtcagttcgg tcagacgctg ttcaaacacc aggcgctgcg gctgcgtatg            | 840  |
| gcggacctgc aggcgcgtgt cgatctgctg cggtagcgcc tgcaaggcat cgctgaacag            | 900  |
| gggagactgg aactgcgcac ggcggcagcg gtcaaagtca ccgccgccc gctcggtgag             | 960  |
| gaagtcattt ccgaatgcat gcacatcttc ggtggggcgg gttatcttgt cgacgaaacg            | 1020 |
| acgcttgcca aatggtggcg ggacatgaag ctgcgccggg tggcgggcgg caccgacgag            | 1080 |

-39-

gtgctgtggg aattggtggc tgccggcatg acgcccgatc acgacgggta cgcagccgtg 1140  
 gtcggagctt ccaaagcg 1158

&lt;210&gt; 23

&lt;211&gt; 306

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 23

Met Val Leu Arg Pro Ile Thr Gly Ala Ile Pro Pro Asp Gly Pro Trp  
 1 5 10 15

Gly Ile Trp Ala Ser Arg Arg Ile Ile Ala Gly Leu Met Gly Thr Phe  
 20 25 30

Gly Pro Ser Leu Ala Gly Thr Arg Val Glu Gln Val Asn Ser Val Leu  
 35 40 45

Pro Asp Gly Arg Arg Val Val Gly Glu Trp Val Tyr Gly Pro His Asn  
 50 55 60

Asn Ala Ile Asn Ala Gly Pro Gly Gly Gly Ala Ile Tyr Tyr Val His  
 65 70 75 80

Gly Ser Gly Tyr Thr Met Cys Ser Pro Arg Thr His Arg Arg Leu Thr  
 85 90 95

Ser Trp Leu Ser Ser Leu Thr Gly Leu Pro Val Phe Ser Val Asp Tyr  
 100 105 110

Arg Leu Ala Pro Arg Tyr Arg Phe Pro Thr Ala Ala Thr Asp Val Arg  
 115 120 125

Ala Ala Trp Asp Trp Leu Ala His Val Cys Gly Leu Ala Ala Glu His  
 130 135 140

Met Val Ile Ala Ala Asp Ser Ala Gly Gly His Leu Thr Val Asp Met  
 145 150 155 160

Leu Leu Gln Pro Glu Val Ala Ala Arg Pro Pro Ala Ala Val Val Leu



-40-

|                                                                 |     |  |     |  |     |
|-----------------------------------------------------------------|-----|--|-----|--|-----|
|                                                                 | 165 |  | 170 |  | 175 |
| Phe Ser Pro Leu Ile Asp Leu Thr Phe Arg Leu Gly Ala Ser Arg Glu |     |  |     |  |     |
|                                                                 | 180 |  | 185 |  | 190 |
| Leu Gln Arg Pro Asp Pro Val Val Arg Ala Asp Arg Ala Ala Arg Ser |     |  |     |  |     |
|                                                                 | 195 |  | 200 |  | 205 |
| Val Ala Leu Tyr Tyr Thr Gly Val Asp Pro Ala His His Arg Leu Ala |     |  |     |  |     |
|                                                                 | 210 |  | 215 |  | 220 |
| Leu Asp Val Ala Gly Gly Pro Pro Leu Pro Pro Thr Leu Ile Gln Val |     |  |     |  |     |
|                                                                 | 225 |  | 230 |  | 235 |
|                                                                 |     |  |     |  | 240 |
| Gly Gly Ala Glu Ile Leu Glu Ala Asp Ala Arg Gln Leu Asp Ala Asp |     |  |     |  |     |
|                                                                 | 245 |  | 250 |  | 255 |
| Ile Arg Ala Ala Gly Gly Ile Cys Glu Leu Gln Val Trp Pro Asp Gln |     |  |     |  |     |
|                                                                 | 260 |  | 265 |  | 270 |
| Met His Val Phe Gln Ala Leu Pro Arg Met Thr Pro Glu Ala Ala Lys |     |  |     |  |     |
|                                                                 | 275 |  | 280 |  | 285 |
| Ala Met Thr Tyr Val Ala Gln Phe Ile Arg Ser Thr Thr Ala Arg Gly |     |  |     |  |     |
|                                                                 | 290 |  | 295 |  | 300 |
| Asp Leu                                                         |     |  |     |  |     |
| 305                                                             |     |  |     |  |     |

&lt;210&gt; 24

&lt;211&gt; 918

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 24

atggtgtgtgc ggcccatcac cggggcgatt cgcgcagacg ggccgtgggg gatatggggc 60

tcgcgccgga tcatcgccgg actcatgggc acgttcgggc cctcgctcgc gggcaccgca 120

gtggaacaag tcaactccgt tctgccggac ggacgccggg tcgtcggcga atgggtgtat 180

ggaccgcaca acaacgcgat caatgccgga cccggtggcg gcgccatcta ttacgtacac 240

-41-

```

ggcagcgggtt acacgatgtg ttgccccga acccaccggc ggctgacatc ctggctgtcg      300
tcattgaccg ggctaccggg attcagtgtc gattaccgac tggcgccgcg ctaccgtttc      360
ccgaccgcgg ccaccgacgt gcgggcagcc tgggattggg tagcgcacgt atgcgggtta      420
gccgcgggagc acatgggtgat cgccgcggat tccgcgggtg gccatctgac cgtcgacatg      480
ctgctgcaac ccgaggtcgc cggccgacct ccggcgggcg tgggtgttgtt ttgcgcgctg      540
atcgacctca ccttcgggtt gggcgccagt cgtgagctgc agcgccccga tccgtgtcgtg      600
cgcgctgacc gtgcggcccg gtcgggttgcg ctgtactaca ccggagtcca tcccgcgccac      660
caccggctgg cgctcgatgt tgccggcggg ccaccgctgc caccgacgt gatccaggtg      720
ggtggagccg agatactcga ggccgatgcg agacaactcg atgccgacat ccgcgctgcc      780
ggcggcatat gcgagttgca agtgtggcct gatcagatgc atgtgttcca ggccctgccg      840
cggatgacgc ccgaagcggc caaagccatg acctatgttg ccagttcat ccgcagtaca      900
acagcacgtg gagacctc                                     918

```

&lt;210&gt; 25

&lt;211&gt; 485

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 25

~~Met Asn Val Val Asp Ile Ser Arg Trp Gln Phe Gly Ile Thr Thr Val~~  
1                      5                      10                      15

Tyr His Phe Ile Phe Val Pro Leu Thr Ile Gly Leu Ala Pro Leu Ile  
                    20                      25                      30

Ala Val Met Gln Thr Leu Trp Val Val Thr Asp Asn Pro Ala Trp Tyr  
                    35                      40                      45

Arg Leu Thr Lys Phe Phe Gly Lys Leu Phe Leu Ile Asn Phe Ala Ile  
                    50                      55                      60

Gly Val Ala Thr Gly Ile Val Gln Glu Phe Gln Phe Gly Met Asn Trp  
65                      70                      75                      80

Ser Glu Tyr Ser Arg Phe Val Gly Asp Val Phe Gly Ala Pro Leu Ala

-42-

85

90

95

Met Glu Gly Leu Ala Ala Phe Phe Phe Glu Ser Thr Phe Ile Gly Leu  
 100 105 110

Trp Ile Phe Gly Trp Asn Arg Leu Pro Arg Leu Val His Leu Ala Cys  
 115 120 125

Ile Trp Ile Val Ala Ile Ala Val Asn Val Ser Ala Phe Phe Ile Ile  
 130 135 140

Ala Ala Asn Ser Phe Met Gln His Pro Val Gly Ala His Tyr Asn Pro  
 145 150 155 160

Thr Thr Gly Arg Ala Glu Leu Ser Ser Ile Val Val Leu Leu Thr Asn  
 165 170 175

Asn Thr Ala Gln Ala Ala Phe Thr His Thr Val Ser Gly Ala Leu Leu  
 180 185 190

Thr Ala Gly Thr Phe Val Ala Ala Val Ser Ala Trp Trp Leu Val Arg  
 195 200 205

Ser Ser Thr Thr His Ala Asp Ser Asp Thr Gln Ala Met Tyr Arg Pro  
 210 215 220

Ala Thr Ile Leu Gly Cys Trp Val Ala Leu Ala Ala Thr Ala Gly Leu  
 225 230 235 240

Leu Phe Thr Gly Asp His Gln Gly Lys Leu Met Phe Gln Gln Gln Pro  
 245 250 255

Met Lys Met Ala Ser Ala Glu Ser Leu Cys Asp Thr Gln Thr Asp Pro  
 260 265 270

Asn Phe Ser Val Leu Thr Val Gly Arg Gln Asn Asn Cys Asp Ser Leu  
 275 280 285

Thr Arg Val Ile Glu Val Pro Tyr Val Leu Pro Phe Leu Ala Glu Gly  
 290 295 300

Arg Ile Ser Gly Val Thr Leu Gln Gly Ile Arg Asp Leu Gln Gln Glu  
 305 310 315 320

Tyr Gln Gln Arg Phe Gly Pro Asn Asp Tyr Arg Pro Asn Leu Phe Val  
325 330 335

Thr Tyr Trp Ser Phe Arg Met Met Ile Gly Leu Met Ala Ile Pro Val  
340 345 350

Leu Phe Ala Leu Ile Ala Leu Trp Leu Thr Arg Gly Gly Gln Ile Pro  
355 360 365

Asn Gln Arg Trp Phe Ser Trp Leu Ala Leu Leu Thr Met Pro Ala Pro  
370 375 380

Phe Leu Ala Asn Ser Ala Gly Trp Val Phe Thr Glu Met Gly Arg Gln  
385                    390                    395                    400

-Pro Trp Val Val Val Pro Asn Pro Thr Gly Asp Gln Leu Val Arg Leu  
405 410 415

Thr Val Lys Ala Gly Val Ser Asp His Ser Ala Thr Val Val Ala Thr  
420 425 430

Ser Leu<sup>1</sup>Leu Met Phe Thr Leu Val Tyr Ala Val Leu Ala Val Ile Trp  
435 440 445

Cys Trp Leu Leu Lys Arg Tyr Ile Val Glu Gly Pro Leu Glu His Asp  
450 455 460

Ala Glu Pro Ala Ala His Gly Ala Pro Arg Asp Asp Glu Val Ala Pro  
465 470 475 480

Leu Ser Phe Ala Tyr  
485

<210> 26

<211> 1455

<212> DNA

<213> Mycobacterium tuberculosis

<400> 26

atgaatgtcg tcgacatttc gcggtggcag ttcggtatca ccaccgtcta tcaattcatt 60

ttcgtaccgc tgaccatcgg cctggccccg ctgatcgcgg tcatgcaaac gctgtgggtc 120

-44-

```

gtcaccgata accccgcctg gtatcgccctc accaaattct tcggcaaatt gttcctgac 180
aactttgccca tcggcggtggc gaccggaatc gtgcaggaat ttcagttcgg catgaactgg 240
agcgagtact cccgattcgt cggcgatgtc ttcggcgccc cgctggccat ggagggcctg 300
gcggccttct tcttcgaatc caccttcacg ggggtgtgga tcttcggctg gaacaggtcg 360
ccccggctgg tgcattctggc ctgcatctgg atcgtcgcaa tcgcggtcaa cgtgtccgcg 420
ttcttcacatc tcggcgcaaa ctcttcacatg cagcatccgg tcggcgcgca ctacaacccg 480
accaccgggc gtgccgagtt gagcagcatc gtctgtctgc tgaccaacaa caccgcacag 540
gcggcgttta cccacactgt cagcgggtgc ctgctgaccg cggggacctt cgtcgccgcg 600
gtgagcgctt ggtggctggt ccgttcgagc accacgcacg ccgactcaga tacccaagcc 660
atgtatcgtc ccgcgaccat cctggggtgt tgggttgctg tggccgccac ggccgggttg 720
ttgttcaccg gcgaccacca aggcaagctg atgttcacgc agcagccgat gaagatggcg 780
tcggccgaat cgttgtgcga taccagaca gatccaaact tctctgtcct gacggctggc 840
cggcaaaaca actgcgacag cctcaccctg gtcatcgaag tgcctatgt gttgcggttc 900
ctcgccgagg gccggatcag cgggtgtgacg ttgcagggta tccgcgatct gcagcaggaa 960
taccagcagc gcttcggacc aaacgactac cggcccaacc tcttcgtcac ctactggtca 1020
tttcgcatga tgatcgggtt gatggcgatc cgggtgctgt tcgcactgat tgcgtctctg 1080
ctcaccctg gcggccagat ccccaatcaa cgctgggttct cctggctggc gctgctaacc 1140
atgcccgccc cgttcctggc caacagcgcc ggatgggtgt tcaccgagat ggggcgcag 1200
ccctgggtcg tcgtccctaa cccgaccggt gatcagctgg ttcgactcac cgtcaaagca 1260
ggcgtctcgg atcactccgc caccgtggtc gccacgtctt tgetgatgtt caccttggtc 1320
tacgcggtac ttgcggtcat ctggtgctgg ctgctcaagc gttacatcgt cgaaggcccc 1380
ctggaacacg acgcggaacc ggctgcgcac ggggcacccc gcgacgacga ggtagcacca 1440
ttgtcgtttg cttac 1455

```

&lt;210&gt; 27

&lt;211&gt; 301

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 27

-45-

Met Pro Arg Ala His Asp Asp Asn Trp Asp Leu Ala Ser Ser Val Gly  
 1 5 10 15

Ala Thr Ala Thr Met Val Ala Ala Gly Arg Ala Leu Ala Thr Lys Asp  
 20 25 30

Pro Arg Gly Leu Ile Asn Asp Pro Phe Ala Glu Pro Leu Val Arg Ala  
 35 40 45

Val Gly Leu Asp Phe Phe Thr Lys Leu Ile Asp Gly Glu Leu Asp Ile  
 50 55 60

Ala Thr Thr Gly Asn Leu Ser Pro Gly Arg Ala Gln Ala Met Ile Asp  
 65 70 75 80

Gly Ile Ala Val Arg Thr Lys Tyr Phe Asp Asp Tyr Phe Arg Thr Ala  
 85 90 95

Thr Asp Gly Gly Val Arg Gln Val Val Ile Leu Ala Ala Gly Leu Asp  
 100 105 110

Ala Arg Ala Tyr Arg Leu Pro Trp Pro Ala Gly Thr Val Val Tyr Glu  
 115 120 125

Ile Asp Gln Pro Gln Val Ile Asp Phe Lys Thr Thr Thr Leu Ala Gly  
 130 135 140

Ile Gly Ala Lys Pro Thr Ala Ile Arg Arg Thr Val Tyr Ile Asp Leu  
 145 150 155 160

Arg Ala Asp Trp Pro Ala Ala Leu Gln Ala Ala Gly Leu Asp Ser Thr  
 165 170 175

Ala Pro Thr Ala Trp Leu Ala Glu Gly Met Leu Ile Tyr Leu Pro Pro  
 180 185 190

Asp Pro Arg Thr Gly Cys Ser Thr Thr Ala Pro Asn Ser Val Leu Arg  
 195 200 205

Ala Ala Arg Ser Leu Pro Asn Leu Ser Arg Ala Leu Trp Ile Ser Thr  
 210 215 220

Gln Ala Gly Tyr Glu Lys Trp Arg Ile Arg Phe Ala Ser Thr Ala Trp  
 225 230 235 240

Thr Ser Thr Trp Arg Arg Trp Cys Ile Pro Ala Asn Ala Ala Thr Ser  
245 250 255

Ser Thr Thr Cys Ala Pro Arg Ala Gly Thr Leu Arg Ala Gln Cys Gly  
260 265 270

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Thr | Tyr | Ser | Gly | Ala | Met | Val | Cys | Pro | Phe | Pro | Pro | His | Thr | Thr |
|     |     | 275 |     |     |     |     | 280 |     |     |     |     | 285 |     |     |     |

Thr Ile Arg Ser Ala Lys Ser Ser Ser Ser Ala Val Val  
290 295 300

<211> 903

<212> DNA

<213> Mycobacterium tuberculosis

|              |            |            |            |            |            |  |     |
|--------------|------------|------------|------------|------------|------------|--|-----|
| <400>        | 28         |            |            |            |            |  |     |
| atgccgcgcgcg | ctcacgacga | caactgggat | ctagcctcca | gcgtcggggc | taccgcgacc |  | 60  |
| atggttgctg   | ccggacgcgc | gttggcgacc | aaggatccac | gaggtttgat | caacgacctg |  | 120 |
| ttcgccgaac   | cgctggtgcg | cgcggtcggg | ctggatttct | tcaccaagtt | gatcgacggc |  | 180 |
| gagctcgata   | tcgcgacgac | cggaacctt  | tcgccggggc | gggcacaggc | gatgatcgac |  | 240 |
| gggatagcgg   | tgcgcaccaa | gtacttcgac | gactacttcc | gcactgccac | ggacggcgga |  | 300 |
| gtgcgacaag   | tggtgatcct | ggcagccggg | ttggacgcgc | gcgcctatcg | gttgccgtgg |  | 360 |
| ccggccggca   | ccgtggtcta | cgagatcgac | caaccacagg | tgatcgactt | caagacaacc |  | 420 |
| acettggccg   | gcacgggcgc | caagcccacc | gccattcggc | gcacgggtga | catcgacttg |  | 480 |
| cgcgcggact   | ggccggcggc | actgcaagct | gccggcctgg | actcgacggc | accgacagca |  | 540 |
| tggttggccg   | aaggcatgct | gatctacctg | ccgccggatc | ccaggaccgg | ttgttcgaca |  | 600 |
| acagcaccga   | actcagtgtt | gccggcagca | cgatcgctac | cgaacttgtc | ccgggcattg |  | 660 |
| tggtatttca   | cgcaggccgg | gtacgagaaa | tggcggattc | gtttcgcaag | cacggcgtgg |  | 720 |
| acatcgacat   | ggcgtcgctg | gtgtattccg | gcgaacgcag | ccacgtcgtc | gactacctgc |  | 780 |
| gcgccaaagg   | ctgggacggt | gagggcacag | tgcggaccga | cctattcagg | cgcaatggtt |  | 840 |
| tgcccgttcc   | cgcgccacac | gacgacgatc | cgctcggcga | aatcatcttc | atcagcggtc |  | 900 |

-47-

gtt

903

&lt;210&gt; 29

&lt;211&gt; 188

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; '29

Met Ala Gly Leu Phe Thr Pro Pro Ala Ser Gly Ala Ala Thr Leu Gln  
 1 5 10 15

Arg Ala Ala Arg Asp Ala Ala Pro Asp Ala Arg Trp Leu Leu Ala Val  
 20 25 30

Ser Asp Arg Asn Gly Ile Val Ser Thr Ser Ala Thr Thr Cys Asn Tyr  
 35 40 45

Pro Pro Ala Ala Lys Asp Ser Ala Gln Asp Gly Phe Arg His Ala Leu  
 50 55 60

Ala Ala Ala Ile Ala Ala Asp Ile Asp Glu Ala Leu Arg His Gly Tyr  
 65 70 75 80

Gly Asp Leu Leu Glu Leu Ala Tyr Pro Leu Met Ser Trp Pro Arg Arg  
 85 90 95

Gly Val Phe Gly Gly Pro Thr Pro Ala Pro Arg Gly Leu Ala Thr Arg  
 100 105 110

Gln Cys Pro Pro Arg Thr Val His Val Asp Arg Val Arg Pro Asn Gly  
 115 120 125

Ala Glu Arg Ala Leu Arg Ala Arg Phe Arg Pro Ile Leu Arg Pro Gln  
 130 135 140

Phe Thr Leu Gly Asp Gly Ala Asn Gly Leu Pro Leu Ala Ala Cys Thr  
 145 150 155 160

Lys Thr Gly Ala Tyr Val Pro His Leu Pro Tyr Ser Pro Ile Ala Val  
 165 170 175



-48-

Asp Pro Gln Pro Ser Ala Gly Gln Gln Gly Pro Ser  
                   180                                  185

&lt;210&gt; 30

&lt;211&gt; 564

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 30

```

atggcgggtc ttttcacgcc cccggttcc ggtgccgca cacttcagcg tgctgcgca      60
gatgctgcc cggacgcgcg ctggctactc gcggtctccg accgcaacgg gatcgtcage    120
acttcggcga cgacgtgcaa ctaccgccc gctgcgaaag actctgcgca agacgggttt    180
aggcacgcac tggccgctgc catcgctgcg gacatcgatg aagcactccg tcacggctac    240
ggagatctgc ttgagcttgc gtaccgctc atgagctggc cgcgcggggg cgtttttggc    300
gggcccaccc cggccccacg tgggctcgct acgcgacagt gcccgccccg gacagttcac    360
gttgaccggg tgaggccaaa cggcgccgag cgtgcactga gggcgagatt ccggccgatt    420
ctccgcctc agttcacgct gggcgacggc gctaacgggc tgcccttggc cgcgtgcacc    480
aagacgggtg catacgtgcc gcacttgcca tactcaccca tcgcggtgga cccccaaccc    540
agtgccggtc aacaagggcc ttcc                                           564

```

&lt;210&gt; 31

&lt;211&gt; 241

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 31

```

Met Ser Thr Val Leu Thr Tyr Ile Arg Ala Val Asp Ile Tyr Glu His
1           5           10          15

Met Thr Glu Ser Leu Asp Leu Glu Phe Glu Ser Ala Tyr Arg Gly Glu
          20           25           30

Ser Val Ala Phe Gly Glu Gly Val Arg Pro Pro Trp Ser Ile Gly Glu
          35           40           45

```

-49-

Pro Gln Pro Glu Leu Ala Ala Leu Ile Val Gln Gly Lys Phe Arg Gly  
 50 55 60

Asp Val Leu Asp Val Gly Cys Gly Glu Ala Ala Ile Ser Leu Ala Leu  
 65 70 75 80

Ala Glu Arg Gly His Thr Thr Val Gly Leu Asp Leu Ser Pro Ala Ala  
 85 90 95

Val Glu Leu Ala Arg His Glu Ala Ala Lys Arg Gly Leu Ala Asn Ala  
 100 105 110

Ser Phe Glu Val Ala Asp Ala Ser Ser Phe Thr Gly Tyr Asp Gly Arg  
 115 120 125

Phe Asp Thr Ile Val Asp Ser Thr Leu Phe His Ser Met Pro Val Glu  
 130 135 140

Ser Arg Glu Gly Tyr Leu Gln Ser Ile Val Arg Ala Ala Ala Pro Gly  
 145 150 155 160

Ala Ser Tyr Phe Val Leu Val Phe Asp Arg Ala Ala Ile Pro Glu Gly  
 165 170 175

Pro Ile Asn Ala Val Thr Glu Asp Glu Leu Arg Ala Ala Val Ser Lys  
 180 185 190

Tyr Trp Ile Ile Asp Glu Ile Lys Pro Ala Arg Leu Tyr Ala Arg Phe  
 195 200 205

Pro Ala Gly Phe Ala Gly Met Pro Ala Leu Leu Asp Ile Arg Glu Glu  
 210 215 220

Pro Asn Gly Leu Gln Ser Ile Gly Gly Trp Leu Leu Ser Ala His Leu  
 225 230 235 240

Gly

<210> 32

<211> 723

<212> DNA

-50-

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 32

```

atgtcaactg tgttgacata tatcagggcc gttgatatat atgaacacat gactgaatcg      60
ctggatcttg agttcgaatc cgcctaccgc ggtgaatccg tcgccttcgg ggagggagtc      120
cgaccgccat ggagcatcgg cgaaccccag cccgagctgg ccgccctgat cgtgcagggc      180
aagttccgcg gcgacgtcct cgacgtgggc tcgggggagg ccgcgatttc gctggcactg      240
gccgaacggg gacacaccac ggtcggactg gacctctccc ccgccgccgt agaactggct      300
cggcatgaag cagcgaagcg cggcctggcc aatgccagct tcgaggtggc cgacgccagt      360
tcgtttaccg gctatgacgg caggttcgac accatcgctc acagcacgct gttccactcc      420
atgccggctg agtcccggga gggctatctg caatcgatcg tcgctgcggc ggcaccgggc      480
gcctcctact tcgtgttggg attcgaccgg gcggcgatac ccgagggggcc gatcaatgcg      540
gtcaccgagg acgagctgcg cgcgcggtg tccaagtact ggatcatcga tgagatcaag      600
cccgcggggc tgtaacgcgag gttcccggcc ggcttcgcgg gcatgccgcg actcctggac      660
atccgcgaag agcccaacgg gctgcagtcg atcggtggct ggctgctctc ggcccacctg      720
ggc                                                                           723

```

&lt;210&gt; 33

&lt;211&gt; 175

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 33

```

Val Ser Arg Leu Leu Leu Ser Tyr Ala Val Val Glu Leu Ala Val Val
1           5           10           15

Phe Ala Leu Ala Ala Thr Ile Gly Phe Gly Trp Thr Leu Leu Val Leu
20           25           30

Leu Ala Thr Phe Val Leu Gly Phe Gly Leu Leu Ala Pro Leu Gly Gly
35           40           45

Trp Gln Leu Gly Arg Arg Leu Leu Trp Leu Arg Ser Gly Leu Ala Glu
50           55           60

```

-51-

Pro Arg Ser Ala Leu Ser Asp Gly Ala Leu Val Thr Val Ala Ser Val  
65 70 75 80

Leu Val Leu Val Pro Gly Leu Val Thr Thr Thr Met Gly Leu Leu Leu  
85 90 95

Leu Val Pro Pro Ile Arg Ala Leu Ala Arg Pro Gly Leu Thr Ala Ile  
100 105 110

Ala Val Arg Gly Phe Leu Arg Asn Val Pro Leu Thr Ala Asp Ala Ala  
115 120 125

Ala Asn Met Ala Gly Ala Phe Gly Glu Ser Gly Thr Asp Pro Asp Phe  
130 135 140

Ile Asp Gly Glu Val Ile Asp Val Ile Asp Val Glu Pro Leu Thr Leu  
145 150 155 160

Gln Pro Pro Arg Val Ala Ala Glu Pro Pro Ser Pro Gly Ser Asn  
165 170 175

<210> 34

<211> 525

<212> DNA

<213> Mycobacterium tuberculosis

---

<400> 34  
gtgtcgcggc tgctgctcag ctacgccgtc gtcgagctcg cgggtggttt cgcgctggcg 60  
gcgacgatcg ggtttggctg gactttgctg gtgttgctgg cgacgttcgt cctcggggttc 120  
ggtctgctgg cgccgctcgg tggtggcag ctccggccgac ggctcctgtg gttgcgatcc 180  
ggcttggcgg aaccacgaag cgactgagt gacggcgccg tggtcaccgt tgctcggtc 240  
ttggtgcttg ttcctggtct ggtcaccaag acgatggggc tgttgctgct ggtgccgcgc 300  
atccggggcg tcgctcgacc cgggctgacc gcgatcgccg tgcgcggttt cctgcggaac 360  
gtgccactga cggccgatgc ggcggccaac atggccgggg ccttcggcga gagcggcacc 420  
gaccgggact ttattgatgg cgaggtcatc gacgtcatag atgtcgagcc gttgaccctt 480  
cagccccctc gggtagccgc agaacctcca tcgccggggc cgaat 525

-52-

&lt;210&gt; 35

&lt;211&gt; 130

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 35

Val Val Trp Met Arg Ser Ala Ile Val Ala Val Ala Leu Gly Val Thr  
1 5 10 15

Val Ala Ala Val Ala Ala Ala Cys Trp Leu Pro Gln Leu His Arg His  
20 25 30

Val Ala His Pro Asn His Pro Leu Thr Thr Ser Val Gly Ser Glu Phe  
35 40 45

Val Ile Asn Thr Asp His Gly His Leu Val Asp Asn Ser Met Pro Pro  
50 55 60

Cys Pro Glu Arg Leu Ala Thr Ala Val Leu Pro Arg Ser Ala Thr Pro  
65 70 75 80

Val Leu Leu Pro Asp Val Val Ala Ala Ala Pro Gly Met Thr Ala Ala  
85 90 95

Leu Thr Asp Pro Val Ala Pro Ala Ala Arg Gly Pro Pro Ala Ala Gln  
100 105 110

Gly Ser Val Arg Thr Gly Gln Asp Leu Leu Thr Arg Phe Cys Leu Ala  
115 120 125

Arg Arg  
130

&lt;210&gt; 36

&lt;211&gt; 390

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

-53-

<400> 36  
 gtggtgtgga tgcgacggc gattgtcgcg gtcgcgctgg gggtgacggg agccgccgtc 60  
 gccgctgcat gctggctccc ccagctccac cgtcatgtgg ctcacccaaa ccaccgcttg 120  
 accacgtccg taggtagcga attcgtcatc aacaccgacc acgggcacct ggtggacaac 180  
 tcgatgccac cgtgcccggg acggctcgcg acggcggtgc tgccgcgctc cgccactccg 240  
 gtgttactac cagacgtcgt ggcggctgcg cccggcatga cagccgcgct taccgacccc 300  
 gtcgcgccgg ccgcgcgagg tccgcggcg gcgcagggat ccgttcgcac cggtaagac 360  
 ctgttgaccc ggttctgcct ggctcgtcgc 390

<210> 37

<211> 314

<212> PRT

<213> Mycobacterium tuberculosis

<400> 37

Val Pro Arg Thr Asp Asn Asp Ser Trp Ala Ile Thr Glu Ser Val Gly  
 1 5 10 15

Ala Thr Ala Leu Gly Val Ala Ala Ala Arg Ala Ala Glu Thr Glu Ser  
 20 25 30

Asp Asn Pro Leu Ile Asn Asp Pro Phe Ala Arg Ile Phe Val Asp Ala  
 35 40 45

Ala Gly Asp Gly Ile Trp Ser Met Tyr Thr Asn Arg Thr Leu Leu Ala  
 50 55 60

Gly Ala Thr Asp Leu Asp Pro Asp Leu Arg Ala Pro Ile Gln Gln Met  
 65 70 75 80

Ile Asp Phe Met Ala Ala Arg Thr Ala Phe Phe Asp Glu Tyr Phe Leu  
 85 90 95

Ala Thr Ala Asp Ala Gly Val Arg Gln Val Val Ile Leu Ala Ser Gly  
 100 105 110

Leu Asp Ser Arg Ala Trp Arg Leu Pro Trp Pro Asp Gly Thr Val Val  
 115 120 125

-54-

Tyr Glu Leu Asp Gln Pro Lys Val Leu Glu Phe Lys Ser Ala Thr Leu  
 130 135 140

Arg Gln His Gly Ala Gln Pro Ala Ser Gln Leu Val Asn Val Pro Ile  
 145 150 155 160

Asp Leu Arg Gln Asp Trp Pro Lys Ala Leu Gln Lys Ala Gly Phe Asp  
 165 170 175

Pro Ser Lys Pro Cys Ala Trp Leu Ala Glu Gly Leu Val Arg Tyr Leu  
 180 185 190

Pro Ala Arg Ala Gln Asp Leu Leu Phe Glu Arg Ile Asp Ala Leu Ser  
 195 200 205

Arg Pro Gly Ser Trp Leu Ala Ser Asn Val Pro Gly Ala Gly Phe Leu  
 210 215 220

Asp Pro Glu Arg Met Arg Arg Gln Arg Ala Asp Met Arg Arg Met Arg  
 225 230 235 240

Ala Ala Ala Ala Lys Leu Val Glu Thr Glu Ile Ser Asp Val Asp Asp  
 245 250 255

Leu Trp Tyr Ala Glu Gln Arg Thr Ala Val Ala Glu Trp Leu Arg Glu  
 260 265 270

Arg Gly Trp Asp Val Ser Thr Ala Thr Leu Pro Glu Leu Leu Ala Arg  
 275 280 285

Tyr Gly Arg Ser Ile Pro His Ser Gly Glu Asp Ser Ile Pro Pro Asn  
 290 295 300

Leu Phe Val Ser Ala Gln Arg Ala Thr Ser  
 305 310

<210> 38

<211> 942

<212> DNA

<213> Mycobacterium tuberculosis

-55-

<400> 38  
 gtgccgcgga cgcacaacga ttctggggcc attaccgaga gcgtggggcg caccgcactg 60  
 ggtgtggcgg cggcgcgctgc ggccgagacc gagagcgaca acccattgat caacgatccg 120  
 ttcgcgcgga tctttgtgga cgcggccggc gacgggatat ggagcatgta cacgaatcgc 180  
 acgttgctgg ccggtgcgac cgacctcgac ccggacctgc gggcgccgat acagcagatg 240  
 atcgatttca tggccgcccc gaccgcgttt ttcgacgagt atttcctggc taccgccgac 300  
 gctgggggtga ggcaagtagt gatcctcgcc tggggcctgg actcgcgctgc ctggcggtg 360  
 ccctgggdcgg acggcacctg ggtgtacgag ctggaccagc ccaaggtgct ggaattcaaa 420  
 tcagccacgt tgcgccagca tggcgcgag ccggcttcgc agctggtgaa cgttcccata 480  
 gaccttcgtc aggactggcc aaaggcactg cagaaagccg gatttgacct atcgaagccg 540  
 tgtgcgtggt tagccgaagg gttggtgcgg tacctgccgg cgcgggctca ggatctgttg 600  
 ttcgagcgta tcgatgcgct cagcaggccg ggcagttggt tggcgccaa cgtcccggc 660  
 gccggttttc tcgacctga gcgaatgcga cgcagcgtg cggacatgcg gcggatgcgg 720  
 gccgcggcag ccaagctggt cgaaactgag atatcagatg tcgatgacct ctggtatgca 780  
 gagcagcgca ccgcggtcgc cgagtggctg cgtgaacgtg gctgggacgt gtcgacggca 840  
 acgttgcccc agctgctggc tcggtatggc cgcagcatcc ctacagtgga cgaagactca 900  
 atccgcgcaa accttttcgt atccgcgag cgggccacga gc 942

&lt;210&gt; 39

&lt;211&gt; 504

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 39

Val Ser Phe Val Val Thr Val Pro Glu Ala Val Ala Ala Ala Ala Gly  
 1 5 10 15

Asp Leu Ala Ala Ile Gly Ser Thr Leu Arg Glu Ala Thr Ala Ala Ala  
 20 25 30

Ala Gly Pro Thr Thr Gly Leu Ala Ala Ala Ala Ala Asp Asp Val Ser  
 35 40 45



-56-

Ile Ala Val Ser Gln Leu Phe Gly Arg Tyr Gly Gln Glu Phe Gln Thr  
 50 55 60

Val Ser Asn Gln Leu Ala Ala Phe His Thr Glu Phe Val Arg Thr Leu  
 65 70 75 80

Asn Arg Gly Ala Ala Ala Tyr Leu Asn Thr Glu Ser Ala Asn Gly Gly  
 85 90 95

Gln Leu Phe Gly Gln Ile Glu Ala Gly Gln Arg Ala Val Ser Ala Ala  
 100 105 110

Ala Ala Ala Ala Pro Gly Gly Ala Tyr Gly Gln Leu Val Ala Asn Thr  
 115 120 125

Ala Thr Asn Leu Glu Ser Leu Tyr Gly Ala Trp Ser Ala Asn Pro Phe  
 130 135 140

Pro Phe Leu Arg Gln Ile Ile Ala Asn Gln Gln Val Tyr Trp Gln Gln  
 145 150 155 160

Ile Ala Ala Ala Leu Ala Asn Ala Val Gln Asn Phe Pro Ala Leu Val  
 165 170 175

Ala Asn Leu Pro Ala Ala Ile Asp Ala Ala Val Gln Gln Phe Leu Ala  
 180 185 190

Phe Asn Ala Ala Tyr Tyr Ile Gln Gln Ile Ile Ser Ser Gln Ile Gly  
 195 200 205

Phe Ala Gln Leu Phe Ala Thr Thr Val Gly Gln Gly Val Thr Ser Val  
 210 215 220

Ile Ala Gly Trp Pro Asn Leu Ala Ala Glu Leu Gln Leu Ala Phe Gln  
 225 230 235 240

Gln Leu Leu Val Gly Asp Tyr Asn Ala Ala Val Ala Asn Leu Gly Lys  
 245 250 255

Ala Met Thr Asn Leu Leu Val Thr Gly Phe Asp Thr Ser Asp Val Thr  
 260 265 270

Ile Gly Thr Met Gly Thr Thr Ile Ser Val Thr Ala Lys Pro Lys Leu  
 275 280 285

-57-

Leu Gly Pro Leu Gly Asp Leu Phe Thr Ile Met Thr Ile Pro Ala Gln  
 290 295 300

Glu Ala Gln Tyr Phe Thr Asn Leu Met Pro Pro Ser Ile Leu Arg Asp  
 305 310 315 320

Met Ser Gln Asn Phe Thr Asn Val Leu Thr Thr Leu Ser Asn Pro Asn  
 325 330 335

Ile Gln Ala Val Ala Ser Phe Asp Ile Ala Thr Thr Ala Gly Thr Leu  
 340 345 350

Ser Thr Phe Phe Gly Val Pro Leu Val Leu Thr Tyr Ala Thr Leu Gly  
 355 360 365

Ala Pro Phe Ala Ser Leu Asn Ala Ile Ala Thr Ser Ala Glu Thr Ile  
 370 375 380

Glu Gln Ala Leu Leu Ala Gly Asn Tyr Leu Gly Ala Val Gly Ala Leu  
 385 390 395 400

Ile Asp Ala Pro Ala His Ala Leu Asp Gly Phe Leu Asn Ser Ala Thr  
 405 410 415

Val Leu Asp Thr Pro Ile Leu Val Pro Thr Gly Leu Pro Ser Pro Leu  
 420 425 430

Pro Pro Thr Val Gly Ile Thr Leu His Leu Pro Phe Asp Gly Ile Leu  
 435 440 445

Val Pro Pro His Pro Val Thr Ala Thr Ile Ser Phe Pro Gly Ala Pro  
 450 455 460

Val Pro Ile Pro Gly Phe Pro Thr Thr Val Thr Val Phe Gly Thr Pro  
 465 470 475 480

Phe Met Gly Met Ala Pro Leu Leu Ile Asn Tyr Ile Pro Gln Gln Leu  
 485 490 495

Ala Leu Ala Ile Lys Pro Ala Ala  
 500

&lt;210&gt; 40

-58-

&lt;211&gt; 1512

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 40

```
gtgtcgttcg tggtcacagt gccggaggcc gtggcggctg cggcggggga tttggcggcc      60
atcggctcga cgcttcggga agcgaccgct gcggcggcgg gccccacgac cgggctggcg      120
gccgcggccg ccgacgacgt gtcgatcgct gtctcgagc tgttcggcag gtacggccag      180
gaatttcaaa ccgtgagcaa ccaactggcc gcgtttcata ccgagttcgt acgcacgttg      240
aaccgcggcg cggcggcgta tctcaacacc gaaagcgcta acggcgggca gctgttcggg      300
cagatcgagg cgggacagcg cgcggtttcc gcggccgcgg ccgcgcctcc gggcggcgca      360
tacggccaac tcgttgccaa cacggccacc aacctggaat cctctacgg cgcattgctg      420
gccaaccgtg tccatttcct ccgccagatc atcgccaacc agcaggttta ctggcagcag      480
atcgccgcgg cgctcgccaa cgcggtccag aacttccccg ccttggtggc gaatttgcca      540
ggggccatcg acgcggccgt ccagcaattc ctggccttca acgcggcgta ctacatccaa      600
cagattatta gctcgagat cggttcgcc cagctattcg ccacgacggg cggtcagggg      660
gtcaccagcg tcattgccgg gtggcccaac cttgcggcgg agcttcagct agcgtttcaa      720
cagcttctgg tgggtgacta caacgcgcgg gtggcgaacc tgggtaaggc catgacaaac      780
cttctggtca ccgggttcga caccagcgac gtgacgatcg gcacaatggg caccaccatt      840
agtgtcaccc cgaaacccaa gctgctgggc ccgctgggag atctgttcac catcatgacc      900
atcccgccac aagaggcgca gtacttcacc aacctgatgc cccctccat cctgcgagac      960
atgtcgcaga acttcaccaa cgtgctcacg acgctctcca acccgaacat ccaggcggtc     1020
gcttcgttcg atatcgcaac caccgccggg actttgagca ccttcttcgg ggtgccattg     1080
gtgctcactt acgccacatt ggggtgcgcg ttcgcgtcac tgaacgcgat tgcgacgagc     1140
gcggaaacca tcgagcagge cctggttgcc ggcaactacc taggggcggg ggggtgcgctt     1200
atcgacgccc cggccacgc gttagacggc ttcctcaaca gcgcaaccgt gttggatacg     1260
ccgatcctgg tgccacggg gctcccgtcc cctctgcccc cgacggtcgg gatcacgctg     1320
cacttgctt tcgacgggat tctcgtgccg ccgcattccg tcaccgggac gatcagcttc     1380
ccgggtgctc cggttcctat tcccggtttc ccaaccaccg taaccgtttt cggcacaccc     1440
ttcatgggaa tggctccgct gctgatcaac tacattcccc aacagctcgc cctggcaatc     1500
```

-59-

aaaccggcgg ct

1512

&lt;210&gt; 41

&lt;211&gt; 368

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; '41

Met Thr Ser Gly Ser Leu Gln Phe Thr Val Leu Arg Ala Val Asn Pro  
 1 5 10 15

Ala Thr Asp Ala Gln Arg Glu Ser Met Leu Arg Glu Pro Gly Phe Gly  
 20 25 30

Lys Tyr His Thr Asp His Met Val Ser Ile Asp Tyr Ala Glu Gly Arg  
 35 40 45

Gly Trp His Asn Ala Arg Val Ile Pro Tyr Gly Pro Ile Glu Leu Asp  
 50 55 60

Pro Ser Ala Ile Val Leu His Tyr Ala Gln Glu Val Phe Glu Gly Leu  
 65 70 75 80

Lys Ala Tyr Arg Trp Ala Asp Gly Ser Ile Val Ser Phe Arg Ala Asp  
 85 90 95

Ala Asn Ala Ala Arg Leu Arg Ser Ser Ala Arg Arg Leu Ala Ile Pro  
 100 105 110

Glu Leu Pro Asp Ala Val Phe Ile Glu Ser Leu Arg Gln Leu Ile Ala  
 115 120 125

Val Asp Lys Ala Trp Val Pro Gly Ala Gly Gly Glu Glu Ala Leu Tyr  
 130 135 140

Leu Arg Pro Phe Ile Phe Ala Thr Glu Pro Gly Leu Gly Val Arg Pro  
 145 150 155 160

Ala Thr Gln Tyr Arg Tyr Leu Leu Ile Ala Ser Pro Ala Gly Ala Tyr  
 165 170 175

-60-

Phe Lys Gly Gly Ile Ala Pro Val Ser Val Trp Val Ser Thr Glu Tyr  
                   180                                  185                                  190

Val Arg Ala Cys Pro Gly Gly Thr Gly Ala Ala Lys Phe Gly Gly Asn  
                   195                                  200                                  205

Tyr Ala Ala Ser Leu Leu Ala Gln Ala Glu Ala Ala Glu Asn Gly Cys  
                   210                                  215                                  220

Asp Gln Val Val Trp Leu Asp Ala Val Glu Arg Arg Tyr Ile Glu Glu  
                   225                                  230                                  235                                  240

Met Gly Gly Met Asn Ile Phe Phe Val Leu Gly Ser Gly Gly Ser Ala  
                                   245                                  250                                  255

Arg Leu Val Thr Pro Glu Leu Ser Gly Ser Leu Leu Pro Gly Ile Thr  
                   260                                  265                                  270

Arg Asp Ser Leu Leu Gln Leu Ala Ile Asp Ala Gly Phe Ala Val Glu  
                   275                                  280                                  285

Glu Arg Arg Ile Asp Ile Asp Glu Trp Gln Lys Lys Ala Ala Ala Gly  
                   290                                  295                                  300

Glu Ile Thr Glu Val Phe Ala Cys Gly Thr Ala Ala Val Ile Thr Pro  
                   305                                  310                                  315                                  320

Val Ala Arg Val Arg His Gly Ala Ser Glu Phe Arg Ile Ala Asp Gly  
                                   325                                  330                                  335

Gln Pro Gly Glu Val Thr Met Ala Leu Arg Asp Thr Leu Thr Gly Ile  
                   340                                  345                                  350

Gln Arg Gly Thr Phe Ala Asp Thr His Gly Trp Met Ala Arg Leu Gly  
                   355                                  360                                  365

<210> 42

<211> 1104

<212> DNA

<213> Mycobacterium tuberculosis

-61-

<400> 42  
 atgaccagcg gctcccttca attcacgggtg ttacgtgcgg tcaatccggc caccgacgcg 60  
 cagcgtgaat cgatgctgcg ggagccgggt ttcggcaaata accacaccca ccatatgggtg 120  
 tcgatcgact atgccgaggg ccgtgggttg cacaacgcgc gggtaatccc ttatggcccg 180  
 atcgagctgg atccctcggc gatcgtgctg cactatgcgc aggaggtggt cgaagggtc 240  
 aaagcctacc gctgggcca cgggtccatc gtgtcgtttc gcgccgacgc caacgccgcc 300  
 aggttgcggt cgtcggcgcg gcggttggtg attccgaac tgcccgacgc ggtgttcac 360  
 gaatccctgc gccagctaata cgctgtcgac aaagcttggg tgcccggtgc cggcggtgag 420  
 gaggcgctgt atctgcggcc gttcatcttc gccaccgagc cgggactggg cgtgcggcct 480  
 gccaccaat accgttacct gttgatcgcc tcgccggccg gtgcgtactt caaggcgggc 540  
 atgccccctg tcagcgtctg gggttcgacg gagtatgtac gggcctgtcc gggcggcacc 600  
 ggtgcggcca agttcggcg ccaactacgc gcctcgttgc tggcgagggc cgaagccgcc 660  
 gagaacggat ggcaccaggt ggtgtggctg gacgctgtgg aacgccgcta tatcgaagag 720  
 atgggtggca tgaacatctt ctctgtgctc ggcagcgggc gatcggcgcg gctggtcacc 780  
 ccggagctgt ccggttcctt gctgcccggg atcacacggg attcgttggt gcagttggct 840  
 attgatgccg gattcgcggc cgaggaacgc aggattgata tcgacgagtg gcagaagaaa 900  
 gccgccgccg gcgagatcac cgaggtgttt gcgtgcggca ccgccgctgt catcaccccg 960  
 gtcgcgcggg tcgggcacgg tgccagcgag ttcagaatcg ccgacggcca gccgggtgag 1020  
 gtgaccatgg cactacgga tacgctgacc ggcattccgc ggggcacctt cgcggacacc 1080  
 cacggctgga tggcgcggtt gggg 1104

&lt;210&gt; 43

&lt;211&gt; 249

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 43

Val Thr Ala Asp Trp Val Val Thr Phe Thr Phe Asp Ala Asp Pro Ser  
 1 5 10 15

Met Glu Thr Met Asp Ala Trp Glu Thr Gln Leu Glu Gly Phe Asp Ala  
 20 25 30

-62-

Leu Val Ser Arg Val Pro Gly His Gly Ile Asp Val Thr Val Tyr Ala  
 35 40 45

Pro Gly Asp Trp Ser Val Phe Asp Ala Leu Ala Lys Met Ala Gly Glu  
 50 55 60

Val Met Pro Val Val Gln Ala Lys Ser Pro Ile Ala Val Gln Ile Ile  
 65 70 75 80

Ser Glu Pro Glu His Arg Leu Arg Ala Glu Ala Phe Thr Thr Pro Glu  
 85 90 95

Leu Met Ser Ala Ala Glu Ile Ala Asp Glu Leu Gly Val Ser Arg Gln  
 100 105 110

Arg Val His Gln Leu Arg Ser Thr Ala Gly Phe Pro Ala Pro Leu Ala  
 115 120 125

Asp Leu Arg Gly Gly Ala Val Trp Asp Ala Ala Ala Val Arg Arg Phe  
 130 135 140

Ala Glu Thr Trp Glu Arg Lys Pro Gly Arg Pro His Thr Gly Thr Ala  
 145 150 155 160

Lys Phe Ala Tyr Ser Trp Ala Val Gly Pro Ala Val Gly Arg Ser Gly  
 165 170 175

Lys Ala Pro Asn Val Arg Trp Arg Val Glu Asn Pro Asp Lys Ile Arg  
 180 185 190

Phe Val Leu Arg Asn Ile Gly Asp Asp Ile Ala Glu Asp Val Glu Ile  
 195 200 205

Asp Leu Ser Arg Ile Asp Ala Ile Thr Arg Asn Val Pro Lys Lys Thr  
 210 215 220

Val Ile Arg Pro Gly Glu Gly Leu Asn Met Val Leu Ile Ala Ala Trp  
 225 230 235 240

Gly His Pro Leu Pro Asn Gln Leu Tyr  
 245

&lt;210&gt; 44

-63-

&lt;211&gt; 747

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 44

```

gtgacagccg actgggtcgt caccttcacg tttgatgctg acccttcgat ggagaccatg      60
gacgcctggg agacgcagct cgagggcttc gacgcactgg tatctcgggt ccaggacac      120
ggcattgacg tcacggteta tgcgcccggc gattggagtg tgttcgacgc gctcgccaag      180
atggctggcg aggttatgcc ggtagttcaa gccaagagtc ccattgctgt gcagatcatt      240
agcgagccag agcatcgtct gcgcgtgag gcgttcacaa cgcccagatt gatgtctgcg      300
gctgagatcg cggatgagtt ggggggtttcg cgtcagaggg tgcaccaatt gaggtcgaca      360
gcaggggttc ccgctccgtt ggcagatttg cgtggaggcg cgggtgtggga tgcggcagcg      420
gtgcgcaggt ttgcggagac ctgggagcga aagcccggtc ggccgcatac cgggactgcc      480
aagttcgcgt actcgtgggc ggtgggaccg gcggtcggca ggtccggtaa ggcacctaac      540
gtccgggtggc gtgtcgagaa cccagacaaa atccgctttg tgttgcgcaa catcggcgac      600
gatatcgagc aagatgtcga gattgacctc tcgcgaatcg atgcgatcac tcgaaatgtc      660
ccgaagaaga cggtgattcg ccccgagagc gggctcaaca tggctcttgat agcggcttgg      720
ggccatcccc ttccaaatca gctatac      747

```

&lt;210&gt; 45

&lt;211&gt; 129

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 45

```

Met Arg Leu Ile Leu Asn Val Ile Trp Leu Val Phe Gly Gly Leu Trp
1           5           10           15

Leu Ala Leu Gly Tyr Leu Leu Ala Ser Leu Val Cys Phe Leu Leu Ile
20           25           30

Ile Thr Ile Pro Phe Gly Phe Ala Ala Leu Arg Ile Ala Ser Tyr Ala
35           40           45

```



-64-

Leu Trp Pro Phe Gly Arg Thr Ile Val Glu Lys Pro Thr Ala Gly Thr  
 50 55 60

Gly Ala Leu Ile Gly Asn Val Ile Trp Val Leu Leu Phe Gly Ile Trp  
 65 70 75 80

Leu Ala Leu Gly His Leu Val Ser Ala Ala Ala Met Ala Val Thr Ile  
 85 90 95

Ile Gly Ile Pro Leu Ala Leu Ala Asn Leu Lys Leu Ile Pro Val Ser  
 100 105 110

Leu Val Pro Leu Gly Lys Asp Ile Val Gly Val Asn Ser Gln Val Pro  
 115 120 125

Thr

<210> 46

<211> 387

<212> DNA

<213> Mycobacterium tuberculosis

<400> 46

atgcgactaa tccatgaacgt tatctgggtg gtgttcgggtg gcctctgggt ggccctcggg 60  
 tacctgctgg cgtcgttgt ctgcttctg ctcatcatca ccattccgtt tggcttcgcg 120  
 gcgctgcgca tcgctcgta cgcgttggtg ccgttcggcc ggacgatcgt cgaaaagcca 180  
 accgccggga cgggggcctt gatcggcaac gtcattctgg tgctgctgtt cgggatctgg 240  
 ctggccctcg ggcatttggt gagtgccgcg gcaatggcag tcacgatcat cggcattccg 300  
 ctagcactgg ccaacttgaa actgatcccg gtgtcgtgtg tgccgctggg caaggacatc 360  
 gtcgggggtca actcacaggt gccaca 387

<210> 47

<211> 346

<212> PRT

<213> Mycobacterium tuberculosis

-65-

&lt;400&gt; 47

Met Asp Phe Thr Ile Phe Pro Pro Glu Phe Asn Ser Leu Asn Ile Gln  
 1 5 10 15

Gly Ser Ala Arg Pro Phe Leu Val Ala Ala Asn Ala Trp Lys Asn Leu  
 20 25 30

Ser Asn Glu Leu Ser Tyr Ala Ala Ser Arg Phe Glu Ser Glu Ile Asn  
 35 40 45

Gly Leu Ile Thr Ser Trp Arg Gly Pro Ser Ser Thr Ile Met Ala Ala  
 50 55 60

Ala Val Ala Pro Phe Arg Ala Trp Ile Val Thr Thr Ala Ser Leu Ala  
 65 70 75 80

Glu Leu Val Ala Asp His Ile Ser Val Val Ala Gly Ala Tyr Glu Ala  
 85 90 95

Ala His Ala Ala His Val Pro Leu Pro Val Ile Glu Thr Asn Arg Leu  
 100 105 110

Thr Arg Leu Ala Leu Ala Thr Thr Asn Ile Phe Gly Ile His Thr Pro  
 115 120 125

Ala Ile Phe Ala Leu Asp Ala Leu Tyr Ala Gln Tyr Trp Ser Gln Asp  
 130 135 140

Gly Glu Ala Met Asn Leu Tyr Ala Thr Met Ala Ala Ala Ala Arg  
 145 150 155 160

Leu Thr Pro Phe Ser Pro Pro Ala Pro Ile Ala Asn Pro Gly Ala Leu  
 165 170 175

Ala Arg Leu Tyr Glu Leu Ile Gly Ser Val Ser Glu Thr Val Gly Ser  
 180 185 190

Phe Ala Ala Pro Ala Thr Lys Asn Leu Pro Ser Lys Leu Trp Thr Leu  
 195 200 205

Leu Thr Lys Gly Thr Tyr Pro Leu Thr Ala Ala Arg Ile Ser Ser Ile  
 210 215 220

-66-

Pro Val Glu Tyr Val Leu Ala Phe Val Glu Gly Ser Asn Met Gly Gln  
225 230 235 240

Met Met Gly Asn Leu Ala Met Arg Ser Leu Thr Pro Thr Leu Lys Gly  
245 250 255

Pro Leu Glu Leu Leu Pro Asn Ala Val Arg Pro Ala Val Ser Ala Thr  
260 265 270

Leu Gly Asn Ala Asp Thr Ile Gly Gly Leu Ser Val Pro Pro Ser Trp  
275 280 285

Val Ala Asp Lys Ser Ile Thr Pro Leu Ala Lys Ala Val Pro Thr Ser  
290 295 300

Ala Pro Gly Gly Pro Ser Gly Thr Ser Trp Ala Gln Leu Gly Leu Ala  
305 310 315 320

Ser Leu Ala Gly Gly Ala Val Gly Ala Val Ala Ala Arg Thr Arg Ser  
325 330 335

Gly Val Ile Leu Arg Ser Pro Ala Ala Gly  
340 345

&lt;210&gt; 48

&lt;211&gt; 1038

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 48

```

atggatttca caatttttcc gccggagttc aactccctca acatccaagg tagcgctcgt      60
ccgtttctag tagccgcgaa cgcttgaag aatctgtcca acgagctgag ctacgcggcc      120
agtcggttcg agagtgagat caacgggctg atcacatcgt gccggggggcc atcgtcgacg      180
atcatggcag ctgcggtcgc cccatttcgg gcctggattg tcaogaccgc ttccctggct      240
gaactcgtcg ccgaccacat cagcgtcgtg gcaggcgctt atgaagcggc gcacgcagca      300
cacgtgccgc tgccggtgat cgagaccaac cgactgacgc gcctcgctct cgccacgacc      360
aacattttcg ggattcacac ccccgcgatc ttgcccctcg atgaactgta tgcccagtac      420

```

-67-

```

tggtcccaag atggcgaggc gatgaacctc tacgccacaa tggcggcggc cgccgcacgg      480
ctgacaccgt tctcgcccc ggcgccgata gccaaaccgg gcgcgctggc cagactttat      540
gaactgatcg gttcgggtgc cgagacggtg gggtcattcg ccgcgccggc gaccaagaat      600
ctgccttcga agctgtggac gctgttgacg aagggcacct acccgctcac agccgcgcga      660
atctcgtcga taccggtgga atacgtgttg gcctttgtcg agggcagcaa catgggccag      720
atgatgggca acctcgccat gcggagcctg acaccacgc tcaagggcc gctggagttg      780
ctaccaaacg cggtcaggcc cgcggtgtcg gcaacattgg gaaatgcgga tacgatcggg      840
gggttgctcg tgccccccag ctgggttgcg gacaaatcga ttacgccgtt ggccaaagcc      900
gtcccgacct ccgcgccggg cggtcgctcg ggaacctcgt gggcccagct gggattggca      960
agcctggccg ggggcgctgt gggcgccgtc gcggcaagaa cccgttcgg agtgatactg     1020
cggtcacccg ccgccggc                                     1038

```

&lt;210&gt; 49

&lt;211&gt; 876

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 49

```

Met Leu Pro Lys Ser Trp Asp Pro Ala Ala Met Glu Ser Ala Ile Tyr
1           5           10           15

```

```

Gln Lys Trp Leu Asp Ala Gly Tyr Phe Thr Ala Asp Pro Thr Ser Thr
20           25           30

```

```

Lys Pro Ala Tyr Ser Ile Val Leu Pro Pro Pro Asn Val Thr Gly Ser
35           40           45

```

```

Leu His Met Gly His Ala Leu Glu His Thr Met Met Asp Ala Leu Thr
50           55           60

```

```

Arg Arg Lys Arg Met Gln Gly Tyr Glu Val Leu Trp Gln Pro Gly Thr
65           70           75           80

```

```

Asp His Ala Gly Ile Ala Thr Gln Ser Val Val Glu Gln Gln Leu Ala
85           90           95

```

-68-

Val Asp Gly Lys Thr Lys Glu Asp Leu Gly Arg Glu Leu Phe Val Asp  
 100 105 110

Lys Val Trp Asp Trp Lys Arg Glu Ser Gly Gly Ala Ile Gly Gly Gln  
 115 120 125

Met Arg Arg Leu Gly Asp Gly Val Asp Trp Ser Arg Asp Arg Phe Thr  
 130 135 140

Met Asp Glu Gly Leu Ser Arg Ala Val Arg Thr Ile Phe Lys Arg Leu  
 145 150 155 160

Tyr Asp Ala Gly Leu Ile Tyr Arg Ala Glu Arg Leu Val Asn Trp Ser  
 165 170 175

Pro Val Leu Gln Thr Ala Ile Ser Asp Leu Glu Val Asn Tyr Arg Asp  
 180 185 190

Val Glu Gly Glu Leu Val Ser Phe Arg Tyr Gly Ser Leu Asp Asp Ser  
 195 200 205

Gln Pro His Ile Val Val Ala Thr Thr Arg Val Glu Thr Met Leu Gly  
 210 215 220

Asp Thr Ala Ile Ala Val His Pro Asp Asp Glu Arg Tyr Arg His Leu  
 225 230 235 240

Val Gly Thr Ser Leu Ala His Pro Phe Val Asp Arg Glu Leu Ala Ile  
 245 250 255

Val Ala Asp Glu His Val Asp Pro Glu Phe Gly Thr Gly Ala Val Lys  
 260 265 270

Val Thr Pro Ala His Asp Pro Asn Asp Phe Glu Ile Gly Val Arg His  
 275 280 285

Gln Leu Pro Met Pro Ser Ile Leu Asp Thr Lys Gly Arg Ile Val Asp  
 290 295 300

Thr Gly Thr Arg Phe Asp Gly Met Asp Arg Phe Glu Ala Arg Val Ala  
 305 310 315 320

Val Arg Gln Ala Leu Ala Ala Gln Gly Arg Val Val Glu Glu Lys Arg  
 325 330 335

-69-

Pro Tyr Leu His Ser Val Gly His Ser Glu Arg Ser Gly Glu Pro Ile  
 340 345 350

Glu Pro Arg Leu Ser Leu Gln Trp Trp Val Arg Val Glu Ser Leu Ala  
 355 360 365

Lys Ala Ala Gly Asp Ala Val Arg Asn Gly Asp Thr Val Ile His Pro  
 370 375 380

Ala Ser Met Glu Pro Arg Trp Phe Ser Trp Val Asp Asp Met His Asp  
 385 390 395 400

Trp Cys Ile Ser Arg Gln Leu Trp Trp Gly His Arg Ile Pro Ile Trp  
 405 410 415

Tyr Gly Pro Asp Gly Glu Gln Val Cys Val Gly Pro Asp Glu Thr Pro  
 420 425 430

Pro Gln Gly Trp Glu Gln Asp Pro Asp Val Leu Asp Thr Trp Phe Ser  
 435 440 445

Ser Ala Leu Trp Pro Phe Ser Thr Leu Gly Trp Pro Asp Lys Thr Ala  
 450 455 460

Glu Leu Glu Lys Phe Tyr Pro Thr Ser Val Leu Val Thr Gly Tyr Asp  
 465 470 475 480

Ile Leu Phe Phe Trp Val Ala Arg Met Met Met Phe Gly Thr Phe Val  
 485 490 495

Gly Asp Asp Ala Ala Ile Thr Leu Asp Gly Arg Arg Gly Pro Gln Val  
 500 505 510

Pro Phe Thr Asp Val Phe Leu His Gly Leu Ile Arg Asp Glu Ser Gly  
 515 520 525

Arg Lys Met Ser Lys Ser Lys Gly Asn Val Ile Asp Pro Leu Asp Trp  
 530 535 540

Val Glu Met Phe Gly Ala Asp Ala Leu Arg Phe Thr Leu Ala Arg Gly  
 545 550 555 560

Ala Ser Pro Gly Gly Asp Leu Ala Val Ser Glu Asp Ala Val Arg Ala

-70-

565

570

575

Ser Arg Asn Phe Gly Thr Lys Leu Phe Asn Ala Thr Arg Tyr Ala Leu  
                   580                                  585                                  590

Leu Asn Gly Ala Ala Pro Ala Pro Leu Pro Ser Pro Asn Glu Leu Thr  
                   595                                  600                                  605

Asp Ala Asp Arg Trp Ile Leu Gly Arg Leu Glu Glu Val Arg Ala Glu  
           610                                  615                                  620

Val Asp Ser Ala Phe Asp Gly Tyr Glu Phe Ser Arg Ala Cys Glu Ser  
   625                                  630                                  635                                  640

Leu Tyr His Phe Ala Trp Asp Glu Phe Cys Asp Trp Tyr Leu Glu Leu  
                   645                                  650                                  655

Ala Lys Thr Gln Leu Ala Gln Gly Leu Thr His Thr Thr Ala Val Leu  
                   660                                  665                                  670

Ala Ala Gly Leu Asp Thr Leu Leu Arg Leu Leu His Pro Val Ile Pro  
                   675                                  680                                  685

Phe Leu Thr Glu Ala Leu Trp Leu Ala Leu Thr Gly Arg Glu Ser Leu  
   690                                  695                                  700

Val Ser Ala Asp Trp Pro Glu Pro Ser Gly Ile Ser Val Asp Leu Val  
   705                                  710                                  715                                  720

Ala Ala Gln Arg Ile Asn Asp Met Gln Lys Leu Val Thr Glu Val Arg  
                   725                                  730                                  735

Arg Phe Arg Ser Asp Gln Gly Leu Ala Asp Arg Gln Lys Val Pro Ala  
                   740                                  745                                  750

Arg Met His Gly Val Arg Asp Ser Asp Leu Ser Asn Gln Val Ala Ala  
                   755                                  760                                  765

Val Thr Ser Leu Ala Trp Leu Thr Glu Pro Gly Pro Asp Phe Glu Pro  
   770                                  775                                  780

Ser Val Ser Leu Glu Val Arg Leu Gly Pro Glu Met Asn Arg Thr Val  
   785                                  790                                  795                                  800

-71-

Val Val Glu Leu Asp Thr Ser Gly Thr Ile Asp Val Ala Ala Glu Arg  
805 810 815

Arg Arg Leu Glu Lys Glu Leu Ala Gly Ala Gln Lys Glu Leu Ala Ser  
820 825 830

Thr Ala Ala Lys Leu Ala Asn Ala Asp Phe Leu Ala Lys Ala Pro Asp  
835 840 845

Ala Val Ile Ala Lys Ile Arg Asp Arg Gln Arg Val Ala Gln Gln Glu  
850 855 860

Thr Glu Arg Ile Thr Thr Arg Leu Ala Ala Leu Gln  
865 870 875

&lt;210&gt; 50

&lt;211&gt; 2628

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 50

|                                                                    |     |
|--------------------------------------------------------------------|-----|
| atgctgcccc agtcgtggga tccggccgcg atggagagcg ccatctatca gaagtggctg  | 60  |
| gacgttggtt acttcaccgc ggacccgacc agcaccaagc cggcctatct gatcgtgctg  | 120 |
| ccgcccgcga acgtgaccgg cagcctgcac atggggccacg cgctggaaca caccatgatg | 180 |
| gacgccttga cgcgccgcaa gcggatgcag ggctatgagg tgctctggca gccgggcacc  | 240 |
| gaccatgccg ggatcgccac ccagagcgtg gtcgagcagc agctggcggt cgacggcaag  | 300 |
| actaaagaag acctcgccg cgagctgttc gtggacaagg tgtgggattg gaagcgagag   | 360 |
| tctggcggtg ccatcgccgg ccagatgcgc cgactcggtg acgggggtga ctggagccgc  | 420 |
| gaccggttca ccatggacga aggtctgtcg cgggcggtgc gcacgatctt caagcggtt   | 480 |
| tatgacgccg ggctgatcta tcgggccgag cggctggtca actggtcgcc ggtgctgcag  | 540 |
| accgcgatct ccgacctga ggtcaactac cgcgacgtcg aaggcgagct ggtgtcgttt   | 600 |
| aggtacggct cgcttgacga ctcgcaacc caccatcggtg tcgccaccac ccgggtcgag  | 660 |
| acgatgctgg gcgataccgc gatcgccgtc catcccgatg acgagcgcta ccgtcacctg  | 720 |
| gtcggcacca gcctggcgca cccattcgtc gaccgggagc tggccattgt cgccgacgag  | 780 |
| cacgtggacc ctgaattcgg caccggcgcg gtcaaagtca caccgcccc cgaccccaac   | 840 |



-72-

|                                                                    |      |
|--------------------------------------------------------------------|------|
| gacttcgaaa tcgggggtgcg ccaccagctg ccgatgccct cgatcctgga caccaagggc | 900  |
| cggatcgctg acaccggaac gcgattcgac ggcattggacc gcttcgaggc acgggtcgcg | 960  |
| gtgcgccaaag cgtcgcggc ccagggccgc gtggtcgaag aaaagcgacc ctacctgcac  | 1020 |
| agcgtcggac actccgaacg cagcggcgag ccgatcgagc cgcggctatc cctgcagtgg  | 1080 |
| tgggtccggg tggaatcgct ggccaaagcg gccggggatg cgggtcgcaa cggggacacc  | 1140 |
| gtgattcacc cggccagcat ggaaccccg cggttctcct gggtcgacga catgcacgac   | 1200 |
| tgggtcatct cgcgacagct ctggtggggg catcggatcc cgatctggta cggacccgac  | 1260 |
| ggcgaacagg tgtgcgtcgg cccggacgaa acacccccgc agggctggga acaggatcct  | 1320 |
| gacgtgctgg atacctggtt ttctcggcg ctgtggcgt ttccacgct gggttggccg     | 1380 |
| gacaagacgg cggagctgga aaagttctat ccgacaagcg ttctggttac cggctatgac  | 1440 |
| atcttgttct tttgggtggc cagaatgatg atgttcggca ccttcgtcgg cgacgacgc   | 1500 |
| gccatcacc tcgacggccg cgggggccc caggtgccgt tcaccgacgt gtttctgcat    | 1560 |
| gggctgatcc gcgacgagtc tggccgcaag atgagcaagt ccaagggcaa cgtcatcgac  | 1620 |
| ccgctggatt ggggtgaaat gttcggggcc gatgcgctgc ggttcacgct ggcccgcggg  | 1680 |
| gccagtccc gtggtgactt ggcggtgagc gaggatgccg tgcgggcgtc gcgcaatttc   | 1740 |
| gggaccaagc tgttcaacgc cactcggtag gcaactgctca atggcgccgc gccagcacc  | 1800 |
| ctgccatcgc cgaacgagct gaccgacgcc gaccgctgga ttctcggaag gttggaagag  | 1860 |
| gttcgggccc aagttgattc ggccttcgac ggatacgagt tcagccgcgc ttgtgagtcc  | 1920 |
| ctgtatcaact tcgcctggga cgaattctgc gactggtagc tcgaactggc caaaacgcag | 1980 |
| cttgcccagg gactcacaca caccaccgcc gtgctggccg cgggctgga cacgctgctg   | 2040 |
| cgcctgctgc acccgtgat tcccttcctc accgaggcgc tatggctggc gctgaccggc   | 2100 |
| agggaatcgc tggtcagcgc cgactggccg gagccttcgc ggattagcgt ggaccttgtt  | 2160 |
| gccgcgcaac ggattaacga tatgcagaag ttggtgaccg aagtgcggcg gttccgcagc  | 2220 |
| gatcaaggtc tggccgaccg gcagaagggt cgggcccga tgcacgggtg gcgggactcg   | 2280 |
| gatctgagca accaggtggc cgcctgacc tcgctggcgt ggctcaccga gccgggccc    | 2340 |
| gattttgagc cgtcggctct gttggagggt cggctcggcc ccgagatgaa ccgcaccgtc  | 2400 |
| gtcgtcgagc tcgacacctc gggcaccatc gacgtggccg ccgagcgtcg ccgcctggaa  | 2460 |
| aaggagttgg ccggcgccca aaaggagctg gcgtcgacc cggccaagtt ggccaacgcg   | 2520 |
| gactttctgg ccaaagcgcc cgacgccgtc attgccaaaga tccgggaccg ccagcgcgtg | 2580 |

-73-

gcgcagcagg aaaccgagcg catcaccacc cgggtggctg cgctgcaa

2628

&lt;210&gt; 51

&lt;211&gt; 431

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; '51

Met Asn Pro Thr Leu Ala Val Leu Gly Ala Gly Ala Lys Ala Val Ala  
 1 5 10 15

Val Ala Ala Lys Ala Ser Val Leu Arg Asp Met Gly Val Asp Val Pro  
 20 25 30

Asp Val Ile Ala Val Glu Arg Ile Gly Val Gly Ala Asn Trp Gln Ala  
 35 40 45

Ser Gly Gly Trp Thr Asp Gly Ala His Arg Leu Gly Thr Ser Pro Glu  
 50 55 60

Lys Asp Val Gly Phe Pro Tyr Arg Ser Ala Leu Val Pro Arg Arg Asn  
 65 70 75 80

Ala Glu Leu Asp Glu Arg Met Thr Arg Tyr Ser Trp Gln Ser Tyr Leu  
 85 90 95

Ile Ala Thr Ala Ser Phe Ala Glu Trp Ile Asp Arg Gly Arg Pro Ala  
 100 105 110

Pro Thr His Arg Arg Trp Ser Gln Tyr Leu Ala Trp Val Ala Asp His  
 115 120 125

Ile Gly Leu Lys Val Ile His Gly Glu Val Glu Arg Leu Ala Val Thr  
 130 135 140

Gly Asp Arg Trp Ala Leu Cys Thr His Glu Thr Thr Val Gln Ala Asp  
 145 150 155 160

Ala Leu Met Ile Thr Gly Pro Gly Gln Ala Glu Lys Ser Leu Leu Pro  
 165 170 175

-74-

Gly Asn Pro Arg Val Leu Ser Ile Ala Gln Phe Trp Asp Arg Ala Ala  
 180 185 190

Gly His Asp Arg Ile Asn Ala Glu Arg Val Ala Val Ile Gly Gly Gly  
 195 200 205

Glu Thr Ala Ala Ser Met Leu Asn Glu Leu Phe Arg His Arg Val Ser  
 210 215 220

Thr Ile Thr Val Ile Ser Pro Gln Val Thr Leu Phe Thr Arg Gly Glu  
 225 230 235 240

Gly Phe Phe Glu Asn Ser Leu Phe Ser Asp Pro Thr Asp Trp Ala Ala  
 245 250 255

Leu Thr Phe Asp Glu Arg Arg Asp Ala Leu Ala Arg Thr Asp Arg Gly  
 260 265 270

Val Phe Ser Ala Thr Val Gln Glu Ala Leu Leu Ala Asp Asp Arg Ile  
 275 280 285

His His Leu Arg Gly Arg Val Ala His Ala Val Gly Arg Gln Gly Gln  
 290 295 300

Ile Arg Leu Thr Leu Ser Thr Asn Arg Gly Ser Glu Asn Phe Glu Thr  
 305 310 315 320

Val His Gly Phe Asp Leu Val Ile Asp Gly Ser Gly Ala Asp Pro Leu  
 325 330 335

Trp Phe Thr Ser Leu Phe Ser Gln His Thr Leu Asp Leu Leu Glu Leu  
 340 345 350

Gly Leu Gly Gly Pro Leu Thr Ala Asp Arg Leu Gln Glu Ala Ile Gly  
 355 360 365

Tyr Asp Leu Ala Val Thr Asp Val Thr Pro Lys Leu Phe Leu Pro Thr  
 370 375 380

Leu Ser Gly Leu Thr Gln Gly Pro Gly Phe Pro Asn Leu Ser Cys Leu  
 385 390 395 400

Gly Leu Leu Ser Asp Arg Val Leu Gly Ala Gly Ile Phe Thr Pro Thr  
 405 410 415

-75-

Lys His Asn Asp Thr Arg Arg Ser Gly Glu His Gln Ser Phe Arg  
 420 425 430

&lt;210&gt; 52

&lt;211&gt; 1293

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 52

```

atgaatccga cgctcgcggt cctgggcgct ggagccaagg cggtaggcggt cgcggccaag      60
gcatccgtgc tgcgtgacat gggggtcgac gtgcccgcag tgatcgccgt cgaacgcatac      120
ggggtcgggg ccaactggca ggccagcggt ggctggaccg acggagccca ccggctgggc      180
accagcccag aaaaggatgt cggttttccc taccggtcgg cgctggtgcc acggcgcaac      240
gcagaattgg acgagcggat gacccgctac agctggcagt cgtatctgat cgccaccgcg      300
tcgttcgcgg aatggatcga ccggggccgc ccggcgccca cccatcgag gtggagtcag      360
tacctagcct gggtagccga tcacattggc ctcaaggatga tccacggcga ggtcgaacgg      420
ctcgccgtca ccggtgaccg ctgggcgttg tgcaccacg agaccaccgt gcaggccgac      480
gcgttgatga tcaccgggccc cggccaggct gaaaagtcgc tactgcccgg aaaccgcgcg      540
gtgctctcaa tcgcacagtt ctgggaccgt gccgcgggcc acgaccggat caacgccgag      600
cgggtcgcgg tgatcggtgg cggagagacg gccgcatacga tgcatacga gctgttcgg      660
catcgggtct caaccatcac cgtcatctcc ccgcaggtaa ccctgttcac ccgcggcgag      720
ggattcttcg agaactcaat gttttccgat ccgaccgact gggcggcctt gacgttcgac      780
gaacggcgcg acgcgtggc ccgcaccgac cgaggagtgt tctcggcgac cgtgcaggaa      840
gcgctgctgg ccgatgaccg catccatcat ctgcgtggcc gggtcgcca cgcggtgggc      900
cgtcaggggc agatccggtt gacgctgagc accaaccggg gcagcgagaa cttcgagacc      960
gtgcacggat tcgatctcgt catcgacggc tcgggcggcc atccgctgtg gttcacctca     1020
ctgttcagtc agcacacct cgacctgctc gagctgggac tgggtggacc gctgaccgcc     1080
gaccgcctgc aggaagcgat cggctacgac ttggcagtca ccgacgtcac gcccaagctg     1140
ttcctgcca ccctgtccgg actcaccag gggcccgggt tcccaacct gagctgcctc     1200
ggcttgttgt cggaccgggt gctcggcgcc ggcattctta cgccgaccaa acacaacgac     1260

```

-76-

acaaggagaa gcggtgagca ccaatccttt cga

1293

&lt;210&gt; 53

&lt;211&gt; 71

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 53

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Ser | Thr | Asn | Pro | Phe | Asp | Asp | Asp | Asn | Gly | Ala | Phe | Phe | Val | Leu |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Asn | Asp | Glu | Asp | Gln | His | Ser | Leu | Trp | Pro | Val | Phe | Ala | Asp | Ile |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Ala | Gly | Trp | Arg | Val | Val | His | Gly | Glu | Ala | Ser | Arg | Ala | Ala | Cys |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Asp | Tyr | Val | Glu | Lys | Asn | Trp | Thr | Asp | Leu | Arg | Pro | Lys | Ser | Leu |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |

|     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|
| Arg | Asp | Ala | Met | Val | Glu | Asp |
| 65  |     |     |     |     | 70  |     |

&lt;210&gt; 54

&lt;211&gt; 213

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 54

gtgagcacca atcctttcga tgacgacaac ggcgattct tctgtctggt caacgacgaa 60

gaccagcaca gcctgtggcc ggtgttcgcc gatatcccgg ccggctggcg cgtggtgcac 120

ggcgaagcca gccgtgccgc ctgcctggac tacgtggaaa agaactggac cgatctgcgg 180

ccgaagagcc tgcgtgacgc catggtcgag gac 213

&lt;210&gt; 55

&lt;211&gt; 201

-77-

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 55

Val Thr Ala Val Ala Ala Gly Ala Leu Val Val Glu Thr Asp Ser Phe  
 1 5 10 15

Arg Leu Arg Leu Leu Asp Gly Leu Val Ala Ser Ile Gly Glu Arg Gly  
 20 25 30

Tyr Arg Ala Thr Thr Val Ser Asp Ile Val Arg His Ala Arg Thr Ser  
 35 40 45

Lys Arg Thr Phe Tyr Asp Arg Phe Thr Ser Lys Glu Gln Cys Phe Leu  
 50 55 60

Glu Leu Leu Leu Ala Asp Asn Glu Thr Leu Gly Asn Ser Ile Arg Ala  
 65 70 75 80

Ala Val Asp Pro Asn Ala Asp Trp His Asp Gln Ile Arg Gln Ala Val  
 85 90 95

Glu Ala Tyr Val Thr His Ile Glu Ser Arg Pro Ala Val Thr Leu Ser  
 100 105 110

Trp Ile Arg Glu Phe Pro Ser Leu Gly Ala Ala Ala Tyr Pro Val Gln  
 115 120 125

Arg Arg Gly Met Glu Gln Leu Thr Ser Leu Leu Ile Glu Leu Ser Ala  
 130 135 140

Ser Pro Gly Phe Arg Arg Ala Asn Leu Pro Pro Leu Asn Val Pro Leu  
 145 150 155 160

Ala Val Ile Leu Leu Gly Gly Leu Arg Glu Leu Thr Ala Leu Thr Val  
 165 170 175

Glu Asp Gly Gln Pro Ile Arg Asn Ile Val Glu Pro Ala Val Asp Ala  
 180 185 190

Ser Ile Ala Leu Leu Gly Pro Arg Ser  
 195 200

-78-

&lt;210&gt; 56

&lt;211&gt; 603

&lt;212&gt; DNA

<213> *Mycobacterium tuberculosis*

&lt;400&gt; 56

```

gtgacagcag tcgccgccgg cgcgttggtc gtcgagaccg actcgtttcg gctacgggtg      60
ctcgacgggcc tggtcgctc gatcggtgag cggggttatc gcgccaccac cgtctccgac      120
atcgtcgggc acgcccgcac atccaagcgc acgttctacg accgggttcac cagcaaggaa      180
cagtgccttt tggaactcct gctagcggac aacgagacgt tgggcaacag catccgggcg      240
gccgtcgatc caaacgccga ctggcacgac cagattcgtc aggcggtcga ggccctacgtc      300
acctatatcg aatccaggcc ggcggtgacg ttgagttgga tccgtgaatt cccgtcgctc      360
ggtgccgcgc cttaccccggt ccagcgccgc ggcatggagc agctaaccag cctgctgac      420
gagctcagcg ccagccctgg gttccggcgg gctaacctac cgccactgaa tgtgccactg      480
gccgtaatct tgctgggcgg tttgcgtgaa ctgaccgcgc tgaccgtcga ggacggccag      540
ccgatccgga acatcgtcga gccggcggtg gatgcgtcaa tcgcgctgct cgggtcccgc      600
agc                                          603

```

&lt;210&gt; 57

&lt;211&gt; 534

&lt;212&gt; PRT

<213> *Mycobacterium tuberculosis*

&lt;400&gt; 57

```

Val Ser Gln Ile Pro Val Lys Leu Leu Val Asn Gly Arg Val Tyr Ser
1              5              10              15

Pro Thr His Pro Glu Ala Thr Ala Met Ala Val Arg Gly Asp Val Val
                20                25                30

Ala Trp Leu Gly Ser Asp Asp Val Gly Arg Asp Gln Phe Pro Asp Ala
35              40              45

```

-79-

Asp Val Gln Asp Leu Asp Gly Arg Phe Val Ala Pro Gly Phe Val Asp  
 50 55 60

Ser His Ile His Leu Thr Ala Thr Gly Leu Met Leu Ser Gly Leu Asp  
 65 70 75 80

Leu Arg Pro Ala Thr Ser Arg Ala Gln Cys Leu Arg Met Val Ala Asp  
 85 90 95

Tyr Ala Ala Asp His Pro Gly Gln Pro Leu Trp Gly His Gly Trp Asp  
 100 105 110

Glu Ser Ala Trp Pro Glu Asn Ala Ala Pro Ser Thr Ala Asp Leu Asp  
 115 120 125

Ala Val Leu Gly Asp Cys Pro Ala Tyr Leu Ala Arg Ile Asp Ser His  
 130 135 140

Ser Ala Leu Val Ser Ser Gly Leu Arg Arg Leu Val Pro Glu Leu Ala  
 145 150 155 160

Ala Ala Thr Gly Tyr Thr Ala Gln Arg Pro Leu Thr Gly Asp Ala His  
 165 170 175

His Leu Ala Arg Ala Ala Ala Arg Tyr Leu Leu Thr Asp Val Gln Leu  
 180 185 190

Ala Asp Ala Arg Ala Val Ala Leu Gln Ala Ile Ala Ala Ala Gly Val  
 195 200 205

Val Ala Val His Glu Cys Ala Gly Pro Glu Ile Gly Gly Leu Asp Asp  
 210 215 220

Trp Leu Arg Leu Arg Ala Leu Glu His Gly Val Glu Val Ile Gly Tyr  
 225 230 235 240

Trp Gly Glu Ala Val Ala Thr Pro Ala Gln Ala Arg Asp Leu Val Thr  
 245 250 255

Glu Thr Gly Ala Arg Gly Leu Ala Gly Asp Leu Phe Val Asp Gly Ala  
 260 265 270

Leu Gly Ser Arg Thr Ala Trp Leu His Glu Pro Tyr Ala Asp Ala Pro  
 275 280 285



-80-

Asp Cys Ile Gly Thr Cys His Leu Asp Val Asp Gly Ile Glu Ala His  
 290 295 300

Val Arg Ala Cys Thr Lys Ala Glu Val Thr Ala Gly Phe His Val Ile  
 305 310 315 320

Gly Asp Ala Ala Val Ser Ala Ala Val Ala Ala Phe Glu Arg Val Val  
 325 330 335

Ala Asp Leu Gly Val Val Ala Val Ala Arg Cys Gly His Arg Leu Glu  
 340 345 350

His Val Glu Met Val Thr Ala Asp Gln Ala Ala Lys Leu Gly Ala Trp  
 355 360 365

Gly Val Ile Ala Ser Val Gln Pro Asn Phe Asp Glu Leu Trp Gly Gly  
 370 375 380

Gly Asp Gly Met Tyr Ala Arg Arg Leu Gly Ala Gln Arg Gly Ser Glu  
 385 390 395 400

Leu Asn Pro Leu Ala Leu Leu Ala Ser Gln Gly Val Pro Leu Ala Leu  
 405 410 415

Gly Ser Asp Ala Pro Val Thr Gly Phe Asp Pro Trp Ala Ser Val Arg  
 420 425 430

Ala Ala Val Asn His Arg Thr Pro Gly Ser Gly Val Ser Ala Arg Ala  
 435 440 445

Ala Phe Ala Ala Ala Thr Arg Gly Gly Trp Arg Ala Gly Gly Val Arg  
 450 455 460

Asp Gly Arg Ile Gly Thr Leu Val Pro Gly Ala Pro Ala Ser Tyr Ala  
 465 470 475 480

Ile Trp Asp Ala Gly Asp Phe Asp Val Asp Ala Pro Arg Asp Ala Val  
 485 490 495

Gln Arg Trp Ser Thr Asp Pro Arg Ser Arg Val Pro Ala Leu Pro Arg  
 500 505 510

Leu Gly Pro Thr Asp Ala Leu Pro Arg Cys Arg Gln Thr Val His Arg

-81-

515

520

525

Gly Ala Val Ile Tyr Gly  
530

&lt;210&gt; 58

&lt;211&gt; 1602

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 58

|                                                                     |      |
|---------------------------------------------------------------------|------|
| gtgagccaga ttcccgtaa actcctggtc aacggccggg tgtacagccc caccaccccc    | 60   |
| gaagceaccg cgatggcggg ggcggcgat gtcgtcgctt ggttgggcag cgacgacgtc    | 120  |
| ggccgcgacc agttcccaga cgctgacgtg caggatctcg acggccgatt cgtggcgccg   | 180  |
| gggttcgtgg acagccacat ccacctgacc gcgaccggtc tgatgctcag cgggctggac   | 240  |
| ttcgggcccc cgacctcacg cgcgcagtgc ctacggatgg tcgccgacta tgcggccgac   | 300  |
| catccgggtc agccgctgtg gggtcacggg tgggatgagt cggcctggcc ggagaatgct   | 360  |
| gcgcccagca ccgcccacct agacgcgggt ctcggtgact gtcccgccca cctggccagg   | 420  |
| atcgactcgc actccgcggt ggtctctctc ggactgcggc ggctgggtccc cgagctggcg  | 480  |
| gcggcaaccg gttacacggc ccagcggccg ctgaccgggt atgcccacca cctagcccgg   | 540  |
| gccgcgcac gctacctctt gaccgacgtc cagcttgccg acgcccgggc cgtggcgctg    | 600  |
| caggccatag ccgcgcccg cgtcgtcgcc gtgcacgaat gcgccgggtc ggaaatcggc    | 660  |
| gggctcgacg actggttgcg gctgcgtgca ctcgagcacg gagtcgaggt gatcgggtac   | 720  |
| tggggtgagg ccgtggccac gccggcccag gcccgtagcc tggtagccga gaccggggct   | 780  |
| cgagggctgg ccggtgattt gttcgtcgac ggggcgctcg ggtcgcgcac cgcctggctg   | 840  |
| cacgagccct acgcggacgc cccgactgc atcggcacct gccacctga cgtagacggc     | 900  |
| atcgaagcgc acgtacgagc atgcaccaag gccgaagtga ccgccggctt ccacgtcatc   | 960  |
| ggcgacgctg cgggtgctggc cgcagtcgcc gccttcgaac ggggtggtggc agatctcggc | 1020 |
| gtgggttgccg tcgcccgtg cggccaccgc ctcgagcatg tggagatggt caccgcgga    | 1080 |
| caggccgcga agctgggcgc ttgggggggtc atcgccagtg tgcagcccaa cttcgatgag  | 1140 |
| ctgtggggcg gtggcgacgg catgtacgct cgcgcctgg gcgcccagcg aggcagcgaa    | 1200 |

-82-

ctcaaccgcg tggcgetggt agcatcccaa ggcgtgcccc tcgcgcttgg ctccgacgcg 1260  
 cccgtcacgg gctttgatcc ctgggccagc gtgcgcgcgg cggatcaatca ccgcacgcgg 1320  
 ggcagcgggg tatcggcgcg ggcggcggtt gctgcgcga cccgcggcgg ctggcggggc 1380  
 ggtggtgttc gagacggcgg gatcggcacc ctggtgcgg gcgcgcccgc gtcctacgcg 1440  
 atatgggacg ccggggactt tgacgtcgac gcaccgcgcg acgcagtcca gcgctggtct 1500  
 accgaccgcg gctccggggt accgcattg ccgcggctgg gcccgaccga cgccttgccg 1560  
 cgttgccgcc aaaccgtgca tcgaggtgcg gtcatttatg gc 1602

&lt;210&gt; 59

&lt;211&gt; 151

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 59

Met Leu Lys Gly Phe Lys Glu Phe Leu Ala Arg Gly Asn Ile Val Asp  
 1 5 10 15

Leu Ala Val Ala Val Val Ile Gly Thr Ala Phe Thr Ala Leu Val Thr  
 20 25 30

Lys Phe Thr Asp Ser Ile Ile Thr Pro Leu Ile Asn Arg Ile Gly Val  
 35 40 45

Asn Ala Gln Ser Asp Val Gly Ile Leu Arg Ile Gly Ile Gly Gly Gly  
 50 55 60

Gln Thr Ile Asp Leu Asn Val Leu Leu Ser Ala Ala Ile Asn Phe Phe  
 65 70 75 80

Leu Ile Ala Phe Ala Val Tyr Phe Leu Val Val Leu Pro Tyr Asn Thr  
 85 90 95

Leu Arg Lys Lys Gly Glu Val Glu Gln Pro Gly Asp Thr Gln Val Val  
 100 105 110

Leu Leu Thr Glu Ile Arg Asp Leu Leu Ala Gln Thr Asn Gly Asp Ser  
 115 120 125

-83-

Pro Gly Arg His Gly Gly Arg Gly Thr Pro Ser Pro Thr Asp Gly Pro  
 130 135 140

Arg Ala Ser Thr Glu Ser Gln  
 145 150

&lt;210&gt; 60

&lt;211&gt; 453

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 60

atgctcaaaag gattcaagga gtttctcgcg cgggtaata tcgtcgacct ggctgtcgcg 60  
 gtggtaatcg gcacagcggt caggcggtg gtcaccaagt tcaccgacag catcattacg 120  
 ccgctgatca accggatcgg cgtcaacgca cagtcgacg tcggcatctt gggatcgggt 180  
 atcggcggtg gtcagaccat tgacttgaac gtcttgttgt cggcagcgat caactttttc 240  
 ctgatecggt tcgcggtgta ctctctagtc gtgtgcctt acaacacact acgcaagaag 300  
 ggggaggtcg agcagccggg cgacacccaa gtctgtctgc tcaccgaaat ccgcgatctg 360  
 ctgcgcgaaa cgaacgggga ctgcgcgggg aggcacggcg gccgtgggac accatcgcca 420  
 accgacgggc ctgcgcgag cacagaatcg caa 453

&lt;210&gt; 61

&lt;211&gt; 759

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 61

Met Gly Ser Ala Ser Glu Gln Arg Val Thr Leu Thr Asn Ala Asp Lys  
 1 5 10 15

Val Leu Tyr Pro Ala Thr Gly Thr Thr Lys Ser Asp Ile Phe Asp Tyr  
 20 25 30

Tyr Ala Gly Val Ala Glu Val Met Leu Gly His Ile Ala Gly Arg Pro  
 35 40 45

-84-

Ala Thr Arg Lys Arg Trp Pro Asn Gly Val Asp Gln Pro Ala Phe Phe  
 50 55 60

Glu Lys Gln Leu Ala Leu Ser Ala Pro Pro Trp Leu Ser Arg Ala Thr  
 65 70 75 80

Val Ala His Arg Ser Gly Thr Thr Thr Tyr Pro Ile Ile Asp Ser Ala  
 85 90 95

Thr Gly Leu Ala Trp Ile Ala Gln Gln Ala Ala Leu Glu Val His Val  
 100 105 110

Pro Gln Trp Arg Phe Val Ala Glu Pro Gly Ser Gly Glu Leu Asn Pro  
 115 120 125

Gly Pro Ala Thr Arg Leu Val Phe Asp Leu Asp Pro Gly Glu Gly Val  
 130 135 140

Met Met Ala Gln Leu Ala Glu Val Ala Arg Ala Val Arg Asp Leu Leu  
 145 150 155 160

Ala Asp Ile Gly Leu Val Thr Phe Pro Val Thr Ser Gly Ser Lys Gly  
 165 170 175

Leu His Leu Tyr Thr Pro Leu Asp Glu Pro Val Ser Ser Arg Gly Ala  
 180 185 190

Thr Val Leu Ala Lys Arg Val Ala Gln Arg Leu Glu Gln Ala Met Pro  
 195 200 205

Ala Leu Val Thr Ser Thr Met Thr Lys Ser Leu Arg Ala Gly Lys Val  
 210 215 220

Phe Val Asp Trp Ser Gln Asn Ser Gly Ser Lys Thr Thr Ile Ala Pro  
 225 230 235 240

Tyr Ser Leu Arg Gly Arg Thr His Pro Thr Val Ala Ala Pro Arg Thr  
 245 250 255

Trp Ala Glu Leu Asp Asp Pro Ala Leu Arg Gln Leu Ser Tyr Asp Glu  
 260 265 270

Val Leu Thr Arg Ile Ala Arg Asp Gly Asp Leu Leu Glu Arg Leu Asp

-85-

|                                                                 |     |         |
|-----------------------------------------------------------------|-----|---------|
| 275                                                             | 280 | 285     |
| Ala Asp Ala Pro Val Ala Asp Arg Leu Thr Arg Tyr Arg Arg Met Arg |     |         |
| 290                                                             | 295 | 300     |
| Asp Ala Ser Lys Thr Pro Glu Pro Ile Pro Thr Ala Lys Pro Val Thr |     |         |
| 305                                                             | 310 | 315 320 |
| Gly Asp Gly Asn Thr Phe Val Ile Gln Glu His His Ala Arg Arg Pro |     |         |
| 325                                                             | 330 | 335     |
| His Tyr Asp Phe Arg Leu Glu Cys Asp Gly Val Leu Val Ser Trp Ala |     |         |
| 340                                                             | 345 | 350     |
| Val Pro Lys Asn Leu Pro Asp Asn Thr Ser Val Asn His Leu Ala Ile |     |         |
| 355                                                             | 360 | 365     |
| His Thr Glu Asp His Pro Leu Glu Tyr Ala Thr Phe Glu Gly Ala Ile |     |         |
| 370                                                             | 375 | 380     |
| Pro Ser Gly Glu Tyr Gly Ala Gly Lys Val Ile Ile Trp Asp Ser Gly |     |         |
| 385                                                             | 390 | 395 400 |
| Thr Tyr Asp Thr Glu Lys Phe His Asp Asp Pro His Thr Gly Glu Val |     |         |
| 405                                                             | 410 | 415     |
| Ile Val Asn Leu His Gly Gly Arg Ile Ser Gly Arg Tyr Ala Leu Ile |     |         |
| 420                                                             | 425 | 430     |
| Arg Thr Asn Gly Asp Arg Trp Leu Ala His Arg Leu Lys Asn Gln Lys |     |         |
| 435                                                             | 440 | 445     |
| Asp Gln Lys Val Phe Glu Phe Asp Asn Leu Ala Pro Met Leu Ala Thr |     |         |
| 450                                                             | 455 | 460     |
| His Gly Thr Val Ala Gly Leu Lys Ala Ser Gln Trp Ala Phe Glu Gly |     |         |
| 465                                                             | 470 | 475 480 |
| Lys Trp Asp Gly Tyr Arg Leu Leu Val Glu Ala Asp His Gly Ala Val |     |         |
| 485                                                             | 490 | 495     |
| Arg Leu Arg Ser Arg Ser Gly Arg Asp Val Thr Ala Glu Tyr Pro Gln |     |         |
| 500                                                             | 505 | 510     |

-86-

Leu Arg Ala Leu Ala Glu Asp Leu Ala Asp His His Val Val Leu Asp  
 515 520 525

Gly Glu Ala Val Val Leu Asp Ser Ser Gly Val Pro Ser Phe Ser Gln  
 530 535 540

Met Gln Asn Arg Gly Arg Asp Thr Arg Val Glu Phe Trp Ala Phe Asp  
 545 550 555 560

Leu Leu Tyr Leu Asp Gly Arg Ala Leu Leu Gly Thr Arg Tyr Gln Asp  
 565 570 575

Arg Arg Lys Leu Leu Glu Thr Leu Ala Asn Ala Thr Ser Leu Thr Val  
 580 585 590

Pro Glu Leu Leu Pro Gly Asp Gly Ala Gln Ala Phe Ala Cys Ser Arg  
 595 600 605

Lys His Gly Trp Glu Gly Val Ile Ala Lys Arg Arg Asp Ser Arg Tyr  
 610 615 620

Gln Pro Gly Arg Arg Cys Ala Ser Trp Val Lys Asp Lys His Trp Asn  
 625 630 635 640

Thr Gln Glu Val Val Ile Gly Gly Trp Arg Ala Gly Glu Gly Gly Arg  
 645 650 655

Ser Ser Gly Val Gly Ser Leu Leu Met Gly Ile Pro Gly Pro Gly Gly  
 660 665 670

Leu Gln Phe Ala Gly Arg Val Gly Thr Gly Leu Ser Glu Arg Glu Leu  
 675 680 685

Ala Asn Leu Lys Glu Met Leu Ala Pro Leu His Thr Asp Glu Ser Pro  
 690 695 700

Phe Asp Val Pro Leu Pro Ala Arg Asp Ala Lys Gly Ile Thr Tyr Val  
 705 710 715 720

Lys Pro Ala Leu Val Ala Glu Val Arg Tyr Ser Glu Trp Thr Pro Glu  
 725 730 735

Gly Arg Leu Arg Gln Ser Ser Trp Arg Gly Leu Arg Pro Asp Lys Lys  
 740 745 750

-87-

Pro Ser Glu Val Val Arg Glu  
755

&lt;210&gt; 62

&lt;211&gt; 2277

&lt;212&gt; DNA

<213> *Mycobacterium tuberculosis*

&lt;400&gt; 62

|             |             |             |             |             |            |      |
|-------------|-------------|-------------|-------------|-------------|------------|------|
| atgggttcgg  | cgtcggagca  | acgggtgacg  | ctgaccaacg  | ccgacaagggt | gctctatccc | 60   |
| gccaccggga  | ccacaaagtc  | cgatatcttc  | gactactacg  | ccggtgttgc  | cgaagtcatg | 120  |
| ctcggccaca  | tcgcgggacg  | gccggcgacg  | cgcaagcgct  | ggcctaacgg  | cgtcgaccaa | 180  |
| cccgcgttct  | tcgaaaagca  | gttggcggtg  | tcggcgccgc  | cttggtgtgc  | acgtgcaacg | 240  |
| gtggcgccacc | ggtcggggac  | gacgacctat  | ccgatcatcg  | atagcgcaac  | cgggctggcc | 300  |
| tggatcgccc  | aacaggcggc  | gctggagggtg | cacgtgcgcg  | agtggcggtt  | tgtcgcccag | 360  |
| cccggatcag  | gtgagttaaa  | tcggggcccc  | gcaacgcggt  | tggtgttcga  | cctggacccc | 420  |
| ggcgaaggcg  | tgatgatggc  | ccagctggcc  | gaggtggcgc  | gcgcggttcg  | tgatcttctc | 480  |
| gccgatatcg  | ggttgggtcac | cttcccggtc  | accagcggca  | gcaagggatt  | gcatctgtac | 540  |
| acaccgctgg  | atgagccggt  | gagcagcagg  | ggagccacgg  | tggtggccaa  | gcgcgtcgcg | 600  |
| cagcgattgg  | agcaggcgat  | gcccgcgttg  | gtcacctcga  | ccatgaccaa  | aagcctgcgg | 660  |
| gccgggaagg  | tgtttgtgga  | ctggagccag  | aacagcggct  | cgaagaccac  | catcgcgccg | 720  |
| tactcactac  | gtggccggac  | gcatccgacc  | gtcgcggcgc  | cacgcacctg  | ggcggagctc | 780  |
| gacgaccccc  | cactgcgtca  | gctctcctac  | gacgaggtgc  | tgacctggat  | tgcccgcgac | 840  |
| ggcgatctgc  | tcgagcggct  | ggatgcccgc  | gctccggtag  | cggaccgggt  | gacccgatac | 900  |
| cgccgcatgc  | gcgacgcata  | gaaaactccc  | gagccgattc  | ccacggcgaa  | acccgttacc | 960  |
| ggagacggca  | atacgttcgt  | catccaggag  | catcacgcgc  | gtcggccgca  | ctacgatttc | 1020 |
| cggctggaat  | gcgacggcgt  | gctggtctcg  | tgggcgggtac | cgaaaaacct  | gcccgacaac | 1080 |
| acatcggtta  | accatctage  | gatacacacc  | gaggaccacc  | cgctggaata  | cgccacgttc | 1140 |
| gagggcgcga  | ttcccagcgg  | ggagtacggc  | gccggcaagg  | tgatcatctg  | ggactccggc | 1200 |
| acttacgaca  | ccgagaagtt  | ccacgatgac  | ccgcacacgg  | gggagggtcat | cgtgaatctg | 1260 |



-88-

cacggcgggcc ggatctctgg gcgttatgcg ctgattcggg ccaacggcga tcggtggctg 1320  
 ggcacccgcc taaagaatca gaaagaccag aaggtgttcg agttcgacaa tctggcccca 1380  
 atgcttgcca cgcacggcac ggtggccggg ctaaaggcca gccagtgggc gttcgaaggc 1440  
 aagtgggacg gctaccggtt gctgggtgag gctgaccacg gcgccgtgcg gctgcgggtcc 1500  
 cgcagcgggc gcgatgtcac cgcagagtat ccgcaattgc gggcattggc ggaggatctc 1560  
 gccgatcacc acgtggtgct ggacggcgag gccgtcgtac ttgactcctc tgggtgtgcc 1620  
 agcttcagcc agatgcagaa tcggggccgc gacacccgtg tcgagttctg ggcgttcgac 1680  
 ctgctctacc tcgacggccg cgcgctgcta ggcacccgt accaagaccg gcgtaagctg 1740  
 ctcgaaaccc tagctaacgc aaccagtctc accgttcccg agctgctgcc cggtgacggc 1800  
 gcccgaagcg ttgctgtctc gcgcaagcac ggctgggagg gcgtgatcgc caagaggcgt 1860  
 gactcgcgt atcagccggg cgggcgctgc gcgtcgtggg tcaaggacaa gcactggaac 1920  
 acccaggaag tcgtcattgg tggtggcgc gccggggaag gcgggcgcag cagtggcgtc 1980  
 gggtcgctgc tcatgggcat ccccggtcca ggtgggctgc agttcgccgg gcgggtcggt 2040  
 accggcctca gcgaacgcga actggccaac ctcaaggaga tgctggcgcc gctgcatacc 2100  
 gacgagtccc ccttcgacgt accactgccc gcgcgtgacg ccaagggcat cacatatgtc 2160  
 aagccggcgc tgggtgcaga ggtgcgtac agcgagtga ctccggaggg ccggctgcgt 2220  
 caatcaagct ggcgtgggct gcggccggac aagaaacca gtgaggtggg gcgcgaa 2277

&lt;210&gt; 63

&lt;211&gt; 170

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 63

Val Val Pro Ala Gln His Arg Pro Pro Asp Arg Pro Gly Asp Pro Ala  
 1 5 10 15

His Asp Pro Gly Arg Gly Arg Arg Leu Gly Ile Asp Val Gly Ala Ala  
 20 25 30

Arg Ile Gly Val Ala Cys Ser Asp Pro Asp Ala Ile Leu Ala Thr Pro  
 35 40 45

-89-

Val Glu Thr Val Arg Arg Asp Arg Ser Gly Lys His Leu Arg Arg Leu  
 50 55 60

Ala Ala Leu Ala Ala Glu Leu Glu Ala Val Glu Val Ile Val Gly Leu  
 65 70 75 80

Pro Arg Thr Leu Ala Asp Arg Ile Gly Arg Ser Ala Gln Asp Ala Ile  
 85 90 95

Glu Leu Ala Glu Ala Leu Ala Arg Arg Val Ser Pro Thr Pro Val Arg  
 100 105 110

Leu Ala Asp Glu Arg Leu Thr Thr Val Ser Ala Gln Arg Ser Leu Arg  
 115 120 125

Gln Ala Gly Val Arg Ala Ser Glu Gln Arg Ala Val Ile Asp Gln Ala  
 130 135 140

Ala Ala Val Ala Ile Leu Gln Ser Trp Leu Asp Glu Arg Leu Ala Ala  
 145 150 155 160

Met Ala Gly Thr Gln Glu Gly Ser Asp Ala  
 165 170

&lt;210&gt; 64

&lt;211&gt; 510

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 64

gtgggtcccag cacagcaccg cccgcccgac cggcccgccg atccagcgca cgaccctgga 60

cggggacgac gcctcggtat cgacgtgggc gccgcgcgta tcggcgtggc ttgcagcgac 120

ccggacgcga tcttgccac cccggtggaa acggtgcgcc gcgacgttc cggaagcac 180

ctgcgcaggc tgggtgcgt gccgcgcgag ttggaggcgg tcgaggtgat cgtcgggctc 240

ccgcgcacgc tggccgaccg catcgccgc tcggcccaag acgcaatcga actggccgag 300

gcgctggcac gccgtgtttc tctacgcgc gtgcggctgg ccgacgagcg gctcaccacg 360

gtcagtgtc aacgatcttt gcggcaggcg ggggtgcggg cctccgagca gcgtgcggtg 420

atcgaccaag cggccgcagt ggcaatactg cagagctggc tggatgaacg tctcggggcg 480

-90-

atggccggga ctcaagaagg ctccgatgcc

510

&lt;210&gt; 65

&lt;211&gt; 120

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; '65

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Thr | Ala | Pro | Glu | Thr | Pro | Ala | Ala | Gln | His | Ala | Glu | Pro | Ala | Ile |
| 1   |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Val | Glu | Arg | Ile | Arg | Thr | Ala | Leu | Leu | Gly | Tyr | Arg | Ile | Met | Ala |
|     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Trp | Thr | Thr | Gly | Leu | Trp | Leu | Ile | Ala | Leu | Cys | Tyr | Glu | Ile | Val | Val |
|     |     | 35  |     |     |     | 40  |     |     |     |     |     | 45  |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Tyr | Val | Val | Lys | Val | Asp | Asn | Pro | Pro | Thr | Trp | Ile | Gly | Val | Val |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| His | Gly | Trp | Val | Tyr | Phe | Thr | Tyr | Leu | Leu | Leu | Thr | Leu | Asn | Leu | Ala |
| 65  |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Lys | Val | Arg | Trp | Pro | Leu | Gly | Lys | Thr | Ala | Gly | Val | Leu | Leu | Ala |
|     |     |     | 85  |     |     |     |     | 90  |     |     |     |     |     | 95  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Thr | Ile | Pro | Leu | Leu | Gly | Ile | Val | Val | Glu | His | Phe | Gln | Thr | Lys |
|     |     | 100 |     |     |     |     | 105 |     |     |     |     |     | 110 |     |     |

|     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Ile | Lys | Ala | Arg | Phe | Gly | Leu |
|     | 115 |     |     |     |     |     | 120 |

&lt;210&gt; 66

&lt;211&gt; 360

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 66

-91-

```

atgaccgcac ccgaaacgcc cgcggcgagc cagcgccgagc ctgccatcgc cgtcgagagg      60
attcgcacccg ctttgctcgg ctaccggatc atggcgtgga cgacggggcct ctggctcatc      120
gcactgtgct acgagatcgt ggtccgctac gtcgtcaagg ttgacaatcc gccgacgtgg      180
atcgggtgtgg tgcacggctg ggtgtacttc acgtatctgc ttctgacgtt gaacctggcg      240
gtcaagggtcc gctggccgct cggcaaaaca gccgggtgttc tgctcgccgg cacaattccg      300
ctgctcggca tcgtcgtcga gcacttcag accaaagaga tcaaggcccg cttcgggctt      360

```

&lt;210&gt; 67

&lt;211&gt; 122

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 67

```

Leu Leu Ala Thr Phe Trp Gly Trp Arg Ala Gln Gln Leu Pro Asp Gly
1           5           10           15

```

```

Thr Val Ile Trp Thr Leu Pro Gly Asp Gln Thr Tyr Val Thr Thr Pro
          20           25           30

```

```

Gly Ser Ala Leu Leu Phe Pro Ala Leu Cys Thr Pro Thr Gly Asp Pro
          35           40           45

```

```

Pro Arg Pro Asp Pro Ala Arg Ala Asp Arg Arg Gly Gln Arg Thr Ala
50           55           60

```

```

Met Met Pro Arg Arg Ala Ser Thr Arg Ala Gln Asn Arg Ala His Tyr
65           70           75           80

```

```

Ile Ala Ala Glu Arg His Arg Asn His Gln Ala Arg Arg Ile Ala His
          85           90           95

```

```

Val Val Thr Gln Thr Ala Thr Thr Ala Pro Glu Thr Asn Gly Pro Pro
100           105           110

```

```

Pro Asp Pro Asp Asp Asp Pro Pro Pro Phe
115           120

```

&lt;210&gt; 68

-92-

&lt;211&gt; 366

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 68

```

ttgctggcca ccttctgggg ctggcgcgcc cagcaactgc cgcacggcac cgtgatttgg      60
acgctgccgg gtgaccagac ctatgtcacc accccgggca gcgcgtgct gttcccggcg      120
ctgtgcaccc ccaccggtga cccacctga cccgacccgg cccgcgccga ccgccgcggg      180
cagcgcaccg cgatgatgcc gcgccggggc agcacccgag cgcaaaaccg cgcccactac      240
atcgccgccg aacgccaccg caaccaccaa gcccgccgga ttgccacgt ggtcacccaa      300
accgccacaa ccgccccga gactaacggc ccaccaccg atcccgacga cgaccgcgcg      360
cccttc                                           366

```

&lt;210&gt; 69

&lt;211&gt; 208

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 69

```

Val Ser Val Gly Glu Gly Pro Asp Thr Lys Pro Thr Ala Arg Gly Gln
1              5              10              15

Pro Ala Ala Val Gly Arg Val Val Val Leu Ser Gly Pro Ser Ala Val
20              25              30

Gly Lys Ser Thr Val Val Arg Cys Leu Arg Glu Arg Ile Pro Asn Leu
35              40              45

His Phe Ser Val Ser Ala Thr Thr Arg Ala Pro Arg Pro Gly Glu Val
50              55              60

Asp Gly Val Asp Tyr His Phe Ile Asp Pro Thr Arg Phe Gln Gln Leu
65              70              75              80

Ile Asp Gln Gly Glu Leu Leu Glu Trp Ala Glu Ile His Gly Gly Leu
85              90              95

```

-93-

His Arg Ser Gly Thr Leu Ala Gln Pro Val Arg Ala Ala Ala Thr  
 100 105 110

Gly Val Pro Val Leu Ile Glu Val Asp Leu Ala Gly Ala Arg Ala Ile  
 115 120 125

Lys Lys Thr Met Pro Glu Ala Val Thr Val Phe Leu Ala Pro Pro Ser  
 130 135 140

Trp Gln Asp Leu Gln Ala Arg Leu Ile Gly Arg Gly Thr Glu Thr Ala  
 145 150 155 160

Asp Val Ile Gln Arg Arg Leu Asp Thr Ala Arg Ile Glu Leu Ala Ala  
 165 170 175

Gln Gly Asp Phe Asp Lys Val Val Val Asn Arg Arg Leu Glu Ser Ala  
 180 185 190

Cys Ala Glu Leu Val Ser Leu Leu Val Gly Thr Ala Pro Gly Ser Pro  
 195 200 205

<210> 70

<211> 624

<212> DNA

<213> Mycobacterium tuberculosis

<400> 70

gtgagcgtcg gcgagggacc ggacaccaag cccaccgcgc gtggccaacc ggcggcagtg 60  
 ggacgtgtgg tgggtgctgtc cggtccttcc gcggtcggca aatccacggt ggttcggtgt 120  
 ctgcgcgagc ggatcccgaa tctgcatttc agtgtctcgg ccacgacgcg ggcgccacgc 180  
 ccgggcgagg tcgacggtgt cgactaccac ttcatecgacc ccacccgctt tcagcagctc 240  
 atcgaccagg gtgagttgct ggaatgggca gaaatccacg gcggcctgca ccggtcgggc 300  
 actttggccc agccggtgcg ggcggccgcg gcgactggtg tgccggtgct tatcgaggtt 360  
 gacctggccg gggccagggc gatcaagaag acgatgcccg aggctgtcac cgtgtttctg 420  
 gcgccaccta gctggcagga tcttcaggcc agactgattg gccgggcac cgaaacagct 480  
 gacgttatcc aacgccgcct ggacaccgcg cggatcgaat tggcagcgca gggcgacttt 540

-94-

gacaaggctg tggatgaacag gcgattagag tctgcgtgtg cggaattggt atccttgctg 600  
gtgggaacgg caccgggctc cccg 624

&lt;210&gt; 71

&lt;211&gt; 122

&lt;212&gt; PRT

<213> *Mycobacterium tuberculosis*

&lt;400&gt; 71

Met Thr Lys Lys Pro Arg Asn Pro Ala Asp Tyr Val Ile Gly Asp Asp  
1 5 10 15

Val Glu Val Ser Asp Val Asp Leu Lys Gln Glu Glu Val Tyr Val Asp  
20 25 30

Gly Glu Arg Leu Thr Asp Glu Arg Val Glu Gln Met Ala Ser Glu Ser  
35 40 45

Leu Arg Leu Ala Arg Glu Arg Glu Ala Asn Leu Ile Pro Gly Gly Lys  
50 55 60

Ser Leu Ser Gly Gly Ser Ala His Ser Pro Ala Val Gln Val Val Val  
65 70 75 80

Ser Lys Ala Thr His Ala Lys Leu Lys Glu Leu Ala Arg Ser Arg Lys  
85 90 95

Met Ser Val Ser Lys Leu Leu Arg Pro Val Leu Asp Glu Phe Val Gln  
100 105 110

Arg Glu Thr Gly Arg Ile Leu Pro Arg Arg  
115 120

&lt;210&gt; 72

&lt;211&gt; 366

&lt;212&gt; DNA

<213> *Mycobacterium tuberculosis*

-95-

<400> 72  
 atgacgaaga agccacgtaa ccccgccgac tacgtgatcg gcgacgatgt cgaggtgtct 60  
 gagctcgatc tcaagcaaga ggaggtctat gtcgatggcg agcggctaac ggacgagcgc 120  
 gtcgagcaga tggtcttcaga gtcgctgcgg ctggcgcgcg aacgagaagc caacctgatt 180  
 cctggcggca agtctctgtc cggcggctct gcgcactcgc cggctgtgca ggtggtcggt 240  
 tcgaaggcta cccacgccaa gctcaaggag ctggcgcgca gccggaagat gagcgtatct 300  
 aagctgetgc gtcccgtgct cgacgagttc gtacagcgag aaacgggtcg gattctccca 360  
 cggcgt 366

&lt;210&gt; 73

&lt;211&gt; 333

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 73

Met Phe Tyr Asp Asp Asp Ala Asp Leu Ser Ile Ile Gln Gly Arg Lys  
 1 5 10 15

Val Gly Val Ile Gly Tyr Gly Ser Gln Gly His Ala His Ser Leu Ser  
 20 25 30

Leu Arg Asp Ser Gly Val Gln Val Arg Val Gly Leu Lys Gln Gly Ser  
 35 40 45

Arg Ser Arg Pro Lys Val Glu Glu Gln Gly Leu Asp Val Asp Thr Pro  
 50 55 60

Ala Glu Val Ala Lys Trp Ala Asp Val Val Met Val Leu Ala Pro Asp  
 65 70 75 80

Thr Ala Gln Ala Glu Ile Phe Ala Gly Asp Ile Glu Pro Asn Leu Lys  
 85 90 95

Pro Gly Asp Ala Leu Phe Phe Gly His Gly Leu Asn Val His Phe Gly  
 100 105 110

Leu Ile Lys Pro Pro Ala Asp Val Ala Val Ala Met Val Ala Pro Lys  
 115 120 125



-96-

Gly Pro Gly His Leu Val Arg Arg Gln Phe Val Asp Gly Lys Gly Val  
 130 135 140

Pro Cys Leu Val Ala Val Glu Gln Asp Pro Arg Gly Asp Gly Leu Ala  
 145 150 155 160

Leu Ala Leu Ser Tyr Ala Lys Ala Ile Gly Gly Thr Arg Ala Gly Val  
 165 170 175

Ile Lys Thr Thr Phe Lys Asp Glu Thr Glu Thr Asp Leu Phe Gly Glu  
 180 185 190

Gln Thr Val Leu Cys Gly Gly Thr Glu Glu Leu Val Lys Ala Gly Phe  
 195 200 205

Glu Val Met Val Glu Ala Gly Tyr Pro Ala Glu Leu Ala Tyr Phe Glu  
 210 215 220

Val Leu His Glu Leu Lys Leu Ile Val Asp Leu Met Tyr Glu Gly Gly  
 225 230 235 240

Leu Ala Arg Met Tyr Tyr Ser Val Ser Asp Thr Ala Glu Phe Gly Gly  
 245 250 255

Tyr Leu Ser Gly Pro Arg Val Ile Asp Ala Gly Thr Lys Glu Arg Met  
 260 265 270

~~Arg Asp Ile Leu Arg Glu Ile Gln Asp Gly Ser Phe Val His Lys Leu~~  
 275 280 285

Val Ala Asp Val Glu Gly Gly Asn Lys Gln Leu Glu Glu Leu Arg Arg  
 290 295 300

Gln Asn Ala Glu His Pro Ile Glu Val Val Gly Lys Lys Leu Arg Asp  
 305 310 315 320

Leu Met Ser Trp Val Asp Arg Pro Ile Thr Glu Thr Ala  
 325 330

<210> 74

<211> 999

<212> DNA

-97-

<213> *Mycobacterium tuberculosis*

&lt;400&gt; 74

```

atgttctacg acgacgacgc agacctgtcg atcattcagg gccgcaaggt tgggtgtgatc      60
ggctacggca gccaggggca cgcgcactcg ctaagcctgc gcgactcggg tgtgcagggtg      120
cgcgtcgggc tgaagcaggg ttcgcggtcg cggcccaagg tagaagagca gggcctggac      180
gtcgacactc ccgccgaggt cgccaaatgg gccgatgtgg tcatgggtgtt ggcccccgac      240
accgcccagg ccgagatctt cgcaggagac atcgaacca acctcaagcc cggtgacgcg      300
ctgttcttcg gtcacggact caacgttcac ttcggcttga tcaagccgcc cgcgcacgtc      360
gccgtcgcga tggctgcccc gaagggaccg ggtcatttgg tgcgccgcca gtctgtcgac      420
ggcaagggtg tgccgtgttt ggttgccgta gagcaggatc cgcgaggcga cggcttgccg      480
ctggcgctgt cgtatgccaa agcgatcggc ggcacccggg ccggcgatcat caagacgcgc      540
ttcaaagacg agaccgaaac cgacctgttc ggtgagcaaa cgggtgttgtg cggcggcacc      600
gaggaatttg tcaaggcccg gtctcgaggtc atggtcgaag ccggctacct cgcggaattg      660
gcctacttcg aggtgctgca cgagctgaag ctgatcgtcg acttgatgta cgaggggtggc      720
ctggcgcgga tgtactactc ggtgtcggac accgcggaat tcggcggcta cctctcaggc      780
ccgcgcgtca tcgatgccgg caccaaggag cggatgcgcg acatcctgcg ggagatccag      840
gacggtagct ttgtccacaa gctggtcgcc gacgtcgagg gcggcaacaa acagctcgaa      900
gagttgcgcc ggcaaaacgc cgagcacccc atcgaggtcg tcggcaagaa actccgcgac      960
ctgatgagct ggggtggaccg cccgatcacc gagacggcc      999

```

&lt;210&gt; 75

&lt;211&gt; 258

&lt;212&gt; PRT

<213> *Mycobacterium tuberculosis*

&lt;400&gt; 75

```

Met Pro Pro Leu Thr Ser Leu Ala Pro Thr Thr Ala Glu Arg Ile Arg
1           5           10           15

Ser Ala Cys Ala Arg Ala Gly Gly Ala Leu Leu Val Val Glu Arg Glu
20           25           30

```

-98-

Asp Pro Val Pro Val Pro Ile His His Leu Leu Tyr Asp Gly Ser Phe  
           35                          40                          45

Ala Val Ala Val Pro Val Asp Arg Gly Glu Val Ser Gly Ser Gln Ala  
       50                          55                          60

Leu Leu Glu Leu Thr Asp Tyr Ala Pro Leu Pro Val Arg Glu Pro Val  
       65                          70                          75                          80

Arg Ser Leu Val Trp Ile Arg Gly Cys Leu His Gln Ile Pro Pro Ala  
                           85                          90                          95

Glu Leu Val Glu Thr Leu Asp Leu Ile Ala Thr Asp Asn Pro Asn Pro  
                           100                          105                          110

Ala Leu Leu Gln Val Glu Thr Pro Arg Pro Gly Pro Ala Asp Ala Ala  
       115                          120                          125

Glu Thr Arg Tyr Thr Met Gln Arg Leu Glu Ile Glu Ser Val Val Val  
       130                          135                          140

Thr Asp Ala Thr Gly Ala Glu Pro Val Thr Val Ala Asp Leu Leu Ala  
       145                          150                          155                          160

Ala Arg Pro Asp Pro Phe Cys Glu Ile Glu Ser Thr Leu Leu Trp His  
                           165                          170                          175

~~Leu Ala Thr Ala His Asp Asp Val Val Ala Arg Leu Val Ser Arg Leu~~  
~~180                          185                          190~~

Pro Ala Pro Leu Arg Arg Gly Gln Ile Arg Pro Leu Gly Leu Asp Arg  
       195                          200                          205

Tyr Gly Val Arg Phe Arg Ile Glu Ala Arg Asp Gly Asp Arg Asp Ile  
       210                          215                          220

Arg Leu Pro Phe His Lys Pro Val Asp Asp Met Thr Gly Leu Ser Gln  
       225                          230                          235                          240

Ala Ile Arg Val Leu Met Gly Cys Pro Phe Arg Asn Gly Leu Arg Ala  
                           245                          250                          255

Arg Arg

-99-

&lt;210&gt; 76

&lt;211&gt; 774

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 76

```

atgccgccgc tcaccagtct cgcgccgact actgccgagc gaattcgcag cgcctgcgcg      60
cgggccgggg ggccttgct ggtggttgag cgggaggatc cggccccgt gccatacac      120
catttggtgt acgacgggtc ctccgcgtg gcggttcgg tcgatcgtgg cgaggtgtcc      180
ggttcgcaag cgctgctgga gttgactgac tatgcgccgc tgccggtgcg tgaaccgcgc      240
cgttcgctgg tgtggatccg cggtgcctc caccagatcc cggccgcaga gctggttgag      300
accctggacc tgatcgccac cgataatccg aatccggccc tgctacaagt cgagaccccg      360
aggcccgggc cggccgatgc ggcggagacc cggtatacca tgcagcggct ggagatcgaa      420
tccgtagtgg tgaccgacgc caccggcgcc gaaccggtta ccgtggcgga cctgctcgcg      480
gcccgacccg atccgttttg tgaaatcgaa tcaaccttgc tctggcacct agccaccgcc      540
catgacgatg tggtcgcgcg gctggtatcc aggtgcgcg caccgctacg acgcggacag      600
atccgcccc tcggtctcga tcggtacggc gtccggttcc gcattgaagc tcgcgacgga      660
gaccgcgaca tccgactgcc gttccataag ccggtggacg acatgaccgg gctaagccag      720
gccatccggg tgcctatggg ttgcccgttc cgcaacgggc tgcgcgcccg cagg      774

```

&lt;210&gt; 77

&lt;211&gt; 384

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 77

```

Met Arg Ala Lys Arg Glu Ala Pro Lys Ser Arg Ser Ser Asp Arg Arg
1           5           10          15

```

```

Arg Arg Ala Asp Ser Pro Ala Ala Ala Thr Arg Arg Thr Thr Thr Asn

```

-100-

|                                                                 |     |     |
|-----------------------------------------------------------------|-----|-----|
| 20                                                              | 25  | 30  |
| Ser Ala Pro Ser Arg Arg Ile Arg Ser Arg Ala Gly Lys Thr Ser Ala |     |     |
| 35                                                              | 40  | 45  |
| Pro Gly Arg Gln Ala Arg Val Ser Arg Pro Gly Pro Gln Thr Ser Pro |     |     |
| 50                                                              | 55  | 60  |
| Met Leu Ser Pro Phe Asp Arg Pro Ala Pro Ala Lys Asn Thr Ser Gln |     |     |
| 65                                                              | 70  | 75  |
| Ala Lys Ala Arg Ala Lys Ala Arg Lys Ala Lys Ala Pro Lys Leu Val |     |     |
| 85                                                              | 90  | 95  |
| Arg Pro Thr Pro Met Glu Arg Leu Ala Ala Arg Leu Thr Ser Ile Asp |     |     |
| 100                                                             | 105 | 110 |
| Leu Arg Pro Arg Thr Leu Ala Asn Lys Val Pro Phe Val Val Leu Val |     |     |
| 115                                                             | 120 | 125 |
| Ile Gly Ser Leu Gly Val Gly Leu Gly Leu Thr Leu Trp Leu Ser Thr |     |     |
| 130                                                             | 135 | 140 |
| Asp Ala Ala Glu Arg Ser Tyr Gln Leu Ser Asn Ala Arg Glu Arg Thr |     |     |
| 145                                                             | 150 | 155 |
| Arg Met Leu Gln Gln His Lys Glu Ala Leu Glu Arg Asp Val Arg Glu |     |     |
| 165                                                             | 170 | 175 |
| Ala Ala Ser Ala Pro Ala Leu Ala Glu Ala Ala Arg Arg Gln Gly Met |     |     |
| 180                                                             | 185 | 190 |
| Ile Pro Thr Arg Asp Thr Ala His Leu Val Gln Asp Pro Asp Gly Asn |     |     |
| 195                                                             | 200 | 205 |
| Trp Val Val Val Gly Thr Pro Lys Pro Ala Asp Gly Val Pro Pro Pro |     |     |
| 210                                                             | 215 | 220 |
| Pro Leu Asn Thr Lys Leu Pro Glu Asp Pro Pro Pro Pro Pro Lys Pro |     |     |
| 225                                                             | 230 | 235 |
| Ala Ala Val Pro Leu Glu Val Pro Val Arg Val Thr Pro Gly Pro Asp |     |     |
| 245                                                             | 250 | 255 |

-101-

Asp Pro Ala Pro Pro Ala Arg Ser Gly Pro Glu Val Leu Val Arg Thr  
                   260                  265                  270

Pro Asp Gly Thr Ala Thr Leu Gly Gly Ala Thr His Leu Pro Thr Gln  
                   275                  280                  285

Ala Gly Pro Gln Leu Pro Gly Pro Val Pro Ile Pro Gly Ala Pro Gly  
                   290                  295                  300

Pro Met Pro Ala Pro Pro Leu Gly Ala Val Pro Ser Pro Ala Pro Ala  
                   305                  310                  315                  320

Glu Asn Pro Val Pro Leu Gln Val Gly Ala Ala Pro Pro Ala Gly Leu  
                   325                  330                  335

Pro Gly Pro Ala Pro Val Ala Ala Thr Pro Gly Leu Ser Gly Gly Ser  
                   340                  345                  350

Gln Pro Met Val Ala Pro Pro Ala Pro Val Pro Ala Asn Gly Glu Gln  
                   355                  360                  365

Phe Gly Pro Val Thr Ala Pro Val Pro Thr Ala Pro Gly Ala Pro Arg  
                   370                  375                  380

&lt;210&gt; 78

&lt;211&gt; 1152

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 78

atgagggcca agcgtgaggc accgaaaagc cgcagcagcg atcgtcgcag gagagccgac 60  
 agtcctgccg cggcgacgag gcgaacgact acgaactcgg cgcctgcg cgcacatccgg 120  
 agccgtgccg gcaagacctc ggcacccggc cggcaggccc ggggtgcg ccttgaccg 180  
 caaaccagcc cgatgctcag ccggttcgac cggccggccc ccgcaaagaa caccagccag 240  
 gccaaaggcg gggccaaggc ccgaaaagcc aaggcgccca agctgggtccg tctacgccg 300  
 atggagcgtc tcgccgcccg gctcacgtcg atcgacctgc ggccgcgcac gttggcaaac 360  
 aaggttccgt ttgtggtgct gggttatcgg tcgctcggcg tcggactagg cctcacactg 420  
 tggttgtcca ccgatgccgc cgagaggtcc taccagctga gcaacgcccg ggagcggacc 480

-102-

```

cggatgctgc agcagcaciaa ggaagcgctg gaacgcgacg tacgcgagggc tgcgtcggcg      540
ccggcgctgg ccgaggcggc tcgtcgccag ggcagatcc cgacgaggga taccgcccac      600
ctgggttcagg atccggacgg caattgggtg gtggtcggtta caccgaagcc ggctgacgga      660
gttcaccgcg cgccgctgaa cacgaagttg cccgaagatc cgccgcgcgc cccgaaaccc      720
gcggcgggtgc ccctcgaggt gccgggtccgg gtgacaccag gcccgatga tcccgctccg      780
cccgcccggt ctggcccgga ggtgctgggt cgtaccccag acggcacagc gacgctgggc      840
ggcgcaaccc acctgcccac ccaggccggc ccgcagctgc ccggtccggt gccgatacct      900
ggggcgccgg gtccgatgcc ggctcctccg ctgggcgcag tgccatcccc ggcaccagcg      960
gaaaatccgg tgccgctcca ggtgggtgcg gcgcccccg ccgggctccc tggaccagca     1020
ccggtggctg cgacgcccgg gctgtcgggt gggtcgcaac ccattggtggc accaccgct     1080
ccagtgcggg ccaacggcga acagttcggg cccgtcacgg cgccggtgcc aacggcgccg     1140
ggggctccca gg                                                    1152

```

&lt;210&gt; 79

&lt;211&gt; 346

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 79

```

Met Asn Gly Leu Gly Asp Val Leu Ala Val Ala Arg Lys Ala Arg Gly
1           5           10          15

```

```

Leu Thr Gln Ile Glu Leu Ala Glu Leu Val Gly Leu Thr Gln Pro Ala
20           25           30

```

```

Ile Asn Arg Tyr Glu Ser Gly Asp Arg Asp Pro Asp Gln His Ile Val
35           40           45

```

```

Ala Lys Leu Ala Glu Ile Leu Gly Val Thr Asp Asp Leu Leu Ile His
50           55           60

```

```

Gly Asn Arg Phe Arg Gly Ala Leu Ala Val Asp Ala His Met Arg Arg
65           70           75           80

```

```

His Lys Thr Thr Lys Ala Ser Ala Trp Arg Gln Leu Glu Ala Arg Leu

```

-103-

|                                                                 |     |  |     |  |     |
|-----------------------------------------------------------------|-----|--|-----|--|-----|
|                                                                 | 85  |  | 90  |  | 95  |
| Asn Leu Leu Arg Val His Ala Ser Phe Leu Phe Glu Glu Val Ala Ile | 100 |  | 105 |  | 110 |
| Asn Ser Glu Gln His Val Pro Ala Phe Asp Pro Glu Phe Thr Ala Ala | 115 |  | 120 |  | 125 |
| Glu Asp Ala Ala Arg Leu Val Arg Ala Gln Trp Arg Met Pro Met Gly | 130 |  | 135 |  | 140 |
| Pro Val Val Asn Leu Thr Arg Trp Met Glu Ala Ala Gly Cys Leu Val | 145 |  | 150 |  | 155 |
|                                                                 |     |  |     |  | 160 |
| Phe Glu Glu Asp Phe Ala Thr Gln Arg Ile Asp Gly Leu Ser Gln Trp | 165 |  | 170 |  | 175 |
| Val Asp Asp Tyr Pro Val Met Leu Ile Asn Ala Asn Ala Ala Pro Asp | 180 |  | 185 |  | 190 |
| Arg Lys Arg Leu Thr Leu Ala His Glu Leu Gly His Leu Val Leu His | 195 |  | 200 |  | 205 |
| Ser Thr Asn Pro Thr Glu Asn Met Glu Thr Glu Ala Thr Ala Phe Ala | 210 |  | 215 |  | 220 |
| Ala Glu Phe Leu Met Pro Glu Ser Glu Ile Arg Pro Glu Leu Arg Arg | 225 |  | 230 |  | 235 |
|                                                                 |     |  |     |  | 240 |
| Leu Asp Leu Gly Lys Leu Leu Glu Leu Lys Arg Glu Trp Gly Val Ser | 245 |  | 250 |  | 255 |
| Met Gln Ala Leu Leu Ala Arg Ala Tyr Arg Met Gly Leu Val Ser Ala | 260 |  | 265 |  | 270 |
| Glu Ala Arg Thr Lys Leu Tyr Lys Ala Met Asn Ala Arg Gly Trp Lys | 275 |  | 280 |  | 285 |
| Thr Lys Glu Pro Gly Ile Glu Ser Ile Val Arg Glu Lys Pro Ser Leu | 290 |  | 295 |  | 300 |
| Pro Ala His Ile Gly Met Thr Leu Arg Ser Arg Gly Phe Thr Asp Gln | 305 |  | 310 |  | 315 |
|                                                                 |     |  |     |  | 320 |





-105-

&lt;211&gt; 139

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 81

Met Ile Val Asp Thr Ser Ala Val Val Ala Leu Val Gln Gly Glu Arg  
 1 5 10 15

Pro His Ala Thr Leu Val Ala Ala Ala Leu Ala Gly Ala His Ser Pro  
 20 25 30

Val Met Ser Ala Pro Thr Val Ala Glu Cys Leu Ile Val Leu Thr Ala  
 35 40 45

Arg His Gly Pro Val Ala Arg Thr Ile Phe Glu Arg Leu Arg Ser Glu  
 50 55 60

Ile Gly Leu Ser Val Ser Ser Phe Thr Ala Glu His Ala Ala Ala Thr  
 65 70 75 80

Gln Arg Ala Phe Leu Arg Tyr Gly Lys Gly Arg His Arg Ala Ala Leu  
 85 90 95

Asn Phe Gly Asp Cys Met Thr Tyr Ala Thr Ala Gln Leu Gly His Gln  
 100 105 110

Pro Leu Leu Ala Val Gly Asn Asp Phe Pro Gln Thr Asp Leu Glu Phe  
 115 120 125

Arg Gly Val Val Gly Tyr Trp Pro Gly Val Ala  
 130 135

&lt;210&gt; 82

&lt;211&gt; 417

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 82

atgatcgtgg acacaagcgc cgtggtggcc ctggttcaag gcgagcggcc gcacgccacc 60

-106-

```

ctggtcgcgg ccgccctggc cggcgcccat agccccgtca tgtctgcacc caccgtcgcc 120
gaatgcctga ttgtcttgac cgcccgtcac ggccccgttg cgcgcacgat cttcgaacga 180
cttcgcagcg aaatcggett gagcgtgtca tttttcaccg ccgagcatgc cgtgcccacg 240
caacgagcct ttctgcgata cggcaagggg cgccaccgcg cggtctctcaa cttcggagac 300
tgtatgacgt acgcgaccgc ccagctgggc caccaaccac tgctggccgt cggcaacgac 360
ttcccgcaaa ccgaccttga gttccgcggc gtctgtgggt actggccagg cgtcgcg 417

```

&lt;210&gt; '83

&lt;211&gt; 376

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 83

```

Leu Ile Cys Phe Asp Asp Val Ser Lys Val Tyr Ala His Gly Ala Thr
1           5           10           15

```

```

Ala Val Asp Arg Leu Thr Leu Glu Val Pro Asn Gly Met Leu Thr Val
          20           25           30

```

```

Phe Val Gly Pro Ser Gly Cys Gly Lys Thr Thr Ala Leu Arg Met Ile
          35           40           45

```

```

...Asn Arg Met Val Asp Pro Thr Ser Gly Thr Ile Thr Val Asp Gly Thr
          50           55           60

```

```

Asp Val Ser Thr Val Asn Ala Val Lys Leu Arg Leu Gly Ile Gly Tyr
65           70           75           80

```

```

Val Ile Gln Asn Ala Gly Leu Met Pro His Gln Arg Val Ile Asp Asn
          85           90           95

```

```

Val Ala Thr Val Pro Val Leu Lys Gly Gln Pro Arg Arg Ala Ala Arg
          100          105          110

```

```

Lys Ala Gly Tyr Glu Val Leu Glu Arg Val Gly Leu Asp Pro Lys Val
          115          120          125

```

```

Ala Thr Arg Tyr Pro Ala Gln Leu Ser Gly Gly Glu Gln Gln Arg Val

```

-107-

|                                                                 |     |     |     |
|-----------------------------------------------------------------|-----|-----|-----|
| 130                                                             | 135 | 140 |     |
| Gly Val Ala Arg Ala Leu Ala Ala Asp Pro Pro Ile Leu Leu Met Asp |     |     |     |
| 145                                                             | 150 | 155 | 160 |
| Glu Pro Phe Ser Ala Val Asp Pro Val Val Arg His Glu Leu Gln Asn |     |     |     |
|                                                                 | 165 | 170 | 175 |
| Glu Ile Leu Arg Leu Gln Ala Glu Leu His Lys Thr Ile Val Phe Val |     |     |     |
|                                                                 | 180 | 185 | 190 |
| Thr His Asp Ile Asp Glu Ala Leu Lys Leu Ala Asp Leu Val Ala Val |     |     |     |
|                                                                 | 195 | 200 | 205 |
| Phe Ala Pro Gly Gly Ala Leu Ala Gln Tyr Asp Glu Thr Ala Arg Leu |     |     |     |
|                                                                 | 210 | 215 | 220 |
| Leu Ser Ser Pro Ala Asn Asp Phe Val Ser Lys Phe Ile Gly Leu Gly |     |     |     |
| 225                                                             | 230 | 235 | 240 |
| Arg Gly Tyr Arg Trp Leu Gln Leu Phe Asp Ala Ala Gly Leu Pro Val |     |     |     |
|                                                                 | 245 | 250 | 255 |
| Arg Asp Ile Glu Gln Val Ser Val Asn Gly Leu Ser Asp Ala Arg Asp |     |     |     |
|                                                                 | 260 | 265 | 270 |
| Arg Gln Val Arg Asp Gly Trp Val Leu Val Val Asp Gly Ala Gly Ala |     |     |     |
|                                                                 | 275 | 280 | 285 |
| Pro Leu Gly Trp Ile Asp Ala Asp Gly Arg Arg Arg His Arg Gly Gly |     |     |     |
|                                                                 | 290 | 295 | 300 |
| Ala Ala Leu Ser Asp Ala Met Thr Val Gly Gly Ser Val Phe Arg Pro |     |     |     |
| 305                                                             | 310 | 315 | 320 |
| Asn Gly Asn Leu Ser Gln Ala Leu Asp Ala Ala Leu Ser Ser Pro Ser |     |     |     |
|                                                                 | 325 | 330 | 335 |
| Gly Val Gly Val Ala Val Asp Gly Gly Gly Lys Val Ile Gly Gly Ile |     |     |     |
|                                                                 | 340 | 345 | 350 |
| Leu Ala Ala Asp Val Leu Ala Glu Phe Gln Lys Gly Lys Lys Ala Gly |     |     |     |
|                                                                 | 355 | 360 | 365 |

-108-

Gly Gly Ala Lys Pro Cys Thr Thr  
 370 375

&lt;210&gt; 84

&lt;211&gt; 1128

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 84

```

ttgatctgct ttgacgatgt cagcaagggtg tacgcacacg gtgccaccgc cgtagaccgg      60
ctgacgctgg aagtccttaa cggcatgctg accgtcttcg tggccctc cggctgcggc      120
aagacgacgg cgctgcgaat gatcaaccga atggtggatc cgacctcggg caccatcact      180
gtcgacggta ccgacgtgtc gacggtcaat gcggtgaagc tgcgcctggg aattggctat      240
gtcatccaga acgcggggct gatgcctcat caacgggtca tcgacaacgt cgcaacgggtg      300
ccggtgctga agggtcagcc gcgcccggca gcccgcaaag ccggttatga ggtgcttgag      360
cgtgtcgggc tggaccccaa ggtcgccacc cgctaccggg ccagctctc gggcggcgaa      420
cagcaacggg tcggcgtggc acgggcactc gcgccgcatc cgccgatctt gttgatggac      480
gagccgttct cggccgtcga cccggtggtt cgccacgagc tacagaacga aatacttcgt      540
ctgcaagccg agttgcacaa gaccattgtc ttcgtgacgc acgacatcga cgaggcgttg      600
aagctcgccg atctggtggc ggtgttcgcc ccgggcggcg cgcttgcgca gtacgacgaa      660
actgccgggc tgttatccag tcgggcgaat gacttcgtgt cgaagttcat cggctctcgg      720
cgcggtatc ggtggctgca gctgttcgac gcgccgggac tacctgtgcg cgacatcgag      780
caagtctcgg tgaacggcct ttccgatgcc cgggacaggc aagttcgtga cggctgggtg      840
ctggtggtcg acggtgcggg tgcgcgttg ggtggatcg acgccgatgg ccggcggcgt      900
caccgcgggc gcgcggcatt gtcggatgcc atgaccgtcg gcggttcggt gttccgccc      960
aacggtaacc tcagccaggc gctggacgcc gccttgctct cgccgtcggg ggtcgggtgtc     1020
gccgttgacg gcggtggcaa ggtcatcgcc gggatactgg ccgccgacgt gctggccgag     1080
ttccaaaag gcaagaaggc cggcggcgga gctaagccat gcactacc     1128

```

&lt;210&gt; 85

&lt;211&gt; 145

-109-

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 85

Val Ser Glu Thr Phe Asp Val Asp Val Leu Val His Ala Thr His Arg  
1 5 10 15

Ala Ser Pro Phe His Asp Lys Ala Lys Thr Leu Val Glu Arg Phe Leu  
20 25 30

Ala Gly Pro Gly Leu Val Tyr Leu Leu Trp Pro Val Ala Leu Gly Tyr  
35 40 45

Leu Arg Val Val Thr His Pro Thr Leu Leu Gly Ala Pro Leu Ala Pro  
50 55 60

Glu Val Ala Val Glu Asn Ile Glu Gln Phe Thr Ser Arg Pro His Val  
65 70 75 80

Arg Gln Val Gly Glu Ala Asn Gly Phe Trp Pro Val Tyr Arg Arg Val  
85 90 95

Ala Asp Pro Val Lys Pro Arg Gly Asn Leu Val Pro Asp Ala His Leu  
100 105 110

Val Ala Leu Met Arg His His Gly Ile Ala Thr Ile Trp Ser His Asp  
115 120 125

Arg Asp Phe Arg Lys Phe Glu Gly Ile Arg Ile Arg Asp Pro Phe Ser  
130 135 140

Gly  
145

&lt;210&gt; 86

&lt;211&gt; 435

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

-110-

<400> 86  
 gtgagcgaaa cctttgacgt cgatgttctg gtccatgcga cgcaccgagc cagcccgttt 60  
 caccataagg cgaagacgct cgttgagcga ttcttggtg gccagggt ggtatatcta 120  
 ttgtggcccg tcgcgtggg ttatctacgg gttgtcacc atccgacgtt gttgggtgcg 180  
 ccgctggcgc ctgaggtcgc cgtcgaaaac atcgagcaat tcacctcacg accgcacgtg 240  
 cggcaggctc gcgaggccaa cggattctgg ccgctctatc gccgagtagc cgacccggtc 300  
 aagccgcgag gcaatctggt tcccgacgcc cacctcgtc cgctcatgcg ccatacaggc 360  
 atcgccacga tctggagtca cgaccgcgac ttccgcaagt tcgagggcat tagaattcgc 420  
 gacccttct ccggc 435

&lt;210&gt; 87

&lt;211&gt; 185

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 87

Met Ser Arg Gln Trp His Trp Leu Ala Ala Thr Leu Leu Leu Ile Thr  
 1 5 10 15

Thr Ala Ala Cys Ser Arg Pro Gly Thr Glu Glu Pro Asp Cys Pro Thr  
 20 25 30

Lys Ile Thr Leu Pro Pro Gly Ala Thr Pro Thr Thr Thr Leu Asp Pro  
 35 40 45

Arg Cys Ile Val Arg Ala Thr Thr Thr Gly Thr Ala Asp Gly Asp Ala  
 50 55 60

Ala Ser Arg Trp Thr Gly Thr Val Arg Ile Ala Gly Phe Tyr Ala Ser  
 65 70 75 80

Ile Cys Asn Ala Val Trp Asp Gly Asn Val Ser Leu Ala Gly Lys Asp  
 85 90 95

Glu Leu Thr Gly Lys Ala Thr Leu Ile Leu Val Glu Thr Ser Cys Pro  
 100 105 110

-111-

Gly Lys Val Val Ala Gly Glu Leu Val Leu Lys Gly Asn Val Gly Ser  
 115 120 125

Asp Ser Leu Ala Ile Thr Trp Ala His Pro Glu Leu Pro Gln Arg Ala  
 130 135 140

Phe Asp Leu Gly Ala Gly Gln Gly Thr Ile Arg Arg Ser Gly Asp Arg  
 145 150 155 160

Ala Glu Gly Thr Phe Asn Ser Asp Met Gly Gly Gly Thr Glu Phe Phe  
 165 170 175

Leu Thr Trp Ser Leu Thr Met Arg Asn  
 180 185

&lt;210&gt; 88

&lt;211&gt; 555

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 88

atgagtcgac agtggcactg gctggcagcg acgctgctcc tgatcaccac cgccgcgtgc 60  
 agtcgtccgg gcaccgagga accggattgc ccgacgaaaa taaccttgcc gcccggtgct 120  
 acgcccacca cgacctcga cccgagatgc atagtgcgcg cgaccaccac cggcacagcc 180  
 gacggcgatg cggcgtcgcg ctggaccgga accgtgcgga tcgccgggtt ctatgcctcg 240  
 atctgcaacg cggtatggga cgggaacgtc agccttgcg gaaaggacga gctgaccggc 300  
 aaggctacgc ttatcctcgt cgaaaccagt tgcccgggca aggttgctgc cggcgaactc 360  
 gtgctgaagg ggaacgtcgg ttcggacagc ctgcgatca cctgggcgca ccccgaaactc 420  
 ccgcagcggg cgttcgacct cggcgccgga cagggcacga tccgccgatc gggcgaccgt 480  
 gccgagggaa cgttcaactc ggatatgggt gggggcaccg agttcttctt gacgtggtcg 540  
 ctgacgatgc gtaac 555

&lt;210&gt; 89

&lt;211&gt; 219

&lt;212&gt; PRT



-112-

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 89

Met Ala Val His Gly Phe Leu Leu Glu Arg Val Ser Val Val Arg Asp  
 1 5 10 15

Glu Ala Thr Val Leu Arg Gln Val Ser Ala His Phe Pro Ala Gly Arg  
 20 25 30

Cys Ser Ala Val Arg Gly Ala Ser Gly Ser Gly Lys Thr Thr Leu Leu  
 35 40 45

Arg Leu Leu Asn Arg Leu Ile Asp Pro Thr Ser Gly Lys Val Trp Leu  
 50 55 60

Asp Gly Val Pro Leu Thr Asp Leu Asp Val Leu Val Leu Arg Arg Arg  
 65 70 75 80

Val Gly Leu Val Ala Gln Ala Pro Val Val Leu Thr Asp Ala Val Leu  
 85 90 95

Asn Glu Val Arg Val Gly Arg Pro Asp Leu Pro Glu Gly Arg Val Thr  
 100 105 110

Glu Leu Leu Ala Arg Leu Cys Leu Gly Gln Ser Ala Arg Glu Ala Phe  
 115 120 125

Leu Pro His Gln Arg Ser Ala Leu Arg Thr Ala Leu Ile Pro Ala Ile  
 130 135 140

Asp Ser Thr Lys Val Val Gly Leu Ile Ser Leu Pro Gly Ala Met Ser  
 145 150 155 160

Gly Leu Ile Leu Ala Gly Val Asp Pro Leu Thr Ala Ile Arg Tyr Gln  
 165 170 175

Ile Val Val Met Tyr Leu Leu Leu Ala Ala Thr Ala Val Ala Ala Leu  
 180 185 190

Thr Cys Ala Arg Leu Ala Glu Arg Ala Leu Phe Asp Arg Ala His Arg  
 195 200 205

-113-

Leu Val Ser Leu Pro Ala Ala Thr Arg Arg Ala  
 210 215

&lt;210&gt; 90

&lt;211&gt; 657

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 90

```

atggcggtgc atggtttcct gctcgaacgg gtcagcgtgg tgcgcgaaga ggcgacggtg      60
ctgcggcagg tcagcgcgca ttttcccgct ggccgctgca gtgcggtgcg gggcgccagt      120
ggatcgggaa agaccacgct gctgcggttg ctgaaccggc tcatcgatcc gacgtccgga      180
aaagtctggc ttgacggtgt gccgctcacc gatctggatg tgctcgtgtt acgtcggcgg      240
gtcggcctgg ttgcgcaggc tcccggtggtg cttaccgatg cggtgctcaa tgaggttcgc      300
gtcggacgcc cggacctgcc agaaggtcga gtgaccgagc tgctggcgcg gctgtgtctc      360
ggccagtccg caccggaagc gttcttgccg caccaacgat ccgccttgcg cactgcgctg      420
ataccgcgca tcgactccac gaaagtcggt gggctgatta gccttcgggg tcgatgtcc      480
ggaattatcc tggccggggt cgaccogctg accgcgatcc gctacaaaat cgtggtgatg      540
tacctgctgc tcgcccacac cgcggtggca gcgctgacct gtgcacgcct ggctgaacgt      600
gccttattcg accgcgcgca ccggetcggt tcgctgcccg cggcgactcg tcgggca      657

```

&lt;210&gt; 91

&lt;211&gt; 358

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 91

Val Arg Ala Arg Phe Gly Asp Arg Ala Pro Trp Leu Val Glu Thr Thr  
 1 5 10 15

Leu Leu Arg Arg Arg Ala Ala Gly Lys Leu Gly Glu Leu Cys Pro Asn  
 20 25 30

-114-

Val Gly Val Ser Gln Trp Leu Phe Thr Asp Glu Ala Leu Gln Gln Ala  
 35 40 45

Thr Ala Ala Pro Val Ala Arg His Arg Ala Arg Arg Leu Ala Gly Arg  
 50 55 60

Val Val His Asp Ala Thr Cys Ser Ile Gly Thr Glu Leu Ala Ala Leu  
 65 70 75 80

Arg Glu Leu Ala Val Arg Ala Val Gly Ser Asp Ile Asp Pro Val Arg  
 85 90 95

Leu Ala Met Ala Arg His Asn Leu Ala Ala Leu Gly Met Glu Ala Asp  
 100 105 110

Leu Cys Arg Ala Asp Val Leu His Pro Val Thr Arg Asp Ala Val Val  
 115 120 125

Val Ile Asp Pro Ala Arg Arg Ser Asn Gly Arg Arg Arg Phe His Leu  
 130 135 140

Ala Asp Tyr Gln Pro Gly Leu Gly Pro Leu Leu Asp Arg Tyr Arg Gly  
 145 150 155 160

Arg Asp Val Val Val Lys Cys Ala Pro Gly Ile Asp Phe Glu Glu Val  
 165 170 175

Gly Arg Leu Gly Phe Glu Gly Glu Ile Glu Val Ile Ser Tyr Arg Gly  
 180 185 190

Gly Val Arg Glu Ala Cys Leu Trp Ser Ala Gly Leu Ala Gly Ser Gly  
 195 200 205

Ile Arg Arg Arg Ala Ser Ile Leu Asp Ser Gly Glu Gln Ile Gly Asp  
 210 215 220

Asp Glu Pro Asp Asp Cys Gly Val Arg Pro Ala Gly Lys Trp Ile Val  
 225 230 235 240

Asp Pro Asp Gly Ala Val Val Arg Ala Gly Leu Val Arg Asn Tyr Gly  
 245 250 255

Ala Arg His Gly Leu Trp Gln Leu Asp Pro Gln Ile Ala Tyr Leu Ser  
 260 265 270

-115-

Gly Asp Arg Leu Pro Pro Ala Leu Arg Gly Phe Glu Val Leu Glu Gln  
 275 280 285

Leu Ala Phe Asp Glu Arg Arg Leu Arg Gln Val Leu Ser Ala Leu Asp  
 290 295 300

Cys Gly Ala Ala Glu Ile Leu Val Arg Gly Val Ala Ile Asp Pro Asp  
 305 310 315 320

Ala Leu Arg Arg Arg Leu Arg Leu Arg Gly Ser Arg Pro Leu Ala Val  
 325 330 335

Val Ile Thr Arg Ile Gly Ala Gly Ser Leu Ser His Val Thr Ala Tyr  
 340 345 350

Val Cys Arg Pro Ser Arg  
 355

<210> 92

<211> 1074

<212> DNA

<213> Mycobacterium tuberculosis

<400> 92

```

gtgcgcgccc ggtttggcga tcgggcgcgc tggtctggtg agaccacgct gctgcgcgcg      60
cgcgccgcgc gcaaactggg cgagctgtgt ccgaacgltg ggggtgtcgca atggctattc      120
accgatgagg cgctgcagca ggctaccgca gcaccgctgg cccggcaccg ggccaggcga      180
ctggccggtc gggtagtgca cgacgcgacc tgctccatcg gcaccgagct ggccgcgctg      240
cgcgagctag ctgtccgggc ggtcggcagc gatatcgacc cgggtgcggct ggccatggcg      300
cgccacaacc tggccgccct gggaatggaa gctgacctgt gccgcgccga tgtgctgcat      360
ccggtgaccc gcgacgcggt cgtcgtcatc gaccgcggcg gtcgcagcaa cgggcggcga      420
cgcttcacac tcgccgacta ccagcccggc ctgggccccc tactggaccg ctaccgcggc      480
cgtgatgtgg tcgtcaagtg cgctcccgga atagatttcg aggaggtggg ccggctcggt      540
ttcgagggcg agatcgaggt gatctcatc cgcgggtggg ttcgagaagc atgtctttgg      600
tcggccgggt tggccggatc gggatatcgc cgtcgagcca gcaccccgga ttccggtgaa      660

```

-116-

```

caaatcgggtg acgacgagcc cgacgactgc ggtgtgcggc ccgccgggaa atggatcgtc   720
gaccccgacg gcgccgtcgt ccgtgccggc ctggtacgca actacggcgc ccggcatggg   780
ctgtggcagc tcgatcccca aatcgcttac ctgtccgggtg accggctgcc gcctgcgttg   840
cgcggggttcg aggtgctcga gcagctggcc ttcgacgagc gtcggctgcg tcaggtgctg   900
tcagcgtctgg attgcggggc agccgaaatc ctggtgcgcg gcgttgcgat cgatcccgac   960
gctctgcggc gacggctccg gctgcggggc agcagaccgc tggcggtggt catcaccgcg  1020
attggtgccg ggtccttgag ccatgtgacc gcctatgtgt gtcggccgtc ccgg      1074

```

&lt;210&gt; 93

&lt;211&gt; 471

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 93

```

Val Thr Glu Thr Ala Ser Glu Thr Gly Ser Trp Arg Glu Leu Leu Ser
1           5           10           15

```

```

Arg Tyr Leu Gly Thr Ser Ile Val Leu Ala Gly Gly Val Ala Leu Tyr
          20           25           30

```

```

Ala Thr Asn Glu Phe Leu Thr Ile Ser Leu Leu Pro Ser Thr Ile Ala
          35           40           45

```

```

Asp Ile Gly Gly Ser Arg Leu Tyr Ala Trp Val Thr Thr Leu Tyr Leu
          50           55           60

```

```

Val Gly Ser Val Val Ala Ala Thr Thr Val Asn Thr Met Leu Leu Arg
65           70           75           80

```

```

Val Gly Ala Arg Ser Ser Tyr Leu Met Gly Leu Ala Val Phe Gly Leu
          85           90           95

```

```

Ala Ser Leu Val Cys Ala Ala Ala Pro Ser Met Gln Ile Leu Val Ala
          100          105          110

```

```

Gly Arg Thr Leu Gln Gly Ile Ala Gly Gly Leu Leu Ala Gly Leu Gly
          115          120          125

```

-117-

Tyr Ala Leu Ile Asn Ser Thr Leu Pro Lys Ser Leu Trp Thr Arg Gly  
 130 135 140

Ser Ala Leu Val Ser Ala Met Trp Gly Val Ala Thr Leu Ile Gly Pro  
 145 150 155 160

Ala Thr Gly Gly Leu Phe Ala Gln Leu Gly Leu Trp Arg Trp Ala Phe  
 165 170 175

Gly Val Met Thr Leu Leu Thr Ala Leu Met Ala Met Leu Val Pro Val  
 180 185 190

Ala Leu Gly Ala Gly Gly Val Gly Pro Gly Gly Glu Thr Pro Val Gly  
 195 200 205

Ser Thr His Lys Val Pro Val Trp Ser Leu Leu Leu Met Gly Ala Ala  
 210 215 220

Ala Leu Ala Ile Ser Val Ala Ala Leu Pro Asn Tyr Leu Val Gln Thr  
 225 230 235 240

Ala Gly Leu Leu Ala Ala Ala Ala Leu Leu Val Ala Val Phe Val Val  
 245 250 255

Val Asp Trp Arg Ile His Ala Ala Val Leu Pro Pro Ser Val Phe Gly  
 260 265 270

Ser Gly Pro Leu Lys Trp Ile Tyr Leu Thr Met Ser Val Gln Met Ile  
 275 280 285

Ala Ala Met Val Asp Thr Tyr Val Pro Leu Phe Gly Gln Arg Leu Gly  
 290 295 300

His Leu Thr Pro Val Ala Ala Gly Phe Leu Gly Ala Ala Leu Ala Val  
 305 310 315 320

Gly Trp Thr Val Gly Glu Val Ala Ser Ala Ser Leu Asn Ser Ala Arg  
 325 330 335

Val Ile Gly His Val Val Ala Ala Ala Pro Leu Val Met Ala Ser Gly  
 340 345 350

Leu Ala Leu Gly Ala Val Thr Gln Arg Ala Asp Ala Pro Val Gly Ile  
 355 360 365

-118-

Ile Ala Leu Trp Ala Leu Ala Leu Leu Ile Ile Gly Thr Gly Ile Gly  
 370 375 380

Ile Ala Trp Pro His Leu Thr Val Arg Ala Met Asp Ser Val Ala Asp  
 385 390 395 400

Pro Ala Glu Ser Ser Ala Ala Ala Ala Ala Ile Asn Val Val Gln Leu  
 405 410 415

Ile Ser Gly Ala Phe Gly Ala Gly Leu Ala Gly Val Val Val Asn Thr  
 420 425 430

Ala Lys Gly Gly Glu Val Ala Ala Ala Arg Gly Leu Tyr Met Ala Phe  
 435 440 445

Thr Val Leu Ala Ala Ala Gly Val Ile Ala Ser Tyr Gln Ala Thr His  
 450 455 460

Arg Asp Arg Arg Leu Pro Arg  
 465 470

<210> 94

<211> 1413

<212> DNA

<213> Mycobacterium tuberculosis

<400> 94

|                                                                    |     |
|--------------------------------------------------------------------|-----|
| gtgaccgaaa cagcgagcga gaccggcagc tggcgtgagc tactgagcag gtatctgggc  | 60  |
| acctccatag tgctggccgg tggcgtcgcg ctttacgcca ccaacgagtt tctgacaatc  | 120 |
| agcctgctgc cgagcacaat cgccgacatc gggggtagcc ggctgtacgc ctgggtgaca  | 180 |
| accctgtatc tggtcggggtc ggtggtggcg ggcaccaccg tcaatacgat gttgctgcgc | 240 |
| gtcggggcgc gctcgtcgta tctgatgggg ttggccgtct tcggtctggc cagcctggta  | 300 |
| tgtgcggcgg cgccgagcat gcagattctg gtggccgggc gtaccttgca aggaatagcc  | 360 |
| ggtgggctgc tggccggcct aggctacgcg ctgatcaact cgaccttgcc caagtcgctg  | 420 |
| tggaccctg gctcagcact ggtgtcggcg atgtgggggg tcgcgacgct gatcggaccg   | 480 |
| gcgaccggag gccttttcgc gcagctcggg ctgtggcgat gggcggttcgg cgtgatgacg | 540 |

-119-

```

ttgctgaccg cgttgatggc catgttggtg ccggtcgcg cgggtgccgg gggggtcggc 600
ccgggcgggc agacgccggt gggcagcaca cacaagggtg cgggtgtggtc gctattgctg 660
atggggggccg ccgcactggc gatcagcgtc gccgcgcttc egaactacct cgtccagacg 720
gccgggctgc tagccgccgc cgcgctgctg gttgcgggtg ttgtggtagt cgactggcgg 780
atacacgcag cgggtgttgc gccagcgta tttggctccg gaccgttgaa atggatttac 840
ctgaccatgt cgggtgcagat gattgcccga atggtcgata cctacgtgcc gctgttcggt 900
cagcgactgg gacacctgac ccgggtggca gccgggttct tgggtgccgc gctggcgggtg 960
ggctggacgg tcggtgaggt cgccagcgcc tcgttgaaca gtgcacgagt tatcgggcat 1020
gtcgtggcag ccgcaccgct ggtgatggcg tcgggggttg cgctaggcgc cgtcaccag 1080
cgcgccgatg cgccggtggg gatcatcgcg ctgtgggcgc tggcgctgct gatcatcggg 1140
accggcatcg ggatcgctg gccgcattca acggtgcgcg ctatggattc tgtcgccgac 1200
ccggccgaga gcagcgcggc ggccgcgcg atcaatgtcg tacagctgat ctccggtgct 1260
ttcggcgccg ggtggcggg tgtggtggtc aacactgcc aaggcggcga agtggcgcg 1320
gctcgtgggc tatacatggc atttacggtg ctggccgccc ctggtgtcat cgcttcctac 1380
caggccacgc accgcgaccg gcgcttaccg cgt 1413

```

&lt;210&gt; 95

&lt;211&gt; 325

&lt;212&gt; PRT

<213> *Mycobacterium tuberculosis*

&lt;400&gt; 95

```

Met Thr Ser Ala Pro Ala Thr Met Arg Trp Gly Asn Leu Pro Leu Ala
1           5           10           15

```

```

Gly Glu Ser Gly Thr Met Thr Leu Arg Gln Ala Ile Asp Leu Ala Ala
20           25           30

```

```

Ala Leu Leu Ala Glu Ala Gly Val Asp Ser Ala Arg Cys Asp Ala Glu
35           40           45

```

```

Gln Leu Ala Ala His Leu Ala Gly Thr Asp Arg Gly Arg Leu Pro Leu
50           55           60

```



-120-

Phe Glu Pro Pro Gly Asp Glu Phe Phe Gly Arg Tyr Arg Asp Ile Val  
 65 70 75 80

Thr Ala Arg Ala Arg Arg Val Pro Leu Gln His Leu Ile Gly Thr Val  
 85 90 95

Ser Phe Gly Pro Val Val Leu His Val Gly Pro Gly Val Phe Val Pro  
 100 105 110

Arg Pro Glu Thr Glu Ala Ile Leu Ala Trp Ala Thr Ala Gln Ser Leu  
 115 120 125

Pro Ala Arg Pro Leu Ile Val Asp Ala Cys Thr Gly Ser Gly Ala Leu  
 130 135 140

Ala Val Ala Leu Ala Gln His Arg Ala Asn Leu Gly Leu Lys Ala Arg  
 145 150 155 160

Ile Ile Gly Ile Asp Asp Ser Asp Cys Ala Leu Asp Tyr Ala Arg Arg  
 165 170 175

Asn Ala Ala Gly Thr Pro Val Glu Leu Val Arg Ala Asp Val Thr Thr  
 180 185 190

Pro Arg Leu Leu Pro Glu Leu Asp Gly Gln Val Asp Leu Met Val Ser  
 195 200 205

Asn Pro Pro Tyr Ile Pro Asp Ala Ala Val Leu Glu Pro Glu Val Ala  
 210 215 220

Gln His Asp Pro His His Ala Leu Phe Gly Gly Pro Asp Gly Met Thr  
 225 230 235 240

Val Ile Ser Ala Val Val Gly Leu Ala Gly Arg Trp Leu Arg Pro Gly  
 245 250 255

Gly Leu Phe Ala Val Glu His Asp Asp Thr Thr Ser Ser Ser Thr Val  
 260 265 270

Asp Leu Val Ser Ser Thr Lys Leu Phe Val Asp Val Gln Ala Arg Lys  
 275 280 285

Asp Leu Ala Gly Arg Pro Arg Phe Val Thr Ala Met Arg Trp Gly His  
 290 295 300

-121-

Leu Pro Leu Ala Gly Glu Asn Gly Ala Ile Asp Pro Arg Gln Arg Arg  
 305 310 315 320

Cys Arg Ala Lys Arg  
 325

&lt;210&gt; 96

&lt;211&gt; 975

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 96

```

atgacctccg cgccggcgac gatgcggtgg gggaacctcc cgcttgccgg ggagagcggc      60
acaatgacct tgcgtcaggc gatcgacttg gctgctgcgc tattggccga agcggggggtc    120
gactcggcgc gttgcgacgc tgagcagttg gccgctcacc tagcgggcac agaccgcggt      180
aggetacccc tgttcgagcc gcccgggcgc gagttcttcg ggcgctatcg cgacatcgtc      240
accgctcgtg cgccggcgggt gccggttcag catctcatcg ggactgtgtc gtttggggcc      300
gtggtgctgc atgtcggccc ggggtgtgtt gtaccgcgtc eggagaccga agccattttg      360
gcctggggca ccgcgcagtc gctgccggcg cggccgctga ttgtcgacgc atgcacggga      420
tctggcgctg tggcggtcgc attggcccag caccgggcca accttggact aaaggcccg      480
atcatcggca ttgacgactc cgactgcgcc cttgactatg cccgccgcaa tgcggcgggt      540
-----
accccggtag agttggtgcg tgccgacgtc accacgcccc gcctgctccc cgaactcgac      600
ggacaagtcg acctgatggt ttccaacctg cctacatcc ctgatgctgc tgttttggaa      660
cctgaagtag cgcaacatga cccgcacac gcgttggtcg gcggtcccga cgggatgacg      720
gtgatatccg cggtcgtcgg gcttgctggg cgctggctgc gtcccggtag cctgttcgcc      780
gtcgaacacg acgacaccac gtctgctcga actgtcgatt tggtcagcag caaaaactt      840
ttcgtggacg tacaagcccg gaaagatctg gccggacggc cgaggtttgt gacggcgatg      900
aggtgggggc acctcccgtc tgcaggggag aacggcgcca ttgacctcg ccagcgacga      960
tgcagagcga agcga                                           975

```

&lt;210&gt; 97

&lt;211&gt; 163

-122-

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 97

Met Ser Pro Ser Pro Ala Ala Ala Asn Arg Ser Glu Val Gly Gly Pro  
 1 5 10 15

Leu Pro Gly Leu Gly Ala Asp Leu Leu Ala Val Val Ala Arg Leu Asn  
 20 25 30

Arg Leu Ala Thr Gln Arg Ile Gln Met Pro Leu Pro Ala Ala Gln Ala  
 35 40 45

Arg Leu Leu Ala Thr Ile Glu Ala Gln Gly Glu Ala Arg Ile Gly Asp  
 50 55 60

Leu Ala Ala Val Asp His Cys Ser Gln Pro Thr Met Thr Thr Gln Val  
 65 70 75 80

Arg Arg Leu Glu Asp Ala Gly Leu Val Thr Arg Thr Ala Asp Pro Gly  
 85 90 95

Asp Ala Arg Ala Val Arg Ile Arg Ile Thr Pro Glu Gly Ile Arg Thr  
 100 105 110

Leu Thr Ala Val Arg Ala Asp Arg Ala Ala Ala Ile Glu Pro Gln Leu  
 115 120 125

Ala Leu Leu Pro Pro Ala Asp Arg Arg Val Leu Ala Asp Ala Val Asp  
 130 135 140

Val Leu Arg Arg Leu Leu Asp His Ala Ala Thr Thr Pro Gly Arg Ala  
 145 150 155 160

Thr Arg Gln

&lt;210&gt; 98

&lt;211&gt; 489

&lt;212&gt; DNA

-123-

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 98

```

atgagtcctt cccccgccgc cgccaaccgc agcgaggctc gggggccact accgggctg      60
ggagcggatc tggtggcagt ggtcgcgcgg ctcaaccgcc tagccacgca ggcgcatccag    120
atgccactgc ccgcggctca agccagactg ctggccacca tcgaagccca gggggaagcc      180
cggatcggcg acttgggcgc cgtcgatcac tgctcgcaac caacgatgac cagcgaggta    240
cgacgactcg aggacgctgg actgggttacc cgaaccgccg acccgggaga cgcccgggcg    300
gtccgcatcc gcatcaagcc ggaaggcatc cgcacgttga ccgcggtgcg ggcagaccgc    360
ggggtgcca tcgagcctca gctggccctg ctcccaccgg cggaccgccg ggtgttggcg    420
gatgcggtag acgtgttgcg ccggctgctc gaccatgccg ccaccacgcc gggccgggcg    480
acgcggcaa                                     489

```

&lt;210&gt; 99

&lt;211&gt; 257

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 99

```

Met Glu Leu Leu Gly Gly Pro Arg Val Gly Asn Thr Glu Ser Gln Leu
1           5           10          15

Cys Val Ala Asp Gly Asp Asp Leu Pro Thr Tyr Cys Ser Ala Asn Ser
          20           25           30

Glu Asp Leu Asn Ile Thr Thr Ile Thr Thr Leu Ser Pro Thr Ser Met
          35           40           45

Ser His Pro Gln Gln Val Arg Asp Asp Gln Trp Val Glu Pro Ser Asp
          50           55           60

Gln Leu Gln Gly Thr Ala Val Phe Asp Ala Thr Gly Asp Lys Ala Thr
65           70           75           80

Met Pro Ser Trp Asp Glu Leu Val Arg Gln His Ala Asp Arg Val Tyr
          85           90           95

```

-124-

Arg Leu Ala Tyr Arg Leu Ser Gly Asn Gln His Asp Ala Glu Asp Leu  
 100 105 110

Thr Gln Glu Thr Phe Ile Arg Val Phe Arg Ser Val Gln Asn Tyr Gln  
 115 120 125

Pro Gly Thr Phe Glu Gly Trp Leu His Arg Ile Thr Thr Asn Leu Phe  
 130 135 140

Leu Asp Met Val Arg Arg Arg Ala Arg Ile Arg Met Glu Ala Leu Pro  
 145 150 155 160

Glu Asp Tyr Asp Arg Val Pro Ala Asp Glu Pro Asn Pro Glu Gln Ile  
 165 170 175

Tyr His Asp Ala Arg Leu Gly Pro Asp Leu Gln Ala Ala Leu Ala Ser  
 180 185 190

Leu Pro Pro Glu Phe Arg Ala Ala Val Val Leu Cys Asp Ile Glu Gly  
 195 200 205

Leu Ser Tyr Glu Glu Ile Gly Ala Thr Leu Gly Val Lys Leu Gly Thr  
 210 215 220

Val Arg Ser Arg Ile His Arg Gly Arg Gln Ala Leu Arg Asp Tyr Leu  
 225 230 235 240

Ala Ala His Pro Glu His Gly Glu Cys Ala Val His Val Asn Pro Val  
 245 250 255

Arg

&lt;210&gt; 100

&lt;211&gt; 771

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 100

atggaactcc tcggcggacc ccgggttggg aatacgggaat cgcaactttg cgttgccgac

60

-125-

```

ggtgacgact tgccaactta ttgcagtgc aattcggagg atctcaatat cacgaccatc 120
acgaccttga gtccgaccag catgtctcat ccccaacagg tccgcgatga ccagtgggtg 180
gagccgtctg accaattgca gggcaccgcc gtattcgacg ccaccgggga caagggcacc 240
atgccgtcct gggatgagct ggtccgtcag cacgccgatc ggggtgtaccg gctggcttat 300
cggctctccg gcaaccagca cgatgccgaa gacctgacct aggagacctt tatcaggggtg 360
ttccggtcgg tccagaatta ccagccgggc accttcgaag gctggctaca ccgcatcacc 420
accaacttgt tcctggacat ggtccgccgc cgggctcgca tccggatgga ggcgttacct 480
gaggactacg accgggtgcc cgccgatgag cccaaccccg agcagatcta ccacgacgca 540
cggctgggac ctgacctgca ggctgccttg gcctcgctgc cgccggagtt tcgtgccgcg 600
gtggtgctgt gtgacatcga gggctctgtc tacgaggaga tcggcgccac actgggcgtg 660
aagctcggga cggtagctag ccggatacac cgccgacgcc aggcactgcg ggactacctg 720
gcagcgcacc ccgaacatgg cgagtgcgca gttcacgtca acccagttcg c 771

```

&lt;210&gt; 101

&lt;211&gt; 472

&lt;212&gt; PRT

<213> *Mycobacterium tuberculosis*

&lt;400&gt; 101

```

Val Thr Arg Arg Gly Lys Ile Val Cys Thr Leu Gly Pro Ala Thr Gln
1           5           10           15

```

```

Arg Asp Asp Leu Val Arg Ala Leu Val Glu Ala Gly Met Asp Val Ala
20           25           30

```

```

Arg Met Asn Phe Ser His Gly Asp Tyr Asp Asp His Lys Val Ala Tyr
35           40           45

```

```

Glu Arg Val Arg Val Ala Ser Asp Ala Thr Gly Arg Ala Val Gly Val
50           55           60

```

```

Leu Ala Asp Leu Gln Gly Pro Lys Ile Arg Leu Gly Arg Phe Ala Ser
65           70           75           80

```

```

Gly Ala Thr His Trp Ala Glu Gly Glu Thr Val Arg Ile Thr Val Gly

```

-126-

85

90

95

Ala Cys Glu Gly Ser His Asp Arg Val Ser Thr Thr Tyr Lys Arg Leu  
 100 105 110

Ala Gln Asp Ala Val Ala Gly Asp Arg Val Leu Val Asp Asp Gly Lys  
 115 120 125

Val Ala Leu Val Val Asp Ala Val Glu Gly Asp Asp Val Val Cys Thr  
 130 135 140

Val Val Glu Gly Gly Pro Val Ser Asp Asn Lys Gly Ile Ser Leu Pro  
 145 150 155 160

Gly Met Asn Val Thr Ala Pro Ala Leu Ser Glu Lys Asp Ile Glu Asp  
 165 170 175

Leu Thr Phe Ala Leu Asn Leu Gly Val Asp Met Val Ala Leu Ser Phe  
 180 185 190

Val Arg Ser Pro Ala Asp Val Glu Leu Val His Glu Val Met Asp Arg  
 195 200 205

Ile Gly Arg Arg Val Pro Val Ile Ala Lys Leu Glu Lys Pro Glu Ala  
 210 215 220

Ile Asp Asn Leu Glu Ala Ile Val Leu Ala Phe Asp Ala Val Met Val  
 225 230 235 240

Ala Arg Gly Asp Leu Gly Val Glu Leu Pro Leu Glu Glu Val Pro Leu  
 245 250 255

Val Gln Lys Arg Ala Ile Gln Met Ala Arg Glu Asn Ala Lys Pro Val  
 260 265 270

Ile Val Ala Thr Gln Met Leu Asp Ser Met Ile Glu Asn Ser Arg Pro  
 275 280 285

Thr Arg Ala Glu Ala Ser Asp Val Ala Asn Ala Val Leu Asp Gly Ala  
 290 295 300

Asp Ala Leu Met Leu Ser Gly Glu Thr Ser Val Gly Lys Tyr Pro Leu  
 305 310 315 320

-127-

Ala Ala Val Arg Thr Met Ser Arg Ile Ile Cys Ala Val Glu Glu Asn  
                   325                                  330                                  335

Ser Thr Ala Ala Pro Pro Leu Thr His Ile Pro Arg Thr Lys Arg Gly  
                   340                                  345                                  350

Val Ile Ser Tyr Ala Ala Arg Asp Ile Gly Glu Arg Leu Asp Ala Lys  
                   355                                  360                                  365

Ala Leu Val Ala Phe Thr Gln Ser Gly Asp Thr Val Arg Arg Leu Ala  
                   370                                  375                                  380

Arg Leu His Thr Pro Leu Pro Leu Leu Ala Phe Thr Ala Trp Pro Glu  
                   385                                  390                                  395                                  400

Val Arg Ser Gln Leu Ala Met Thr Trp Gly Thr Glu Thr Phe Ile Val  
                   405                                  410                                  415

Pro Lys Met Gln Ser Thr Asp Gly Met Ile Arg Gln Val Asp Lys Ser  
                   420                                  425                                  430

Leu Leu Glu Leu Ala Arg Tyr Lys Arg Gly Asp Leu Val Val Ile Val  
                   435                                  440                                  445

Ala Gly Ala Pro Pro Gly Thr Val Gly Ser Thr Asn Leu Ile His Val  
                   450                                  455                                  460

His Arg Ile Gly Glu Asp Asp Val  
                   465                                  470

&lt;210&gt; 102

&lt;211&gt; 1416

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 102

gtgacgagac gcgggaaaat cgtctgcact ctcgggccgg ccaccagcg ggaacgacctg 60

gtcagagcgc tggctcaggc cggaatggac gtcgcccga tgaacttcag ccacggcgac 120

tacgacgata acaaggctgc ctatgagcgg gtccgggtag cctccgacgc caccggggcgc 180

gcggctcggc tgctgcgca cctgcagggc ccgaagatca gggtgggacg cttegocctcc 240



-128-

```

ggggccaccc actgggccga aggcgaaacc gtccggatca ccgtgggcgc ctgcgagggc 300
agccacgatc ggggtgtccac cacctacaag cggctagccc aggacgcggt ggccggtgac 360
cgggtgctgg tcgacgacgg caaagtcgca ttggtggtcg acgccgtcga gggcgacgac 420
gtggtctgca ccgtcgtcga aggcggcccg gtcagcgaca acaagggcac ctcggtgccc 480
ggaatgaacg tgaccgcgcc ggccctgtcg gagaaggaca tcgaggatct cacgttcgcg 540
ctgaacctcg gcgtcgacat ggtggcgctt tccttcgtcc gctccccggc cgatgtcgaa 600
ctggtccacg aggtgatgga tcggatcggg cgacgggtgc cggtgatcgc caagctggag 660
aagccggaag ccacgcacaa tctcgaagcg atcgtgctgg cgttcgacgc cgtcatggtc 720
gctcggggcg acctaggtgt tgagctgccg ctccaagagg tcccgtggt acagaagcga 780
gccatccaga tggcccgga gaacgccaag ccggtcattg tggcgacca gatgctcgac 840
tcgatgatcg agaactcgcg gccgaccga gctgaggcct ccgacgtcgc caacgcggtg 900
ctcgatggcg ccgacgcgct gatgctgtcc ggggaaacct cggtagggaa gtaccccctt 960
gctgcggtcc ggacaatgtc gcgcacatc tgcgcggtcg aggagaactc cacggccgca 1020
ccgccgttga cacacattcc ccggaccaag cgtgggggtca tctcgtatgc ggcccgtgac 1080
atcggcgaac gactcgacgc caaggccttg gtggccttca ctcagtcgg tgataccgtg 1140
cggcgactgg ccgcctgca taccgcgtg ccgctgctgg ccttcaccgc gtggcccgag 1200
gtgcgcagcc aactggcgat gacctggggc accgagacgt tcacgtgcc gaagatgcag 1260
tccaccgatg gcatgatccg ccaggtcgac aaatcgctgc tcgaactcgc ccgctacaag 1320
cgtggtgact tgggtgtcat cgtcgcgggt gcgccgccag gcacagtggg ttcgaccaac 1380
ctgatccacg tgcaccgat cggggaagat gacgtc 1416

```

&lt;210&gt; 103

&lt;211&gt; 269

&lt;212&gt; PRT

<213> *Mycobacterium tuberculosis*

&lt;400&gt; 103

```

Met Thr Ser Val Lys Leu Asp Leu Asp Ala Ala Asp Leu Arg Ile Ser
1           5           10           15

```

```

Arg Gly Ser Val Pro Ala Ser Thr Gln Leu Ala Glu Ala Leu Lys Ala

```

-129-

|                                                                 |     |     |
|-----------------------------------------------------------------|-----|-----|
| 20                                                              | 25  | 30  |
| Gln Ile Ile Gln Gln Arg Leu Pro Arg Gly Gly Arg Leu Pro Ser Glu |     |     |
| 35                                                              | 40  | 45  |
| Arg Glu Leu Ile Asp Arg Ser Gly Leu Ser Arg Val Thr Val Arg Ala |     |     |
| 50                                                              | 55  | 60  |
| Ala Val Gly Met Leu Gln Arg Gln Gly Trp Leu Val Arg Arg Gln Gly |     |     |
| 65                                                              | 70  | 75  |
| 80                                                              |     |     |
| Leu Gly Thr Phe Val Ala Asp Pro Val Glu Gln Glu Leu Ser Cys Gly |     |     |
| 85                                                              | 90  | 95  |
| Val Arg Thr Ile Thr Glu Val Leu Leu Ser Cys Gly Val Thr Pro Gln |     |     |
| 100                                                             | 105 | 110 |
| Val Asp Val Leu Ser His Gln Thr Gly Pro Ala Pro Gln Arg Ile Ser |     |     |
| 115                                                             | 120 | 125 |
| Glu Thr Leu Gly Leu Val Glu Val Leu Cys Ile Arg Arg Arg Ile Arg |     |     |
| 130                                                             | 135 | 140 |
| Thr Gly Asp Gln Pro Leu Ala Leu Val Thr Ala Tyr Leu Pro Pro Gly |     |     |
| 145                                                             | 150 | 155 |
| 160                                                             |     |     |
| Val Gly Pro Ala Val Glu Pro Leu Leu Ser Gly Ser Ala Asp Thr Glu |     |     |
| 165                                                             | 170 | 175 |
| Thr Thr Tyr Ala Met Trp Glu Arg Arg Leu Gly Val Arg Ile Ala Gln |     |     |
| 180                                                             | 185 | 190 |
| Ala Thr His Glu Ile His Ala Ala Gly Ala Ser Pro Asp Val Ala Asp |     |     |
| 195                                                             | 200 | 205 |
| Ala Leu Gly Leu Ala Val Gly Ser Pro Val Leu Val Val Asp Arg Thr |     |     |
| 210                                                             | 215 | 220 |
| Ser Tyr Thr Asn Asp Gly Lys Pro Leu Glu Val Val Val Phe His His |     |     |
| 225                                                             | 230 | 235 |
| 240                                                             |     |     |
| Arg Pro Glu Arg Tyr Gln Phe Ser Val Thr Leu Pro Arg Thr Leu Pro |     |     |
| 245                                                             | 250 | 255 |

-130-

Gly Ser Gly Ala Gly Ile Ile Glu Lys Arg Asp Phe Ala  
 260 265

&lt;210&gt; 104

&lt;211&gt; 807

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 104

```

atgacatctg tcaagctgga cctggacgct gccgatctgc ggatatcgcg tggcagcgctg      60
ccggcgagta ccagcttgcc cgaggcgcta aaggcccaga tcatccagca gcggctgccc      120
cgcggcgggc gcttgcccag cgaacgagaa ttgatcgacc gttccggttt gagccgcgtg      180
accgtgcgcg cggcggtcgg catgctgcaa cgtcagggat ggctagtgcg ccggcaaggc      240
ttgggtacct tcgtcgccga tccggtggaa caggagctca gttgcggcgt gcgcaccatc      300
acagaggtgt tggtgagctg tgggtgtacc ccgcaggtcg acgtgctgtc acaccagacc      360
ggaccggcgc cgcaacggat ttccgagacg ctggggtttgg ttgaggtcct ctgtattcgc      420
cggcgcatcc gcactggcga tcaacccttg gccctgggtca cggcctatct tccgcccggc      480
gtgggcccag ccgtcgagcc gttgctatcg ggcagcgcgg acaccgaaac cacatatgcy      540
atgtgggagc ggcgactggg tgtacgcatt gcacaggcta cccacgaaat ccatgcgcgc      600
ggggcctccc ccgacgtagc cgacgcgttg ggtctggcgg tgggttcgcc ggtactggtc      660
gtcgaccgca ccagctacac caatgacggc aagccccttg aagtggtcgt gttccaccat      720
cgccccgagc ggtaccagtt ctccgtcacg ttaccccgaa cgttgcccgg atcaggtgcc      780
ggaattatcg agaaacgaga tttcgca                                     807

```

&lt;210&gt; 105

&lt;211&gt; 293

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 105

Val Phe Ala Leu Ser Asn Asn Leu Asn Arg Val Asn Ala Cys Met Asp  
 1 5 10 15

-131-

Gly Phe Leu Ala Arg Ile Arg Ser His Val Asp Ala His Ala Pro Glu  
                   20                  25                  30

Leu Arg Ser Leu Phe Asp Thr Met Ala Ala Glu Ala Arg Phe Ala Arg  
           35                  40                  45

Asp Trp Leu Ser Glu Asp Leu Ala Arg Leu Pro Val Gly Ala Ala Leu  
       50                  55                  60

Leu Glu Val Gly Gly Gly Val Leu Leu Leu Ser Cys Gln Leu Ala Ala  
   65                  70                  75                  80

Glu Gly Phe Asp Ile Thr Ala Ile Glu Pro Thr Gly Glu Gly Phe Gly  
                   85                  90                  95

Lys Phe Arg Gln Leu Gly Asp Ile Val Leu Glu Leu Ala Ala Arg  
           100                  105                  110

Pro Thr Ile Ala Pro Cys Lys Ala Glu Asp Phe Ile Ser Glu Lys Arg  
       115                  120                  125

Phe Asp Phe Ala Phe Ser Leu Asn Val Met Glu His Ile Asp Leu Pro  
       130                  135                  140

Asp Glu Ala Val Arg Arg Val Ser Glu Val Leu Lys Pro Gly Ala Ser  
   145                  150                  155                  160

Tyr His Phe Leu Cys Pro Asn Tyr Val Phe Pro Tyr Glu Pro His Phe  
           165                  170                  175

Asn Ile Pro Thr Phe Phe Thr Lys Glu Leu Thr Cys Arg Val Met Arg  
           180                  185                  190

His Arg Ile Glu Gly Asn Thr Gly Met Asp Asp Pro Lys Gly Val Trp  
       195                  200                  205

Arg Ser Leu Asn Trp Ile Thr Val Pro Lys Val Lys Arg Phe Ala Ala  
       210                  215                  220

Lys Asp Ala Thr Leu Thr Leu Arg Phe His Arg Ala Met Leu Val Trp  
   225                  230                  235                  240

Met Leu Glu Arg Ala Leu Thr Asp Lys Glu Phe Ala Gly Arg Arg Ala

-132-

245

250

255

Gln Trp Met Val Ala Ala Ile Arg Ser Ala Val Lys Leu Arg Val His  
 260 265 270

His Leu Ala Gly Tyr Val Pro Ala Thr Leu Gln Pro Ile Met Asp Val  
 275 280 285

Arg Leu Thr Lys Arg  
 290

&lt;210&gt; 106

&lt;211&gt; 879

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 106

gtgtttgcgt tgagtaataa tctgaaccgt gtgaacgcat gcatggatgg attccttgcc 60  
 cgtatccgct cacatgttga tgcgcacgcg ccagaattgc gttoactgtt cgatacgatg 120  
 gcggccgagg cccgatttgc acgcgactgg ctgtccgagg acctcgcgcg gttgcctgtc 180  
 ggtgcagcat tgctggaagt gggcgggggg gtacttctgc tcagctgtca actggcggcg 240  
 gagggatttg acatcaccgc catcgagccg acgggtgaag gttttggcaa gttcagacag 300  
 cttggcgaca tcgtgctgga attggctgca gcacgacca ccacgcgccc atgcaaggcg 360  
 gaagacttta tttccgagaa gcggttcgac ttgcctttct cgctgaatgt gatggagcac 420  
 atcgaccttc cggatgaggc agtcaggcgg gtatcggaag tgctgaaacc gggggccagt 480  
 taccacttcc tgtgcccga ttaactattc ccgtacgaac cgcatttcaa tatcccaaca 540  
 ttcttcacca aagagctgac atgccgggtg atgcgacatc gcatcgaggg caatacgggc 600  
 atggatgacc cgaaggaggt ctggcgttcg ctcaactgga ttacggttcc caagggtgaaa 660  
 cgctttgcgg cgaaggatgc gacgctgacc ttgcgcttcc accgtgcaat gttggtatgg 720  
 atgctggaac gcgcgctgac ggataaggaa ttgcgtggtc gccgggcaca atggatggtc 780  
 gctgctattc gctcggcggt gaaattgctg gtgcacatc tggcaggcta tgttcccgct 840  
 acgctgcagc ccatcatgga tgtgcggcta acgaagagg 879

&lt;210&gt; 107

-133-

&lt;211&gt; 412

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 107

Val Thr Pro His Tyr Arg Gln Ala Ala Ala Ser Arg Leu Asp Thr His  
 1 5 10 15

Arg Thr Gln Lys Leu Arg Ser Gln Thr Asn Gly Gly Lys Asp Arg His  
 20 25 30

Gln Leu Thr Tyr Glu Gln Phe Ala Arg Met Leu Thr Leu Met Gly Pro  
 35 40 45

Ser Asp Leu Trp Thr Val Glu Arg Ala Ala Arg His Trp Gly Val Ser  
 50 55 60

Ala Ser Arg Ala Arg Ala Ile Leu Ser Ser Arg His Ile His Arg Val  
 65 70 75 80

Ser Gly Tyr Pro Ala Gln Ala Ile Lys Ala Val Thr Leu Arg Gln Gly  
 85 90 95

Ala Arg Thr Asp Leu Lys Thr Ala Asn His Leu Val Pro Ala Ala Gln  
 100 105 110

Ala Phe Thr Met Ala Glu Thr Gly Ala Ala Ile Gly Glu Thr Glu Asp  
 115 120 125

Glu Arg Ala Arg Leu Arg Ile Phe Phe Glu Phe Leu Arg Gly Ala Asp  
 130 135 140

Glu Thr Gly Thr Ser Ala Leu Asp Leu Ile Val Asp Glu Pro Ala Leu  
 145 150 155 160

Ile Gly Glu His Arg Phe Asp Ala Leu Leu Ala Ala Ala Ala Glu Tyr  
 165 170 175

Ile Ser Ala Arg Trp Gly Arg Pro Gly Pro Leu Trp Ser Val Ser Ile  
 180 185 190

-134-

Glu Arg Phe Leu Asp Thr Ala Trp Trp Val Ser Asp Leu Pro Ser Ala  
 195 200 205

Arg Ala Phe Ala Ala Val Trp Thr Pro Ala Pro Phe Arg Arg Arg Gly  
 210 215 220

Ile Tyr Leu Asp Arg His Asp Leu Thr Ser Asp Gly Val Cys Val Met  
 225 230 235 240

Pro Glu Pro Val Phe Asn Arg Thr Glu Leu Gln Arg Ala Phe Thr Ala  
 245 250 255

Leu Ala Ala Lys Leu Glu Arg Arg Gly Val Val Gly Gln Val His Val  
 260 265 270

Val Gly Gly Ala Ala Met Leu Leu Ala Tyr Asn Ser Arg Val Thr Thr  
 275 280 285

Arg Asp Ile Asp Ala Leu Phe Ser Thr Asp Gly Pro Met Leu Glu Ala  
 290 295 300

Ile Arg Glu Val Ala Asp Glu Met Gly Trp Pro Arg Thr Trp Leu Asn  
 305 310 315 320

Asn Gln Ala Ser Gly Tyr Val Ser Arg Thr Pro Gly Glu Gly Ala Pro  
 325 330 335

Val Phe Asp His Pro Phe Leu His Val Val Ala Thr Pro Ala Gln His  
 340 345 350

Leu Leu Ala Met Lys Val Val Ala Ala Arg Gly Val Arg Asp Gly Glu  
 355 360 365

Asp Ile Arg Leu Leu Leu Asp Arg Leu Arg Ile Thr Ser Ala Ala Gly  
 370 375 380

Val Trp Glu Ile Val Ala Arg Tyr Phe Pro Ala Glu Thr Ile Thr Asp  
 385 390 395 400

Arg Ser Arg Leu Leu Val Glu Asp Leu Leu Asn Gln  
 405 410

&lt;210&gt; 108

-135-

&lt;211&gt; 1236

&lt;212&gt; DNA

<213> *Mycobacterium tuberculosis*

&lt;400&gt; 108

```
gtgacccac actatcgcca agccgcggcg tcgcggtcgc ataccacccg cagcctaaag    60
ctccgttccc agaccaacgg agggaaggac cggcaccagt tgacatacga gcagttcgcct    120
cgtatgttga cgctgatggg gccgagcgat ctgtggacgg tggaaacggc ggcgcgccat    180
tggggcgtga gcgcgtcgcg cgctcgcgct atcctgtcga gccgccacat tcaccgggctc    240
agcggctacc ccgcgcaggc gatcaaggcg gtcaccctgc gccaggggtgc gcgcaccgac    300
ctcaaaaccg ccaaccatct cgtgccggcc gcacaagcgt tcaccatggc cgagacgggt    360
gccgcgatcg gagagaccga agatgagcgg gcacgactgc gcattttctt cgagttcctc    420
cgcggcgcgc atgagaccgg gacatccgcg ctcgatctca tcgttgacga gccgcgcgtg    480
atcgggtgagc accggttcga tgctttgttg gccgcggctg cggaatacat ttccggcgcgc    540
tggggccggc ctggaccctt gtggtcggtg agtatcgaac ggttttctga caccggcctgg    600
tgggtcagcg acctcccgtc ggcacgagcg tttgccgcgc tgtggacgcc ggcgccgttc    660
cggcgccgcg gcatttacct agatcgccac gacctcacga gcgatggagt gtgtgtcatg    720
cccgaaccgg tgttcaaccg aaccgagctc cagcgggctg tcaactgcctt ggcggccaag    780
ctggaacgca gaggcgttgt cggtcagggtg cacgttgctg gcggggcggc gatgctactc    840
gcctacaaat cccgtgtcac cactcgcgat atcgacgcgt tgtttctaac tgacgggctc    900
atgctcgaag cgattcgtga ggctcgtgac gaaatggggt ggccgcgaac gtggctcaac    960
aatcaggcca gcggttacgt ctcccgcaaa ccagggtgaag gcgccccctt ttccgatcac   1020
ccattcctgc atgtcgtagc cacaccgcgc cagcaccttc tcgcgatgaa agtcggttgcg   1080
gcacgcggcg tcggtgacgg cgaagacatt cgcctcctgc tcgatcggct gcgaatcacc   1140
agcgcggccg gcgtatggga gattgtcgca cgctactttc ccgccgaaac catcaccgac   1200
cggctcagggc tcctcgtcga ggacctctc aaccaa                                1236
```

&lt;210&gt; 109

&lt;211&gt; 328

&lt;212&gt; PRT



-136-

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 109

Val Pro Gly Ala Arg Glu Leu Thr Leu Arg Val Glu Arg Gly Ala Leu  
 1 5 10 15

Phe Arg Arg Arg Trp Ala Ala Ser Ala Ala Ser Ser Ala Arg Ala Ala  
 20 25 30

Ile Arg Arg Asp Pro Arg Arg Cys Ala Leu Gly Thr Arg Pro Arg Trp  
 35 40 45

Val Ser Phe Leu Val Ile Val Leu Val Ile Met Asn Val Val Thr Ala  
 50 55 60

His Pro Lys Tyr Pro Asn Asp Pro Leu Ala Leu Val Leu Ile Glu Leu  
 65 70 75 80

Arg His Pro Arg Thr Glu Pro Pro Val Pro Ser Ala Ile Ser Ile Leu  
 85 90 95

Lys Glu Glu Leu Ala Arg Trp Thr Pro Ile Leu Glu Gln Glu Glu Val  
 100 105 110

Arg Gln Val Asn Leu Glu Thr Gly Glu His Thr Ala His Ser Gln Lys  
 115 120 125

Lys Leu Val Ala Arg Asp Arg Arg Thr Ala Ile Thr Phe Arg Pro Asp  
 130 135 140

Ala Met Thr Leu Glu Val Thr Asp Tyr Pro Gly Trp Glu Glu Phe Arg  
 145 150 155 160

Ser Ile Val His Ala Met Val Thr Ala Arg Gln Asp Val Ala Pro Val  
 165 170 175

Asp Gly Cys Ile Arg Ile Gly Leu Arg Tyr Ile Asn Glu Ile Arg Ala  
 180 185 190

Ser Leu Ala Glu Pro Ser Gly Trp Ala Tyr Trp Val Ala Glu Ser Leu  
 195 200 205

-137-

Leu Gly Pro Gly Thr Gln Leu Ala Asp Leu Lys Leu Thr Thr Thr Ala  
 210 215 220

Gln Arg His Val Ile Gln Cys Glu Gly Pro Glu Pro Gly Asp Ser Leu  
 225 230 235 240

Thr Leu Arg Tyr Ala Gly Ala Arg Gly Ala Val Ile Gln Ser Thr Pro  
 245 250 255

Phe Leu Gln Arg Leu Lys Glu Pro Pro Ala Glu Gly Asp Phe Phe Leu  
 260 265 270

Ile Asp Ile Asp Ser Ala Trp Ser Asp Pro Cys Lys Gly Ile Pro Ala  
 275 280 285

Leu Asp Ala His Leu Val Asp Glu Val Ala Glu Arg Leu His Thr Pro  
 290 295 300

Ile Gly Pro Leu Phe Glu Ser Leu Ile Thr Ser Glu Leu Arg Thr Lys  
 305 310 315 320

Val Leu Gln Gln Pro Gly Gln Glu  
 325

<210> 110

<211> 984

<212> DNA

<213> Mycobacterium tuberculosis

<400> 110

|                                                                    |     |
|--------------------------------------------------------------------|-----|
| gtgcccggcg cgcgcgagtt gacgctgcgc gtcgagcgcg gggetctatt tcggcgctga  | 60  |
| tgggcagcat cggcagcgtc atcagctcgc gcagcaattc gtcgtgatcc gcggcgctgc  | 120 |
| gcgctgggta cccggcctcg atgggtatca tttttggtta tcgttctggt tatcatgaat  | 180 |
| gttgtgacgg cccatcccaa gtaccggaat gaccctcttg cgctggtatt gattgaactg  | 240 |
| cgccatccgc ggaccgagcc gccggtgcca tctgctatct ccatcctgaa ggaggagctg  | 300 |
| gcgcgatgga ctcccatact cgaacaggag gaggtgcggc aggtcaacct agaaacgggc  | 360 |
| gaacataccg cacactcaca gaagaagctc gttgcccgtg atcgccgcac cgcgatcacg  | 420 |
| tttcgacccg acgccaatgac cctcgaagtc accgactacc cgggctggga ggagtctcgg | 480 |

-138-

```

tccatcggtc acgcgatggt cacagccgc caggacgtgg cccagtcga tggctgcac 540
cggatcggtc tgcgctacat caacgagatt cgggcatcgc tggcggagcc atccggtgg 600
gcgtactggg tggcggaaag tctcctcggg cctgggacac agcttgccga tctcaaactc 660
accaccaccg cgcaacggca cgtcattcag tgcgaaggcc cggagccagg cgactccttg 720
aactgaggt acgccggtgc gcgcggcgcg gtcattcagt caaccccggt tctccagcgg 780
ttgaaagaac ctccggcaga aggagatttc ttctcatcg atatcgacag cgcgtggagc 840
gaccctgca agggcatccc agcgtcgcac gccacactgg tggacgaggt cggcgaagg 900
ctccacacac ccatcggccc actgttcgaa tcgctgataa ctccgaact ccgtacaaag 960
gtgctgcaac aacctgggca ggag 984

```

&lt;210&gt; 111

&lt;211&gt; 463

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 111

```

Met Ala Ile Arg Gln His Val Gly Ala Leu Phe Thr Asp Leu Tyr Glu
1           5           10           15

```

```

Val Thr Met Ala Gln Ala Tyr Trp Ala Glu Arg Met Ser Gly Thr Ala
          20           25           30

```

```

Val Phe Glu Ile Phe Phe Arg Lys Leu Pro Pro Gly Arg Ser Tyr Ile
          35           40           45

```

```

Met Ala Ala Gly Leu Ala Asp Val Val Glu Phe Leu Glu Ala Phe Arg
          50           55           60

```

```

Phe Asp Glu Gln Asp Leu Arg Tyr Leu Arg Gly Leu Gly Gln Phe Ser
65           70           75           80

```

```

Asp Glu Phe Leu Arg Trp Leu Ala Gly Val Arg Phe Thr Gly Asp Val
          85           90           95

```

```

Trp Ala Ala Pro Glu Gly Thr Val Ile Phe Pro Asn Glu Pro Ala Val
          100          105          110

```

-139-

Gln Leu Ile Ala Pro Ile Ile Glu Ala Gln Leu Val Glu Thr Phe Val  
 115 120 125

Leu Asn Gln Ile His Leu Gln Ser Val Leu Ala Ser Lys Ala Ala Arg  
 130 135 140

Val Val Ala Ala Ala Arg Gly Arg Pro Val Val Asp Phe Gly Ala Arg  
 145 150 155 160

Arg Ala His Gly Thr Asp Ala Ala Cys Lys Val Ala Arg Thr Ser Tyr  
 165 170 175

Leu Ala Gly Ala Ala Gly Thr Ser Asn Leu Leu Ala Ala Arg Gln Tyr  
 180 185 190

Gly Ile Pro Thr Phe Gly Thr Met Ala His Ser Phe Val Gln Ala Phe  
 195 200 205

Asp Ser Glu Val Ala Ala Phe Glu Ala Phe Ala Arg Leu Tyr Pro Ala  
 210 215 220

Thr Met Leu Leu Val Asp Thr Tyr Asp Thr Leu Arg Gly Val Asp His  
 225 230 235 240

Val Ile Glu Leu Ala Lys Arg Leu Gly Asn Arg Phe Asp Val Arg Ala  
 245 250 255

Val Arg Leu Asp Ser Gly Asp Leu Asp Glu Leu Ser Lys Ala Thr Arg  
 260 265 270

Ala Arg Leu Asp Thr Ala Gly Leu Glu Gln Val Glu Ile Phe Ala Ser  
 275 280 285

Ser Gly Leu Asp Glu Asn Arg Ile Ala Ala Leu Leu Ala Ala Arg Cys  
 290 295 300

Pro Ile Asp Gly Phe Gly Val Gly Thr Gln Leu Val Val Ala Gln Asp  
 305 310 315 320

Ala Pro Ala Leu Asp Met Ala Tyr Lys Leu Val Ala Tyr Asp Gly Ser  
 325 330 335

Gly Arg Thr Lys Phe Ser Ser Gly Lys Val Ile Tyr Pro Gly Arg Lys  
 340 345 350

-140-

Gln Val Phe Arg Lys Leu Glu His Gly Val Phe Cys Gly Asp Thr Leu  
 355 360 365

Gly Glu His Gly Glu Asn Leu Pro Gly Asp Pro Leu Leu Val Pro Ile  
 370 375 380

Met Thr Asn Gly Arg Arg Ile Arg Gln His Ala Pro Thr Leu Asp Gly  
 385 390 395 400

Ala Arg Asp Trp Ala Arg Gln Gln Ile Asp Ala Leu Pro Pro Glu Leu  
 405 410 415

Arg Ser Leu Glu Asp Thr Gly Tyr Ser Tyr Pro Val Ala Val Ser Asp  
 420 425 430

Arg Ile Val Gly Glu Leu Ala Arg Leu Arg His Ala Asp Thr Ala Glu  
 435 440 445

Ala His Pro Gly Ser Asn Val Val Gly Ala Lys Ala Lys Arg Pro  
 450 455 460

&lt;210&gt; 112

&lt;211&gt; 1389

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 112

```

atggcgatcc gccaacacgt cggcgcgctg ttcaccgacc tgtacgaggt gacgatggcc      60
caggcctact gggccgaaag aatgtcgggc acagcggttt tcgagatatt cttccgcaag      120
cttcgcctg gcaggtccta catcatggcc gccgggctgg ccgatgtggt cgagttcttc      180
gaagcgtttc gattcgacga gcaggatctg cgttacctgc gtggcctggg ccagttttcc      240
gacgagttcc tgaggtggct ggccggagtg cgtttcaccg gagatgtctg ggccgcgcgc      300
gaaggaaccg tgatttttcc gaacgaaccc gcggtccagc tgatcgcgcc aatcatcgag      360
gccagcttg tcgagacgtt tgtgctgaac cagattcatc tgcaaagcgt gctcgcgagc      420
aaggccgcgc ggggtggtgc cgcgcgcgcg ggacgaccgg tgggtggattt cggcgcgcgg      480
cgcgctcacg gcaccgacgc ggctgcaag gtgcgcgcga ccagttatct cgcgggcgct      540

```

-141-

```

gcgggcacgt cgaatctgct cgcggcccgc caatatggga tcccgcagtt cggcaccatg      600
gcgcacagct ttgttcaagc cttcgacagt gaggtggccg cgttcgaggc gttcgcccgg      660
ctctacccag ccaccatgct gctcgtggac acctacgaca cgctacgagg cgtcgatcac      720
gtcatcgagt tggccaagcg gctgggcaat cgcttcgatg tgcgcgcggg ccggtctggat      780
tccggcgacc tcgatgagct gtccaaggcg acccgtgcac ggctcgacac cgccggtctc      840
gagcaggtcg agatcttcgc gtcgtcgggc ctogacgaaa accgcctcgc cgcgcttttg      900
gctgcccgtc gtccgatcga cggttcggc gtgggcaccc agctcgtcgt ggctcaagac      960
gcgcccgcgc tggacatggc ctacaagctg gtggcatacg acggcagcgg gcgcaccaag     1020
ttctccagcg gcaaggtgat ctaccgggga cgcaagcagg tgttccgtaa gctcgagcac     1080
ggagtctttt gcggcgacac gctcggcgag cacgggtgaaa accttccgg ggacccgttg     1140
ctggtgcca tcatgaccaa eggccgacgc atccggcagc atgcacccac attggacggc     1200
gcgcgggact gggcccgcca gcagatcgac gcgtcccgc cggagctgcg ctgctcgag     1260
gacaccggct actcgtatcc ggtggcggtc agcgacagga tcgtgggcga actcgcccgg     1320
ctcgggcacg ccgacacggc cgaagcccac cccgggtcca acgtcgtcgg gcggaaggcc     1380
aaacgaccc                                     1389

```

&lt;210&gt; 113

&lt;211&gt; 138

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 113

```

Leu Gln Pro Asp Arg Asn Leu Leu Ala Asp Leu Asp His Ile Phe Val
1           5           10           15

```

```

Asp Arg Ser Leu Gly Ala Val Gln Val Pro Gln Leu Leu Arg Asp Ala
20           25           30

```

```

Gly Phe Arg Leu Thr Thr Met Arg Glu His Tyr Gly Glu Thr Gln Ala
35           40           45

```

```

Gln Ser Val Ser Asp His Lys Trp Ile Ala Met Thr Ala Glu Cys Gly
50           55           60

```

-142-

Trp Ile Gly Phe His Lys Asp Ala Asn Ile Arg Arg Asn Ala Val Glu  
65 70 75 80

Arg Arg Thr Val Leu Asp Thr Gly Ala Arg Leu Phe Cys Val Pro Arg  
85 90 95

Ala Asp Ile Leu Ala Glu Gln Val Ala Ala Arg Tyr Ile Ala Ser Leu  
100 105 110

Ala Ala Ile Ala Arg Ala Ala Arg Phe Pro Gly Pro Phe Ile Tyr Thr  
115 120 125

Val His Pro Ser Lys Ile Val Arg Val Leu  
130 135

&lt;210&gt; 114

&lt;211&gt; 414

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 114

ttgcagcctg atcggaatct cctcgccgac ctcgatcaca tctttgtoga ccggagtttg 60  
ggcgctgtgc aagtccecgca actccttcgg gatgcgggat tccggctgac aacgatgcgg 120  
gagcactacg gcgagacgca ggctcagagt gtcagcgacc acaagtggat cgcaatgacc 180  
gccgagtgcg gctggattgg atttcacaag gatgccata tccggcgcaa cgccgtcgag 240  
cgacggacgg tgctcgacac gggagcccgg ctattctgtg tgccgcgggc cgacatcctg 300  
gcagagcaag tcgcggcacg gtatattgcg tcccttgagg cgattgcccg tgccgcacga 360  
tttcggggac cattcatcta cacggttcac ccgagcaaga tcgttcgcgt gctc 414

&lt;210&gt; 115

&lt;211&gt; 288

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 115

-143-

Met Asn Ser Pro Arg Glu Pro Leu Val Pro Pro Pro Thr Pro Arg Pro  
 1 5 10 15

Ala Ala Thr Val Met Leu Val Arg Asp Pro Asp Ala Gly Ser Ala Ser  
 20 25 30

Gly Leu Ala Val Phe Leu Met Arg Arg His Ala Ala Met Asp Phe Ala  
 35 40 45

Ala Gly Val Met Val Phe Pro Gly Gly Gly Val Asp Asp Arg Asp Arg  
 50 55 60

Asp Ala Asp Leu Gly Arg Leu Gly Ala Trp Ala Gly Pro Pro Pro Gln  
 65 70 75 80

Trp-Trp Ala Gln Arg Phe Gly Ile Glu Pro Asp Leu Ala Glu Ala Leu  
 85 90 95

Val Cys Ala Ala Ala Arg Glu Thr Phe Glu Glu Ser Gly Val Leu Phe  
 100 105 110

Ala Gly Pro Val Asp Gln Asp His Ser Ala Pro Asn Ser Ile Val Ser  
 115 120 125

Asp Ala Ser Val Tyr Gly Asp Ala Arg Arg Ala Leu Ala Asp Arg Thr  
 130 135 140

Leu Ser Phe Ala Asp Phe Leu Gln Arg Glu Lys Leu Val Leu Arg Ser  
 145 150 155 160

Asp Leu Leu Arg Pro Trp Ala Asn Trp Val Thr Pro Glu Ala Glu Leu  
 165 170 175

Thr Arg Arg Tyr Asp Thr Tyr Phe Phe Val Gly Ala Leu Pro Glu Gly  
 180 185 190

Gln Arg Ala Asp Gly Glu Asn Thr Glu Ser Asp Arg Ala Gly Trp Val  
 195 200 205

Leu Pro Ala Asp Ala Ile Ala Asp Phe Ala Ala Gly Arg Asn Phe Leu  
 210 215 220

Leu Pro Pro Thr Trp Thr Gln Leu Asp Ser Leu Ala Gly His Thr Val  
 225 230 235 240



-144-

Ala Asp Val Leu Ala Val Glu Arg Gln Ile Val Pro Val Gln Pro Gln  
 245 250 255

Leu Ala Arg Asn Gly Asp Asn Trp Glu Ile Glu Phe Phe Asp Ser Asp  
 260 265 270

Arg Tyr Asn Gln Ala Arg Arg Ser Gly Gly Ser Thr Gly Trp Pro Leu  
 275 280 285

&lt;210&gt; '116

&lt;211&gt; 864

&lt;212&gt; DNA

<213> *Mycobacterium tuberculosis*

&lt;400&gt; 116

```

atgaattcac ctcgcgagcc actggtaccc cgcctacac cgaggccggc ggcgaccgtg      60
atgttggtcc ggcacccgga cgccggatca ggcgtccgtc tggcgtctt cttgatgcgg      120
cggcacgctg cgatggattt cgccgccggg gtaatggtgt ttcccggcgg gggagtcgac      180
gaccgcgacc ggcagccgga cttgggcccgg ctgggggcat gggccgggtc gccgccgcag      240
tggtgggcgc agcgggttcgg catcgagcct gatctcgccg aagccttggt ctgcgcggcg      300
gcccgcgaga cgttcgagga gtcgggggtg ctattcgccg ggccggtcga tcaggaccat      360
tcggcacgga acagcatcgt ctccgatgcc tcggtgtacg gcgacgcgcg tcgcgcactg      420
-----
gccgaccgga cgctgtcctt cgcggacttc ctgcagcggg aaaagctggt gctgcgatcc      480
gacctgctac ggccttgggc caactgggtc acccggagg ccgaactgac ccggcgctac      540
gacacctact tctttgtggg tgccctacct gaaggtcagc gcgccgacgg cgagaacacc      600
gaatccgacc gggctggttg ggtggtgcca gcgacgcta tcgccgactt cgccgccggc      660
cgcaacttct tgctgccgcc gacctggacg caactggact cgctggccgg tcataccgtt      720
gccgacgtgc tggccgtcga acgcctaatc gtcccgggtg agccacagct ggcccgaac      780
ggcgacaact gggagatcga gttcttcgat tccgaccgct ataaccaggc ccggagatcg      840
ggcggatcga ccgggtggcc gctg                                     864

```

&lt;210&gt; 117

&lt;211&gt; 456

-145-

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 117

Met Val Ser Thr His Ala Val Val Ala Gly Glu Thr Leu Ser Ala Leu  
1 5 10 15

Ala Leu Arg Phe Tyr Gly Asp Ala Glu Leu Tyr Arg Leu Ile Ala Ala  
20 25 30

Ala Ser Gly Ile Ala Asp Pro Asp Val Val Asn Val Gly Gln Arg Leu  
35 40 45

Ile Met Pro Asp Phe Thr Arg Tyr Thr Val Val Ala Gly Asp Thr Leu  
50 55 60

Ser Ala Leu Ala Leu Arg Phe Tyr Gly Asp Ala Glu Leu Asn Trp Leu  
65 70 75 80

Ile Ala Ala Ala Ser Gly Ile Ala Asp Pro Asp Val Val Asn Val Gly  
85 90 95

Gln Arg Leu Ile Met Pro Asp Phe Thr Arg Tyr Thr Val Val Ala Gly  
100 105 110

Asp Thr Leu Ser Ala Leu Ala Ala Arg Phe Tyr Gly Asp Ala Ser Leu  
115 120 125

Tyr Pro Leu Ile Ala Ala Val Asn Gly Ile Ala Asp Pro Gly Val Ile  
130 135 140

Asp Val Gly Gln Val Leu Val Ile Phe Ile Gly Arg Ser Asp Gly Phe  
145 150 155 160

Gly Leu Arg Ile Val Asp Arg Asn Glu Asn Asp Pro Arg Leu Trp Tyr  
165 170 175

Tyr Arg Phe Gln Thr Ser Ala Ile Gly Trp Asn Pro Gly Val Asn Val  
180 185 190

Leu Leu Pro Asp Asp Tyr Arg Thr Ser Gly Arg Thr Tyr Pro Val Leu  
195 200 205

-146-

Tyr Leu Phe His Gly Gly Gly Thr Asp Gln Asp Phe Arg Thr Phe Asp  
 210 215 220

Phe Leu Gly Ile Arg Asp Leu Thr Ala Gly Lys Pro Ile Ile Ile Val  
 225 230 235 240

Met Pro Asp Gly Gly His Ala Gly Trp Tyr Ser Asn Pro Val Ser Ser  
 245 250 255

Phe Val Gly Pro Arg Asn Trp Glu Thr Phe His Ile Ala Gln Leu Leu  
 260 265 270

Pro Trp Ile Glu Ala Asn Phe Arg Thr Tyr Ala Glu Tyr Asp Gly Arg  
 275 280 285

Ala Val Ala Gly Phe Ser Met Gly Gly Phe Gly Ala Leu Lys Tyr Ala  
 290 295 300

Ala Lys Tyr Tyr Gly His Phe Ala Ser Ala Ser Ser His Ser Gly Pro  
 305 310 315 320

Ala Ser Leu Arg Arg Asp Phe Gly Leu Val Val His Trp Ala Asn Leu  
 325 330 335

Ser Ser Ala Val Leu Asp Leu Gly Gly Gly Thr Val Tyr Gly Ala Pro  
 340 345 350

Leu Trp Asp Gln Ala Arg Val Ser Ala Asp Asn Pro Val Glu Arg Ile  
 355 360 365

Asp Ser Tyr Arg Asn Lys Arg Ile Phe Leu Val Ala Gly Thr Ser Pro  
 370 375 380

Asp Pro Ala Asn Trp Phe Asp Ser Val Asn Glu Thr Gln Val Leu Ala  
 385 390 395 400

Gly Gln Arg Glu Phe Arg Glu Arg Leu Ser Asn Ala Gly Ile Pro His  
 405 410 415

Glu Ser His Glu Val Pro Gly Gly His Val Phe Arg Pro Asp Met Phe  
 420 425 430

Arg Leu Asp Leu Asp Gly Ile Val Ala Arg Leu Arg Pro Ala Ser Ile

-147-

435

440

445

Gly Ala Ala Ala Glu Arg Ala Asp

450

455

&lt;210&gt; 118

&lt;211&gt; 1368

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 118

|                                                                   |      |
|-------------------------------------------------------------------|------|
| atggtcagca cacatgcggt tgtcgcgggg gagacgctgt cggcggtggc gttgcgcttc | 60   |
| tatggcgacg cggaactgta tcggctgata gccgcgccca gcgggatcgc cgatcccgac | 120  |
| gtcgtcaatg tggggcagcg gctgattatg cctgacttca cgcgatacac cgttgttgcc | 180  |
| ggggacaacg tgtcggcggt ggcggttgcc ttctatggcg acgcggaatt gaattggctg | 240  |
| atcgccgcgc ccagcgggat cgccgatccc gacgtcgtca atgtggggca gcggtgatt  | 300  |
| atgcctgact tcacgcgata caccgttggt gccggggaca cgctgtcggc attggctgcg | 360  |
| cgcttctatg gcgacgcctc cctatatccg cttatcgccg ccgtcaatgg catcgccgat | 420  |
| cctggcgta tcgacgtcgg gcaggtactg gtcatattca tcgggcgtag cgacgggttc  | 480  |
| ggcctaagga tcgtggaccg caacgagaac gatccccgcc tgtggtacta ccggttcag  | 540  |
| acctcgcga tcggctggaa ccccgagtc aacgtcctgc ttcccgatga ctaccgcacc   | 600  |
| agcggacgca cctatccgt cctctacctg ttccacggcg gcggcaccga ccaggatttc  | 660  |
| cgcacgttcg actttctggg catccgcgac ctgaccgccg gaaagccgat catcatcgtg | 720  |
| atgcccgcgc gcgggcacgc gggctggtat tccaaccggc tcagctcgtt cgtcggccca | 780  |
| cggaactggg agacattcca catcgcccag ctgctcccct ggatcgaggc gaacttcga  | 840  |
| acctacgccg aatacgacgc ccgcgcggtc gccgggtttt cgatgggtgg cttcggcgcg | 900  |
| ctgaagtacg cagcaaagta ctacggccac ttcgcgtcgg cgagcagcca ctccggaccg | 960  |
| gcaagtctgc gccgcgactt cggcctggta gtgcattggg caaacctgtc ctcggcggtg | 1020 |
| ctggatctag gcggcggcac ggtttacggc gcgcgctct gggaccaagc tagggtcagc  | 1080 |
| gccgacaacc cggtcgagcg tatcgacagc taccgcaaca agcggatctt cctggctgcc | 1140 |
| ggcaccagtc cggacccggc caactggttc gacagcgtga acgagaccca ggtgctagcc | 1200 |

-148-

gggcagaggg agttccgcga acgectcagc aacgcgggca tcccgcacga atcgacagag 1260  
 gtgcctggcg gtcacgtctt ccggcccgac atgttccgtc tcgacctcga cggcatcgtc 1320  
 gcccggctgc gcccgcgag catcggggcg gccgcagaac gcgccgat 1368

&lt;210&gt; 119

&lt;211&gt; 224

&lt;212&gt; PRT

&lt;213&gt; 'Mycobacterium tuberculosis

&lt;400&gt; 119

Met Ser Gly Arg Ser Arg Leu Pro Gly Ser Ser Ser Arg Arg Asp Ala  
 1 5 10 15

Ala Arg Ile Val Ala Glu Arg Val Val Ala Thr Val Ala Gly Val Ala  
 20 25 30

Val Ala Val Asp Glu Val Asp Ala Ala Glu Ala Arg Leu Arg Asp Gly  
 35 40 45

Pro Arg Ala Ala Ala Leu Pro Ala Ser Gly Thr Ser Glu Gly Arg Gln  
 50 55 60

Leu Arg Arg Trp Leu Thr Gln Leu Ile Val Thr Glu Arg Val Val Ala  
 65 70 75 80

Ala Glu Ala Ala Ala Arg Gly Leu Thr Ala Ala Gly Ala Pro Ala Glu  
 85 90 95

Ala Asp Leu Leu Pro Asp Ala Thr Ala Arg Leu Glu Ile Gly Ser Val  
 100 105 110

Ala Ala Ala Val Leu Ala Asp Pro Leu Ala Arg Ala Leu Phe Ala Ala  
 115 120 125

Val Thr Ala Arg Val Ala Val Thr Asp Asp Ala Val Ala Asp Tyr His  
 130 135 140

Ala Arg Asn Pro Leu Arg Phe Ala Ala Pro Cys Pro Gly Gln His Gly  
 145 150 155 160

-149-

Trp Arg Ala Pro Ala Ala Ala Ala Pro Pro Leu Asp Gln Val Arg Arg  
                   165                                  170                                  175

Ala Ile Thr Glu His Leu Leu Gly Ala Ala Arg Arg Arg Ala Phe Arg  
                   180                                  185                                  190

Val Trp Leu Asp Ala Arg Arg Asn Ala Leu Val Val Leu Ala Pro Gly  
                   195                                  200                                  205

Tyr Glu His Pro Gly Asp Pro Arg Gln Pro Asp Asn Thr Arg Arg His  
                   210                                  215                                  220

&lt;210&gt; 120

&lt;211&gt; 672

&lt;212&gt; -DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 120

```

atgagcgggc gaagccgatt gcccggtcc tctcacgcc gcgacgcggc gcgcatcgtc      60
gccgagcggg tggtcgcgac cgtcgccggt gtcgcggtag cggtcgacga ggtcgacgcg      120
gccgaagcgc ggctgcgcga cggaccgcgc gcggccgcgc tgcgggcgag cggcaccagc      180
gagggacgcc aactgcggcg ctggctcacc caactgatcg tgaccgagcg ggtggtagcc      240
gccgaggccg ccgcacgtgg tctgaccgcg gcgggcgccc ccgccgaggc ggacctgctg      300
cccgaacgca cggctcggtt ggagatcggc agcgtcgccg ccgcgggtgt ggcggatcct      360
ttggcgcggg cgttggttcg ccgcgtcacc gcgcgggtcg cggtcaccga cgacgcgctg      420
gccgactacc atgcccgcaa cccgctgcgg ttgcgcgcgc catgtcccgg ccagcacggc      480
tggcgtgccc cggcggcggc cgcgccaccg ctggatcagg tgcgcgcgcg gatcaccgag      540
catctgttgg gggccgcgcg ccgccgcgcc ttccgggtgt ggctggacgc gcgccgaac      600
gccctggtgg tgcctggccc cggctatgag caccgcggcg acccgcgcca acccgacaac      660
accgcgcggc ac                                         672

```

&lt;210&gt; 121

&lt;211&gt; 307

&lt;212&gt; PRT

-150-

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 121

Met Asp Arg Cys Cys Gln Arg Ala Thr Ala Phe Ala Cys Ala Leu Arg  
 1 5 10 15

Pro Thr Lys Leu Ile Asp Tyr Glu Glu Met Phe Arg Gly Ala Met Gln  
 20 25 30

Ala Arg Ala Met Val Ala Asn Pro Asp Gln Trp Ala Asp Ser Asp Arg  
 35 40 45

Asp Gln Val Asn Thr Arg His Tyr Leu Ser Thr Ser Met Arg Val Ala  
 50 55 60

Leu Asp Arg Gly Glu Phe Phe Leu Val Tyr Gln Pro Ile Ile Arg Leu  
 65 70 75 80

Ala Asp Asn Arg Ile Ile Gly Ala Glu Ala Leu Leu Arg Trp Glu His  
 85 90 95

Pro Thr Leu Gly Thr Leu Leu Pro Gly Arg Phe Ile Asp Arg Ala Glu  
 100 105 110

Asn Asn Gly Leu Met Val Pro Leu Thr Ala Phe Val Leu Glu Gln Ala  
 115 120 125

Cys Arg His Val Arg Ser Trp Arg Asp His Ser Thr Asp Pro Gln Pro  
 130 135 140

Phe Val Ser Val Asn Val Ser Ala Ser Thr Ile Cys Asp Pro Gly Phe  
 145 150 155 160

Leu Val Leu Val Glu Gly Val Leu Gly Glu Thr Gly Leu Pro Ala His  
 165 170 175

Ala Leu Gln Leu Glu Leu Ala Glu Asp Ala Arg Leu Ser Arg Asp Glu  
 180 185 190

Lys Ala Val Thr Arg Leu Gln Glu Leu Ser Ala Leu Gly Val Gly Ile  
 195 200 205

-151-

Ala Ile Asp Asp Phe Gly Ile Gly Phe Ser Ser Leu Ala Tyr Leu Pro  
 210 215 220

Arg Leu Pro Val Asp Val Val Lys Leu Gly Gly Lys Phe Ile Glu Cys  
 225 230 235 240

Leu Asp Gly Asp Ile Gln Ala Arg Leu Ala Asn Glu Gln Ile Thr Arg  
 245 250 255

Ala Met Ile Asp Leu Gly Asp Lys Leu Gly Ile Thr Val Thr Ala Lys  
 260 265 270

Leu Val Glu Thr Pro Ser Gln Ala Ala Arg Leu Arg Ala Phe Gly Cys  
 275 280 285

Lys Ala Ala Gln Gly Trp His Phe Ala Lys Ala Leu Pro Val Asp Phe  
 290 295 300

Phe Arg Glu  
 305

<210> 122

<211> 921

<212> DNA

<213> Mycobacterium tuberculosis

<400> 122

|                                                                   |     |
|-------------------------------------------------------------------|-----|
| atggatcgtt gttgtcagcg cgctacagcg ttgcgttgcg cgctcaggcc gaccaagttg | 60  |
| atcgactacg aagagatggt taggggcgcg atgcaagcgc gagcgatggt agccaatcct | 120 |
| gaccaatggg cggactccga ccgcgaccag gtcaacactc gccattatct gtccactteg | 180 |
| atgcgcgtgg cactggatcg cggatgaattc ttctcgtct accagccaat catccggtt  | 240 |
| gccgacaacc gcatcatcgg cgcgaggcc ctgctgcgct gggaacaccc gacgttgggc  | 300 |
| acgctactcc cgggcccgtt catcgaccgt gccgagaaca acggactgat ggtgccgctc | 360 |
| acggccttcg tgcctgagca ggcccgccgc cactccgca gttggcgtga ccacagcacc  | 420 |
| gaccgcgaac cgtttgtcag cgtcaacgtc tccgccagca ccattctgca tcccggcttc | 480 |
| ctggtgctgg tcgaagggtg gctcggcgaa accggcctgc ccgccatgc cctgcagctc  | 540 |
| gaactggccg aggacgcgcg ccttagcaga gacgagaagg cggtgaccag gctacaagaa | 600 |



-152-

```

ttgtccgctc tggcgctcgg catcgccatc gacgacttcg gcattggatt ctccagcctc   660
gcctaccttc cccgcctccc cgtcgacgtg gtcaaactcg ggggaaagtt catcgagtgc   720
ctcgatggcg acattcaagc tgggtggcc aacgaacaga tcacccgggc aatgatogac   780
cttggcgaca agctcggtat caccgtcact gcaaagctag tcgaaacccc cagccaagcc   840
gcccggttgc gcgccttcgg ctgtaaagcc gcacaaggct ggcactttgc caaggcactg   900
ccggtcgact ttttcagaga g                                           921

```

&lt;210&gt; 123

&lt;211&gt; 379

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 123

```

Met Ser Val Arg Leu Ala Asp Val Ile Asp Val Leu Asp Gln Ala Tyr
1           5           10           15

```

```

Pro Pro Arg Leu Ala Gln Ser Trp Asp Ser Val Gly Leu Val Cys Gly
          20           25           30

```

```

Asp Pro Asp Asp Val Val Asp Ser Val Thr Val Ala Val Asp Ala Thr
          35           40           45

```

```

Pro Ala Val Val Asp Gln Val Pro Gln Ala Gly Leu Leu Leu Val His
          50           55           60

```

```

His Pro Leu Leu Leu Arg Gly Val Asp Thr Val Ala Ala Asn Thr Pro
65           70           75           80

```

```

Lys Gly Val Leu Val His Arg Leu Ile Arg Thr Gly Arg Ser Leu Phe
          85           90           95

```

```

Thr Ala His Thr Asn Ala Asp Ser Ala Ser Pro Gly Val Ser Asp Ala
          100          105          110

```

```

Leu Ala His Ala Val Gly Leu Thr Val Asp Ala Val Leu Asp Pro Val
          115          120          125

```

```

Pro Gly Ala Ala Asp Leu Asp Lys Trp Val Ile Tyr Val Pro Arg Glu

```

-153-

|                     |                 |                             |
|---------------------|-----------------|-----------------------------|
| 130                 | 135             | 140                         |
| Asn Ser Glu Ala Val | Arg Ala Ala Val | Phe Glu Ala Gly Ala Gly His |
| 145                 | 150             | 155 160                     |
| Ile Gly Asp Tyr Ser | His Cys Ser Trp | Ser Val Ala Gly Thr Gly Gln |
| 165                 | 170             | 175                         |
| Phe Leu Ala His Asp | Gly Ala Ser Pro | Ala Ile Gly Ser Val Gly Thr |
| 180                 | 185             | 190                         |
| Val Glu Arg Val Ala | Glu Asp Arg Val | Glu Val Val Ala Pro Ala Arg |
| 195                 | 200             | 205                         |
| Ala Arg Ala Glu Val | Leu Ala Ala Met | Arg Ala Ala His Pro Tyr Glu |
| 210                 | 215             | 220                         |
| Glu Pro Ala Phe Asp | Ile Phe Ala Leu | Val Pro Pro Pro Val Gly Ser |
| 225                 | 230             | 235 240                     |
| Gly Leu Gly Arg Ile | Gly Arg Leu Pro | Lys Pro Glu Pro Leu Arg Thr |
| 245                 | 250             | 255                         |
| Phe Val Ala Arg Leu | Glu Ala Ala Leu | Pro Pro Thr Ala Thr Gly Val |
| 260                 | 265             | 270                         |
| Arg Ala Ala Gly Asp | Pro Asp Leu Leu | Val Ser Arg Val Ala Val Cys |
| 275                 | 280             | 285                         |
| Gly Gly Ala Gly Asp | Ser Leu Leu Ala | Thr Val Ala Ala Ala Asp Val |
| 290                 | 295             | 300                         |
| Gln Ala Tyr Val Thr | Ala Asp Leu Arg | His His Pro Ala Asp Glu His |
| 305                 | 310             | 315 320                     |
| Cys Arg Ala Ser Gln | Val Ala Leu Ile | Asp Val Ala His Trp Ala Ser |
| 325                 | 330             | 335                         |
| Glu Phe Pro Trp Cys | Gly Gln Ala Ala | Glu Val Leu Arg Ser His Phe |
| 340                 | 345             | 350                         |
| Gly Ala Ser Leu Pro | Val Arg Val Cys | Thr Ile Cys Thr Asp Pro Trp |
| 355                 | 360             | 365                         |

-154-

Asn Leu Asp His Glu Thr Gly Arg Asp Gln Ala  
 370 375

&lt;210&gt; 124

&lt;211&gt; 1137

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 124

```

atgagtgtgc ggctggccga tgtcatcgac gtgctggacc aggcctaccc gccgcggctt      60
gccagtcgt gggattcggg ggggtctggg tgccggcgacc ccgacgacgt ggtggattcg      120
gtgaccgctt cggtggacgc gacgccggcg gtggtggacc aggttcccca ggccggactg      180
ctattggtgc accaccggtt gttactgctg ggggtcgata cggtcgcggc caacacgcca      240
aagggtgtgc tgggtgcaccg cctgatccgg accggtcgct cgttgtttac cgcgcacacc      300
aacgccgact cggcgctgcc ggggtgtgtcc gacgcgctgg cacacgctgt tggctctgacc      360
gtcgacgcgc ttctcgaccc ggtgcccggg gcggcgcatc tcgacaagtg ggtcatctat      420
gtgccgcgcg agaactcaga ggcgggtgcgg gcagcggctc ttgaggccgg tgccggccat      480
atcggcgact actcgactg cagctggagt gtcgcgggta ccgggcagtt cctggcgcac      540
gacggggcgt cggccgcatc aggcagcgtc ggtaccgtcg aacgggtggc cgaggaccgg      600
gtcgaggtcg tcgcaccgcg acgagcgcgc gccgaggtgt tggcggcgat gcgcgccgcg      660
cacccttacg agggagccggc attcgacatc ttgcgcgtgg taccaccgcc ggtcggcagc      720
gggttaggcc ggattggcag actgccaaaa ccgaaccgc tcgcacactt tgttgcccgt      780
ctggaggccg cgttgccgcc gactgcgacc ggtgtgcgcg ccgccgggga tcccgacctg      840
ctggtgtcgc gggtcgcggg ctgcggcggc gccggggact cgttgcttgc caccgtggcc      900
gccgcggacg tgcaagcgta cgttacggcc gatctgcgac atcatccagc cgacgagcat      960
tgccgagctt cgcaagtggc cctgatcgac gtcgcgcatt gggcaagcga attcccgtgg     1020
tgccggccagg ccgccgaagt gttgcggctc catttcggcg cgtcgctgcc ggtgcgtgtg     1080
tgcaccatct gcaccgaccc gtggaacctc gatcacgaaa ctgggagaga tcaggca      1137

```

&lt;210&gt; 125

&lt;211&gt; 167

-155-

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 125

Met Thr His Arg Ser Ser Arg Leu Glu Val Gly Pro Val Ala Arg Gly  
1 5 10 15

Asp Val Ala Thr Ile Glu His Ala Glu Leu Pro Pro Gly Trp Val Leu  
20 25 30

Thr Thr Ser Gly Arg Ile Ser Gly Val Thr Glu Pro Gly Glu Leu Ser  
35 40 45

Val His Tyr Pro Phe Pro Ile Ala Asp Leu Val Ala Leu Asp Asp Ala  
50 55 60

Leu Thr Tyr Ser Ser Arg Ala Cys Gln Val Arg Phe Ala Ile Tyr Leu  
65 70 75 80

Gly Asp Leu Gly Arg Asp Thr Ala Ala Arg Ala Arg Glu Ile Leu Gly  
85 90 95

Lys Val Pro Thr Pro Asp Asn Ala Val Leu Leu Ala Val Ser Pro Asn  
100 105 110

Gln Cys Ala Ile Glu Val Val Tyr Gly Ser Gln Val Arg Gly Arg Gly  
115 120 125

Ala Glu Ser Ala Ala Pro Leu Gly Val Ala Ala Ala Ser Ser Ala Phe  
130 135 140

Glu Gln Gly Glu Leu Val Asp Gly Leu Ile Ser Ala Ile Arg Val Leu  
145 150 155 160

Ser Ala Gly Ile Ala Pro Gly  
165

&lt;210&gt; 126

&lt;211&gt; 501

&lt;212&gt; DNA

-156-

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 126

```

atgacgcacg ggagttcacg gttggaggtg gggccagtgg cacgtggtga cgttgcgacg      60
attgagcacg ccgagctgcc gccgggttgg gtgctgacca ccagcggacg gatctcgggg      120
gtcaccgagc cccgggaact gtccgtgcac taccgttcc ccatcgaga tctcgtcgcc      180
ctggacgacg cgctgacctc cagctcgagg gcgtgtcagg tgaggttcgc catctacctc      240
ggcgacttgg gtcgtgacac cgccgcgcgg gcccgcgaga tcttgggcaa ggtgcccacg      300
ccggacaatg ctgtgctgct cgcggtctcg cccaaccagt gcgccatcga agtgggtctac      360
ggctcgcaag tccgcggccg cgggtccgag tcggcggtc cgctcggggg tgccgcgcgt      420
tcctcagcgt tcgagcaggg tgagctggta gatgggtga tcagcgcgat ccgcgtgctc      480
agcgcgggga tcgcgccggg c                                          501

```

&lt;210&gt; 127

&lt;211&gt; 494

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 127

```

Met Thr Asp Ile Ile Arg Ser Asp Ala Ala Thr Leu Ala Ala Lys Ile
1-----5-----10-----15
Ala Ile Lys Glu Val Ser Ser Ala Glu Ile Thr Arg Ala Cys Leu Asp
20-----25-----30
Gln Ile Glu Ala Thr Asp Glu Thr Tyr His Ala Phe Leu His Val Ala
35-----40-----45
Ala Asp Glu Ala Leu Ala Ala Ala Ala Ala Ile Asp Lys Gln Val Ala
50-----55-----60
Ala Gly Glu Pro Leu Pro Ser Ala Leu Ala Gly Val Pro Leu Ala Leu
65-----70-----75-----80
Lys Asp Val Phe Thr Thr Ser Asp Met Pro Thr Thr Cys Gly Ser Lys
85-----90-----95

```

-157-

Ile Leu Glu Gly Trp Arg Ser Pro Tyr Asp Ala Thr Leu Thr Ala Arg  
 100 105 110

Leu Arg Ala Ala Gly Ile Pro Ile Leu Gly Lys Thr Asn Met Asp Glu  
 115 120 125

Phe Ala Met Gly Ser Ser Thr Glu Asn Ser Ala Tyr Gly Pro Thr Arg  
 130 135 140

Asn Pro Trp Asn Leu Asp Arg Val Pro Gly Gly Ser Gly Gly Gly Ser  
 145 150 155 160

Ala Ala Ala Leu Ala Ala Phe Gln Ala Pro Leu Ala Ile Gly Ser Asp  
 165 170 175

Thr Gly Gly Ser Ile Arg Gln Pro Ala Ala Leu Thr Ala Thr Val Gly  
 180 185 190

Val Lys Pro Thr Tyr Gly Thr Val Ser Arg Tyr Gly Leu Val Ala Cys  
 195 200 205

Ala Ser Ser Leu Asp Gln Gly Gly Pro Cys Ala Arg Thr Val Leu Asp  
 210 215 220

Thr Ala Leu Leu His Gln Val Ile Ala Gly His Asp Pro Arg Asp Ser  
 225 230 235 240

Thr Ser Val Asp Ala Glu Val Pro Asp Val Val Gly Ala Ala Arg Ala  
 245 250 255

Gly Ala Val Gly Asp Leu Arg Gly Val Arg Val Gly Val Val Arg Gln  
 260 265 270

Leu His Gly Gly Glu Gly Tyr Gln Pro Gly Val Leu Ala Ser Phe Glu  
 275 280 285

Ala Ala Val Glu Gln Leu Thr Ala Leu Gly Ala Glu Val Ser Glu Val  
 290 295 300

Asp Cys Pro His Phe Asp His Ala Leu Ala Ala Tyr Tyr Leu Ile Leu  
 305 310 315 320

Pro Ser Glu Val Ser Ser Asn Leu Ala Arg Phe Asp Ala Met Arg Tyr

325

330

335

Ala Met Thr Arg Ala Ala Gly Phe Gly Pro Glu Val Lys Arg Arg Ile  
355 360 365

Met Ile Gly Thr Tyr Ala Leu Ser Ala Gly Tyr Tyr Asp Ala Tyr Tyr  
370 375 380

Asn Gln Ala Gln Lys Val Arg Thr Leu Ile Ala Arg Asp Leu Asp Ala  
385 390 395 400

Ala Tyr Arg Ser Val Asp Val Leu Val Ser Pro Thr Thr Pro Thr Thr  
405 410 415

Ala Phe Arg Met Gly Glu Lys Val Asp Asp Pro Leu Ala Met Tyr Leu  
420 425 430

Phe Asp Leu Cys Thr Leu Pro Leu Asn Leu Ala Gly His Cys Gly Met  
435 440 445

Ser Val Pro Ser Gly Leu Ser Pro Asp Asp Gly Leu Pro Val Gly Leu  
450 455 460

Gln Ile Met Ala Pro Ala Leu Ala Asp Asp Arg Leu Tyr Arg Val Gly  
465 470 475 480

Ala Ala Tyr Glu Ala Ala Arg Gly Pro Leu Leu Ser Ala Ile  
485 490

<210> 128

<211> 1482

<212> DNA

<213> Mycobacterium tuberculosis

<400> 128

gtgacggaca tcattccgatt cgacgccgcg acgctggccg ccaagatcgc catcaaggag 60

gtgtcgtcgg ccgagatcac ccgggcctgc ctggatcaga tcgaggcgac cgacgagacg 120

-159-

taccaacgcct tcctgcatgt ggcgccgat gaggcgctgg cggcggcggc cgccatcgac 180  
aagcaggtgg ccgctggaga acccttgccg tcggcgctgg ccggggtgcc gctggcgctc 240  
aaggacgtct tcaccaccag cgacatgccc accacctgcg ggtcaaaaat cctggaggga 300  
tggcgatctc cctacgacgc cacgctgacc gcgcggttgc gcgcgcggg gatcccgatc 360  
ctgggcaaga ccaacatgga cgagttcgcg atgggctcgt cgacggagaa ctccgcttac 420  
gggtcccaccc gcaacccgtg gaatctcgac cgggtacccg gcggttcggg tggcggcagc 480  
gcggcggcgc tggcgcggtt ccaggcgccg ctggccatcg gatccgacac cggggggctg 540  
atccgccagc cggcgcgct gaccgcgacc gtccggctca aaccaccta cggcacggtg 600  
tcgcgctatg ggctggtggc ctgcgcgtcc tcgctggatc agggcggccc gtgtgcgcgc 660  
accgtcttgg acaccgcgct gttgcatcag gtgatcgccg gccacgaccc gcgcgactcc 720  
acgtcggctg acgccgaggt gcccgacgtg gtgggcgcgc ctagggccgg cgcggtcggg 780  
gatctgcgtg gcgtgcgggt cggcgtggtt cgacagctgc acggcggcga gggctaccag 840  
ccgggcgtgc tggcctcctt cgaggctgcc gtggagcagc taaccgcgct gggcgctgag 900  
gtcagcgagg tcgactgccc gcaactcgac catgccctgg ccgcctatta cctgattctg 960  
ccctcggagg tgtcgagcaa tctggcgcgc ttcgacgcga tgcgctacgg gctgcgggtc 1020  
ggcgacgacg gcacccgcag cgcgaggag gtgatggcga tgaccgggc cgccggtttc 1080  
gggcccgagg tcaagcggcg catcatgatc ggcacctacg cgttgctggc cggctactac 1140  
gacgcctatt acaaccaggc gcagaagggt gcgacgctga tcgccgcga cctcgacgcg 1200  
gcgtatcggc cgtcgacgt gctggtgtcg ccacgaccc cgaccaccgc gttccggatg 1260  
ggtgagaagg tggacgatcc gctggcgatg tacttggtcg acctgtgcac gctgccgctg 1320  
aacttggccg gccactgcgg catgtctgtg ccgtcggggc tctccccgga cgacgggttg 1380  
ccggttgccc tacagatcat ggcccgccga ttggccgacg accggctcta ccgggtgggg 1440  
gcggcttatg aggcgcgccg cggcccgcta ctgagcgcca tt 1482

&lt;210&gt; 129

&lt;211&gt; 387

&lt;212&gt; PRT

<213> *Mycobacterium tuberculosis*

&lt;400&gt; 129



-160-

Met Thr Val Gly Leu Gly Met Pro Gln Pro Pro Ala Pro Thr Leu Ala  
1 5 10 15

Pro Arg Arg Ala Thr Arg Gln Leu Met Val Gly Asn Val Gly Val Gly  
20 25 30

Ser Asp His Pro Val Ser Val Gln Ser Met Cys Thr Thr Lys Thr His  
35 40 45

Asp Val Asn Ser Thr Leu Gln Gln Ile Ala Glu Leu Thr Ala Ala Gly  
50 55 60

Cys Asp Ile Val Arg Val Ala Cys Pro Arg Gln Glu Asp Ala Asp Ala  
65 70 75 80

Leu Ala Glu Ile Ala Arg His Ser Gln Ile Pro Val Val Ala Asp Ile  
85 90 95

His Phe Gln Pro Arg Tyr Ile Phe Ala Ala Ile Asp Ala Gly Cys Ala  
100 105 110

Ala Val Arg Val Asn Pro Gly Asn Ile Lys Glu Phe Asp Gly Arg Val  
115 120 125

Gly Glu Val Ala Lys Ala Ala Gly Ala Ala Gly Ile Pro Ile Arg Ile  
130 135 140

Gly Val Asn Ala Gly Ser Leu Asp Lys Arg Phe Met Glu Lys Tyr Gly  
145 150 155 160

Lys Ala Thr Pro Glu Ala Leu Val Glu Ser Ala Leu Trp Glu Ala Ser  
165 170 175

Leu Phe Glu Glu His Gly Phe Gly Asp Ile Lys Ile Ser Val Lys His  
180 185 190

Asn Asp Pro Val Val Met Val Ala Ala Tyr Glu Leu Leu Ala Ala Arg  
195 200 205

Cys Asp Tyr Pro Leu His Leu Gly Val Thr Glu Ala Gly Pro Ala Phe  
210 215 220

Gln Gly Thr Ile Lys Ser Ala Val Ala Phe Gly Ala Leu Leu Ser Arg  
225 230 235 240

-161-

Gly Ile Gly Asp Thr Ile Arg Val Ser Leu Ser Ala Pro Pro Val Glu  
 245 250 255

Glu Val Lys Val Gly Asn Gln Val Leu Glu Ser Leu Asn Leu Arg Pro  
 260 265 270

Arg Ser Leu Glu Ile Val Ser Cys Pro Ser Cys Gly Arg Ala Gln Val  
 275 280 285

Asp Val Tyr Thr Leu Ala Asn Glu Val Thr Ala Gly Leu Asp Gly Leu  
 290 295 300

Asp Val Pro Leu Arg Val Ala Val Met Gly Cys Val Val Asn Gly Pro  
 305 310 315 320

Gly Glu Ala Arg Glu Ala Asp Leu Gly Val Ala Ser Gly Asn Gly Lys  
 325 330 335

Gly Gln Ile Phe Val Arg Gly Glu Val Ile Lys Thr Val Pro Glu Ala  
 340 345 350

Gln Ile Val Glu Thr Leu Ile Glu Glu Ala Met Arg Leu Ala Ala Glu  
 355 360 365

Met Gly Glu Gln Asp Pro Gly Ala Thr Pro Ser Gly Ser Pro Ile Val  
 370 375 380

Thr Val Ser  
 385

<210> 130

<211> 1161

<212> DNA

<213> Mycobacterium tuberculosis

<400> 130

gtgactgtag gcttgggcat gccgcagccc ccggcaccca cgctcgctcc ccggcgcgcc 60

accgctcagc tgatggtcgg caacgtcggc gtgggcagtg accatccggt ctcggtgcaa 120

togatgtgca ccacaaaaac ccacgacgtc aactcgacat tgcaacaaat cgccgagctg 180

-162-

```

accgcggccg gatgcgacat cgtgcgggtg gcctgccgc gccaggagga cgccgacgcg      240
ctggccgaga tcgccggca cagccagatc ccggtagtcg cggacatata ttccagccg      300
cgctacatat tcgccccat cgacgctgga tgtgccgcgg tcggggtcaa cccgggcaac      360
atcaaggagt ttgacggccg ggtgggtgag gtgccaaagg cggcgggtgc ggccgggatc      420
ccgatccgaa tcggtgtcaa cggcggttcg ctggacaaac gggtcatgga gaagtatggc      480
aaagccacgc ccgaggcgct ggttgagtcg gcgctgtggg aggcttcgct ttccgaggag      540
catggcttcg gtgacatcaa gatcagcgtc aagcacaacg acccggtggt gatggtcgcc      600
gcctacgagc tgcttgctgc acggtgcgac taccactgc acctcggtgt caccgaggcc      660
ggccctgctt tccagggcac catcaagtcc gcggttgctt tcggcgcggt gctgtcgcgg      720
ggcataggcg acaccatccg ggtgtcgttg tcggccccgc cggtcgagga agtcaagggtg      780
ggcaatcagg ttctcgagtc gttgaacctg cggccgcggt cgctcgagat cgtgtcttgc      840
ccgtcgtgcg gtgcgcgcga agtcgacgtc tacacctgg ccaacgaggt aaccgccggc      900
ctggatggtc tcgatgtgcc gttgcgggtg gccgtgatgg ggtgtgtcgt caatggtcg      960
ggtgaagcac gtgaggccga cctgggcgtg gcgtccggca acggcaaagg tcagatcttt    1020
gtacggggcg aagtgatcaa gaccgtgccc gaagcacaga tcgtcgagac gctgatcgag    1080
gaggcgatgc ggctggccgc cgaaatgggc gagcaagatc cgggcgcgac accgagcgg      1140
tcgcctattg tgaccgtaag c                                          1161

```

&lt;210&gt; 131

&lt;211&gt; 132

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 131

```

Met Thr Met Thr Asp Pro Ile Ala Asp Phe Leu Thr Arg Leu Arg Asn
1           5           10           15

```

```

Ala Asn Ser Ala Tyr His Asp Glu Val Ser Leu Pro His Ser Lys Leu
20           25           30

```

```

Lys Ala Asn Ile Ala Gln Ile Leu Lys Asn Glu Gly Tyr Ile Ser Asp
35           40           45

```

-163-

Phe Arg Thr Glu Asp Ala Arg Val Gly Lys Ser Leu Val Ile Gln Leu  
 50 55 60

Lys Tyr Gly Pro Ser Arg Glu Arg Ser Ile Ala Gly Leu Arg Arg Val  
 65 70 75 80

Ser Lys Pro Gly Leu Arg Val Tyr Ala Lys Ser Thr Asn Leu Pro Arg  
 85 90 95

Val Leu Gly Gly Leu Gly Val Ala Ile Ile Ser Thr Ser Ser Gly Leu  
 100 105 110

Leu Thr Asp Arg Gln Ala Ala Arg Gln Gly Val Gly Gly Glu Val Leu  
 115 120 125

Ala Tyr Val Trp  
 130

&lt;210&gt; 132

&lt;211&gt; 396

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 132

atgacgatga cggaccgat cgcagacttt ttgaccgctc tgcgtaacgc caactcggcg 60  
 .tatcacgacg aggtcagctt gccgcactcc aagctcaagg ccaacatcgc gcagattctc 120  
 aagaacgagg ggtacatcag cgacttccga accgaggacg ctcggggtcgg taaatcgctg 180  
 gttatccagc tcaagtacgg ccctagccgg gagcgcagca tcgccggggt gcggcgggtg 240  
 tccaagcccg gcctgcgggt gtacgcgaaa tccaccaatc tgccgcgggt gctcggcggc 300  
 ctgggcgtgg cgatcatctc gacctcctcg gccctgctga ctgaccggca ggcagctaga 360  
 cagggcgtgg gcggcgaagt cctcgcatat gtctgg 396

&lt;210&gt; 133

&lt;211&gt; 388

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

-164-

&lt;400&gt; 133

Met Ala Gly Ser Ala Thr Val Glu Lys Arg Leu Asp Phe Gly Leu Leu  
 1 5 10 15

Gly Pro Leu Gln Met Thr Ile Asp Gly Thr Pro Val Pro Ser Gly Thr  
 20 25 30

Pro Lys Gln Arg Ala Val Leu Ala Met Leu Val Ile Asn Arg Asn Arg  
 35 40 45

Pro Val Gly Val Asp Ala Leu Ile Thr Ala Leu Trp Glu Glu Trp Pro  
 50 55 60

Pro Ser Gly Ala Arg Ala Ser Ile His Ser Tyr Val Ser Asn Leu Arg  
 65 70 75 80

Lys Leu Leu Gly Gly Ala Gly Ile Asp Pro Arg Val Val Leu Ala Ala  
 85 90 95

Ala Pro Pro Gly Tyr Arg Leu Ser Ile Pro Asp Asn Thr Cys Asp Leu  
 100 105 110

Gly Arg Phe Val Ala Glu Lys Thr Ala Gly Val His Ala Ala Ala Ala  
 115 120 125

Gly Arg Phe Glu Gln Ala Ser Arg His Leu Ser Ala Ala Leu Arg Glu  
 130 135 140

Trp Arg Gly Pro Val Leu Asp Asp Leu Arg Asp Phe Gln Phe Val Glu  
 145 150 155 160

Pro Phe Ala Thr Ala Leu Val Glu Asp Lys Val Leu Ala His Thr Ala  
 165 170 175

Lys Ala Glu Ala Glu Ile Ala Cys Gly Arg Ala Ser Ala Val Ile Ala  
 180 185 190

Glu Leu Glu Ala Leu Thr Phe Glu His Pro Tyr Arg Glu Pro Leu Trp  
 195 200 205

Thr Gln Leu Ile Thr Ala Tyr Tyr Leu Ser Asp Arg Gln Ser Asp Ala  
 210 215 220

-165-

Leu Gly Ala Tyr Arg Arg Val Lys Thr Thr Leu Ala Asp Asp Leu Gly  
 225 230 235 240

Ile Asp Pro Gly Pro Thr Leu Arg Ala Leu Asn Glu Arg Ile Leu Arg  
 245 250 255

Gln Gln Pro Leu Asp Ala Lys Lys Ser Ala Lys Thr Thr Ala Ala Gly  
 260 265 270

Thr Val Thr Val Leu Asp Gln Arg Thr Met Ala Ser Gly Gln Gln Ala  
 275 280 285

Val Ala Tyr Leu His Asp Ile Ala Ser Gly Arg Gly Tyr Pro Leu Gln  
 290 295 300

Ala Ala Ala Thr Arg Ile Gly Arg Leu His Asp Asn Asp Ile Val Leu  
 305 310 315 320

Asp Ser Ala Asn Val Ser Arg His His Ala Val Ile Val Asp Thr Gly  
 325 330 335

Thr Asn Tyr Val Ile Asn Asp Leu Arg Ser Ser Asn Gly Val His Val  
 340 345 350

Gln His Glu Arg Ile Arg Ser Ala Val Thr Leu Asn Asp Gly Asp His  
 355 360 365

Ile Arg Ile Cys Asp His Glu Phe Thr Phe Gln Ile Ser Ala Gly Thr  
 370 375 380

His Gly Gly Thr  
 385

<210> 134

<211> 1164

<212> DNA

<213> Mycobacterium tuberculosis

<400> 134

atggctggta ggcgcacagt ggagaagcgg ctcgacttcg gcctgcttgg accattgcag 60

atgactatcg acggcaccoc ggtgccatcg ggcaccccca agcaacgggc tgtgctagcc 120

-166-

```

atgttgggtca tcaaccgcaa caggcccgta ggagtcgacg ccctaatac cgcctctctgg 180
gaggagtggc caccctcggg cgcacgcgcg agtatccact cctacgtgtc taatctgcgt 240
aagctcctcg gtggcgccgg gatcgacca cgggtggtgt tggccgcagc gccgccgggt 300
tatcggtca gcatccccga caacacttgc gatctggggc ggtttgttgc cgaaaaaacc 360
gccccggtgc acgccccgc cgcggccgg ttcgaacaag ccagccgcca cctgtcggcc 420
gcattgagag aatggcggtg gcgggtgctc gatgacctgc gcgacttcca gttcgtcgaa 480
ccctttgcca cggcgctggt agaagacaag gttcttgccc ataccgcaa ggcgaggcc 540
gaaatcgct gtgggcgggc cagcgcagt atcgccgagc tcgaggctct gacattcgaa 600
caccctacc gggagccgct gtggacacag ctgatcacg cctactacct ctccgaccgg 660
caatccgatg cgtgggcgc ctatcgccgg gtgaagacaa cactggccga cgacctggc 720
atcgaccccg gtccgacgtt gcgcgtctc aacgagcgga ttctgcgtca gcaaccgctg 780
gatgccaa ga agtccgcaa aaccaccgct gccggcaccg tcacgggtgct cgatcagcgc 840
accatggcgt cgggcccagca ggcggtggc tacctgcag acatgcctc gggtcgcggc 900
taccactgc aagccgcggc gaccgggatc gggcgctctg atgacaacga catcgtccta 960
gacagcgcca acgtcagccg ccaccacgcc gtcacgtcg acacgggcac caactacgtc 1020
atcaacgacc tccgatcgtc caacggcgtg catgtgcagc acgagcgaat ccgctccgcg 1080
gtcacgtga acgacggcga ccacattcgc atctgtgacc atgaattcac gttccagatc 1140
agcgcgggga cgcattggcg cacg 1164

```

&lt;210&gt; 135

&lt;211&gt; 441

&lt;212&gt; PRT

<213> *Mycobacterium tuberculosis*

&lt;400&gt; 135

```

Met Pro Gly Asp Glu Lys Pro Val Gly Val Ala Val Leu Gly Leu Gly
1           5           10          15

```

```

Asn Val Gly Ser Glu Val Val Arg Ile Ile Glu Asn Ser Ala Glu Asp
          20          25          30

```

```

Leu Ala Ala Arg Val Gly Ala Pro Leu Val Leu Arg Gly Ile Gly Val

```

-167-

|                                                                 |  |     |  |     |
|-----------------------------------------------------------------|--|-----|--|-----|
| 35                                                              |  | 40  |  | 45  |
| Arg Arg Val Thr Thr Asp Arg Gly Val Pro Ile Glu Leu Leu Thr Asp |  |     |  |     |
| 50                                                              |  | 55  |  | 60  |
| Asp Ile Glu Glu Leu Val Ala Arg Glu Asp Val Asp Ile Val Val Glu |  |     |  |     |
| 65                                                              |  | 70  |  | 75  |
|                                                                 |  |     |  | 80  |
| Val Met Gly Pro Val Glu Pro Ser Arg Lys Ala Ile Leu Gly Ala Leu |  |     |  |     |
|                                                                 |  | 85  |  | 90  |
|                                                                 |  |     |  | 95  |
| Glu Arg Gly Lys Ser Val Val Thr Ala Asn Lys Ala Leu Leu Ala Thr |  |     |  |     |
|                                                                 |  | 100 |  | 105 |
|                                                                 |  |     |  | 110 |
| Ser Thr Gly Glu Leu Ala Gln Ala Ala Glu Ser Ala His Val Asp Leu |  |     |  |     |
|                                                                 |  | 115 |  | 120 |
|                                                                 |  |     |  | 125 |
| Tyr Phe Glu Ala Ala Val Ala Gly Ala Ile Pro Val Ile Arg Pro Leu |  |     |  |     |
|                                                                 |  | 130 |  | 135 |
|                                                                 |  |     |  | 140 |
| Thr Gln Ser Leu Ala Gly Asp Thr Val Leu Arg Val Ala Gly Ile Val |  |     |  |     |
| 145                                                             |  | 150 |  | 155 |
|                                                                 |  |     |  | 160 |
| Asn Gly Thr Thr Asn Tyr Ile Leu Ser Ala Met Asp Ser Thr Gly Ala |  |     |  |     |
|                                                                 |  | 165 |  | 170 |
|                                                                 |  |     |  | 175 |
| Asp Tyr Ala Ser Ala Leu Ala Asp Ala Ser Ala Leu Gly Tyr Ala Glu |  |     |  |     |
|                                                                 |  | 180 |  | 185 |
|                                                                 |  |     |  | 190 |
| Ala Asp Pro Thr Ala Asp Val Glu Gly Tyr Asp Ala Ala Ala Lys Ala |  |     |  |     |
|                                                                 |  | 195 |  | 200 |
|                                                                 |  |     |  | 205 |
| Ala Ile Leu Ala Ser Ile Ala Phe His Thr Arg Val Thr Ala Asp Asp |  |     |  |     |
|                                                                 |  | 210 |  | 215 |
|                                                                 |  |     |  | 220 |
| Val Tyr Arg Glu Gly Ile Thr Lys Val Thr Pro Ala Asp Phe Gly Ser |  |     |  |     |
| 225                                                             |  | 230 |  | 235 |
|                                                                 |  |     |  | 240 |
| Ala His Ala Leu Gly Cys Thr Ile Lys Leu Leu Ser Ile Cys Glu Arg |  |     |  |     |
|                                                                 |  | 245 |  | 250 |
|                                                                 |  |     |  | 255 |
| Ile Thr Thr Asp Glu Gly Ser Gln Arg Val Ser Ala Arg Val Tyr Pro |  |     |  |     |
|                                                                 |  | 260 |  | 265 |
|                                                                 |  |     |  | 270 |



-168-

Ala Leu Val Pro Leu Ser His Pro Leu Ala Ala Val Asn Gly Ala Phe  
 275 280 285

Asn Ala Val Val Val Glu Ala Glu Ala Ala Gly Arg Leu Met Phe Tyr  
 290 295 300

Gly Gln Gly Ala Gly Gly Ala Pro Thr Ala Ser Ala Val Thr Gly Asp  
 305 310 315 320

Leu Val Met Ala Ala Arg Asn Arg Val Leu Gly Ser Arg Gly Pro Arg  
 325 330 335

Glu Ser Lys Tyr Ala Gln Leu Pro Val Ala Pro Met Gly Phe Ile Glu  
 340 345 350

Thr Arg Tyr Tyr Val Ser Met Asn Val Ala Asp Lys Pro Gly Val Leu  
 355 360 365

Ser Ala Val Ala Ala Glu Phe Ala Lys Arg Glu Val Ser Ile Ala Glu  
 370 375 380

Val Arg Gln Glu Gly Val Val Asp Glu Gly Gly Arg Arg Val Gly Ala  
 385 390 395 400

Arg Ile Val Val Val Thr His Leu Ala Thr Asp Ala Ala Leu Ser Glu  
 405 410 415

Thr Val Asp Ala Leu Asp Asp Leu Asp Val Val Gln Gly Val Ser Ser  
 420 425 430

Val Ile Arg Leu Glu Gly Thr Gly Leu  
 435 440

&lt;210&gt; 136

&lt;211&gt; 1323

&lt;212&gt; DNA

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 136

gtgcccggtg acgaaaagcc ggtcggcgta gcggtactcg gtttgggcaa cgtcggcagc 60

gaggttgtcc gcatcatcga gaacagcgcc gaggatctcg cggtcgtgt cgggtcccca 120

-169-

```

ttggtcctgc ggggcatcgg cgtgcgccgc gtgacgaccg atcgcggcgt gccgatcgaa 180
ttgttgaccg acgacattga agagctcgtg gcccgcgagg atgtcgatat cgtggtggaa 240
gtgatggggc cgggtggaacc gtcgcgcaag gcgatcctgg gcgcccttga gcgcggcaag 300
tccgtcgtaa cggcgaacaa ggctttactc gccacctcca ccggcgaatt ggcacaggcc 360
gccgaaagcg cccatgttga tctgtatttc gaggcggccg tggcggggcg cattccggtc 420
atccgtccgc tcacccagtc gctggccggc gacacgggtg tgcgagtggc cgggatcgtc 480
aacggcacca ccaactacat cctctcggcg atggacagca ccggcgctga ctatgccagc 540
gccctggccg acgcaagtgc gctgggctat gcggaggctg atcccaccgc agacgtcgaa 600
ggctacgacg ccgcggccaa ggcagcgatc ctggcatcca ttgccttcca caccgggtg 660
accgcagacg acgtgtatcg cgaaggcatc accaaggcca ctccggccga cttcggatcc 720
gcgcacgcgc tgggttgacac catcaaactg ctgtcgatct gtgagcgcat aaccaccgac 780
gaaggttcgc agcgggtatc ggcccgcgtc tatccggccc tggtaacctc gtcgcatccg 840
cttgccgcgg tcaacggcgc gttcaatgcc gtggtggtcg aggcgaggc cgcgggcccg 900
ctgatgttct acggccaggg ccggggcggc gcgcgcaccg cctctgcggg gaccggtgac 960
ctagtgatgg ccgccgcaa ccgggtactc ggcagccgcg gccccctga gtctaaatac 1020
gctcaacttc cgggtggcacc aatgggtttc attgaaacgc gctattacgt cagcatgaac 1080
gtcgcgcaca agcggggcgt cttgtccgcg gtggcggcgg aattcgccaa acgcgaggtg 1140
agcatcgccg aggtgcgcca ggagggcggt gtggacgaag gtggtcgacg ggtgggagcc 1200
cgaatcgtag tggtcacgca cctcgccaat gacgcgcgac tctcgaaaac cgttgatgca 1260
ctggacgact tggatgtcgt gcagggtgtg tccagcgtga tacgactgga aggaaccggc 1320
tta 1323

```

&lt;210&gt; 137

&lt;211&gt; 216

&lt;212&gt; PRT

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 137

```

Met Ser Asn Pro Gln Pro Glu Lys Val Arg Val Val Val Gly Asp Asp
1           5           10           15

```

-170-

His Pro Leu Phe Arg Glu Gly Val Val Arg Ala Leu Ser Leu Ser Gly  
 20 25 30

Ser Val Asn Val Val Gly Glu Ala Asp Asp Gly Ala Ala Ala Leu Glu  
 35 40 45

Leu Ile Lys Ala His Leu Pro Asp Val Ala Leu Leu Asp Tyr Arg Met  
 50 55 60

Pro Gly Met Asp Gly Ala Gln Val Ala Ala Ala Val Arg Ser Tyr Glu  
 65 70 75 80

Leu Pro Thr Arg Val Leu Leu Ile Ser Ala His Asp Glu Pro Ala Ile  
 85 90 95

Val Tyr Gln Ala-Leu-Gln Gln Gly Ala-Ala Gly Phe Leu Leu Lys Asp  
 100 105 110

Ser Thr Arg Thr Glu Ile Val Lys Ala Val Leu Asp Cys Ala Lys Gly  
 115 120 125

Arg Asp Val Val Ala Pro Ser Leu Val Gly Gly Leu Ala Gly Glu Ile  
 130 135 140

Arg Gln Arg Ala Ala Pro Val Ala Pro Val Leu Ser Ala Arg Glu Arg  
 145 150 155 160

Glu Val Leu Asn Arg-Ile Ala Cys Gly Gln Ser Ile Pro Ala Ile Ala  
 165 170 175

Ala Glu Leu Tyr Val Ala Pro Ser Thr Val Lys Thr His Val Gln Arg  
 180 185 190

Leu Tyr Glu Lys Leu Gly Val Ser Asp Arg Ala Ala Ala Val Ala Glu  
 195 200 205

Ala Met Arg Gln Arg Leu Leu Asp  
 210 215

&lt;210&gt; 138

&lt;211&gt; 648

&lt;212&gt; DNA

-171-

&lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 138

|                                                                    |     |
|--------------------------------------------------------------------|-----|
| atgagcaatc cgcagccgga gaaagtgcgc gtggtggtcg gcgacgacca cccgttattt  | 60  |
| cgcgagggcg ttgtgcgagc gctttcgttg agtggctcgg tgaacgtggt cggcgaggcc  | 120 |
| gacgacggcg ccgcggccct ggagttgata aaggccatt tgcccgcgct cgcattgctg   | 180 |
| gactaccgca tgcccggcat ggacggcgcg caggttgcgg cggcgggtcg cagctacgag  | 240 |
| ttgccaaacc ggggtgctgct tatttcgcgc cacgacgagc cggcgatcgt ctaccaggca | 300 |
| ctccaacagg gcgccgcggg attcctgctc aaggattcga ctgcaccga gatcgtcaag   | 360 |
| gcggtgctcg attgcgcgaa gggccgcgac gtggtggcgc cctcgtggt cgggggcctc   | 420 |
| gccggggaga ttcgccagcg cgcggcaccc gtggccccgg tgctcagcgc gcgcgagcgc  | 480 |
| gaggtgctca atcgcattgc gtgcggtcaa agcatccccg cgatcgagc cgagctatat   | 540 |
| gtggcgccgt cgacggtaaa gacccacgtg caacggttgt acgagaagct cggcgtcagc  | 600 |
| gaccgagctg ccgcggtcgc cgaggcgatg cggcagaggc tgctcgac               | 648 |